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Abstract
Background
Many people with epilepsy (PWE) experience cognitive problems as a consequence of their 
epilepsy and its treatment However, relatively few longitudinal studies have been conducted 
to investigate how these problems progress during the course of the disorder, particularly in 
those who are newly diagnosed. This research was undertaken in the context of a pragmatic, 
randomised, unblinded, parallel-group, clinical trial assessing the clinical and cost 
effectiveness of standard and new antiepileptic drugs (SANAD). This trial provided a unique 
opportunity to investigate the natural history of cognitive functioning in people with newly 
diagnosed epilepsy.
Methods
A total of 222 people with newly diagnosed epilepsy were assessed using a comprehensive 
neuropsychological test battery before they started antiepileptic drug treatment. One hundred 
and forty seven were re-assessed after 12 months and a further 50 were followed-up after a 
mean of five years. Their cognitive performance at baseline and 12 months was compared to 
a healthy volunteer group (n=87) recruited from the general population.
Results
After adjusting for age, sex and education, PWE were cognitively compromised at the time of 
diagnosis, especially on measures assessing memory and psychomotor speed. After 12 
months, PWE had a different cognitive trajectory compared with the healthy volunteers that 
was characterised by a lower than expected performance. After five years, the majority of 
measures remained stable, although significant declines were noted for memory and 
psychomotor speed domains. Not all PWE were affected, however, with 54% demonstrating 
impairment at baseline and 38% experiencing cognitive decline at five year follow-up.
Conclusions
For a proportion of people with newly diagnosed epilepsy, cognitive impairments were 
identified at the beginning of their epilepsy and this may be followed by further cognitive 
decline. In an ideal world, people with new-onset epilepsy should be referred for 
neuropsychological assessment at the time of diagnosis so those at risk can be identified for 
appropriate intervention.
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Chapter 1 Introduction
This chapter will briefly introduce the main issues that will be explored in this thesis and 
provide a short summary of its structure.
Epilepsy is one of the most common neurological conditions, affecting approximately 50 
million people worldwide and 450 000 people in the United Kingdom. Around 3.5 million 
people are diagnosed with epilepsy every year. The majority of these will be managed with 
antiepileptic drugs (AEDs), which aim to control seizures with minimal adverse effects. The 
majority of people will become seizure free, although approximately 20-40% will continue to 
have seizures despite AED treatment. Chapter 2 will provide an overview of epilepsy and its 
management.
As illustrated in Figure 1.1, epilepsy is ‘more than seizures’ having impacts on multiple 
aspects of an individual’s life (Engel, Jr. & Pedley, 2008). The International League Against 
Epilepsy (ILAE) is recognising this in a move towards a new definition of epilepsy that 
encompasses its neurobiologicai, cognitive, psychological and social consequences (Fisher et 
a/., 2005).
This thesis will focus specifically on the effects of epilepsy on cognitive functioning. Cognitive 
functioning incorporates higher-order processes such as perception, attention, memory and 
learning, thinking, language, planning and problem-solving. These abilities allow us to process 
information, which enable us to interact with the world and other people. As cognitive 
difficulties can affect our social relationships, psychological well-being and quality of life, this 
area is worthy of significant investigation.
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Figure 1.1: The multiple, interacting factors that contribute to the experience of epilepsy for an 
individual patient (taken from Engel, Jr. & Pedley, 2008)
Associated neurological 
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Chapter 3 will review the substantial body of literature that has investigated the nature and 
cause of cognitive impairments in people with epilepsy. Several factors have been identified 
that contribute to the maintenance and development of cognitive dysfunction. These include 
the effects of the underlying aetiology; the effects of recurrent seizures, the side effects of 
antiepileptic drug treatment and psychosocial issues. Whilst a lot of attention has 
concentrated on the causes of cognitive impairment, particularly, the effects of antiepileptic 
drug treatment, Chapter 4 will illustrate the recent interest in determining when and how these 
impairments develop during the course of the disorder. A number of studies have suggested 
that people with epilepsy are already cognitively compromised at the time of diagnosis, before 
the start of antiepileptic drug medication. However, there is a lack of prospective longitudinal 
studies assessing whether these impairments get worse with the additional impact of seizures 
and treatment.
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This thesis will explore the natural history1 of cognitive functioning in people with newly 
diagnosed epilepsy by conducting a prospective, longitudinal study, as part of a larger, 
pragmatic, randomised clinical trial [Standard and New Antiepileptic Drugs (SANAD) trial 
(Marson et a/., 2007a, 2007b)]. The methods employed will be detailed in Chapter 5. A series 
of analyses will be undertaken that aim:
• To compare the cognitive profile of healthy volunteers with people with newly 
diagnosed epilepsy, before the administration of antiepileptic drug medication 
(Chapter 6)
• To compare the cognitive trajectories of people with newly diagnosed epilepsy 
and healthy volunteers over the first 12 months after starting AED treatment 
(Chapter 7)
• To document the longer term impact (3-8 years) of epilepsy and its treatment on 
cognitive functioning in people with newly diagnosed epilepsy (Chapter 8)
A discussion of the results and how they contribute to our understanding of the consequences 
of newly diagnosed epilepsy will be provided in Chapter 9. This chapter will also summarise 
the clinical implications and recommendations for future research.
1 The term ‘natural history' implies the course of a disorder from onset without intervention until it resolves or 
death (Berg, 2008). However, in industrialised countries, most people are treated with antiepileptic drugs at the 
time of diagnosis (Kwan & Sander, 2004), A ‘true natural history’ may only be possible in the developing world, 
where in some countries (e.g. Pakistan and the Philippines), 94% of people with active epilepsy are not receiving 
treatment (Shorvon, 2009). For the purposes of this thesis, ‘natural history’ will refer to the course of cognitive 
functioning in those treated with AEDs. This approach has been adopted by other authors e.g. Hermann etal. 
(2006a, 2008a) who have referred to the ‘natural history’ of neuropsychological abnormalities and 
neurobehavioural comorbidities in people with epilepsy, and Seidenberg etal. (2007) who have used the term 
the ‘natural course’ of epilepsy, to mean without intervening surgery.
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Chapter 2 Epilepsy and its treatment
2.1 Overview of the chapter
This chapter will provide a brief overview of epilepsy and its treatment. Epilepsy and epileptic 
seizures will be defined and the current classifications of epilepsy and epilepsy syndromes will 
be described. The incidence and prevalence will be reported and the causes of epilepsy will 
be discussed, as well as how a diagnosis of epilepsy is formed. There will be an overview of 
the history of epilepsy treatments from ancient remedies to modern day antiepileptic drugs. 
The current AEDs in clinical use and their indication will be provided. Treatment with AEDs is 
currently the first line approach in the management of epilepsy but other alternative 
treatments, such as, epilepsy surgery, vagal nerve stimulation, the ketogenic diet and 
psychological interventions will be reviewed.
2.2 Epilepsy
2.2.1 Definition of epilepsy
Traditionally, epilepsy has been defined as ‘a chronic disorder characterised by recurrent 
epileptic seizures’ (Gastaut, 1973). An epileptic seizure is ‘a transient occurrence of signs 
and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain' 
(Fisher et al., 2005). Epilepsy is not a single disease but encompasses a variety of 
heterogeneous disorders that are all symptoms of an underlying neurological disorder (Stokes 
ef a/., 2004).
There is now recognition that epilepsy is more than a clinical condition, with consequences on 
an individual’s life that can be more debilitating than the seizures themselves. Therefore, the 
ILAE has moved towards a new definition that acknowledges these consequences. They have 
defined epilepsy as: ‘a disorder of the brain characterised by an enduring predisposition to 
generate epileptic seizures and by the neurobiological, cognitive, psychological, and social
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consequences of the condition. The definition of epilepsy requires the occurrence of at least 
one epileptic seizure1 (Fisher et a/., 2005).
2.2.2 Classification of seizures
There are many different types of seizures. Their ciinical presentation generally depends on 
the location of the seizure in the brain and how the seizure spreads throughout the cerebral 
cortex. The ILAE 1981 classification of seizure types, as shown in Table 2.1, is the most 
commonly used and adopted classification. It divides seizures into:
• Partial seizures where seizure activity originates from part of one cerebral 
hemisphere;
• Generalised seizures where seizure onset involves both hemispheres. 
Consciousness is usually altered due to the extensive cortical involvement.
Partial seizures are subdivided into three types:
• Simple partial seizures do not have an alteration of consciousness. They 
usually only last for a few seconds. The seizures originate from a localised brain 
area and the sensations experienced (e.g. jerking, spasm or burning), depend on 
the localisation of the seizure. For example, simple partial seizures with motor 
signs, involve the motor cortex.
• Complex partial seizures involve alterations of consciousness. Before a 
complex partial seizure, an individual may experience an aura (a simple partial 
seizure) that acts as a warning. During the seizure, an individual may 
demonstrate automatisms (automatic behaviours), for example, lip smacking, 
gestures or verbal utterances. They may appear awake but do not respond to 
verbal instructions or questions. These usually last for one to two minutes. The 
postictal period may last up to a few hours.
• Either simple partial or complex partial seizures can evolve, by spreading 
through neuronal networks, to generalised seizures, which may be generalised
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tonic-clonic, tonic or clonic. These are known as secondarily generalised 
seizures.
Table 2.1: Classification of seizure types (taken from the Commission of the ILAE, 1981)
Partial (focal)
Simple partial (consciousness not impaired)
• With motor signs
• With somatosensory or special sensory symptoms (e.g. simple 
hallucinations)
• With autonomic symptoms or signs (e.g. flushing)
• With psychic symptoms (e.g. deja vu)
Complex partial seizures (with impairment of consciousness)
• With simple partial onset followed by impairment of 
consciousness
• With impairment of consciousness at onset
Partial seizures evolving to secondarily generalised seizures 
(may be generalised tonic-clonic, tonic or clonic)
• Simple partial seizures evolving to generalised seizures
• Complex partial seizures evolving to generalised seizures
• Simple partial seizures evolving to complex partial seizures 
evolving to generalised seizures
Absence seizures
• Typical absence
• Atypical absence
Generalised (convulsive or Myoclonic seizures
non-convulsive) Clonic seizures
Tonic seizures
Tonic-clonic seizures
Atonic seizures
Unclassified Unclassified seizures
Generalised seizures are subdivided into six main types:
• Absence seizures (formerly ‘petit mal’ seizures) have a sudden onset and an 
abrupt end. During the absence, an individual may demonstrate a vacant/staring 
appearance that lasts for a few seconds. There is no postictal confusion.
• Tonic-clonic seizures (formerly 'grand mal1 seizures) involve sudden contraction 
of the muscles, which is followed by clonic convulsive movements. These last no 
more than two to three minutes. They may be accompanied by tongue biting and
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urinary incontinence. Afterwards, an individual may remain unconsciousness for a 
time or sleep deeply.
• Clonic seizures may occur on their own without the tonic phase (rhythmic 
muscle contractions).
• Tonic seizures may occur without the clonic phase (stiffening of muscles).
• Myoclonic seizures are characterised by single or multiple jerking movements. 
These can particularly occur on falling asleep or waking.
• Atonic seizures involve a loss of muscle tone. This can vary in severity from 
causing the head to drop or jaw to slacken to causing an individual to drop to the 
ground. These are sometimes known as drop attacks or astatic seizures.
Unclassified seizures are those that cannot be determined whether the seizure is generalised 
or partial with secondarily generalisation. About one third of seizures cannot be classified 
according to the ILAE classification (Shorvon, 2000).
In addition to these seizure types, clinicians distinguish unprovoked seizures from provoked 
seizures (or acute symptomatic seizures). Acute symptomatic seizures 'occur at the time of a 
systemic insuit or in close temporal association with a documented brain insult' (Beghi et a/., 
2009). There is debate about whether these should be included in a diagnosis of epilepsy 
because they do not recur when the cause is removed.
Another important condition is status epilepticus (SE). Status epilepticus is either a single 
clinical seizure that lasts for more than 30 minutes or repeated tonic-clonic seizures over a 
period of more than 30 minutes without recovery of consciousness. However, urgent 
treatment should be sought after five minutes. SE can lead to anoxic brain damage and 
cognitive deterioration due to the cessation of respiration during the tonic phase of the 
seizure. Tonic-clonic SE is the most recognised but non-convulsive status may occur, such as 
absence or complex partial status.
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Causes of epileptic seizures
Epileptic seizures may be caused by a number of factors and a number of seizure precipitants 
have been identified. These include stress; sleep deprivation and fatigue; sleep/wake cycle; 
alcohol and alcohol withdrawal; antiepileptic drug noncompliance; metabolic disturbances; 
toxins and drugs; exercise and the menstrual cycle (Shorvon, 2000, Jallon & Zifkin, 2008). 
Identifying seizure precipitants for an individual may help in treatment, for example, avoidance 
of situations that are known to trigger seizures, or psychological therapy to reduce stress, 
which may improve seizure control.
2.2.3 Classification of epilepsy syndromes
To supplement the classification of seizures, there is also a classification system for 
epilepsies and epilepsy syndromes. ‘An epilepsy syndrome is an epileptic disorder 
characterised by a cluster of signs and symptoms customarily occurring together 
(Commission of the ILAE, 1989). These signs and symptoms include types of seizures; 
aetiology; age of onset; family history; other neurological signs and electroencephalogram 
(EEG) findings. Table 2.2 is the 1989 classification for epilepsies and epileptic syndromes 
from the Commission on Classification and Terminology of the ILAE (1989). The epilepsies 
are classified as to whether they are localisation-related (i.e. have partial-onset seizures) or 
generalised (i.e. have generalised seizures) and whether the underlying cause is idiopathic, 
symptomatic or cryptogenic. Idiopathic means the only cause is a possible hereditary 
disposition. Symptomatic is the result of a lesion or other identifiable underlying pathology. 
Cryptogenic is when the cause is unknown but is presumed to be symptomatic. With the 
advancing of imaging, many epilepsies that were previously cryptogenic can now be classified 
as symptomatic (Shorvon, 2000).
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Benign childhood epilepsy with centrotemporal 
spikes
Childhood epilepsy with occipital paroxysms 
Primary reading epilepsy______________________
Chronic progressive epilepsia partialis continua of 
childhood
Characterised by specific modes of precipitation 
(e.g. temporal lobe, frontal lobe, parietal lobe, 
occipital lobe, bi-and multilobar epilepsies)________
Cryptogenic epilepsy
Benign neonatal familial convulsions 
Benign neonatal convulsions 
Benign myoclonic epilepsy in infancy 
Childhood absence epilepsy 
Juvenile absence epilepsy 
Juvenile myoclonic epilepsy 
Epilepsy with GTCS on awakening 
Other idiopathic generalised epilepsies 
Epilepsies precipitated by specific modes of 
activation___________________________________
West syndrome (infantile spasms)
Generalised Cryptogenic or • Lennox-Gastaut syndrome
symptomatic • Epilepsy with myoclonic-astatic seizures
________________________• Epilepsy with myoclonic absences_______________
• Non-specific aetiology
o Early myoclonic encephalopathy 
o Early infantile epileptic encephalopathy with 
suppression burst
Symptomatic • Specific syndromes
o Caused by malformations 
o Proven or suspected inborn errors of 
metabolism
Table 2.2: Classification of the epilepsies and epileptic syndromes (Commission of the ILAE, 1989)
Other symptomatic generalised epilepsies
Undetermined 
(focal or 
generalised)
With both 
generalised and 
focal seizures
• Neonatal seizures
• Severe myoclonic epilepsy in infancy
• Epilepsy with continuous spike-waves during sleep
• Acquired epileptic aphasia (Landau-Kleffner)
Without unequivocal 
generalised or focal 
features
• Without unequivocal generalised or focal features
• Febrile convulsions
Special Situation-related • Isolated seizures or isolated status epilepticus
syndromes seizures • Seizures due to acute metabolic or toxic factors
• Reflex epilepsy
Idiopathic 
(with age-related 
onset)
Idiopathic 
(with age-related
Localisation- onset) 
related
(focal, partial)
Symptomatic
Cryptogenic
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Due to several criticisms of the classifications, and advancements in knowledge about 
epilepsy, there have been attempts to update them in 2001 and 2006. in 2001, the iLAE Task 
Force proposed a multi-axial diagnostic scheme for describing individual patients. They 
proposed that patients should be classified according to their ictal phenomenology; seizure 
type; syndrome; aetiology and optionally their degree of impairment (Engel, Jr., 2001). The 
diagnostic scheme was designed to help clinicians determine the diagnostic tests and 
treatment to be used in individual patients. However, the ILAE Task Force in 2006 reported 
that this proposal had not replaced the previous classifications and so the earlier versions 
should continue to be employed until a better classification has been devised (Engel, Jr., 
2006). The classifications have been reviewed again in 2009 and a new classification has still 
not been proposed, although updates have been made to terminology and concepts. For 
example, syndromes should no longer be characterised as being generalised or focal 
(localisation-related), and the terms idiopathic, symptomatic and cryptogenic should be 
replaced by genetic, structural/metabolic and unknown (Berg etai, 2010).
2.2.4 Incidence and prevalence
Epilepsy is the one of the most common neurological conditions. One in ten people will have 
at least one epileptic seizure in their lifetime and a third of these will go on to develop epilepsy 
(Engel, Jr. & Pedley, 2008). Approximately 50 million people have epilepsy worldwide (World 
Health Organisation, 2009) and approximately 450 000 people have epilepsy in the United 
Kingdom (Joint Epilepsy Council of the UK and Ireland, 2005). The prevalence of active 
epilepsy ranges between 4 and 10 per 1000 persons (Sander, 2003) and in the UK a 
prospective community-based study found a lifetime prevalence of active epilepsy of 4 per 
1000 persons [95% Confidence Intervals (Cl) 4,5] (MacDonald ef a/., 2000).
A meta-analysis of 40 incidence studies conducted worldwide between 1966 and 1999 found 
a median incidence rate of epilepsy of 47.4 cases per 100 000 per year (Kotsopoulos et a/., 
2002). However, the incidence rate was higher in developing countries (e.g. industrialised 
countries median 43.4 per 100 000 per year vs. developing countries median 68.7 per 100 
000 per year) (Kotsopoulos et al., 2002). This is possibly the result of developing countries 
having poorer medical facilities; poorer general health; lower standard of living and more
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infections of the central nervous system (CNS), such as tuberculosis and human 
immunodeficiency virus (HIV) (Bharucha et al., 2009). In the UK, the incidence of epilepsy is 
46 per 100 000 per year (95%CI 36, 60) (MacDonald et al., 2000). The risk of an individual 
developing epilepsy in their lifetime is between 3 and 5% (Shorvon, 2000).
Figure 2.1: Age-specific incidence rates for epilepsy adjusted to the UK population (data from 
MacDonald et al., 2000)
The onset of epilepsy is more common in young children, particularly during the first few 
months, and older adults (see Figure 2.1). However, recent studies have shown that the 
incidence rate in children is decreasing while the incidence rate in those aged over 60 years is 
increasing (Kotsopoulos et al., 2002, Sander, 2003). A decrease in childhood may be due to 
the adoption of healthier lifestyles by expectant mothers; improved antenatal and prenatal 
care, and enhanced immunisation programmes. This may lead to a reduction in neuronal 
migration defects, in birth hypoxia and in CNS viral infections, which may be involved in the 
development of epilepsy (Sander, 2003). The increase in older adults may be the result of a 
rise in the number of people who have had a history of a stroke, which is a risk factor for 
developing epilepsy (Sander, 2003, Banerjee & Hauser, 2008).
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The incidence of epilepsy is higher in males than in females, although this is not always 
statistically significant (Banerjee & Hauser, 2008). In the meta-analysis by (Kotsopoulos et a/., 
2002), the median incidence for males was 50.7 per 100 000 per year compared with 46.2 per 
100 000 per year for females. Possible reasons for the difference are that males have a 
higher incidence of risk factors for epilepsy such as head injury, stroke and CNS infection 
(Kotsopoulos etal., 2002).
2.2.5 Mortality of epilepsy
There is a higher risk of mortality in people with epilepsy. The standardised mortality ratio 
(SMR) is two to three times higher than the general population. The risk is increased in those 
who have chronic epilepsy, especially younger people, and those with symptomatic epilepsy 
(Sander, 2003). The cause of death may be related to the underlying aetiology; drowning; 
burns; aspiration; pneumonia; status epilepticus and suicide. There is evidence to suggest an 
increased risk of suicide in people with epilepsy compared to the general population (Bell & 
Sander, 2009). A recent meta-analysis has found an overall SMR for suicide in people with 
epilepsy of 3.3 (95%CI 2.8,3.7). However, the risk is increased for those with a psychiatric co­
morbidity, particularly an affective disorder (Bell et a/., 2009). Epilepsy-related deaths may 
also be accounted for by Sudden Unexpected Death in Epilepsy (SUDEP). SUDEP is 
‘sudden, unexpected, witnessed or unwitnessed, non-traumatic and non-drowning death in 
patients with epilepsy, with or without evidence of a seizure and excluding documented status 
epilepticus, in which post mortem examination does not reveal toxoiogical or anatomic cause 
of death’ (Nashef, 1997). The mechanisms that lead to SUDEP are unknown but risk factors 
include generalised tonic-clonic seizures; young age; uncontrolled epilepsy; learning disability; 
seizures occurring during sleep; unwitnessed seizures and poor adherence to antiepileptic 
drug treatment (Shorvon, 1997).
2.2.6 Causes of epilepsy
There are a wide range of underlying aetiologies for epilepsy, as shown in Table 2.3. 
However, specific aetiologies are usually only identified in approximately one third of people 
with newly diagnosed epilepsy (Banerjee & Hauser, 2008). In the UK National General
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Practice Study of Epilepsy, 61% of people with newly diagnosed epilepsy, or suspected 
epileptic seizures, had no identifiable aetiology. However, vascular disease was the most 
common cause in 15% and cerebral tumour in 6% (Sander et a/., 1990).
Table 2.3: Aetiology of epilepsy (adapted from Shorvon, 2000)
1
1
Inherited
genetic
conditions
Genetic disorders causing epilepsy alone (e.g. juvenile myoclonic epilepsy, 
familial frontal lobe epilepsy)
Inherited conditions with other neurological manifestations
o DNA expansion syndromes (e.g. Down syndrome, Fragile X 
syndrome)
o Other inherited conditions with extrapyramidal features (e.g. Wilson’s 
disease)
o Other inborn errors of metabolism (e.g. phenylketonuria, amino acid 
disorders)
Inherited metabolic disorders with intermittent disturbances (e.g. porphyria) 
Neurocutaneous syndromes (e.g. tuberous sclerosis, neurofibromatosis)
Acquired or
congenital
disorders
Vascular malformations (e.g. arteriovenous malformations, cavernous 
angiomas)
Hippocampal sclerosis
Cortical dysplasia/ dysgensis (e.g. focal cortical dysplasia, heterotopias) 
Immunisation (e.g. diphtheria, tetanus and polio vaccine)
Infection (e.g. bacterial meningitis, viral encephalitis, cerebral abscess)
Cerebral tumours (e.g. oligodendrogliomas, meningiomas)
Post-traumatic epilepsy
Neurosurgery
Cerebrovascular disease (e.g. ischemic stroke, intracranial haemorrhage) 
Antenatal or perinatal injury
Birth trauma (e.g. hypoxia, intracranial haemorrhage)
Alcohol/Drugs (e.g. alcohol withdrawal)
Toxic agents (e,g encephalopathy caused by lead poisoning)
Metabolic disorders (e.g. changes in glucose, calcium, potassium and 
magnesium)
Neurodegenerativce disorders (e.g. Alzheimer’s Disease, Creutzfeldt-Jakob 
disease)
Other diseases (e.g. Coeliac disease, multiple sclerosis)
As shown in Figure 2.2, aetiologies often vary by age. In childhood, congenital, developmental 
and genetic conditions are often associated with the development of epilepsy. Head injuries, 
CNS infections and tumours are more likely to lead to epilepsy in adulthood and 
cerebrovascular disease is the most common risk factor for epilepsy in those aged over 60 
years (Sander, 2003). Similarly, in the UK National General Practice Study of Epilepsy,
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vascular disease was more common in those aged over 60 years (49%) and tumours in those 
aged 50-59 years (Sander etal., 1990).
Figure 2.2: Aetiology of epilepsy at different ages (taken from Brodie et a!., 2005)
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2.2.7 Diagnosis of epilepsy
A diagnosis of epilepsy should be made by an epilepsy specialist (Stokes et al., 2004). It is 
usually only made after the occurrence of at least two unprovoked seizures (Stein & Kanner, 
2009). The diagnosis is based on clinical history and a detailed description of the events 
experienced by a patient, before, during and after a seizure. This description should be from 
the patient and if possible an eyewitness to the seizure. Electroencephalography (EEG) can 
be used to support the clinical diagnosis of epilepsy and help determine whether seizures are 
partial or generalised. However, standard or routine EEGs have variable sensitivity and 
specificity (Stokes et al., 2004). Several studies have shown that the EEG may be abnormal in 
people without epilepsy and may also be normal in people with epilepsy (Fowle & Binnie,
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2000). One study found that 48% of people with epilepsy had a normal EEC (Goodin & 
Aminoff, 1984). Structural neuroimaging, for example magnetic resonance imaging (MRI) and 
computed tomography (CT), can be used to identify structural abnormalities, such as tumours, 
vascular lesions, atrophy or stroke that may have caused the epilepsy. It is particularly 
important in those who present with partial-onset seizures and have adult-onset epilepsy 
(Stokes ef a/., 2004).
2.3 Epilepsy treatment
Treatment with antiepileptic drugs is currently the first approach in the management of people 
with epilepsy. However, there is a long history of treatments for epilepsy, which will be briefly 
detailed below.
2.3.1 History of treatments for epilepsy
"There is scarcely a substance in the world capable of passing through the gullet of a man 
that has not at one time or another enjoyed the reputation of being an antiepileptic”
(Sieveking, taken from Scott, 1993)
Throughout history, many different substances and techniques have been used in the 
treatment of people with epilepsy. Treatments have largely reflected the differing theories of 
causation. In Babylonian and Greek times, epilepsy was thought to be the result of 
possession by a demon or spirit (Reynolds, 2009). Therefore, treatments, such as exorcism, 
were largely based on mysticism and superstition (Haynes & Bennett, 1992). The Hippocratic 
School moved towards a physiological basis for the disorder and ‘the brain being the seat of 
the disease1. Treatment around this time included diet, exercise, sleep and a consideration of 
temperature and climate factors (Temkin, 1971). Herbal remedies included drinking vinegar 
and wormwood (Temkin, 1971) and ancient Indian medicinal treatments involved tree bark, 
sour milk curds, animal parts and even excrement (Scott, 1993).
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In the Middle Ages, the idea that epilepsy was the result of supernatural causes was revived 
and exorcism remained a prevalent form of treatment. Superstitious and religious remedies 
continued to persist, such as the wearing of amulets of peony or stones, drinking blood, and 
pilgrimages to the prior of St Valentine, the patron saint of epilepsy (Temkin, 1971, Haynes & 
Bennett, 1992). During this time, potions contained powdered human skull, liver of vultures 
and mistletoe (Scott, 1993).
In the 19th Century, the idea of demonic possession began to fade, as the knowledge of 
anatomy and physiology increased. It was during the 1850s that the first anticonvulsant drug, 
potassium bromide was introduced by Sir Charles Locock. The use of bromides quickly 
became widespread. Around this time, barbituric acid was first synthesised but it was not until 
1912 that the effectiveness of phenobarbital (PB) as an antiepileptic was recognised by Alfred 
Hauptman (Kwan & Brodie, 2004). Phenobarbital came into use quickly but the next major 
antiepileptic drug, phenytoin (PHI), was not introduced until the late 1930s by Merrit and 
Putman. The previous drugs had been discovered by chance but phenytoin was the first AED 
that resulted from a systematic study to identify new antiepileptic drugs by findings molecules 
that resembled phenobarbital (Daras etal,, 2008).
It was nearly 20 years later before carbamazepine (CBZ) was first synthesised in the search 
for more effective psychoactive drugs (Shorvon, 2009). But carbamazepine was not used as 
an antiepileptic until the early 1960s. Meanwhile, during the early 1950s, primidone (PRM) 
and euthosuximide (EXM) were licensed for use. At a similar time, the antiepileptic properties 
of sodium valproate (VPA) were discovered by chance. Sodium valproate was initially used an 
organic solvent in screening studies of new antiepileptic drugs. However, it was soon realised 
that it was the solvent, not the tested compounds, which was the effective antiepileptic agent. 
The first clinical trials of sodium valproate were undertaken in 1964. It was first marketed in 
France and then licensed for use in the UK in 1973.
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Figure 2.3: Growth in the number of AEDs
During the 1960s and 1970s, more formalised assessments of AED efficacy and tolerability 
were required and so several compounds disappeared as they could not face the cost of 
rigorous testing (Scott, 1993, Glauser et al., 2006). However, over the last two decades, there 
has been a huge growth in the number of AEDs, as shown in Figure 2.3. These have included 
lamotrigine (LTG), gabapentin (GBP), topiramate (TPM) and tiagabine (TGB) in the 1990s and 
levetiracetam (LEV), oxcarbazepine (OXC) and pregabalin (PGB), among other new 
developments in the 2000s. Their development and discovery has been the result of several 
different strategies including: random screening of numerous molecules with a wide range of 
chemical structures (e.g. felbamate2); testing structural analogues of known AEDs (e.g. 
oxcarbazepine) and modifying factors believed to facilitate epileptic activity [e.g. gabapentin 
and gamma-aminobutyric acid (GABA)] (Daras etal., 2008).
2 Felbamate (FBM) is not licensed for use in the United Kingdom. It is licensed for use in the United States but 
only in patients with severe epilepsy due to the risks of aplastic anaemia (Panayiotopoulos, 2007).
17
Treatment with AEDs
The goal of antiepileptic drug treatment is to prevent seizures with minimal side-effects. There 
are a number of AEDs currently licensed for use in the UK, as shown in Table 2.4. The choice 
of AED shouid be determined by seizure type; epilepsy syndrome; indication; childbearing 
potential; co-morbidity; preferences of the individual and/or carer; concomitant medication; 
presence of contraindications to the drug and potential adverse effects (Stokes et a!., 2004). 
The results of the recent SANAD trial suggest that lamotrigine may be a clinically cost- 
effective drug for those with partial-onset seizures (Marson et at., 2007a). Valproate remains 
the most clinically effective drug for those with generalised or unclassified epilepsy (Marson et 
at., 2007b). However, valproate is associated with teratogenic effects (e.g. Adab et at., 2004) 
and so the question of which is the most appropriate drug for women of child-bearing age is a 
difficult issue.
Patients should be treated with a single drug (monotherapy) first and if that fails, either due to 
inadequate seizure control or unacceptable events, they should be treated with an alternative 
drug (Stokes et at., 2004). Patients may be treated with more than two drugs (polytherapy) if 
monotherapy has not resulted in seizure freedom. However, this is associated with more side 
effects; pharmacokinetic interactions, increased risk of teratogenecity and more complex and 
intrusive AED regimen (Shorvon, 2000). Some have suggested that selecting a second drug 
that has a differing mechanism of action is a rational approach. However, others say that 
there is little evidence to suggest that this has an effect (Shorvon, 2000).
The mechanisms of action of several of the most commonly used AEDs and their adverse 
effect profiles are shown in Table 2.5. For many AEDs their mechanisms of action are still not 
fully understood and several have more than one mechanism of action (Perucca, 2005). 
Some work by blocking different ion channels in the brain, while others work by increasing the 
levels of GABA in the brain, which is the main inhibitory neurotransmitter. However, a 
discussion of the pharmacokinetics of AEDs is beyond the scope of this thesis.
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Table 2.4: AEDs currently licensed for use in the UK and their indication (adapted from the Joint 
Formulary Committee, 2009)
Generation AED Indication
Phenobarbital • All forms of epilepsy except absence seizures
Phenytoin • All forms of epilepsy except absence seizures
Primidone • All forms of epilepsy except absence seizures
^st Ethosuximide • Absence seizures
Carbamazepine • Partial and secondary generalised tonic clonic seizures; 
primary generalised tonic-clonic seizures
Sodium valproate • All forms of epilepsy
Vigabatrin * Adjunctive treatment of partial seizures with or without 
secondary generalisation not satisfactorily controlled with 
other AEDs; monotherapy for management of infantile 
spasms (West’s syndrome)
Clobazam • Adjunctive therapy
Clonazepam • All forms of epilepsy
Acetazolamide • Treating epilepsy associated with menstruation; 
adjunctive therapy for tonic clonic and partial seizures; 
occasionally helpful in atypical absences and tonic clonic 
seizures
Lamotrigine • Monotherapy and adjunctive treatment of partial seizures 
and primary and secondarily generalised tonic-clonic 
seizures; seizures associated with Lennox-Gastaut 
syndrome
Gabapentin • Monotherapy and adjunctive treatment of partial seizures 
with or without secondary generalisation
2nd Topiramate • Monotherapy and adjunctive treatment of generalised 
tonic-clonic seizures or partial seizures with or without 
secondary generalisation; adjunctive treatment of 
seizures in Lennox-Gastaut syndrome
Tiagabine • Adjunctive treatment for partial seizures with or without 
secondary generalisation not satisfactorily controlled with 
other AEDs
Levetiracetam • Monotherapy and adjunctive treatment of partial seizures 
with or without secondary generalisation and for 
adjunctive therapy of myoclonic seizures and generalised 
tonic-clonic seizures
Oxcarbazepine • Monotherapy and adjunctive treatment of partial seizures 
with or without secondary generalised tonic-clonic 
seizures
Pregabalin • Adjunctive therapy for partial seizures with or without 
secondary generalisation
Zonisamide • Adjunctive therapy for partial seizures with or without 
secondary generalisation
3rd
Rufinamide • Adjunctive treatment of seizures in Lennox-Gastaut 
syndrome
Lacosamide • Adjunctive therapy of partial seizures with or without 
secondary generalisation
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2.3.2 Prognosis for people with epilepsy
For the majority of people, epilepsy is a relatively benign condition. Most people with newly 
diagnosed epilepsy will achieve seizure freedom. In the United Kingdom, the National General 
Practice Study of Epilepsy found that 54% of newly diagnosed patients were in five year 
remission, nine years after diagnosis (Cockerell et al., 1995). However, approximately 20% of 
patients will never experience seizure remission. Better outcome is associated with absence 
of early life brain damage, absence of generalised epileptiform activity on EEG and no history 
of generalised tonic-clonic seizures (Shafer et al., 1988).
Figure 2.4: The efficacy of AEDs in people with newly diagnosed (taken from Stein & Kanner, 2009 but 
data from Kwan & Brodie, 2000)
Seizure free
Adjunctive
therapy
Seizure free
Seizure free 
47%
Seizure free
3%
Monotherapy 
Is1 AED
Monotherapy 
2nd AED
Monotherapy 
3rd AED
Uncontrolled
seizures
36%
Uncontrolled
seizures
53% Uncontrolledseizures
40% Uncontrolled
seizures
39%
Newly diagnosed 
epilepsy 
(n=470)
In terms of response to AEDs, a prospective long-term study of newly diagnosed patients in 
the UK showed that 64% of patients achieved at least a one year seizure remission after 
starting treatment (Kwan & Brodie, 2000). As shown in Figure 2.4, 47% became seizure free 
on the first drug; 13% on the second drug and 3% on the third drug. Only 1% became seizure
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free on a combination of two drugs (Kwan & Brodie, 2000). This study also found that 
response to the first AED was the most powerful predictor of prognosis (Kwan & Brodie, 
2000). Of those who become seizure free, approximately, 60-70% will be able to withdraw 
from AEDs without experiencing any further seizures (MRC Antiepiieptic Drug Withdrawal 
Study Group, 1991, Kwan & Sander, 2004). Factors predicting outcome after withdrawal are 
length of seizure free periods, polytherapy, history of tonic-clonic or myoclonic seizures and 
seizures after the start of AED therapy (MRC Antiepileptic Drug Withdrawal Study Group, 
1991). However, the decision to withdraw should be taken by the individuals, family and/or 
carers after full discussion of the risks and benefits by an epilepsy specialist (Stokes et a/., 
2004).
Kwan and Sander (2004) have proposed that the prognosis of newly diagnosed epilepsy can 
be classified into three groups:
• Excellent prognosis characterises 20-30% of patients who will enter a long-term 
remission, probably even without AED treatment. If they are treated, they become 
seizure free on the first or second monotherapy, which can be withdrawn after a 
period of seizure freedom. This group may include those with benign neonatal 
seizures, benign rolandic epilepsy and childhood absence epilepsy.
• Remission with treatment only characterises 20-30% of patients who will 
remain seizure free only with continuing AED treatment. Some may require 
combination therapy and seizure may recur if treatment is withdrawn. This group 
may include those with juvenile myoclonic epilepsy and the majority of those with 
localisation-related epilepsies.
• Continuing seizures despite treatment characterises 30-40% of patients whose 
seizures recur despite AED treatment. This group may include those with 
symptomatic or cryptogenic localisation-related epilepsy, particularly, those 
associated with mesial temporal sclerosis, cortical dysplasia, structural brain 
lesions, progressive myoclonic epilepsies and West syndrome.
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There are differing definitions as to what constitutes drug resistant or refractory epilepsy but a 
recent Task Force commissioned by the ILAE has recently defined it as ‘as a failure of 
adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules 
(whether as monotherapies or in combination) to achieve sustained seizure freedom' (Kwan et 
a/., 2009).
Other treatment approaches
Epilepsy surgery
For those with drug resistant epilepsy, epilepsy surgery may be a potential option. The first 
surgical procedure to remove the epileptic focus in an individual with focal motor epilepsy was 
carried out by Horsley in 1886 (Daras et a/., 2008). Epilepsy surgery is a viable option for 
those who have an operable structural abnormality (e.g. hippocampal or medial temporal 
sclerosis). There are different types of resective surgical procedures which include: anterior 
temporal lobectomies; focal resections such as, amygdalohippocampectomy, where the 
hippocampus and amygdala are removed and lesionectomties where the structural lesion 
(e.g. cerebral tumour) is removed. There also different types of functional surgical procedures. 
These include corpus callostomy, hemispherectomy and multiple subpial transections. These 
are carried out to disrupt the pathways that are involved in the spread of epileptiform 
discharges, thereby reducing the frequency and severity of seizures. However, these do not 
remove the epileptogenic focus. A review of non-drug treatments for patients with drug 
resistant epilepsy found that approximately 55% of temporal lobe epilepsy patients were 
seizure free with no auras and 68% were seizure free with auras. After hemispherectomy, 
between 40-71.4% of patients were seizures free, although definitions of seizure freedom 
varied from study to study (Chapell et ai, 2003).
Vagal (vagus) nerve stimulation
For those who are not candidates for epilepsy surgery, vagal (vagus) nerve stimulation (VNS) 
may be used as an adjunctive therapy to pharmacological treatment in patients with partial 
seizures (with or without secondary generalisation) or generalised seizures that are refractory 
to antiepileptic medication. VNS is a non-pharmacological treatment whereby a small pulse
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generator is implanted under the skin. This generates programmed pulses which stimulate the 
vagus nerve to reduce the frequency and severity of seizures. Around 43,000 people 
worldwide have been implanted with vagus nerve stimulators (Epilepsy Action, 2009). VNS is 
well tolerated and the adverse effects associated with implantation and stimulation are 
hoarseness, cough, dyspnoea, pain and paraesthesia. This is different from the side effects 
associated with antiepileptic drugs, suggesting that VNS is a good alternative for those 
individuals who have difficulty tolerating AEDs (Privitera et a/., 2002).
Ketogenic diet
Other treatment approaches include the ketogenic diet. This may be used as an adjunctive 
treatment in children with refractory epilepsy but should not be recommended for adults with 
epilepsy (Stokes et al., 2004). The diet was first developed in the 1920s but has re-emerged 
as an effective treatment for those children who are drug resistant (Zupec-Kania & Spellman, 
2008). It involves eating food that mimics the effects of starvation in the body i.e. a diet high in 
fat and low in carbohydrate and protein. This produces ketones but the mechanism underlying 
the effect on seizures is unclear. The diet needs input from a dietician and is restrictive. Eating 
at school or outside the home may be hard, which makes adherence to the diet difficult. The 
first randomised control trial published in 2008 found that after three months on the diet, 38% 
of children had more than a 50% reduction in seizures and 7% had more than a 90% 
reduction in seizures (Neal et al, 2008). The adverse effects are, like VNS, different from the 
CNS side effects associated with AEDs. They include constipation, gastroesophageal reflux 
disease, kidney stones, abnormal lipid levels, growth retardation, hypoproteinaemia and 
micronutrient deficiencies (Zupec-Kania & Spellman, 2008).
Psychological intervention
Psychological intervention may include relaxation therapy, cognitive behavioural therapy, 
biofeedback and educational interventions. These should be used as adjunctive to 
pharmacological treatment rather than an alternative. However, a recent Cochrane review 
found no reliable evidence to support the use of psychological treatments in reducing seizure 
frequency and the authors recommended further trials (Ramaratnam et al, 2008).
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2.4 Summary
Epilepsy is a common neurological condition affecting approximately 50 million people 
worldwide. It is defined by the tendency to have recurrent epileptic seizures. It is a 
heterogeneous disorder characterised by different seizure types, syndromes and aetiologies. 
Antiepileptic drugs are the first approach in the management of seizures. The majority of 
people will respond to their first or second AED and will remain seizure free. However, for 
around 20-40% of people, their seizures will continue despite AED treatment and they may 
develop chronic, refractory epilepsy. Epilepsy surgery may be an alternative treatment option 
for some.
The ILAE has moved towards a definition of epilepsy that encompasses its neurobiological, 
cognitive, psychological and social consequences. For some people, these consequences 
can have a significant impact on their daily lives. For example, difficulties in areas of cognitive 
functioning can impact on academic achievement, occupational attainment, the ability to 
engage and maintain social relationships and overall quality of life. Therefore, in order to 
understand the effects of epilepsy on an individual, it is important to understand the factors 
that contribute to the development and maintenance of cognitive dysfunction in people with 
epilepsy. While some of these may be treatment-related, there are many other possible 
factors, as discussed in the next chapter.
27
Chapter 3 Neuropsychology of epilepsy
3.1 Overview of chapter
This chapter will review the literature on the neuropsychology of epilepsy. There will be a brief 
overview of the nature of cognitive impairments experienced by people with epilepsy, with 
evidence drawn from both objective and subjective reports. There will be a discussion of the 
causes of these impairments, which will include detailed considerations of the effects of 
epilepsy-related (e.g. epilepsy syndromes, aetiology and seizures), treatment-related (e.g. 
AEDs and epilepsy surgery) and psychosocial-related factors.
3.2 Cognitive functioning in people with epilepsy
Since Ancient times, there has been recognition that epilepsy can have an adverse effect on 
cognitive functioning. The Greek physician, Aretaeus of Cappadocia (1st/2nd century BC), 
described how patients with chronic epilepsy tended to be ‘languid, spiritless, stupid, inhuman 
and unsociable....slow to learn, from torpidity of the understanding and of the senses; dull of 
hearing...have utterances that are indistinct and bewildered, either from the nature of the 
disease, or from wounds during the attacks....' (cited in Magiorkinis et al., 2010). Aristotle 
described how people who have had epilepsy since childhood ‘reach a mental state 
comparable to the stupor of extreme drunkenness' (cited in Temkin, 1971). in the 19th 
century, Gowers (1885) commented that ‘in its slighter forms there is merely defective 
memory, especially for recent acquisitions. In more severe degree there is greater 
imperfection of intellectual power, weakened capacity for attention and often defective moral 
control’(died in Temkin, 1971J.
3.2.1 Performance on objective neuropsychological tests
With the advancement of the field of clinical neuropsychology in the 20111 century, a number of 
studies have shown that people with epilepsy demonstrate impairments on objective 
neuropsychological tests. Several studies have shown that compared to people without
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epilepsy, people with epilepsy have reduced memory and learning, attention and 
concentration problems, slowed information processing and psychomotor speed, language 
deficits and executive dysfunction (e.g. Hermann etal., 1997, Baxendale etal., 1998, Moore & 
Baker, 2002, Oyegbile etal., 2004). However, there is considerable variation between people 
with epilepsy, which probably reflects the heterogeneity of the disorder. For example, 
Hermann et a!., (2007a) proposed three distinct cognitive profiles within people with chronic 
temporal lobe epilepsy: those who were minimally impaired (47%); those who were memory 
impaired (24%) and those who were memory, executive and speed impaired (29%).
Figure 3.1: The mean performance of three cognitive phenotypes in chronic temporal lobe epilepsy 
relative to healthy controls (represented by the x-axis) (data from Hermann et a!., 2007a)
■ Minimally impaired ■ Memory impaired * Memory, executive and speed impaired
As shown in Figure 3.1, these different groups had a different pattern of neuropsychological 
performance across seven cognitive domains and a different pattern of performance 
compared with healthy controls. Those who were in the memory, executive and speed 
impaired group performed significantly worse compared to healthy controls and the other two 
groups across the measures. Those in this group were older, had a longer duration of
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epilepsy and were taking more AEDs in comparison with the minimally impaired group. They 
also had more extensive neuroanatomic abnormalities, such as more abnormal cerebral 
volumes (e.g. white matter, grey matter and cerebrospinal fluid); more extensive cortical 
thinning and increased volume loss and atrophy in subcortical structures (e.g. the 
hippocampus and caudate), the corpus callosum and cerebellum (Hermann et al., 2007a, 
Dabbs et al., 2009). This suggests that some patients may be more susceptible to 
experiencing cognitive impairments and those who have a more severe course of epilepsy 
may be most at risk (Hermann et al., 2007a).
3.2.2 Subjective report of cognitive problems
People with epilepsy are not only at risk of performing poorly on objective neuropsychological 
tests but they also frequently report experiencing subjective cognitive problems, which may 
affect their daily lives (e.g. Thompson & Corcoran, 1992, Baker et al., 1997, Giovagnoli et al., 
1997, International Bureau for Epilepsy, 2004). A large European survey of more than 5000 
people with epilepsy found that 50% of respondents reported experiencing memory problems; 
48% had difficulty concentrating and 40% reported difficulties in thinking clearly (Baker et al., 
1997). A more recent European survey conducted by the International Bureau for Epilepsy 
(IBE) also found similar results. Fifty-nine per cent of the 425 respondents reported 
experiencing sleepiness or tiredness; 48% lethargy or sluggishness; 45% slowness of thought 
and 44% reported difficulties in learning something new. A significant proportion of 
respondents felt that these cognitive effects had a noticeable impact on their work (50%), 
family and relationships (50%), leisure pursuits (46%) and education (45%) (IBE, 2004). 
Thompson & Corcoran (1992) explored the type of everyday memory failures that people with 
epilepsy commonly experience. They found the most frequent problems were: ‘tip of the 
tongue’ phenomena (reported by 43%); going back to check whether something has been 
done (39%) and forgetting where things have been put (33%). Fifty-four percent of 
respondents regarded these memory failures as a moderate or serious nuisance on their day 
to day lives.
Cognitive problems are not only reported by adults with epilepsy. In another recent survey by 
the IBE on the impact of epilepsy and its treatment in children with epilepsy, children
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commonly reported experiencing difficulties working out sums; solving problems; 
concentrating; describing things to other people and remembering things. Many children 
reported feeling worried about being able to keep up with their schoolwork. More than a third 
felt that epilepsy would impact on their lives in the future, affecting their employment 
opportunities and continuing education (Baker etah, 2008).
3.2.3 Discrepancy between objective and subjective report
Despite studies that provide evidence of both objective and subjective reductions in cognitive 
performance, there are also several studies that have suggested that there is a lack of 
correlation between subjective reports of cognitive complaints and performance on objective 
neuropsychological tests (e.g. Thompson & Corcoran, 1992, Elixhauser et a/., 1999, Piazzini 
ef a/., 2001, Andelman etal., 2004, Liik etal., 2009, Marino etal., 2009). Several studies have 
suggested that some patients tend to overestimate their problems, while others have 
suggested that some tend to underestimate them. There have been several reasons proposed 
to explain the discrepancy between objective and subjective report (see Table 3.1).
Table 3.1: Explanations for discrepancy between objective and subjective report
Anxiety and depression • May lower self-esteem, causing patients to over-report their 
difficulties (Thompson & Corcoran, 1992, Corcoran & Thompson, 
1993, Giovagnoli etal., 1997, Piazzini etal., 2001, Liik etal., 2009, 
Marino et a/., 2009, Salas-Puig et a/., 2009)
Personality traits (e.g. 
neuroticism)
• Have been associated with an increased number of cognitive 
complaints (Vermeulen etal., 1993, Uijl etal., 2006)
Right hemisphere 
epileptogenic lesions
• Have been associated with a systematic bias in self-awareness for 
memory, which may cause a tendency to over-estimate memory 
abilities (Andelman eta/., 2004)
Neuropsychological 
tests may not measure 
everyday difficulties
• E.g. remembering names of familiar people, remembering where 
things have been put, or remembering personal facts or events 
(remote memory) is different from remembering a list of unrelated 
words in a verbal list learning task (Elixhauser et al., 1999)
Patient’s concepts of 
memory problems are 
different from those of a 
neuropsychologist
• Eg. patients may consider forgetting the names of objects a 
memory problem but a neuropsychologist would consider this a 
naming deficit and would assess this using a confrontation naming 
task (Helmstaedter & Eiger, 2000)
Impairment of long-term 
recall beyond what is 
assessed in traditional 
memory assessments
• Patients may demonstrate ‘normal’ learning and memory over 
these relatively short retention intervals but have accelerated 
forgetting over longer intervals (e.g. days and weeks) (O'Connor et 
al., 1997, Blake etal., 2000, Mameniskiene etal., 2006)
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The discrepancy between subjective and objective report means that clinicians and 
researchers need to be aware that patient’s perceptions of their cognitive problems (or lack of 
problems) may not accurately reflect their cognitive abilities, as measured on objective tests. 
A reliable and comprehensive neuropsychological assessment, taking into account emotional 
state and the nature of self-reported difficulties, may be needed to uncover the extent of 
cognitive dysfunction in an individual patient (Thompson & Corcoran, 1992, Piazzini et aL, 
2001).
3.3 Causes of cognitive impairment in people with epilepsy
Despite these discrepancies, it is clear that people with epilepsy are at risk of developing 
cognitive impairment. As cognitive impairment can have a negative impact on day to day 
functioning (e.g. education, employment, family life and social relationships), psychological 
well-being (e.g. self-confidence, self-esteem, anxiety and depression) and overall quality of 
life (Perrine & Kiolbasa, 1999, Giovagnoli & Avanzini, 2000, Baker et a/., 2009, Meneses et 
al., 2009), it is important to understand the factors that contribute to the maintenance and 
development of cognitive dysfunction. There are several factors, as shown in Table 3.2. 
These include: the effects of the underlying aetiology, the effects of recurrent seizures; the 
side effects of antiepileptic drug treatment and psychosocial issues (Kwan & Brodie, 2001, 
Meador, 2002, Motamedi & Meador, 2003, Aldenkamp & Bodde, 2005).
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Table 3.2: Factors affecting cognitive functioning in people with epilepsy
Aetiology • Presence of underlying brain damage
• Localisation of epileptogenic focus
Epilepsy-related factors • Epilepsy syndrome
• Age of onset
Seizure-related factors
• Seizure type
• Seizure freguency
• Duration of epilepsy
• Interictal activity
• Status epilepticus
Treatment-related factors
• TypeofAED
• Dose
• Drug interactions
• Epilepsy surgery
• Vagal nerve stimulation
Psychosocial-related factors
• Depression and anxiety
• Public attitudes/stigma
• Self-esteem
• Educational/occupational attainment
There are complex potential interactions between these factors, as shown in Figure 3.2. 
Antiepileptic drugs, for example, can both enhance, by improving seizure control, and impair 
cognition, whereas seizure activity, psychosocial problems and neuronal dysfunction may 
have a negative effect (Aldenkamp, 2006). These complex interactions make it difficult to 
determine their individual relative contribution to cognitive dysfunction. However, there has 
been a significant body of research undertaken to understand the causes of cognitive 
impairments, in particular the cognitive side effects of antiepileptic drug treatment. In the 
following sections, there will be a review of the literature investigating the cognitive effects of 
each of these epilepsy, treatment and psychosocial-related factors.
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Figure 3.2: Non-independent contributory factors for cognitive dysfunction (Aldenkamp, 2006)
Seizures/Epileptiform
activity
Psychosocial
problems
© '
AEDs
Cognitive ~
processes ___________^ Negative
effect
Positive
effect
3.3.1 Epilepsy-related
Epilepsy syndrome and underlying aetiology
Symptomatic/cryptogenic epilepsies
As defined in the previous chapter, symptomatic epilepsy is the result of a lesion or other 
underlying identifiable pathology, and cryptogenic epilepsy is when the cause is unknown but 
is presumed to be symptomatic. Some of these underlying aetiologies can impact on cognition 
independently of epilepsy-related factors, such as seizures or antiepileptic drug treatment 
(Eiger et al., 2004)3. Table 3.3 highlights some of the neuropsychological problems associated 
with both developmental and acquired lesions such as cortical dysplasia, cerebral tumour and 
ischemic infarction. There are also independent effects on cognition of CNS infection,
3 As discussed in the next chapter, there is a growing body of evidence suggesting that people with newly 
diagnosed epilepsy are already cognitively compromised at the time of diagnosis, implicating a strong role for the 
underlying aetiology. However, other factors (e.g. epileptogenesis and psychological factors) may be contributing 
to the observed cognitive dysfunction, further illustrating the complexity of untangling the causes of cognitive 
impairment in people with epilepsy
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traumatic brain injury and degenerative CNS disease (Jokeit & Schacher, 2004). These 
different pathologies can give rise to different cognitive consequences of varying severity 
(Kwan & Brodie, 2001).
In symptomatic epilepsy the pattern of cognitive deficits are often consistent with the 
localisation of the lesion. For example, lesions in the language-dominant hemisphere may 
result in verbal deficits or lesions in the frontal lobes may result in executive dysfunction. One 
of the most studied findings is the effects of temporal lobe epilepsy, particularly mesial 
temporal lobe epilepsy (MILE), on memory functioning. The medial temporal lobes have been 
heavily implicated in memory processes and the hippocampus seems necessary for 
establishing long-term declarative memory (e.g. Scoville & Milner, 1957, Milner et a/., 1968). 
Therefore, it is unsurprising that patients with MTLE usually present with memory deficits 
(Glowinski, 1973, Hermann ef a/., 1997, Baxendale eta!., 1998, Oddo eta/., 2003). In addition 
to the effects of MTLE, there is also lateralisation of memory functioning producing material- 
specific memory deficits. Left temporal lobe epilepsy (TLE) is more commonly associated with 
verbal memory deficits, whereas right TLE is more typically associated with non-verbal 
memory deficits, although this association is less consistently reported (Eiger et al., 2004).
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However, some have suggested that people with temporal lobe epilepsy, not only have 
memory impairments, but have a more generalised pattern of cognitive impairment, involving 
functions associated with other regions, for example, executive dysfunction (Hermann et a/., 
1988, Corcoran & Upton, 1993, Hermann ef a/., 1997, Oyegbile et a/., 2004). This suggests 
that the spread of epileptic activity along neural connections between cortical regions (e.g. 
temporal lobe and prefrontal cortex) may be causing effects in areas distant from the region 
initially affected (Hermann et al., 1997). Alternatively, they may be the result of more diffuse 
generalised abnormalities throughout the brain (Hermann et al., 2009). In support of this, 
several quantitative MRI studies have shown atrophy of both temporal and extratemporal 
regions in those with chronic temporal lobe epilepsy (e.g. Hermann et al., 2007a, Keller & 
Roberts, 2008, Dabbs etal., 2009, Keller etal., 2009). However, others have suggested that a 
deficient hippocampus may be causing impairments, particularly on traditional frontal lobe 
tasks, such as the Wisconsin Card Sorting Test (Corcoran & Upton, 1993, Upton & Corcoran, 
1995, Giovagnoli, 2001). Additionally, other factors such as medication, seizures and mood 
may be contributing to the pattern of generalised impairment.
Idiopathic epilepsies
Those with idiopathic epilepsy are more likely to have normal intelligence than those who 
have symptomatic epilepsy (Klove & Matthews, 1966, Meador, 2002). However, despite 
normal intellectual functioning, there is still evidence of mild cognitive impairment in other 
domains (Klove & Matthews, 1966). For example, several studies have shown a 
neuropsychological profile of executive function deficits, along with impaired verbal and visual 
memory, in those with juvenile myoclonic epilepsy (e.g. Sonmez et al., 2004, Hommet et al., 
2006, Pascalicchio et al., 2007, Piazzini et al., 2008, Iqbal et al., 2009). Eiger et al., (2004) 
noted that the idiopathic epilepsies make good models for studying the effects of epilepsy on 
cognition because they do not have the confounding effects of additional cerebral disease, 
and seizures are usually well-controlled, which removes the negative effects of recurrent 
seizures. However, because many people with idiopathic epilepsy do not experience cognitive 
deficits, there are relatively few studies on their neuropsychological outcome.
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Epileptic encephalopathies
Some specific epilepsy syndromes have been associated with severe cognitive impairment 
(Hirsch et al., 2003). As shown in Figure 3.3, some of the childhood epilepsy syndromes are 
associated with severe cognitive dysfunction, such as West syndrome, Lennox-Gastaut 
syndrome, Landau-Kleffner syndrome and epilepsy with continuous spike-waves during sleep. 
These syndromes are known as epileptic encephalopathies, which are conditions in which the 
cognitive dysfunction is mainly due to epileptic activity [either very frequent or severe seizures 
and/or severely abnormal interictal EEGs (Holmes & Lenck-Santini, 2006)]. In these 
syndromes, once seizures are stopped, with either medications or surgery, children can 
regain normal cognitive function (Holmes & Lenck-Santini, 2006).
Figure 3.3: Epilepsy syndromes and cognitive deficits (taken from Hirsch et al., 2003)
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Age of onset
A separate but related factor is age of onset of epilepsy. Age of onset may modify the effects 
of epilepsy on cognitive functioning and has been shown to be a significant predictor of 
cognitive outcome in people with epilepsy (e.g. Schoenfeld etaL, 1999, Aikia et ai, 2001, van 
Mil et ai, 2008). Several studies have suggested that younger age of onset is associated with 
more cognitive problems (e.g. Meador, 2002, van Mil et a/., 2008). An early study by Dikmen 
et at., (1975) compared those who had a seizure onset under the age of five with those who 
had a later age of onset between 10-25 years. Those who had an early age of onset 
performed more poorly on the neuropsychological test battery than those in the later age of 
onset group and this was significantly lower for measures of intellectual functioning, even after 
controlling for seizure duration and seizure frequency. Similarly, O'Leary et at., (1983) found 
that those whose seizures began before the age of five years performed significantly worse 
than those whose seizures began after the age of five, also after controlling for duration of 
epilepsy.
An earlier age of onset may be associated with cognitive dysfunction due to the impact of 
epilepsy on a developing brain. Early disruption to normal developmental processes (e.g. 
synaptogenesis and myelination) can have severe consequences for ongoing cognitive 
development (Anderson et at., 2001, Brown, 2006). Also, an early age of onset may reflect 
greater seizure-induced damage, due to the increased risk of a higher number of lifetime 
seizures and longer treatment with AEDs. As discussed below, these all have an additional 
impact on cognition. However, a greater impact with earlier age of onset does not fit with 
previous research that has suggested a greater potential for recovery of function in children 
due to the plasticity of the developing brain, which can lead to compensation or cerebral and 
functional reorganisation (e.g. Muller etai, 1998).
Effects of seizures
Immediate impact of seizures
During a seizure, cognitive impairments (e.g. confusion, aphasia) may occur as part of the 
clinical manifestation. In addition, seizures may directly affect alertness, short-term learning
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and problem solving. Nocturnal seizures may affect language functions, memory and 
alertness possibly through the effects of disturbed sleep (Aldenkamp, 1997). Postictally, 
cognitive functioning, particularly attention, may still be affected, although this may not be 
prolonged (Aldenkamp & Bodde, 2005). Goldberg-Stern et al., (2004) assessed postictal 
language effects in those with frontal-onset complex partial seizures. Seizures confined to the 
non-dominant frontal lobe had the shortest postictal language delay (mean 17.3 seconds) 
whilst those originating in the dominant frontal lobe but spread to the ipsilateral temporal lobe 
had the longest delay (median 546.8 seconds). Dodrill (1986) suggested that performance on 
neuropsychological tests may be impaired for up to 30 days after a seizure. Therefore, 
postictal effects should be borne in mind, especially when assessing a patient, particularly for 
epilepsy surgery. However, subsequently, Dodrill & Ojemann (2007) carefully monitored 
patients to make sure that they were neither immediately ictal nor postictal and found no 
cognitive impact of seizures that had occurred on, or the day before, neuropsychological 
testing. The authors suggest that with careful evaluation, recent seizures should not have 
effects on neuropsychological test performance.
Effects of epileptiform EEG discharges
Whilst there is debate about whether recent seizures affect cognitive testing, interictal 
epileptiform EEG discharges, which are not accompanied by obvious clinical manifestations 
(subclinical), may cause transitory cognitive impairment (TCI). This impairment is different 
from that caused by the ictal/postictal effects of seizures, discussed above. TCI has been 
defined as ‘an episode of cognitive impairment occurring exclusively during an episode with 
epileptiform discharges and without any other clinical signs’ (Aldenkamp & Arends, 2004). 
This means that the cognitive impairment cannot be the result of subtle or brief minor seizures 
(Aldenkamp & Arends, 2004). As a result, ‘genuine’ TCI can be difficult to diagnose and is 
considered to be a controversial concept (Aldenkamp & Arends, 2004). This is because some 
have argued that if a discharge is causing an alteration in cognition, then this fits into the 
definition of an epileptic seizure (Aarts etai, 1984, Binnie etal., 1987, Binnie, 2001).
TCI can be detected using sensitive neuropsychological tasks in combination with EEG and 
video monitoring (Binnie et al., 1987). The most sensitive tasks are those that are more
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difficult and measure higher cortical functions such as choice reaction time, signal detection, 
short-term memory and information processing. Simple motor tasks or those that do not 
require complex information processing seem to be little affected by epileptiform EEG 
discharges (Aldenkamp & Arends, 2004). The most commonly used tasks are often presented 
as computer games (Binnie, 2001), for example, two short-term memory computer game 
tasks developed by Aarts et a/., (1984). Using these tasks, Aarts et a/., (1984) found: i) TCI in 
50% of patients with interictal epileptiform discharges; ii) cognition was most affected when 
discharges occurred during stimulus presentation, and iii) evidence for laterality effects. Left­
sided discharges caused impairments on the verbal version (verbal working memory task) and 
right-sided discharges caused impairments on the spatial version (non-verbal working 
memory task). This finding was replicated in a larger series of patients using the same 
assessment materials (Binnie etal., 1987).
TCI may affect educational and occupational functioning (Aarts et ai, 1984). It has been 
shown to impact on daily living skills (e.g. driving, reading), avoiding everyday hazards (e.g. 
crossing the road), and social interaction (e.g. missing parts of conversations, failure to 
respond at the appropriate moment) (Kasteieijn-Nolst Trenite et a/., 1987, 1988, Marston et 
ai, 1993). Suppressing these subclinical epileptiform discharges, through AED medication, 
may improve psychosocial function, as illustrated in two case studies by Aarts et a/., (1984) 
and a randomised double-blind, cross-over trial undertaken in children with epilepsy (Marston 
etal., 1993).
Transient epileptic amnesia
Transient epileptic amnesia (TEA) may also have an immediate impact on cognitive 
functioning, specifically, memory functioning. TEA is a recently described syndrome, and is a 
form of temporal lobe epilepsy, where ‘the principle manifestation of seizures is episodes of 
transient amnesia during which other functions remain intact’ (Butler et a/., 2007, Butler & 
Zeman, 2008). Butler & Zeman (2008) have recently published a review of all case reports 
and case series of TEA associated with epilepsy. They found 94 cases in the literature. Table 
3.4 summarises the demographic and clinical characteristics of the cases.
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Transient epileptic amnesia____________________________________________________
• Syndrome of middle to old age
• More common in males than females (sex ratio two males to one female)
• Median duration of amnesic attacks of 30-60 minutes, which is longer than typical temporal lobe 
seizures but shorter than transient global amnesia (a similar syndrome which results in transient 
impairment of declarative memory due to neuronal dysfunction in the temporal lobes)
• Mean frequency of attacks of 14.8 per year but wide variability between individuals
• Association between an amnesic attack and arousal from sleep in 70.4% of cases
• Characterised by anterograde and/or retrograde amnesia
• May sometimes be accompanied by other features e.g. olfactory/gustatory hallucinations, deja 
vu and automatisms (all of which are commonly associated with temporal lobe epilepsy)
• Interictal memory dysfunction reported in 80.6% of patients but the majority performed normally 
on standard neuropsychological tests. Accelerated long-term forgetting and remote 
autobiographical memory loss may explain this discrepancy (Butler et a/., 2007)
Table 3.4: Clinical characteristics of the syndrome of transient epileptic amnesia
Although the mechanisms underlying the syndrome are still unclear, TEA may be due to non- 
convulsive status epilepticus or may be a result of postictal amnesia possibly following 
subclinical/interictal epileptiform discharges (Butler & Zeman, 2008).
Effects of seizure type
Some studies have suggested that generalised tonic-clonic seizures (GTCS) are associated 
with a greater risk of cognitive impairment than partial seizures (Aldenkamp & Bodde, 2005). 
However, other studies have found inconsistent findings. O’Leary et al., (1983) demonstrated 
that the performance of 106 children with partial seizures was similar to that of children with 
generalised seizures. There was only one significant difference between the two groups 
across a neuropsychological test battery; children with partial seizures performed better than 
those with generalised seizures on the memory subscale of the Tactual Performance Test (a 
measure of incidental memory for shapes). Similarly, there were no differences between those 
with partial or generalised seizures in a study of 52 newly diagnosed adult patients with 
epilepsy (Pulliainen etal., 2000a).
Equally, others have found no differences between those with simple, complex and 
secondarily generalised seizures, for example, the study by O’Leary et al., (1983); although, 
they did find a difference on one measure, with those with secondarily GTCS performing more 
poorly on the location subscale of the Tactual Performance Test (a measure of incidental
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memory for spatial location). However, Prevey et ai, (1998) found that newly diagnosed 
patients with complex partial seizures tended to perform better than those with secondarily 
generalised seizures on most cognitive measures, particularly, those that required 
concentration and mental flexibility. The presence of secondarily generalised seizures has 
also been identified as a risk factor for moderate impairment of verbal memory in patients with 
newly diagnosed left temporal lobe epilepsy (Aikia et a/., 2001). Prevey et ai, (1998) 
suggested that this may be the result of more extensive neural abnormality and structural 
damage in those with secondarily generalised seizures or may result from the different 
pathophysiology of the two types of seizures. As generalised seizures involve loss of 
consciousness due to disruption of the central arousal systems, this may lead to hypoxic- 
metabolic damage or cell death from excitotoxic effects. Also, disruption to these central 
arousal systems impacts on attention and concentration, which may then contribute to poorer 
performance on other cognitive tasks (Mirsky et ai, 1960, Prevey et ai, 1998).
Effects of seizure frequency
More frequent seizures have been associated with greater risk of cognitive impairment 
(Meador, 2002). An early study by Blakemore et ai, (1966) investigated the relationship 
between frequency of seizures and severity of neuropathology and intellectual functioning. 
They grouped patients into four groups on the basis of their frequency of seizures (more/less 
than three per week) and severity of neuropathology (minimum/maximum based on a 
pathological grading scale). There were no differences between the four groups, but while not 
statistically significant, those with higher frequency of seizures (more than three per week) 
had poorer intellectual functioning. Similarly, Dikmen & Matthews (1977) divided 72 patients 
with ‘major motor’ (generalised tonic-clonic) seizures into low, moderate or high seizure 
frequency groups. There were significant differences between the three groups on seven of 
the cognitive measures. Those with high seizure frequency performed more poorly than those 
with low seizure frequency. The moderate seizure frequency group were in the middle, as 
expected, for 13 of the 14 measures. Some of the differences could be considered clinically 
significant, for example, the mean raw IQ scores for the high seizure frequency group were 
more than one standard deviation (SD) lower than the low seizure frequency group [Full Scale 
IQ (FSIQ) 81.04 vs. 94.96]. Impairments were more pronounced in those who also had a long
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seizure history and early age of onset. Those with more frequent seizures often have higher 
AED dosages; are on polytherapy; are at increased risk of psychosocial issues and have a 
more severe underlying pathology, which may also be impacting on cognition, in addition to 
the direct effects of seizures.
Accumulating impact of recurrent seizures
The association between higher seizure frequency and cognitive impairment may be due to a 
more severe underlying brain disorder that is leading to recurrent seizures or recurrent 
seizures may be damaging the brain. There is a long-standing, continuing debate about 
whether seizures cause brain damage (e.g. review by Sutula & Pitkanen, 2002). A series of 
animal studies have suggested that repeated seizures cause molecular and genomic 
alterations, such as protein expression, synaptic reorganisation, necrosis and apoptosis, 
which cause long-term structural and functional changes (e.g. Cole et ai, 2002). In humans, 
the results are less conclusive. A series of imaging studies have found progressive loss of 
volumes with longer duration of epilepsy (Briellmann et al., 2002, Fuerst et ai, 2003, Liu et 
a/., 2003). However, whilst this may reflect secondary cerebral damage from seizures, it may 
also be the result of the underlying epileptic process (Duncan & Thompson, 2003). Consistent 
with this, an increased risk of neocortical damage identified in the longitudinal study by Liu et 
ai, (2003) was not related to a history of documented convulsive or partial seizures but the 
authors speculated was possibly related to an underlying epileptic process or longer exposure 
to AEDs or an increased genetic susceptibility to brain insults.
Other evidence that supports the idea of an accumulating impact of recurrent seizures comes 
from studies that have found a relationship between lifetime number of seizures and cognitive 
dysfunction. Increasing number of seizures were related to poorer intellectual functioning and 
poorer performance across a neuropsychological test battery in a study by Dodrill (1986). 
Those that had a history of more than 100 GTCS had the most declines in functioning and 
greater maladjustment and emotional problems. Similarly, Vlooswijk et ai, (2008) investigated 
the effects of secondarily generalised seizures on cognitive functioning in 16 patients with 
localisation-related epilepsy using both neuropsychological assessment and fMRI (functional 
Magnetic Resonance Imaging). Those with a higher number of secondarily GTCS had lower
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IQ scores, and a trend towards more global cognitive deterioration, than those with a lower 
number of secondarily GTCS. In addition, a higher number of secondarily GTCS was 
associated with an increase in prefrontal activation and a trend towards decreased 
temporofrontal activation. The authors suggest that increased exposure to seizures led to a 
functional reorganisation of working memory. However, it is unclear whether this reflects a 
compensation strategy or the underlying pathological process of cognitive dysfunction.
Additionally, duration of epilepsy is a marker for lifetime number of seizures and several 
studies have found a relationship between duration of epilepsy and cognitive decline4. 
Cognitive decline has been significantly associated with frequency of seizures (Upton & 
Thompson, 1997, Helmstaedter etal., 2003, Thompson & Duncan, 2005, Piazzini etaL, 2006) 
and improvements in seizure frequency have been associated with cognitive improvements 
(Rodin, 1968, Seidenberg et al., 1981). Seizures may not just impact on the site of the 
epileptogenic focus but may have more widespread effects. Blum (2001) carried out a cross- 
sectional study in 30 patients with right TIE and medial temporal sclerosis who were 
undergoing presurgical evaluation. Using the intracarotid amobarbital (Wada) test, they 
assessed verbal memory functioning in the contralateral temporal lobe. Verbal memory 
functioning was significantly negatively associated with longer duration of epilepsy and 
increased lifetime number of seizures, suggesting that seizures in the right temporal lobe led 
to progressive dysfunction of memory in the contralateral side.
However, there are many methodological difficulties with studies trying to isolate the specific 
cognitive effects of seizures. As noted in a review by Vingerhoets (2006), it is difficult to 
untangle the long term effects of epilepsy from the underlying lesion. Many studies fail to 
document the type and number of seizures, and many cannot separate out the highly inter­
related variables of duration of epilepsy, interictal brain activity, number of seizures, exposure 
to AEDs, age of onset and number of seizure-related head injuries. This led to a conclusion 
that ‘there is a mild but measurabie decline of intellectual performance...In adults, memory
4 The issue of progressive decline with increasing duration of epilepsy will be discussed in the next chapter, 
although this will not discuss the specific effects of seizures on cognitive decline but will review the evidence 
from the literature investigating cognitive change over time.
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appears to be the most vulnerable cognitive function. Due to many confounding effects, the 
effects of seizures per se is difficult to estimate, but appears limited’.
Status epilepticus
Status epilepticus (convulsive and non-convulsive) can also contribute to cognitive 
deterioration (Dodrill & Wilensky, 1990, Helmstaedter, 2007), Dodrill & Wilensky (1990) 
reviewed the early literature on cognitive outcome after SE. They highlighted several 
methodological problems with previous work, such as lack of formal neuropsychological 
assessment and that the majority of studies were retrospective. However, they concluded that 
‘there are undoubtedly some adverse effects, at least under certain circumstances, but the 
circumstances under which such effects appear and the degree and nature of further effects 
require further study'. They also reported results of their prospective longitudinal study. They 
followed-up 143 adults with epilepsy over a five year period. Of those, nine patients had at 
least one definitive episode of status during the interval. Four had experienced generalised 
tonic-clonic status and five had experienced complex partial SE. They were then matched on 
sex, age and education with nine patients who did not experience status. However, 
interestingly, across the neuropsychological test battery, the status group demonstrated mild 
to moderate impairment at baseline, with 72% of test variables falling outside normal limits 
compared with 46% for the non-status group. Additionally, the status group had a Full Scale 
IQ score that was a mean 14 points lower than the non-status group (Mean FSIQ 99.78 vs. 
85.56). The authors suggested that this implies that those who are more compromised in 
functioning are more likely to experience SE. After five years, the non-status group improved 
across the battery due to practice effects [e.g. Mean Performance IQ (PIQ) 99.89 at baseline 
vs. 107.80 after five years; % of tests outside normal limits significantly decreased from 46% 
to 31%]. However, the status group either did not improve or declined in functioning [e.g. 
Mean Verbal IQ (VIQ) 90.44 at baseline vs. 85.89 after five years]. Not all of these differences 
reached statistical significance, probably due to the small sample size. The authors concluded 
that SE has a slight adverse effect on cognitive abilities, which may represent a lack of 
practice effect rather than abject decline, but this may be greater for some individuals.
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A more recent review of cognitive outcomes after SE by Helmstaedter (2007) suggests that 
outcomes vary with age, the type and aetiology of epilepsy and the severity of status. The 
review also found evidence to support the view that pre-existing brain damage and cognitive 
impairments may lead to an increased risk of experiencing status rather than status causing 
the impairments.
Summary of the effects of seizures
Seizures are brief episodes of abnormal brain activity. Yet these brief episodes can produce 
cognitive effects that may be more debilitating than the seizure themselves. These effects can 
persist beyond the seizure and there is growing evidence that recurrent seizures can cause 
significant damage to the brain, potentially leading to a decline in cognitive functioning. 
Therefore, it is important that people with epilepsy achieve optimum seizure control and if 
seizures are refractory to medical treatment then early referral for epilepsy surgery could 
potentially stop further damage.
3.3.2 Treatment-related factors
Antiepileptic drug treatment
Patient perceived effects on cognition
Adverse effects of antiepileptic drugs are frequently reported, occurring in approximately 60%- 
70% of patients (Perucca & Meador, 2005, Carpay et ah, 2005, Uijl et a/., 2006). CNS side 
effects are particularly common and include symptoms such as fatigue, headache, blurred 
vision, dizziness, as well as cognitive impairments. A community-based population survey in 
The Netherlands, found that 62% of respondents reported experiencing cognitive side effects, 
of which memory problems were the most frequent (21.4%) (Carpay et a!., 2005). Sixty-one 
per cent of respondents in the IBE Cognitive Function survey (2004) had asked a healthcare 
professional whether their cognitive side effects could be reduced or improved. Additionally, a 
US survey found that 30-40% of respondents felt that their medication had a large negative 
impact on their cognitive level and 85% were concerned about developing thinking and 
memory problems as a result of their treatment (Fisher et a/., 2000).
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As well as contributing to treatment failure, these perceived cognitive side effects can also 
have a considerable impact on day to day functioning and quality of life. Sixty-three per cent 
of respondents in the IBE Cognitive Function survey (2004) thought that AED cognitive effects 
had stopped them from achieving goals or activities, for example staying in education or 
following their chosen career. Therefore, avoiding adverse cognitive effects is an important 
consideration for many patients. When asked to rate areas of importance regarding their 
epilepsy medication, experiencing fewer side effects was ranked the second most important 
issue after seizure control (Fisher et a/., 2000).
Many patients attribute their cognitive impairments to the side effects of AEDs and neglect 
other potential causes, such as their underlying aetiology, recurrent seizures, or mood 
disturbance (Carpay et al., 2005; Baker et ai, 2008). However, whilst 56% of patients 
associated their cognitive problems with their epilepsy medication in the IBE survey (2004), 
only 14% attributed their problems to their medication alone. The remaining 42% recognised 
that they were due to a combination of their condition and their medication.
Effects of AEDs on objective cognitive measures
All AEDs have the potential to affect cognitive function impacting on attention, vigilance and 
mental and psychomotor speed (e.g. Loring & Meador, 2001, Aldenkamp etal., 2003). This is 
because they reduce seizures by decreasing neuronal irritability and suppressing epileptiform 
discharges, but this reduction in neuronal excitability may impair cognition (Motamedi & 
Meador, 2003, 2004, Loring et al., 2007). Their cognitive side effects may be more 
pronounced in higher dosages and in polytherapy (e.g. Kwan & Brodie, 2001, Loring & 
Meador, 2001, Aldenkamp etaL, 2003, Mula & Trimble, 2009). In addition, some patients may 
be more susceptible to developing adverse cognitive events and identifying these patients is a 
currently an important and challenging area of research (Loring et al., 2007).
Different AEDs may have different adverse effects; therefore, knowledge of their individual 
cognitive profiles is important, for both the patient and clinician, when selecting an AED. Yet, 
despite a wealth of studies and comprehensive reviews, our knowledge of the specific 
cognitive effects of individual drugs is still limited. This is mainly due to the methodological
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shortfalls and differences between studies, which reduce confidence in the ability to make firm 
conclusions.
Methodological shortfalls of AED studies
Several authors have reviewed the limitations of studies in this area (e.g. Cochrane et ai, 
1998, Loring et al., 2007) and these are briefly summarised in Table 3.5. Shortfalls include 
small sample sizes; the use of tests not thought to be sensitive to detect AED effects; the use 
of brief exposure periods in healthy volunteer studies; the problems isolating specific AED 
effects in polytherapy studies; lack of appropriate comparison control groups; and failure to 
detail sufficiently methodology, design and analysis (Vermeulen & Aldenkamp, 1995). 
Differences between studies make comparing trials difficult and make it impossible to 
undertake systematic reviews and meta-analysis. These include differences in the populations 
studied; in the different time periods sampled; in the study designs; in the dosages and 
titration schedules, and in neuropsychological tests. Some of these shortfalls have been 
highlighted for over a decade, particularly, the lack of uniformity in selection of a 
neuropsychological test battery (Cochrane etai, 1998, Baker & Marson, 2001).
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Table 3,5: Methodological shortfalls and differences between randomised clinical trials investigating 
the cognitive side effects of AEDs
Methodological shortfall/difference How it affects interpretability 
• Remove confounding effects (e.g. seizures, underlying 
aetiology) and provide information on AEDs that are
Healthy volunteer studies prescribed for other conditions (e.g. gabapentin and 
pain; lamotrigine and anxiety)
• Tend to have small sample sizes, brief drug exposure 
periods and may not be generalised to PWE
Add-on/polytherapy studies
• Cognitive side effects may occur due to interactions 
with other drugs or may be offset by better seizure 
control, making determining their specific effects more 
complex
Different patients studied (e.g. 
refractory or well-controlled)
• Results from one group may not be generalised or 
comparable with another group
Different designs (e.g. parallel- 
group, cross-over, single or 
double-blind)
• Cross-over studies may not have sufficient treatment 
periods to determine longer term effects
• Absence of blinding may introduce bias
Different comparators (e.g. 
placebo, standard or new AEDs)
• Few head-to-head comparisons of newer AEDs means 
there is a lack of information when selecting a new AED
Lack of control groups
• Studies should include placebo controls (in add-on 
studies), untreated volunteers or those who have had 
seizures but have not been treated (in monotherapy 
studies) to assess absolute drug effects.
• Lack of practice effect may be the first indicator of an
AED effect
Small sample sizes
• Do not have adequate power to detect differences 
between drugs and many studies do not include power 
calculations so cannot determine whether study has 
sufficient power
Varying time intervals (e.g. days, 
weeks, months)
• AEDs may have differing effects acutely, during titration 
or during maintenance phase
• Need more information on longer term effects
Varying dosages and titration 
schedules
• May have differing effects on cognitive function
Different or inadequate 
neuropsychological tests
• Tests may not be sensitive to the effects of AEDs or 
have not been standardised for use in PWE
• Many studies have too many outcome measures 
(increasing chances of making a Type 1 error)
Failure to control for the effects of 
confounding variables (e.g. 
seizures, mood)
• Many studies do not control for effects of seizures or 
mood, making determining the specific effects of AEDs 
difficult
• Those who do not achieve seizure reduction by an AED 
may drop out of the study and are not followed-up for 
assessment, introducing selection bias
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Notwithstanding these shortfalls, there have been many comprehensive reviews of this area 
(e.g. Aldenkamp, 2001, Kwan & Brodie, 2001, Loring & Meador, 2001, Brunbech & Sabers, 
2002, Motamedi & Meador, 2004, Loring etal., 2007, Mula & Trimble, 2009), Therefore, the 
following section will only briefly review the cognitive side effects of AEDs. The review will be 
divided into the first, second and third generation drugs. Only evidence from randomised 
clinical trials (RCTs) will be included, as along with systematic reviews, these are considered 
to represent the ‘gold standard’ for evaluating the effects of treatments (Barton, 2000).
First generation AEDs
As the majority of studies involve comparisons between the older drugs (see Table 3.6), this 
section will be divided into the populations studied (e.g. healthy volunteers, patients with 
epilepsy) rather than a review of each individual drug.
Evidence from studies in healthy volunteers
Four studies have compared the cognitive side effects of the first generation AEDs in healthy 
volunteers (Thompson & Trimble, 1981, Meador et a/., 1991, 1993, 1995). Thompson & 
Trimble (1981) found that valproate was no different from placebo in a small (n=10), 
randomised, double-blind, cross-over study. Meador et al, (1991) compared carbamazepine 
and phenytoin in 21 healthy adults in another randomised, double-blind, cross-over study. 
There were two significant differences between the drugs: carbamazepine was associated 
with improvement on a finger tapping task (measure of psychomotor speed) and phenytoin 
was associated with improvement on the Stroop task (measure of mental flexibility and 
inhibition of response). However, the authors noted that these differences were not clinically 
significant. Meador et al, (1993) also found no differences between carbamazepine and 
phenytoin in a randomised, double-blind, cross-over study of 15 healthy adults. However, 
compared to a non-drug condition, both drugs were associated with impaired memory and 
mild EEG slowing. Similarly, phenobarbital, carbamazepine and phenytoin were worse than a 
non-drug condition on several cognitive measures, including memory, sustained attention and 
psychomotor speed in a later study by Meador et al, (1995). However, phenobarbital was 
associated with poorer performance on measures of reaction time, interference, anger and 
concentration.
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Evidence from studies in people with epiiepsy
Eleven studies have investigated the cognitive-side effects of older AEDs in people with 
epilepsy (Dodrill & Troupin, 1977, Smith et ai, 1987, Mitchell & Chavez, 1987, Vining et ai, 
1987, Meador etai, 1990, Forsythe etal., 1991, Craig & Tallis, 1994, Pulliainen & Jokeiainen, 
1994,1995, Chen et ai., 1996, Prevey et al., 1996). Eight of these have included people with 
newly diagnosed epilepsy (five in adults, three in children). Of the adult studies, Smith et al., 
(1987), as part of a five-year randomised, double-blind, Veterans Administration study, 
compared carbamazepine, phenobarbital, phenytoin and primidone in 622 newly diagnosed, 
untreated patients with 75 healthy controls. They found no significant differences between 
drugs on each of the cognitive measures. However, when an overall composite score was 
calculated, carbamazepine had fewer effects than the other three drugs. Furthermore, they 
found that people with epilepsy were characterised by a lack of practice effect, which the 
authors suggested may be the first indicator of some AED effect. There was also a reduction 
in a normal practice effect in a randomised, partially-blinded, parallel-group study of 
carbamazepine and phenytoin involving 59 patients with newly diagnosed epilepsy compared 
with 21 healthy volunteers. After six months of treatment, the untreated healthy volunteers 
had a practice effect for 42% of variables; those randomised to carbamazepine 17% of 
variables, and those randomised to phenytoin 4% of variables (Pulliainen & Jokeiainen, 1994). 
However, after two years, a follow-up study of this cohort revealed improvements across 
several measures and there were no differences between the drugs (Pulliainen & Jokeiainen, 
1995). Similarly, Prevey et al., (1996) compared valproate and carbamazepine in a 
randomised, double-blind study of 65 newly diagnosed patients with symptomatic partial 
epilepsy and 72 healthy controls. This study also demonstrated that the AED group failed to 
show learning and practice effects and there were no differences between the two drugs. 
Likewise, after 12 months, there were few differences between valproate and phenytoin in a 
randomised, single-blind study of 38 newly diagnosed elderly patients (Craig & Tallis, 1994). 
Equally, two randomised, double-blind, cross-over studies in adults with epilepsy found few 
significant differences between carbamazepine, phenobarbital and phenytoin (Meador et ai, 
1990) and carbamazepine and phenytoin (Dodrill & Troupin, 1977).
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The studies from the paediatric literature also suggest that there are relatively few differences 
between these first generation AEDs. Two randomised, parallel-group studies in children with 
newiy diagnosed epilepsy failed to find differences between carbamazepine and 
phenobarbital (Mitchell & Chavez, 1987) and carbamazepine, phenobarbital and valproate 
(Chen et al., 1996). However, children with epilepsy treated with phenobarbital had a poorer 
Performance and Full Scale IQ compared with those treated with valproate in a double-blind, 
cross-over study by Vining et al., (1987). And Forsythe et al., (1991) found that after 6 and 12 
months, scores on measures of memory functioning were better on valproate than 
carbamazepine in a randomised, single-blind study of 64 children with newly diagnosed 
epilepsy. However, there were no differences in measures of vigilance or concentration.
Two studies have compared phenobarbital and placebo in children with febrile seizures 
(Camfield et al., 1979, Farwell et al., 1990). After two years of treatment with phenobarbital, 
those randomised to phenobarbital had a mean IQ that was 8.4 points lower than the placebo 
group. Six months after withdrawal, their mean IQ was only 5.2 points lower than the placebo 
group, suggesting that this impairment was reversible (Farwell et a/., 1990). However, there 
were no differences in IQ between phenobarbital and placebo after 12 months of treatment in 
a randomised, double-blind, placebo-controlled study involving 65 toddlers. Phenobarbital was 
associated with increased fussiness and sleep disturbance, although parents could not 
distinguish between the two drugs; and only 21% correctly guessed that their child was 
randomised to phenobarbital (Camfield eta/., 1979).
Summary of the effects of the 1st generation AEDs
The majority of these studies have suggested that all the older AEDs have some effects on 
cognitive functioning. This may be reflected as either worse performance relative to a non­
drug condition or a lack of normal practice effect. There are relatively few differences between 
the older AEDs, although phenobarbital has been associated with worse performance.
Second generation AEDs
The majority of studies of these newer AEDs have involved comparisons with placebo (see 
Table 3.7) or the established and standard AEDs (e.g. carbamazepine, valproate and
57
phenytoin) (see Table 3.8), Head-to-head comparisons between the newer drugs are 
relatively uncommon (see Table 3.9), which probably reflects the decision by the US Food 
and Drug Administration (FDA) in the early 1980s that new drugs had to demonstrate 
superiority in RCTs rather than equivalence. Many new studies compared the new drug with 
placebo rather than other therapies because of the difficulties in interpreting findings of 
noninferiority (Shorvon, 2009). This section will be divided into studies undertaken in each 
individual treatment.
Gabapentin
Five studies have investigated the cognitive side effects of gabapentin in healthy volunteers 
(Martin et at., 1999, 2001, Meador et ai, 1999, Salinsky et a/., 2002, 2005). Three of the 
studies compared gabapentin with carbamazepine. Meador et al., (1999) conducted a 
randomised, double-blind, cross-over study in 54 healthy participants. Across the 
neuropsychological test battery, gabapentin was associated with significantly better 
performance than carbamazepine on 26% of the variables. Both drugs produced effects on 
cognition, however, compared to a non-drug condition. But gabapentin had fewer effects, with 
worse performance on 27% of variables compared with 87% of variables on carbamazepine. 
Similar results were found in a randomised, double-blind, cross-over study in 35 healthy 
community-dwelling older adults (Martin et ai, 2001). Both drugs affected cognition, with 
gabapentin having fewer effects than carbamazepine compared with a non-drug condition 
(36% vs. 45%). There was only one significant difference between the two drugs on a 
measure of attention/vigilance. Salinsky et ai, (2002) also showed that those treated with 
gabapentin and carbamazepine performed differently to an untreated reference group on 
several cognitive measures in their randomised, double-blind, parallel-group study; but there 
were no differences between the two drugs.
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Martin et al., (1999) compared gabapentin with lamotrigine and topiramate in a randomised, 
single-biind, parallel-group study in 17 healthy young adults, of which only 11 completed the 
trial. They found significant differences between the drugs with topiramate having worse 
performance than gabapentin and lamotrigine on measures of verbal fluency and visual 
attention at an acute dosing phase. After four weeks of treatment, topiramate was associated 
with poorer performance on measures of verbal memory and psychomotor speed. Consistent 
with this, Salinsky et al., (2005) carried out a randomised, double-blind, parallel-group study 
comparing gabapentin with topiramate and placebo in 40 healthy volunteers with an untreated 
reference group. Gabapentin did not differ from placebo on six target measures but was 
significantly better than topiramate on four of the six measures (digit symbol, story recall, 
selective reminding, controlled oral word association).
Only two studies have investigated the cognitive side effects of gabapentin in people with 
epilepsy (Leach ef al., 1997, Dodrill et al., 1999). Leach et al., (1997) compared add-on 
gabapentin with placebo in patients with refractory epilepsy in a randomised, double-blind, 
dose-ranging, placebo-controlled, cross-over study. There was no effect of gabapentin on 
composite memory or psychomotor scores. There was also no change in subjective reports, 
although those on the highest dosage (2400mg) complained of increased tiredness. Similarly, 
no cognitive changes were associated with gabapentin monotherapy treatment in patients 
with refractory epilepsy in a randomised, double-blind, parallel-group, dose-controlled study 
compared with placebo. However, after 26 weeks of treatment, those randomised to receive 
lower dosages (600mg) reported improved mood and psychosocial adjustment (Dodrill et al., 
1999).
Lamotrigine
Three studies have investigated the cognitive side effects of lamotrigine in healthy volunteers 
(Martin et al., 1999, Meador et al., 2001, Aldenkamp et al., 2002a). Meador et al. (2001) 
compared lamotrigine with carbamazepine in a randomised, double-blind, cross-over study. 
Lamotrigine was associated with better performance than carbamazepine on 48% of 
variables. It was only worse than a non-drug condition on 2.5% of variables, compared with 
carbamazepine, which was worse on 62% of variables. This suggests that lamotrigine has
67
fewer adverse effects than carbamazepine. Aldenkamp et al., (2002a) has also found 
improvements in cognitive activation and alertness associated with lamotrigine treatment 
compared with valproate and placebo in a randomised, double-blind, parallel-group design. In 
addition, those on lamotrigine reported fewer cognitive complaints than those on valproate 
and also reported an improvement in mood. As discussed in the previous section, there were 
fewer adverse effects for lamotrigine compared with topiramate in the study by Martin et al., 
(1999). This has also been reported in other studies comparing lamotrigine and topiramate 
(e.g. Meador et al., 2005, Blum et al., 2006) but these will be discussed in a later section (see 
Topiramate).
Only two studies have considered the cognitive effects of lamotrigine in people with epilepsy 
(Smith et al., 1993, Pressler et al., 2006). Both studies compared add-on lamotrigine with 
placebo. Smith et al., (1993) conducted a randomised, double-blind, cross-over study in 81 
patients with refractory partial seizures. There were no differences between lamotrigine and 
placebo on any of the measures, suggesting that lamotrigine is not associated with 
impairment of attention, concentration, motor speed or repetitive mental activity. There were 
also no differences from placebo in a study with the same design involving 61 children with 
well-controlled or mild epilepsy by Pressler et at., (2006).
Levetiracetam
A randomised, double-blind cross-over study by Meador et al., (2007) has investigated the 
cognitive effects of levetiracetam compared with carbamazepine in 28 healthy adults. Across 
the neuropsychological test battery, levetiracetam was associated with significantly better 
performance than carbamazepine on 44% of variables. Compared to a non-drug condition, 
carbamazepine was significantly worse on 76% of variables but levetiracetam was only worse 
on 12% of variables. This suggests that levetiracetam has a more favourable cognitive profile 
than carbamazepine.
Two studies have compared add-on levetiracetam with placebo in people with epilepsy (Zhou 
et a/., 2008, Levisohn et al., 2009). Zhou et al., (2008) carried out a short-term, randomised, 
double-blind, placebo-controlled study in 28 people with refractory seizures, followed by a
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long-term open-label study, where all patients were treated with levetiracetam. In the short­
term study (16 weeks treatment period) those treated with levetiracetam demonstrated 
improvements on 11% of variables while those administered placebo had no improvements. 
In the long-term study (24 weeks treatment period) 53% of variables improved from baseline. 
Those who had changed to levetiracetam from placebo had improvements on 32% of 
variables. A randomised, double-blind, placebo-controlled study in children with refractory 
epilepsy did not find any improvements but did not find any differences between levetiracetam 
and placebo, again suggesting that levetiracetam is not associated with negative effects on 
cognition (Levisohn etal., 2009).
Oxcarbazepine
Two studies have investigated the cognitive side effects of oxcarbazepine in healthy 
volunteers (Curran & Java, 1993, Salinsky et ai, 2004). Curran & Java (1993) compared 
oxcarbazepine and placebo over a two week treatment period in a small (n=12) randomised, 
double-blind, cross-over study. There were no differences between oxcarbazepine and 
placebo on measures of memory. However, when treated with oxcarbazepine, participants 
improved their performance on a digit cancellation task (measure of psychomotor speed and 
sustained attention) and were able to copy more symbols on a symbol copying task (measure 
of psychomotor speed, sustained attention, response speed, visuomotor coordination and 
incidental memory). They also rated themselves as being more alert, quick-witted and clear­
headed and this was dose-related. Those on higher doses reported experiencing more 
symptoms of palpitations and trembling. Salinsky et a/., (2004) compared oxcarbazepine with 
phenytoin in 32 healthy volunteers and an untreated reference group in a randomised, double­
blind, parallel-group study. After 12 weeks, treatment with AEDs was associated with worse 
performance on 25% of variables, particularly, those measuring motor speed and reaction 
time. However, these were modest effects, representing a change of less than one standard 
deviation. There were no differences between oxcarbazepine and phenytoin on the cognitive 
measures, but those randomised to phenytoin reported more subjective problems in mood 
and symptoms of neurotoxicity.
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Three studies have considered the cognitive side effects of oxcarbazepine in people with 
newly diagnosed epilepsy (Aikia et al., 1992, Donati et al., 2006, 2007). Aikia et al., (1992) 
compared oxcarbazepine and phenytoin in 37 adults in a randomised, double-blind, parallel- 
group study. There were no differential effects between the two drugs. Similarly, Donati et al., 
(2006, 2007) found oxcarbazepine did not differ from carbamazepine or valproate in a 
randomised, open-label, parallel-group study involving 112 children and adolescents with 
partial epilepsy. However, the data presented in the two studies by Donati et al., (2006,2007), 
appears to be the same, so this should be taken to represent only one piece of evidence.
Pregabalin
Despite being first licensed for use in the UK in 2004, only one randomised clinical trial has 
investigated the cognitive effects of pregabalin. Hindmarch etai, (2005) compared pregabalin 
to placebo and alprazolam (used for the short-term treatment of moderate or severe anxiety 
and anxiety associated with depression) in 24 healthy volunteers. Pregabalin did not seem to 
affect cognitive functioning. The authors concluded that the drug would have a generally 
benign CNS side effects profile in clinical use. However, studies in people with epilepsy are 
needed to support this finding.
Tiagabine
Six studies have investigated the cognitive side effects of tiagabine in people with refractory 
epilepsy (Sveinbjornsdottir et al., 1994, Kalviainen et al., 1996, Dodrill et al., 1997, 1998, 
2000, Fritz et al., 2005). Three of these studies compared add-on tiagabine to placebo. 
Sveinbjornsdottir et al., (1994) conducted an initial open trial of add-on tiagabine in 22 adults 
with refractory epilepsy followed by a randomised, double-blind, placebo-controlled, cross­
over study in 12 patients who had responded to the drug. There were no differences on any of 
the cognitive measures compared with placebo in either study, although two relatives reported 
that they had noticed improvements while the patients were on tiagabine. Similarly, Kalviainen 
et al., (1996) reported no differences between add-on tiagabine and placebo in a randomised, 
double-blind, parallel-group study in 43 patients with chronic epilepsy. But there were 
significant improvements on a list learning task and in auditory reaction time after 6-24 months 
of an open-label extension study. The lack of difference between the drug and placebo is
70
supported by data from a large (n=162), randomised, double-blind, parallel-group, dose- 
response study undertaken by Dodrill et al., (1997). They found no clinically significant 
changes between add-on tiagabine and placebo over a 12 week treatment period.
Two studies have compared add-on tiagabine to other AEDs used as adjunctive therapy 
(Dodrill et al., 2000; Fritz et al., 2005). There were no differences between add-on tiagabine 
and phenytoin when added to carbamazepine in a randomised, double-blind study of 277 
patients with refractory partial seizures undertaken by Dodrill et al., (2000). However, there 
were differences between add-on tiagabine and carbamazepine when added to phenytoin. 
Add-on tiagabine was associated with improvements in verbal fluency and motor speed. In 
contrast, add-on tiagabine was associated with deteriorations in verbal memory in a 
randomised, open-label, parallel-group study of 41 patients with refractory epilepsy. However, 
these deteriorations were only noted in the titration phase and functions remained stable 
during the three month maintenance phase (Fritz et al., 2005).
A randomised, double-blind, parallel-group study in 123 adults with refractory partial seizures 
has considered the cognitive effects of differing dosages of tiagabine monotherapy. Patients 
were randomised to receive 6 mg or 36 mg/day. There were few changes in cognitive abilities, 
adjustment or mood (Dodrill et al., 1998). One further study has investigated tiagabine 
monotherapy in people with newly diagnosed epilepsy (Aikia et at., 2006a). Aikia et al., 
(2006a) carried out a pooled analysis of two studies comparing tiagabine with carbamazepine 
in 105 patients with newly diagnosed epilepsy and 19 patients who only had one seizure but 
were not treated with AEDs. The authors concluded that tiagabine had a similar cognitive 
profile to carbamazepine and to the untreated patients.
Topiramate
Three studies have investigated the cognitive side effects of topiramate in healthy volunteers 
(Martin et al., 1999, Meador et al., 2005, Salinsky et al., 2005). As discussed in a previous 
section (gabapentin), Martin et al., (1999) and Salinsky et al., (2005) have found poorer 
performance associated with topiramate compared with other newer AEDs, such as 
lamotrigine and gabapentin. In the study by Salinsky et a/,, (2005), the negative effects
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associated with topiramate treatment were large. Several tests had changes of more than two 
standard deviations (considered to be clinically significant) and more than half of the 
participants had a test-retest change of this magnitude for measures of verbal fluency, verbal 
memory and psychomotor speed. Similarly, another healthy volunteer study found worse 
cognitive performance with topiramate compared to lamotrigine. Meador et aL, (2005) 
conducted a randomised, double-blind, cross-over study in 75 healthy volunteers. After 12 
weeks, lamotrigine was significantly better than topiramate on 80% of variables, including 
measures of attention and vigilance, memory, language and mental and motor speed. 
Topiramate was not better than lamotrigine on any of the variables. Both drugs affected 
cognition compared with a non-drug condition; but the non-drug condition was only better than 
lamotrigine for 17% of variables compared with 88% of variables for topiramate. A related 
study by Werz et at., (2006) found that 70% of the healthy volunteers from this study preferred 
lamotrigine and only 16% preferred topiramate.
Five studies have investigated the cognitive side effects of topiramate in people with epilepsy 
(Aldenkamp et aL, 2000, Meador et a/., 2003, Fritz et aL, 2005, Blum et aL, 2006, Lee et aL, 
2006). Four studies have compared add-on topiramate to adjunctive treatment with other 
AEDs. Aldenkamp et aL, (2000) undertook a randomised, observer-blinded, parallel-group 
study comparing add-on topiramate with valproate in 59 patients with partial onset seizures 
already on carbamazepine treatment. After 20 weeks of treatment, a higher proportion of 
patients randomised to topiramate dropped out of the study, often due to cognitive complaints. 
However, there were few differences between the two drugs. The only significant difference 
was on a measure of memory functioning, with topiramate associated with worse scores. A 
higher proportion of those randomised to topiramate also dropped out of a randomised, 
double-blind, placebo-controlled, parallel-group study of 76 patients with refractory epilepsy by 
Meador et aL (2003). They compared add-on topiramate to valproate and placebo. 
Topiramate was associated with poorer performance on a measure of verbal fluency and on a 
symbol digit modalities test (measure of complex scanning and visual tracking). However, the 
authors noted that it was a small subset of patients that appeared to be more negatively 
affected.
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These studies suggest that language-related functions seem to be vulnerable to the effects of 
topiramate. Two further add-on studies have also demonstrated adverse effects on these 
functions, particularly, verbal fluency. Fritz et al., (2005) compared add-on topiramate to add­
on tiagabine in 41 patients with intractable epilepsy. Those on topiramate reported more 
concerns about their cognitive functioning and performed worse on measures of verbal 
fluency, language comprehension and working memory. A randomised, double-blind, parallel- 
group study in 193 adults with partial epilepsy by Blum et al., (2006) also found that 
performance on verbal fluency and the symbol digit modalities test exceeded the minimum 
clinically important difference in the topiramate group. In a related study from the same cohort, 
performance on a driving simulator task, which measures scanning, divided attention and the 
effective field of view, was compromised by add-on topiramate therapy (Mills etal., 2008).
One study has considered the effects of different doses (50, 75, 100mg) of topiramate 
monotherapy in a randomised, open study of 47 patients with newly diagnosed epilepsy. After 
12 months of treatment, 44% of patients complained of cognitive problems. Of these, 42% 
complained of memory deficits, 25% of speech problems, 11% of attention and concentration 
and 6% of psychomotor slowing. Performance on tasks of verbal fluency and working memory 
decreased after 12 months and higher dosages were associated with greater declines. Twelve 
patients withdrew from topiramate over the course of the study because of their cognitive 
deficits. After withdrawal, their scores on working memory and verbal fluency increased, 
suggesting that these are transient, reversible, medication-related deficits (Lee etal., 2006).
Vigabatrin
One study has investigated the cognitive side effects of vigabatrin in healthy volunteers 
(Thomas & Trimble, 1996). Thomas & Trimble (1996) conducted a randomised, double-blind, 
cross-over study comparing add-on vigabatrin and placebo in ten healthy volunteers. After a 
two week treatment period, there were improvements in a measure of information processing 
and no changes on any other cognitive measure.
Five studies have compared add-on vigabatrin with placebo in patients with refractory 
epilepsy (Dodrill etal., 1993,1995, Gillham etal., 1993, Grunewald etal., 1994, Provinciali et
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a/., 1996). There were no differences between adjunctive vigabatrin and placebo on any 
measure of cognition, mood or adjustment in a randomised, double-blind, parallel-group study 
of 168 patients with refractory partial epilepsy conducted by Dodrill et a/., (1993). Equally, 
there were no differences between add-on vigabatrin and placebo in a randomised, double­
blind, cross-over study in 24 patients with refractory epilepsy (Gillham et ai, 1993). However, 
in a follow-on study of 12 patients who had responded to the drug, there were improvements 
in three psychomotor tests, four memory tests and three self-rating scales, measuring general 
health, sedation and subjective side effects, after 14.75 months of treatment. Similarly, there 
were improvements in sustained attention, adaptive abilities and verbal learning after four 
months of adjunctive treatment with vigabatrin in a randomised, single-blind, parallel-group 
study of 40 patients with refractory complex partial seizures (Provinciali et a/., 1996). In 
contrast, Grunewald et al, (1994) found a significant reduction in motor speed and design 
learning associated with add-on vigabatrin in a randomised, double-blind, parallel-group study 
but no evidence of further decline after long-term treatment (up to 18 months). The authors 
suggested that this may have been due to a pre-existing impairment caused by their refractory 
partial seizures. Finally, Dodrill etal, (1995) found poorer performance on a digit cancellation 
task as vigabatrin dosages increased (1g, 3g, 6g) in a randomised, parallel-group, placebo- 
controlled, dose-response study in 174 patients with refractory partial epilepsy but did not find 
dose-related changes on any other measures.
One study undertaken by Kalviainen et al., (1995) has compared vigabatrin monotherapy with 
carbamazepine monotherapy in 100 patients with newly diagnosed epilepsy and 50 patients 
with a single seizure who were not treated with AEDs. After 12 months, those randomised to 
vigabatrin treatment and the untreated patients improved on a measure of attention and 
mental slowing. Those on vigabatrin compared with those on carbamazepine and those who 
were untreated improved on a measure of verbal fluency. This suggests that vigabatrin is not 
associated with adverse effects on cognition.
Zonisamide
Despite being first licensed for use in the UK in 2005, only one randomised clinical trial has 
investigated the cognitive side effects of zonisamide. Park et al., (2008) carried out a
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randomised, open-label study investigating different dosages (100, 200, 300, 400 mg/day) of 
zonisamide in 43 patients with newly diagnosed epilepsy. Nine patients withdrew before the 
end of the 12 month treatment period, three because of cognitive and mood problems. Forty- 
seven per cent of patients complained of cognitive deficits, particularly, memory impairments 
and attention and concentration problems, particularly on higher doses. On objective 
measures of cognitive functioning, there were declines on measures of verbal and visual 
memory, working memory, mental flexibility and verbal fluency, and these were dose-related.
Third generation AEDs
Table 3.10 summarises the only study that has so far been undertaken to investigate the 
cognitive side effects of the third generation AEDs.
Table 3.10: Summary of RCTs investigating the cognitive side effects of third generation AEDs
Study Date AEDs Design Sample Cognitive domains Results
Aldenkamp 2006 RUF Add-on 213 Psychomotor speed, No difference
& Alpherts vs. PWE information
PBO processing, memory
RUF=rufinamide, PBOplacebo, PWE= people with epilepsy
Lacosamide
Lacosamide was first licensed for use in the UK in 2008. To date, there have been no 
published randomised clinical trials of lacosamide that have included measures of cognitive 
function.
Rufinamide
Rufinamide is a relatively new drug that was first licensed for use in the UK in 2007. Only one 
randomised clinical trial has investigated its cognitive effects. Aldenkamp & Alpherts, (2006) 
conducted a large, double-blind, parallel-group study of four dosages of adjunctive rufinamide 
(200, 400, 800, 1600mg/day) compared with placebo in 189 patients with partial seizures. 
There were no significant deteriorations on any of the cognitive measures and no differences
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between the four rufinamide dose groups and placebo. This suggests that there were no 
cognitive effects associated with rufinamide even at higher dosages,
Summary of the effects of the second and third generation AEDs
The studies that have been conducted so far suggest that these newer AEDs have similar or 
more favourable cognitive profiles than the older more established AEDs. However, problems 
with verbal fluency, verbal memory, working memory, attention and language have been 
associated with topiramate and more recently zonisamide. Lamotrigine, gabapentin and 
levetiracetam seem to produce fewer adverse effects compared with the standard AEDs (e.g. 
carbamazepine). But all of these still affect cognition. Their more favourable cognitive profile is 
nicely illustrated in a series of randomised, double-blind, cross-over healthy volunteer studies 
conducted by Meador and colleagues (1991, 1995, 2001). As illustrated in Figure 3.4, all of 
the newer AEDs (gabapentin, lamotrigine and levetiracetam) performed better than 
carbamazepine across a neuropsychological test battery. Lamotrigine was significantly better 
on nearly half the cognitive measures (see Figure A). However, all the AEDs produced 
cognitive effects relative to a non-drug condition but the newer AEDs, produced fewer 
cognitive effects than carbamazepine. Lamotrigine was only significantly worse than the non­
drug condition on 2.5% of variables (see Figure B).
There is still a paucity of data on the neuropsychological effects of some of the more recently 
licensed AEDs, especially, lacosamide, pregabalin, rufinamide and zonisamide. Future 
studies need to be conducted on these drugs, taking into account the methodological 
shortfalls with previous work in this area.
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Summary of the effects of AEDs on cognition
People with epilepsy frequently report experiencing cognitive side effects as a result of their 
AED treatment As a consequence of their mechanisms of action, all AEDs produce adverse 
cognitive effects, particularly, memory impairments, attention problems and mental and motor 
slowing (e.g. Meador et aL, 1993, 1995). These effects can be more pronounced at above 
therapeutic dosages or in polytherapy. Many patients will need to balance the benefits of 
reduced seizures with the negative effects of AEDs. However, their effects are relatively 
modest, especially when compared to the disease itself (Loring et a!., 2007). Their effects may 
be more clinically significant when crucial functions are involved, such as learning ability in 
children; vigilance when driving in adults, or when they impact on pre-existing age-related 
cognitive deficits in older adults (Aldenkamp, 2001).
Despite 25-30 years of research documenting the cognitive side effects of AEDs, no definitive 
conclusions on the impact of individual drugs have been drawn. This is mainly due to the 
methodological shortfalls of many previous studies and the difficult in isolating the effects of 
AEDs from the effects of other factors, such as the underlying aetiology, effects of seizures or 
mood.
However, the studies that have been conducted so far suggest that, in terms of their individual 
profiles, there are few differences between the older AEDs (though phenobarbital is 
considered to have a more detrimental impact on cognition). Few comparisons between the 
newer AEDs have been carried out but the majority seem to have a more favourable cognitive 
profile than the older AEDs (see Table 3.11). However, topiramate and zonisamide have been 
associated with language-related problems, although the risk may be decreased with slower 
titration rates and lower doses.
Understanding the cognitive side effects of AEDs is an important area of research that 
warrants further investigation, particularly as treatment-related side effects are one of the 
causes that is potentially avoidable by appropriate monitoring or changing therapy (Loring et 
al, 2007).
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Table 3.11: Cognitive side effects of individual AEDs (adapted from Named, 2009)
Generation AED Effect on cognition
Phenobarbital +++
1st Phenytoin +
Carbamazepine +
Valproate ++
Gabapentin 0
Lamotrigine 0
Levetiracetam 0
Oxcarbazepine ++
2nd Pregabalin ?
Tiagabine 0
Topiramate +++
Vigabatrin 0
Zonisamide +
■3rd Lacosamide ?0IU
Rufinamide ?
+++ deleterious negative effect; ++ modest negative effect, + mild negative effect, 0 little or negligible negative 
effect, ? unknown {not enough information)
Epilepsy surgery
As this thesis aims to explore the 'natural history’ of cognitive functioning in people with 
epilepsy, those who have undergone intervening epilepsy surgery will not be included in the 
longitudinal studies reported in Chapter 7 and Chapter 8. Therefore, this section will only 
briefly consider the cognitive side effects of epilepsy surgery.
A recent review by Baxendale (2008) on the impact of epilepsy surgery on cognition and 
behaviour found that there have been more than 100 studies investigating cognitive outcomes 
following surgery. These have mainly been published during the last 15 years (Tellez-Zenteno 
& Wiebe, 2008). The majority of these have focused on memory functioning. Following 
epilepsy surgery, there is a risk of deterioration in verbal memory abilities, particularly if the 
resection is in the language-dominant hemisphere. However, verbal memory and intellectual 
functioning is relatively stable or improves following right temporal lobe resection (Spencer & 
Huh, 2008). Those who are rendered seizure free often also have a better cognitive outcome 
(e.g. Selwa et al., 1994, Jokeit & Ebner, 1999, Helmstaedter et al., 2003). For example, in the 
study by Jokeit & Ebner (1999) those who were seizure free six months after anterior temporal
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lobectomy had a small but statistically significant improvement in Full Scale IQ compared with 
those who continued to have seizures. Helmstaedter et al., (2003) in their longitudinal study 
concluded that surgically treated patients were either ‘double winners' (seizure free and had 
cognitive stability or recovery) or ‘double losers’ (continue to have seizures and cognitive 
decline). Seizure control was an important determinant of cognitive prognosis. However, the 
majority of surgery studies only have short follow-up intervals and Baxendale (2008) 
commented that 'despite the burgeoning outcome literature, we stilt know relatively little about 
the long term outcomes of epilepsy surgery1. In support of this, a recent systematic review 
only identified seven surgical studies that reported long-term (i.e. more than five years) 
neuropsychological outcomes. These outcomes are similar to those from short-term follow-up 
studies (Tellez-Zenteno et al., 2007).
The majority of studies reporting cognitive outcomes after surgery are group studies but 
importantly there are individual variations between people with epilepsy. Up to a third may 
experience a decline in memory functioning postsurgically but approximately 10-20% may 
experience a postoperative improvement (Baxendale et al., 2008a). Therefore, knowledge 
and understanding of which patients may be most at risk of developing cognitive decline is 
important when assessing suitability for surgery and counselling patient’s so they can make 
an informed decision.
Several studies have evaluated the risk of experiencing cognitive decline from preoperative 
demographic and clinical factors. Predictors of poor cognitive outcome are illustrated in Table 
3.12, although some of the evidence for these predictors is inconsistent. For example, a study 
by Potter et al., (2009) showed that presurgical cognitive ability was a significant and positive 
predictor of postsurgical ability and having higher preoperative verbal or visual skills predicts 
good cognitive outcomes after anterior temporal lobectomy. The authors suggest that this fits 
with the cerebral reserve hypothesis that those who have a greater cognitive reserve can 
withstand greater brain insults (e.g. Stern, 2002). However, others have suggested that high 
preoperative cognitive performance is a predictor for poor postsurgical cognitive outcome 
(Meador, 2002, Spencer & Huh, 2008). Consequently, further research is needed to allow 
clinicians to more accurately predict which patients are at risk.
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Table 3.12: Predictors of poor cognitive outcome following epilepsy surgery (Meador, 2002, Spencer & 
Huh, 2008)
Predictors of poor cognitive outcome_____________________________________________
• High preoperative cognitive performance
• MRI lesion other than mesial temporal lobe sclerosis
• Absence of ipsilateral hippocampal atrophy/sclerosis
• Mesial temporal sclerosis on the side contralateral to be resected
• Greater functional adequacy of the temporal lobe to be resected
• Resection of the language dominant hemisphere
• Longer duration of epilepsy
• Younger age at surgery 
In a clinical setting, the Wada test is often used to assess the risk of developing a 
postoperative amnesic syndrome and assess language lateralisation in those being 
considered for temporal lobe surgery. However, its usefulness and necessity has been 
debated (e.g. Loring, 2008, Jones-Gotman, 2008, Baxendale et a/., 2008b). An increasing 
number of centres are now using fMRI and the results of baseline neuropsychological testing, 
along with clinical information (e.g. side and type of surgery) rather than the Wada test in the 
prediction of cognitive outcome (Helmstaedter, 2008).
Vagal nerve stimulation
There have been relatively few studies conducted on the cognitive side effects of vagal nerve 
stimulation. Three studies have suggested that there are no cognitive changes associated 
with long-term VMS treatment in both children and adults with epilepsy (Dodrill & Morris, 2001, 
Hoppe et a/., 2001, Hallbook et a/., 2005). In contrast, others have suggested improvements 
in memory following VNS (Liebman et a/., 1998, Clark et a/., 1999, Ghacibeh et al., 2006). 
Clark et a/., (1999) found that participants had better memory retention for highlighted nouns 
in emotionally neutral paragraphs after VNS. Ghacibeh et al., (2006) concluded in their 
experimental study that VNS had no effects on learning but enhanced consolidation, leading 
to improved retention. However, another study by this group showed that VNS impaired 
cognitive flexibility and creativity when administered prior to these tasks. Helmstaedter et al., 
(2001) found reversible deterioration of figural but not verbal memory and accelerated 
decision times during VNS. But the differences in memory findings between this study and the
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one by Clark et al., (1999) may be due to when the stimulation was delivered during the task. 
The latest recent review on the cognitive side effects of VNS by Boon et al., (2006) concluded 
that ‘there Is no evidence in favour of adverse cognitive effects of VNS, but most studies 
suggest that clear-cut positive effects cannot be expected either1.
3.3.3 Psychosocial-related factors
There is a large body of evidence suggesting that people with epilepsy are at an increased 
risk of psychosocial problems (Jacoby, 2002). There is a higher prevalence of mood and 
psychiatric disorders (Dodrill & Batzel, 1986, Hermann etal., 2000, Swinkels etal., 2006), and 
a higher rate of suicide compared to the general population (Jones et al., 2003). People with 
epilepsy are at increased risk of lowered self-esteem and low self-confidence (Watten & 
Watten, 1999), are more likely to be un or under-employed (Ceilings & Chappell, 1994, 
Jacoby et al., 2005), are less likely to be married and experience greater social isolation 
(Baker et al., 2005). They have to manage the psychological sequalae often associated with 
epilepsy. They are concerned about the unpredictability of their seizures, their seizure severity 
and seizure control, their medication and its social implications (Hayden etal., 1992).
Psychological well-being in particular, mood disorders, can impact on cognitive functioning 
(e.g. Austin et al., 1992, Paradise et al., 2001, Airaksinen et al., 2005). Depression tends to 
reduce performance on tasks that require attentional resources or on timed tasks (Reitan & 
Wolfson, 1997). However, there are complex causal relationships between mood, particularly 
depression, and cognition. Cognitive problems may result from depressed mood; depression 
may result as a reaction to cognitive problems; or both may result from a shared 
pathophysiology (Helmstaedter etal., 2004). Mula etal., (2003) have suggested that cognitive 
problems such as mental slowing, concentration impairment and memory deficits may 
represent symptoms of depression.
In addition, epilepsy may impact on educational and occupational attainment. Children with 
epilepsy may have to take significant time out of their schooling, which may affect their 
educational outcome. This may also contribute to lowered expectations by parents, teachers, 
their peers and themselves and lead to a restriction of opportunity (Brown, 2006). Similarly,
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Austin et al., (1998) have shown that seizure severity is a high risk factor for academic 
underachievement and boys with severe epilepsy are most at risk. Academic achievement is 
important because it is highly correlated with intellectual functioning (Matarazzo & Herman, 
1984) and is a marker of cerebral reserve, which may act as a protective factor to further 
cognitive decline (Jokeit & Ebner, 1999, Oyegbile etal., 2004).
3.4 Summary
Throughout the centuries, epilepsy has been associated with cognitive dysfunction. People 
with epilepsy not only commonly report experiencing cognitive impairments, but also perform 
more poorly on objective cognitive measures. Both these objective and subjective complaints 
can disrupt day to day functioning (e.g. education, employment, family life, social 
relationships); affect psychological well-being (e.g. self-confidence, self-esteem, anxiety and 
depression) and impact on overall quality of life.
The causes of cognitive impairments in people with epilepsy are multifactorial. The main 
factors are the effects of the underlying lesion, epilepsy syndrome, seizure frequency, AED 
treatment and presence of a mood disorder. Due to the complex interactions between these 
factors, it can be difficult to untangle their specific effects. In a clinical setting, this makes it 
hard to determine the cause of cognitive dysfunction experienced by an individual patient. In 
addition, it means that many patients, for example, have to balance the risks and benefits of 
achieving seizure control with treatments that may be associated with cognitive side effects.
The majority of research has focused on the nature and cause of cognitive impairments in 
people with epilepsy, in particular, the cognitive side effects of antiepileptic drug treatment. 
However, there is a relatively recent interest in determining when these impairments develop 
and how they progress during the course of the disorder. A growing body of evidence has 
suggested that people with epilepsy may already be experiencing cognitive dysfunction at the 
time of diagnosis, before the impact of many of these factors (e.g. AED treatment, only a few 
seizures). But few prospective longitudinal studies have been conducted to investigate 
whether these impairments get worse over time. This will be discussed in the next chapter.
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Chapter 4 Natural history of cognitive functioning
4.1 Overview of chapter
This chapter will review the literature on how cognitive functioning develops during the course 
of epilepsy. There will be a discussion of the studies that suggest that people with newly 
diagnosed epilepsy are already experiencing cognitive dysfunction at the time of diagnosis, 
before the start of antiepileptic drug treatment and following few seizures. The potential 
explanations for this will be explored. There will be a consideration of whether this cognitive 
dysfunction gets worse over time, drawing on evidence from cross-sectional and longitudinal 
studies. The gaps in our understanding of the cognitive functioning of people with newly 
diagnosed epilepsy will be highlighted and the aims and objectives of this thesis will be 
presented.
4.2 Cognitive impairments present at the time of diagnosis
4.2.1 Nature of cognitive impairments
As discussed in the previous chapter, epilepsy, seizure and treatment-related factors all 
contribute to the development of cognitive dysfunction in people with epilepsy. However, 
several previous studies have demonstrated that adults with epilepsy are already cognitively 
compromised at the time of diagnosis, before the onset of many of these factors (see Table 
4.1). This dysfunction is evident across several cognitive domains with untreated patients with 
newly diagnosed epilepsy performing worse than healthy volunteers on measures of memory, 
sustained attention and concentration, mental flexibility and psychomotor functioning (Brodie 
etal., 1987, Smith etal., 1987, Kaiviainen etaf., 1992, 2003, Helmstaedter ef a/., 1993, 2005, 
Aikia etal., 1995, 2001, Prevey etal., 1998, Ogunrin etal., 2000, Pulliainen etal., 2000a).
However, it is important to note that not all patients with epilepsy experience these difficulties. 
A series of studies have shown that approximately 30-56% of patients experience mild 
memory and attention problems at epilepsy onset compared to healthy controls (Kaiviainen et
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a/., 1992, Aikia et al., 1995, 2001); although it is unclear why some people are more 
susceptible than others. Pulliainen et ai, (2000a) found that lower levels of education, older 
age, symptomatic epilepsy and more abnormal CT findings were associated with worse 
performance. Similarly, a published abstract by Helmstaedter et al, (2005) found older age to 
be associated with poorer cognitive performance, in addition to later onset and a shorter 
duration of epilepsy. Type of seizure may also play a role. Aikia et al, (2001) found moderate 
memory impairment to be associated with secondarily generalised seizures. Prevey et al, 
(1998) showed that those with secondarily GTCS performed worse on concentration and 
mental flexibility tasks, although this was not supported by Pulliainen et al, (2000a). Further 
work, therefore, is needed to identify those who may be already at risk of cognitive 
impairment.
Despite the accumulating evidence that people with epilepsy demonstrate cognitive 
impairment at the time of diagnosis, there are methodological shortfalls with some of these 
studies. Firstly, not all studies have assessed patients before AED medication, some have 
included those who have previously been treated or are presently undertreated (e.g. Brodie et 
al., 1987, Smith etal, 1987, Prevey ef a/., 1998, Pulliainen etal, 2000a, Ogunrin etal, 2000, 
Aikia et al, 2001). Not only may their prior exposure to AEDs negatively affect cognition but 
this suggests that they have a longer duration of epilepsy, which may also have had a 
negative impact through increased number of seizures. In fact, in the study by Smith et al, 
(1987), the mean interval since first seizure and enrolment was 12.2 years. Secondly, some 
studies have small sample sizes, which may not have adequate power to detect differences 
between the groups (e.g. 14 patients in the study by Brodie et al, 1987) and none reported 
power calculations. Finally, not all studies have undertaken comprehensive 
neuropsychological assessments. Some have focused only on verbal memory (e.g. Aikia et 
al, 1995, 2001) and others on reaction time and psychomotor speed (e.g. Brodie etal, 1987), 
missing other potentially affected cognitive domains.
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4.2.2 Causes of impairments
Despite these shortfalls, cognitive problems appear to be present at epilepsy onset, before the 
start of antiepileptic drug treatment and before the accumulating impact of recurrent seizures. 
Studies from the paediatric literature suggest that they may even antedate the first recognised 
seizure (e.g. Austin et a/,, 2001, Berg et ai, 2005). The specific mechanisms causing these 
impairments are unclear but this implies that they may be the result of the epileptic process or 
reflect the underlying CNS dysfunction that has led to the epilepsy.
Role of the underlying aetiology and epilepsy syndrome
Epilepsy is a symptom of an underlying cerebral alteration, which may be the resuit of a wide 
variety of differing aetiologies (see section 2.2.6). As discussed in the previous chapter (see 
section on ‘Epilepsy syndrome and underlying aetiology’), the underlying aetiology and 
structural pathology may affect cognitive functioning independently of the effects of seizures 
and treatment. In the study by Prevey et al, (1998) approximately one third of their patients 
had sustained a head trauma and one third had cerebrovascular disease or another 
neurological disorder, which may account for their poorer cognitive performance. Similarly, a 
small study by Helmstaedter et at., (1993) showed that newly diagnosed patients with a 
structural brain lesion performed significantly more poorly than those without a lesion. More 
abnormal CT findings and symptomatic epilepsy have been associated with worse memory, 
concentration and mental flexibility scores in another study of adults with newly diagnosed 
untreated epilepsy (Pulliainen et ai, 2000a).
Symptomatic/cryptogenic epilepsy was also found to be a risk factor for neuropsychological 
deficits in a study in children with a first recognised seizure (Fastenau et ai, 2009). A previous 
study by this group also found that 14% of children with new onset epilepsy had significant 
structural abnormalities that were judged to be related to their seizures, such as gliosis, 
hippocampal atrophy and cortical dysplasias. These abnormalities were associated with lower 
estimated IQ scores and lower language, processing speed, executive/constructional ability 
and verbal memory and learning scores. This association remained even after excluding 
those with general cognitive problems, defined as low intellectual functioning (IQ <70) (Byars
et a/., 2007). The authors concluded that some of the variability in neuropsychological 
functioning in children with newly recognised seizures might be caused by the presence of an 
underlying structural brain abnormality. Consistent with this, another study in children 
demonstrated that those who had academic problems that predated the onset of epilepsy had 
reduced grey matter volumes in the left occipital and parietal lobes (Hermann et a/., 2006a).
Underlying brain abnormalities may explain some of these observed impairments. However, 
some studies have found cognitive and behavioural dysfunction at epilepsy onset in adults 
and children with no known aetiological factor for their epilepsy and are otherwise 
‘neurologically normal’ (Kalviainen et ah, 1992, Aikia et at., 1995, Oostrom et a/., 2003, 
Hermann etal., 2006a, Berg et at., 2005, Bhise ef a/., 2009).
Role of epileptogenesis
The presence of impairments in those without neuroabnormalities implies that factors 
associated with the underlying epileptogenesis may play a role in cognitive dysfunction 
(Hermann et al, 2006a, 2007b). Epileptogenesis refers to 'the alteration of a normal neural 
network into a hyperexcitab/e network in which recurrent, spontaneous seizures occur' 
(Badawy et al., 2009a, 2009b). Multiple mechanisms underlie epileptogenesis including 
abnormalities of neuronal structure and organisation from cortical malformations; ion channel 
dysfunction from single gene mutations and disturbances in network function (Badawy et al, 
2009a, 2009b). The mechanisms that lead to the development of epilepsy following a lesion or 
insult such as a tumour, head injury or stroke are still not understood. However, alterations 
are thought to occur, which may involve apoptosis, axonal sprouting, changes in excitatory 
and inhibitory neurotransmitters and network reorganisation. These alterations may result in 
the predisposition to have recurrent seizures (Badawy et al., 2009a, 2009b). It is possible that 
these changes could contribute to the observed cognitive dysfunction. In support of this, a 
study by (Hermann et al., 2006a) found no differences in the total cerebral or total lobar 
volumes in children with idiopathic new-onset epilepsy and healthy controls. However, the 
relationship between cognition and white matter volumes was different in the two groups, 
suggesting an altered functional relationship in children with epilepsy.
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Role of psychological factors
As well as neurobiological factors, psychological factors may be an additional explanation for 
the impairments that exist at the time of diagnosis. As discussed in the previous chapter 
(section 3.3.3), there is a large body of evidence suggesting that people with epilepsy are at 
an increased risk of psychosocial problems (e.g. mood and psychiatric disorders, lower self­
esteem, un or under-employment, fear of seizures, worry about stigma and social 
implications), which may impact on their cognitive functioning. In the previous chapter, these 
problems were discussed mainly in relation to those with more severe or established epilepsy. 
However, receiving a diagnosis of epilepsy also triggers a complex psychological adjustment 
process (Velissaris et al., 2007).
Velissaris et at., (2007) found that the initial reactionary period to a first diagnosed seizure 
was characterised by psychological (e.g. emotional reactions such as fear and shock, 
increased sense of vulnerability and diminished sense of self) and social issues (e.g. 
concerns about job security, being able to fulfil role in family and driving limitations) that are 
often experienced as a threat to a person’s sense of control. Having a recent diagnosis of 
epilepsy has also been associated with problems such as decreased psychological well­
being, fear of seizures and fear of stigma in employment (Chaplin et aL, 1992, Kemp et al., 
1999). As shown in the previous chapter, psychological well-being can impact on cognitive 
functioning; therefore, it is feasible that the psychological uncertainty associated with having a 
new diagnosis of epilepsy may impact on cognitive functioning at this time. In support of this 
argument, Oostrom et al., (2003) found that the differences between children with new-onset 
epilepsy and sex and age matched classmates were not related to epilepsy characteristics but 
to the reaction of the child and parent to the diagnosis of epilepsy. However, despite finding 
more symptoms of depression, feelings of bewilderment and less vigour in adults with newly 
diagnosed epilepsy compared to healthy controls, Pulliainen et al., (2000b) found that the 
deficits were not the result of depression or these negative mood states.
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4.2.3 Summary
To summarise, several studies of children and adults have demonstrated that impairments are 
already present, certainly for some people with epilepsy, at the time of diagnosis, before the 
start of treatment and before the accumulating impact of recurrent seizures. The reasons for 
these impairments are unclear but are probably multifactorial reflecting the underlying brain 
dysfunction leading to the epilepsy; the effects of epileptogenesis and a psychological 
reaction to having a diagnosis of a chronic illness. However, another emerging question of 
interest is how these impairments develop over time. Do they get worse with increasing 
duration of epilepsy?
4.3 The development of impairments over time
As briefly mentioned in the previous chapter, a number of studies have been conducted to 
evaluate the relationship between duration of epilepsy and cognitive decline. In that section 
(see Section 3.3.1), the discussion centred on the cumulative effect of recurrent seizures on 
the brain. In this chapter the discussion, will focus on whether epilepsy represents a 
progressive dementia-type disorder. This review will draw on evidence from cross-sectional 
and longitudinal studies.
4.3.1 Findings from cross-sectional studies
A number of cross-sectional studies have found that cognitive functioning declines with 
increasing duration of epilepsy (Jokeit & Ebner 1999, Jokeit et a/., 2000, Hermann et a/., 
2002a, Oyegbile et a/., 2004, Kent et a/., 2006, Marques et a/., 2007). For example, Jokeit & 
Ebner (1999) showed that those with epilepsy duration of more than 30 years had worse Full 
Scale IQ scores than those with duration of less than 30 years. However, higher educational 
attainment, as an indicator of cerebral reserve, may modify this relationship and slow the rate 
of decline (Jokeit & Ebner, 1999, Oyegbile etal., 2004).
Duration of epilepsy is a marker for increased number of seizures; exposure to AEDs; 
interictal epileptic brain activity; chronic and transient metabolic disturbances; risk of seizure-
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related injuries and earlier age of onset, all of which may impact on cognition (Jokeit & Ebner, 
1999, Oyegbile et al.t 2004). However, a number of studies have not found evidence of 
deterioration over time (e.g. Helmstaedter & Eiger, 1999). In fact, Helmstaedter & Eiger 
(1999, 2009) have argued that the association between duration and cognitive decline is 
confounded by the effects of ageing. They suggest that an alternative approach should be to 
compare the age regression measures of people with epilepsy with those of healthy controls 
(see Figure 4,1). Their recently published data from 1156 patients with refractory TIE and 
1000 healthy controls (aged between 6-80yrs) suggest that the memory functioning of patients 
with epilepsy runs parallel to that of healthy volunteers throughout the lifespan but their 
memory performance is at a lower level (see Figure A). The authors say that these results 
imply that there is a neurodeveiopmentai hindrance in chronic TLE, which affects learning and 
memory functioning, but this is then followed by normal physiological ageing and not 
progressive accelerated decline (see Figure B) (Helmstaedter & Eiger, 2009). Similarly, 
Hermann et al., (2002a, 2002b) propose that TIE, particularly of childhood-onset, is also 
associated with a generalised adverse neurodeveiopmentai impact on brain structure and 
function. But they suggest that this represents an early acquired vulnerability, which reduces 
cerebral reserve, and then places patients at risk for progressive cognitive decline.
The findings of cross-sectional studies have been mixed, which impairs the ability to draw firm 
conclusions. Additionally, despite cross-sectional studies being useful to look at the 
relationships between cognition and long duration of epilepsy in large samples of patients 
(Jokeit & Ebner, 2002, Helmstaedter, 2002, Hermann et al., 2008a), they have several 
limitations. For example, cause and effect cannot be determined and there may be 
undetected cohort bias effects, such as improvement in diagnosis or new antiepileptic drugs 
(Jokeit & Ebner, 1999, Helmstaedter, 2002). Therefore, a more appropriate approach to 
investigate changes in cognition is to follow the same group of individuals prospectively in 
longitudinal studies (Seidenberg etal., 2007).
93
Fi
gu
re
 4
.1
: F
ig
ur
e 
A
 ill
us
tra
te
s 
ag
e 
re
gr
es
si
on
s 
of
 v
er
ba
l l
ea
rn
in
g 
in
 p
at
ie
nt
s w
ith
 ch
ro
ni
c T
LE
 a
nd
 h
ea
lth
y 
co
nt
ro
ls
. F
ig
ur
e 
B
 il
lu
st
ra
te
s v
er
ba
l l
ea
rn
in
g 
gr
ou
pe
d 
by
 a
ge
 
in
cr
em
en
ts
 (t
ak
en
 fr
om
 H
el
m
st
ae
dt
er
 &
 E
ig
er
, 2
00
9)
y || is
u
-8
-?
-a
-a
■Co
S’
s«
Ol
S5
S
8 
, M
s
8
•8
8
8
<D« g»
s
8
8
a
8
£
■ 2
94
4.3.2 Findings from longitudinal studies
Comparatively, there have been few longitudinal studies conducted in adults with epilepsy and 
many have small sample sizes. This probably reflects the financial and time resources needed 
to conduct studies of this type. Two recent reviews (Dodrill, 2004, Seidenberg et al., 2007) 
have identified all the published longitudinal studies addressing this issue. Dodrill (2004) 
found 13 studies in adults published since 1942 and Seidenberg et al., (2007) found six 
studies published between 2004 and 2007. For the purposes of this review, two additional 
studies have been identified that were published during this time frame (Aikia et al., 2001, 
Huang et al., 2005). Since the latest review in 2007, no further longitudinal studies have been 
identified. However, there has been a re-analysis of the study by Andersson-Roswal! et al., 
(2004) exploring the reasons for decline in verbal memory (Andersson-Roswall et al., 2007) 
and Hermann et al., (2007a) have applied their three cognitive phenotypes to the patients 
studied in Hermann et al., (2006b). Table 4.2 summarises all the longitudinal studies 
addressing the issue of cognitive progression in adults with epilepsy.
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Similar to the results from the cross-sectional studies, the results from these longitudinal 
studies are mixed. Some have suggested that as a group, people with epilepsy decline in 
areas of functioning, particularly in memory, attention, executive control, speed of response 
and visual-spatial relations (Arieff & Yacorzynski, 1942, Holmes et al,} 1998, Helmstaedter et 
a/., 2000, 2003, Andersson-Roswall etal., 2004, Thompson & Duncan, 2005, Hermann etaL, 
2006b, Piazzini et at., 2006, Griffith et a/., 2007). However, there is variability in cognitive 
outcome. For example, Helmstaedter et al, (2000) identified 37% of patients with temporal 
lobe epilepsy who declined in memory functioning; Arieff & Yacorzynski (1942) also identified 
37% who significantly decreased in intellectual functioning and Hermann et aL, (2006b) 
identified 20-25% who had adverse cognitive outcomes.
In a related study, Hermann et al., (2007a) found that the three cognitive phenotypes they 
identified in patients with chronic TIE (described in section 3.2.1) not only had different 
cognitive profiles but also had a different cognitive course over a period of four years. Those 
who exhibited most impairments (the memory, executive and speed impaired group) had a 
poorer cognitive course than the other two groups. The factors that have been associated with 
cognitive decline include seizure frequency, in particular, frequency of GTCS; baseline 
quantitative MRI abnormalities; lower baseline intellectual capacity; longer duration of epilepsy 
and older age (Rodin, 1968, Seidenberg et al., 1981, Dodrill, 2002, Thompson & Duncan, 
2005, Hermann et al., 2006b, Piazzini et al., 2006). As found in the cross-sectional studies, 
cognitive decline may also be modified by cerebral reserve (Huang et al., 2005, Pai & Tsai, 
2005).
In contrast, several studies have suggested either improvements or generally stable 
functioning overtime (Seidenberg etal., 1981, Kalska, 1991, Dodrill & Wilensky, 1992, Setwa 
et al., 1994, Holmes etal., 1998, Aikia etal., 1999a, 2001, Bjornaes etal., 2001, Dodrill, 2002, 
Griffith et al., 2007). However, the majority of these did not include a comparison control 
group to compare with ‘normal’ change, which will be discussed in more detail below.
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Methodological shortfalls of previous longitudinal studies
Despite using more appropriate longitudinal designs, there are methodological shortcomings 
with many of these studies, which may explain the variability in findings. These have been 
discussed by Seidenberg et a/., (2007) and Hermann et ai, (2008a) and are summarised in 
Table 4.3.
Table 4.3: Methodological shortfalls of longitudinal studies
Methodological shortfalls Why is this important?
No comparison control group • Unable to make conclusions with regards to 'normal’ 
performance
Varied test-retest intervals both • Makes comparing studies difficult
between and within studies • May not be long enough intervals to detect cognitive 
changes
Smali samples sizes • May not have adequate power to detect change
Inconsistency in cognitive domains • Makes comparing studies difficult
studied and choice of 
neuropsychological tests
• Some studies only focused on intellectual 
functioning ignoring cognitive domains (e.g. 
memory) which are known to be vulnerable to the 
effects of epilepsy
Focus on those with severe, chronic, 
intractable epilepsy
• May not be generalisable to those with new onset or 
well-controlled epilepsy
Firstly, until recently, very few studies employed a comparison control group. In fact, only five 
studies have used a control group and these have arrived at different conclusions. These 
controlled studies have found that the patients with epilepsy have a different cognitive 
trajectory to healthy volunteers, which is characterised by a lack of a practice effect (Dodrili, 
2002, Andersson-Roswall et al., 2004, Hermann et a/., 2006b, Piazzini et a/., 2006, Griffith et 
a/., 2007). For example, Hermann et al., (2006b) found improvements by controls on nine of 
16 cognitive measures but improvements by the epilepsy group on only one of the 16 
measures. Similarly, Andersson-Roswall et al., (2004) found that the Performance IQ scores 
of people with epilepsy did not change whilst the healthy controls increased by six points. A 
lack of a practice effect may reflect a deficit or impaired capacity for learning from prior 
exposure to the initial testing experience (Andersson-Roswall et al., 2004, Seidenberg et al., 
2007). The use of a comparison control group means that the performance of people with 
epilepsy can be evaluated against the ‘normal’ performance of healthy volunteers to identify
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‘abnormal’ functioning over time, which may be more apparent than abject deterioration 
(Seidenberg etai, 2007, Hermann etal., 2008a).
Secondly, the studies have used varied test-retest intervals. These have largely ranged 
between one and ten years, although Thompson & Duncan (2005) included an individual with 
a test-retest interval of 27 years in their retrospective study. The differing intervals make 
comparisons across studies difficult and some may not be long enough to detect clinically 
significant cognitive changes. However, Seidenberg et a/., (2007) suggested that a '3-4 year 
interval is likely to be sufficient to detect evidence of significant cognitive change in adults with 
epilepsy and that longer retest intervals may be associated with greater cognitive 
progression1. Additionally, small sample sizes also mean that the studies may not have 
adequate power to detect clinically significant change. The median sample size in the 
longitudinal studies reported above was 46.5 [Interquartile Range (IQR) 31.75-59.50] with the 
smallest study by Griffith etal., (2007) only involving 17 patients.
Thirdly, the studies have investigated different cognitive domains and used different 
neuropsychological assessments. Earlier studies focused solely on intellectual functioning 
(e.g. Arieff & Yacorzynski, 1942, Rodin, 1968, Seidenberg et a!., 1981), which probably 
reflected the fact that epilepsy was historically associated with intellectual deterioration (e.g. 
Gowers, 1885, Lesser et ai, 1986). However, this ignores cognitive domains that are known 
to be vulnerable to the effects of epilepsy and its treatment, in particular memory functioning. 
While later studies have moved towards examining changes in other key neuropsychological 
areas, the domains and tests selected are not consistent across studies. Table 4.4 highlights 
the inconsistency of test selection in the assessment of memory alone.
Seventeen of the 21 longitudinal studies included an assessment of memory functioning. 
Eighteen tests were identified as being used, of which the most frequently employed was the 
Logical Memory subtest from the Wechsler Memory Scale (WMS), which was used in seven 
of the studies (Dodrill & Wiiensky, 1990, 1992, Selwa et ai, 1994, Holmes et ai., 1998, Aikia 
et ai, 2001, Dodrill, 2002, Griffith et ai, 2007). Some form of list learning task was employed 
in five of the studies (Helmstaedter etai, 2000, 2003, Aikia etai, 2001, Andersson-Roswall et 
ai, 2004, Thompson & Duncan, 2005). However, different versions were often used, although
103
this was mainly due to language modifications (e.g. translations into German and Swedish). 
Nine tests were only used once. The lack of uniformity and standardisation in the choice of 
neuropsychological test batteries makes comparing results across studies and drawing firm 
conclusions difficult.
Table 4.4: Heterogeneity of neuropsychological tests used in longitudinal studies in people with 
epilepsy6
Memory assessment___________________________________________ Frequency of use
Wechsler Memory Scale Logical Memory 7
Wechsler Memory Scale Visual Reproduction 5
Seashore Tonal Memory 4
Tactual Performance Test 4
Cognitive Ability Screening Instrument 2
DCS-R (German figural design list-learning test) 2
Rey-Osterrieth Complex Figure Memory Test 2
VLMT (German equivalent of the Rey Auditory Verbal Learning Test) 2 
Wechsler Memory Scale -III or earlier versions (all subtests) 2
Benton Visual Retention Test 1
Claeson-Dahl Learning and Retention Test (list learning task) 1
List learning (modified from the Rey Auditory Verbal Learning Test) 1
List learning from the Adult Memory and Information Processing Battery 1 
Wechsler Memory Scale Paired Associates 1
Cronholm-Molander Memory Test (paired associates task) 1
Paired associate words test (version not specified) 1
Digit span (version not specified) 1
Story test (version not specified)1
Finally, the majority of studies have largely included those with severe, chronic, intractable 
epilepsy often of long duration [e.g. mean duration of 14.8 years in Bjornees et al., (2001); 17 
years in Helmstaedter et aL, (2003) and 20 years in Holmes et al, (1998)]. Only two studies 
by Aikia and colleagues (1999a, 2001) have included those with newly diagnosed epilepsy. 
The study by Aikia et al, (1999a) is a published abstract from a paper that was presented at a 
conference. They followed-up 58 patients with newly diagnosed partial epilepsy over five 
years and found no significant declines across a comprehensive neuropsychological test 
battery. However, in the study by Aikia et al, (2001) they presented preliminary data that only
6 The specific neuropsychological tests used in Aikia et al., (1999) were not reported in their published abstract 
so while this study included an assessment of memory functioning, this study is not included in the table.
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focused on verbal intellectual and verbal memory functioning in 20 patients with newly 
diagnosed TIE. They also found no significant declines after five years in verbal memory. But 
neither of these studies reported on a control group, so no conclusions can be made about 
whether this stable performance represents ‘normal’ functioning. The lack of studies in this 
patient group means our understanding and knowledge of the additional impact of treatment 
and seizures on the pre-existing impairments discussed earlier in this chapter is limited.
4.3.3 Summary
In summary, neither cross-sectional nor longitudinal studies have been able to provide a 
definitive answer as to whether cognitive functioning declines over time in people with 
epilepsy. Cross-sectional designs are associated with limitations in answering this type of 
question, although they are able to provide data from a large number of patients over a long 
duration of epilepsy. A better approach is a longitudinal design, however, there have only 
been 21 longitudinal studies published since 1942. These have also found mixed results, 
which probably reflect their differing methodologies. The studies have varied in their test- 
retest intervals, the cognitive domains studied and neuropsychological tests used and the type 
of patients assessed. A review of this area has highlighted that there is a gap in the literature, 
relating to the cognitive functioning of adults with newly diagnosed epilepsy.
4.4 Gaps in the literature
In comparison to those with chronic, long-standing epilepsy very little is known about the 
cognitive functioning of adults with newly diagnosed epilepsy. A few studies have found that 
people with epilepsy have cognitive impairments at the time of diagnosis but these studies 
have used different methodologies which make determining the mechanisms underlying the 
cognitive impairments present at baseline unclear (e.g. some patients have previously been 
treated; some include those with known pathologies and few measure current mood states). 
No previous study has only included those who are previously untreated with no known 
pathology or aetiology; evaluated a wide variety of cognitive domains, and measured current 
mood state in comparison to a matched healthy control group.
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The issue of cognitive decline in people with epilepsy is still uncertain. It is even less certain 
for those who develop epilepsy in adulthood. Only one published study (Aikia et al., 2001) and 
one published abstract (Aikia et a/., 1999a) have investigated cognitive changes in adults who 
are newly diagnosed. However, these had a relatively small sample size, did not employ a 
control group and the study by Aikia et al., (2001) only evaluated verbal memory performance, 
as part of their preliminary data. In addition, recent studies, particularly by Hermann et al., 
(2007a), have suggested that people with epilepsy have different cognitive trajectories 
compared with healthy controls. No previous study has investigated whether these cognitive 
trajectories are evident in those with newly diagnosed epilepsy. Therefore, there is a need for 
a prospective, longitudinal, controlled study charting cognitive functioning and mood in people 
with epilepsy over a period of years from the time of diagnosis.
4.5 Aims and objectives of the thesis
4.5.1 Aims
The overall aim of this thesis is to gain a greater understanding of the natural history of 
cognitive functioning in people with newly diagnosed epilepsy.
4.5.2 Objectives
• To compare the cognitive profile of healthy volunteers with newly diagnosed 
untreated people with newly diagnosed epilepsy and no known cerebral 
pathology, before the administration of antiepileptic drug medication.
• To compare the cognitive trajectories of people with newly diagnosed epilepsy 
and healthy volunteers over the first 12 months after starting AED treatment.
• To document the longer term effects of epilepsy and its treatment on cognitive 
functioning in people with newly diagnosed epilepsy.
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4.6 Summary
There has been extensive research investigating the nature and cause of cognitive problems 
experienced by people with epilepsy. An area of increasing interest is the timing of these 
impairments in the course of the disease and whether these problems get worse over time. 
Several studies have suggested that patients with newly diagnosed epilepsy are already 
experiencing cognitive dysfunction at the time of diagnosis. However, only two studies have 
followed these patients over the course of their epilepsy. The results of previous longitudinal 
and cross-sectional studies investigating cognitive changes in patients with severe, chronic or 
intractable epilepsy have been mixed. Some have suggested stable functioning over time, 
while others have suggested deteriorations with increasing duration of epilepsy. There are 
methodological differences between these studies, which may account for the mixed findings. 
There is a gap in our understanding of the natural history of cognitive functioning in people 
with newly diagnosed epilepsy. This has led to the development of the aims and objectives of 
this thesis. The next chapter will discuss the research methods used to investigate these 
aims.
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Chapter 5 Design and methods
5.1 Overview of the chapter
This chapter will outline the research methods used to investigate the natural history of 
cognitive functioning in people with newly diagnosed epilepsy. As illustrated in Figure 5.1, this 
research took place in the context of the SANAD trial {Marson et al., 2007a, 2007b). The 
background to this trial and its procedures will be provided. From the SANAD trial, untreated 
patients with newly diagnosed epilepsy were invited to take part in the SANAD 
Neuropsychology study. The neuropsychological profile of these patients was then compared 
to the neuropsychological profile of healthy volunteers recruited from the general population, 
who were also assessed at baseline and 12 months. The background to this study, 
participants and procedure will be described. Patients with epilepsy who had completed 
assessments as part of the SANAD Neuropsychology study were invited to take part in a 
neuropsychology follow-up study. This was to investigate the longer term impact of epilepsy 
and its treatment on cognitive functioning. The design, participants and procedure of this 
study will be reported. The statistical analysis plan for the three results chapters will be 
outlined.
5.2 The SANAD trial
A full description of the methodology for the SANAD trial is contained in the publications by 
Marson et al., (2007a, 2007b) and the National Institute for Health Research (NIHR) Health 
Technology Assessment (HTA) report by Marson et at. (2007c). However, for brevity, only a 
brief summary of the trial’s aims, design and methods will be presented here, to place the 
neuropsychological research in context.
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Figure 5.1: Flowchart explaining the relationship between the Neuropsychology studies in this 
thesis and the SANAD trial
12 month 
assessment
(n=69)
Neuropsychology follow-up 
study
50 PWE
3 month assessment 
179 PWE
12 month assessment 
147 PWE
Untreated healthy 
volunteer reference 
group
(n=87)
SANAD Neuropsychology study
222 PWE
Standard and New Antiepileptic Drug 
(SANAD)Trial
2437 PWE
5.2.1 Aim
SANAD aimed to compare the clinical and cost effectiveness of standard drug treatments 
(carbamazepine or valproate) with comparator new drugs (gabapentin, lamotrigine, 
oxcarbazepine, topiramate) in people with epilepsy.
5.2.2 Design
The SANAD study was a pragmatic, randomised, unblinded, parallel group clinical trial 
comprising two arms. One arm (Arm A) comparing new antiepileptic drugs (gabapentin,
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iamotrigine, oxcarbazepine and topiramate) with carbamazepine, which was widely accepted 
as the drug of first choice for patients with partiai-onset seizures. The other arm (Arm B) 
comparing new antiepileptic drugs (Iamotrigine and topiramate) with valproate (see Figure 
5.2), which was widely accepted as the drug of first choice for patients with generalised onset 
seizures and was recommended for those whose seizures are difficult to classify.
5.2.3 Participants
The SANAD trial recruited patients with epilepsy from hospital outpatient clinics at 90 hospital 
centres in the United Kingdom. The first patient was randomised in January 1999 and 
randomisation continued until August 2004. A total of 1721 patients were randomised to Arm 
A and 716 patients to Arm B. Arm A recruited 88% of patients with symptomatic or 
cryptogenic partial epilepsy and 10% with unclassified epilepsy. Arm B recruited 63% of 
patients with idiopathic generalised epilepsy and 25% with unclassified epilepsy.
Inclusion/exclusion criteria
Patients were recruited into SANAD if they satisfied the inclusion criteria of a history of two or 
more clinically definite unprovoked epileptic seizures in the previous year; if treatment with a 
single AED represented the best therapeutic option and if they had given informed consent. 
This meant that SANAD could comprise patients with newly diagnosed epilepsy; patients who 
had failed treatment with previous monotherapy (as long as drug failure did not include one of 
the drugs involved in SANAD) and patients in remission of epilepsy, who had relapsed 
following the withdrawal of their treatment.
Patients were excluded if the clinician or patient felt that treatment was contraindicated; all 
their seizures had been acute symptomatic seizures including febrile seizures; they were aged 
four years or younger or there was a history of progressive neurological disease.
110
5.2.4 Procedure
Patients with epilepsy were randomised into one of two arms depending on which of the two 
standard treatments (carbamazepine or valproate) the clinician thought was most appropriate 
for the patient.
Figure 5.2: SANAD randomisation procedure (taken from the SANAD Participants Manual)
Eligible patient
No
Select standard 
drug
valproatecarbamazepine
lamotrigine
topiramate
Follow-up at 3, 6 & 12 months and 
yearly intervals thereafter
gabapentin
lamotrigine
oxcarbazepine
topiramate
No further action
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If the clinician thought carbamazepine was the most appropriate, then the patient was 
randomised to Arm A and was then randomly allocated to either the standard drug 
(carbamazepine) or the new drugs (gabapentin, lamotrigine, oxcarbazpine, topiramate). 
Randomisation was in the ratio of 1:1:1:1:1. However, oxcarbazepine was only included in the 
randomisation after 1 June 2001, therefore, fewer patients were randomised to this drug, if the 
clinician thought valproate was the most appropriate drug, then the patient was randomised to 
Arm B and was then randomly allocated to either the standard drug (valproate) or the new 
drugs (lamotrigine, topiramate). Randomisation was in the ratio of 1:1:1 (see Figure 5.2).
Randomisation was undertaken by telephoning the Randomisation Centre at the Centre for 
Cancer Epidemiology, Manchester. Randomisation was balanced across a number of factors 
(centre, sex, previous epilepsy history) to produce comparable groups.
While the choice of drug was randomised, the drug dosage and drug preparation were those 
used by the clinician in their everyday practice. During the study, the clinician and patient 
could agree that withdrawal of the randomised drug was necessary because of intolerable 
side effects; lack of efficacy or remission or that an additional AED drug should be added 
because of lack of efficacy. The choice of additional or alternative drugs was determined by 
the clinician according to their view of optimal clinical practice.
Demographic and clinical information was collected at baseline by the recruiting clinician. The 
information recorded at baseline is shown in Table 5.1. Patients were then followed-up by the 
recruiting clinician at three, six and 12 months and at successive yearly intervals after that. 
Patients were followed up more frequently, if required, as part of their clinical management. At 
every follow-up visit, occurrence of seizures; experience of adverse events; number of 
hospital admissions and AED treatment was recorded. Attempts were made to follow-up all 
patients to, at the latest 31 August 2005, although some follow-up data was collected up until 
31 January 2006. The demographic and clinical data over the first year was made available to 
the author for analysis in this thesis.
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Table 5.1: Information recorded at entry into SANAD
information recorded Definition
Demographics • Sex and age
History of learning disability • A history of at least one of the following: 
o additional educational support in >
2 subjects
o a statement of educational needs 
o attends (or attended) a special 
school
Neurological deficit • Localising neurological signs resulting in 
functional impairment
History of previous or current neurological 
disorder (e.g. stroke/cerebrovascular,
• Head injury was defined as post-traumatic 
amnesia >24 hours or depressed skull
intracranial surgery, head injury, 
meningitis/encephalitis, other)
fracture
History of seizures:
febrile seizures;
acute symptomatic seizures
• Febrile seizures were defined as those 
usually occurring between 3 months and 6 
years. They were associated with fever but 
no evidence of an intracranial infection or a
defined cause.
• Acute symptomatic seizures were defined 
as those that occurred in the presence of an 
encephalopathy due to metabolic 
disturbance or drugs, or due to an acute 
cerebral illness.
History of epilepsy in a first-degree family 
member
• History of epilepsy in a first-degree family 
member
Number and type of seizures (including dates 
of first and most recent of each type)
• Classified according to the ILAE (1981) 
classifications
Epilepsy syndrome • Classified according to the ILAE (1989) 
classifications
Results of EEG or brain imaging (CT/MRI) at 
time of randomisation
• Undertaken within 3 months of 
randomisation
5.2.5 Outcome measures
The two primary clinical outcome measures in the SANAD trial were the time from 
randomisation to treatment failure, and the time from randomisation to the achievement of a 
one year period of remission of seizures. Secondary clinical outcome measures were the time 
from randomisation to a first seizure; the time to achieve a two-year remission, and the 
incidence of clinically important adverse events and side effects emerging after
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randomisation. Data was also collected on quality of life and health economic outcomes but 
these have been reported elsewhere.
5.3 SANAD Neuropsychology study
The SANAD Neuropsychology study was designed by Professor Gus A Baker (see Appendix 
A). Its main aim was to compare the cognitive side effects of standard and new AEDs in 
people with newly diagnosed epilepsy after three and 12 months of treatment. Unfortunately, 
this aim could not be met due to the small numbers of patients who were recruited into each 
drug group. However, for the purposes of this thesis, the SANAD Neuropsychology study 
provided a unique opportunity to investigate the natural history of cognitive functioning in a 
group of previously untreated patients with newly diagnosed epilepsy. Therefore, this study 
was used to investigate two of the objectives of this thesis:
• To compare the cognitive profile of healthy volunteers with people with newly 
diagnosed epilepsy and no known cerebral pathology, before the administration 
of antiepileptic medication.
• To compare the cognitive trajectories of people with newly diagnosed epilepsy 
and healthy volunteers over the first 12 months after starting treatment.
To meet these objectives, a healthy volunteer reference group was recruited and assessed 
from the general population separate to the SANAD Neuropsychology study. The design, 
participants and procedure for the SANAD Neuropsychology study, as well as the procedure 
for recruiting the healthy volunteer group, will be described below.
5.3.1 Design
The SANAD Neuropsychology study was a prospective, multicentre, longitudinal study.
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5.3.2 Recruitment
Patients with epilepsy
At the time of randomisation into the SANAD trial, previously untreated patients with newly 
diagnosed epilepsy from 11 hospital centres were invited to participate in the SANAD 
Neuropsychology study (see Table 5.2).
Table 5.2: Centres involved in the SANAD Neuropsychology study
• Doncaster Royal Infirmary, Doncaster
• Gian Clwyd Hospital, Bodelwyddan
• Hope Hospital, Salford
• Leigh Infirmary, Leigh
• Royal Bolton Hospital, Bolton
• Royal Hallamshire Hospital, Sheffield
• Royal Victoria Infirmary, Newcastle upon Tyne
• University Hospital of Wales, Cardiff
• Walton Centre for Neurology and Neurosurgery, Liverpool
• Whiston Hospital, Prescot
• Wrexham Maelor Hospital, Wrexham
These centres were chosen as they were either the most active recruiting centres in SANAD 
or the most local hospital centres to Liverpool. Patients with epilepsy were recruited between 
October 2000 and August 2004.
Inclusion/exclusion criteria
Patients were recruited into the SANAD Neuropsychology study if they met the inclusion 
criteria for the SANAD trial; they were previously untreated adults with newly diagnosed 
epilepsy and they gave informed consent. Patients were excluded if they had previously taken 
antiepileptic drugs or they were aged less than 15yrs.
Healthy volunteers
Healthy volunteers from the general population were recruited to act as a non-epilepsy 
reference group. Unfortunately, due to a lack of resources (both time and financial), this 
healthy volunteer group was unable to be collected at the same time as the SANAD
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Neuropsychology patients. However, as a reference control group was thought to be 
necessary to assess the effects of epilepsy and its treatment on cognition, this was collected 
by the author at a later date. The healthy volunteers were recruited between March 2007 and 
October 2007.
There were three main reasons why a reference control group was thought to be necessary:
• Healthy volunteers from the general population have been used as a comparison 
group in several similar studies (Smith et al., 1987, Kalviainen et al.r 1992, Aikia 
et al., 1995, 2001, Prevey et al., 1998, Pulliainen et al., 2000, Salinksy et al., 
2002, 2004, 2005).
• The use of a heaithy volunteer group means that patients with epilepsy can be 
compared with their peers to see if they already differ in terms of their cognitive 
functioning at the time of diagnosis.
• The use of a healthy control group, assessed at baseline and 12 months, 
provides an estimate of the test-retest effects of the neuropsychological test 
battery (Salinsky et al., 2001). Their performance can then be used to create 
regression equations, which are applied to the patient’s performance to evaluate 
the clinical significance of any observed cognitive change (see section on 
'Standardised regression-based change scores in section 5.5.3).
The healthy volunteers were recruited by opportunity sampling. Efforts were made to equate 
them in terms of sex and age to the epilepsy group. The majority were friends and family of 
the researchers; some were friends and family of work colleagues; some were non-medical 
staff at the Walton Centre for Neurology and Neurosurgery and some were undergraduate 
students at the University of Liverpool.
Inclusion/exclusion criteria
The healthy volunteers were entered into the study if: they were aged over 15 years; they 
were matched in age and sex to one of the patient’s with epilepsy; they felt they would be 
available to complete the 12 month assessment and they had given informed consent.
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Healthy volunteers were excluded if they had a previous neurological or psychiatric history or 
had previous use of antiepileptic drugs or a history of substance abuse.
Neurological and psychiatric history was assessed informally by self-report in a semi- 
structured interview prior to assessment, for example, healthy volunteers were asked if they 
had ever been treated for anxiety or depression; had ever had a previous head injury or 
neurological disorder. These exclusion criteria were chosen as these may have influenced the 
cognitive functioning of individuals in the healthy volunteer group and the aim of the study was 
to compare newly diagnosed people with epilepsy to healthy people from the general 
population.
5.3.3 Power calculation
The power calculation for the SANAD Neuropsychology study was based on the original aim 
of detecting differences in cognitive functioning between standard and new AEDs. A power 
calculation revealed that 50 patients were needed in each drug group, to detect a mean 
difference of 1/2 standard deviation (SD) on the Finger Tapping task between the groups, 
setting the power at .80 and probability of making a Type 1 error at jo=.05 (see original 
protocol in Appendix A). The numbers who were recruited and remained on their randomised 
drug in each drug group fell short of this and so the study was underpowered to detect the 
differential effects of AEDs.
However, for the purposes of this thesis, the aim was to detect differences between the two 
groups at baseline (patients and healthy volunteers). Therefore, the number of healthy 
volunteers recruited into the study was based on a separate sample size calculation. This was 
based on the finger tapping task for three reasons:
• It is one of the most frequently used tests employed in randomised clinical trials in 
epilepsy (Cochrane et al.f 1998, Baker & Marson, 2001). It is also one of the most 
commonly used tests by neuropsychologists. In a survey in the USA, it came 
sixth among the top 20 tests (Camara et ai, 2000).
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• It is thought to be sensitive to changes in functioning in people with epilepsy and 
has shown statistically significant cognitive effects of AEDs (Cochrane et a/., 
1998, Baker &Marson, 2001).
• It was used as the main outcome measure in the power calculation for the 
SANAD Neuropsychology study.
This power calculation was carried out by Dr Ruwanthi Kolamunnage-Dona and Dr Catrin 
Tudur-Smith at the Centre for Medical Statistics and Health Evaluation (CMSHE) at the 
University of Liverpool. To have a power of at least 80% to detect a difference of 
approximately one third standard deviations between the two groups (patients and control), 87 
healthy controls were needed.
5.3.4 Ethical approval
The SANAD Neuropsychology study received ethical approval from the North West Research 
Ethics Committee in June 2000, as an amendment to the SANAD trial (Ref: MREC 98/8/62). 
Ethical approval to recruit and assess healthy volunteers was granted separately and was 
approved by the North West Research Ethics Committee in October 2006 (Ref: 
06/MRE08/51). All participants gave written informed consent.
5.3.5 Procedure
Patients with epilepsy
Patients with newly diagnosed epilepsy were recruited at the time of randomisation into 
SANAD. They were assessed before the start of antiepileptic drug medication using a 
comprehensive battery of neuropsychological tests (details of the battery will be provided in 
section 5.3.6). As part of the SANAD Neuropsychology study, patients were re-assessed after 
three months in order to assess the cognitive effects of AEDs in the short term. However, as 
this thesis will not focus on AED differences, this data will not be reported here. Before their 
12 month assessment was due, patients were contacted by either letter or telephone, to 
arrange their 12 month assessment. Again, they were re-assessed using the same battery of 
neuropsychological tests. Patients were assessed either at their home or in their local hospital
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at the same time as their SANAD follow-up appointments. They were recruited and assessed 
by trained research assistants employed at the various recruiting centres.
Healthy volunteers
Healthy volunteers were approached by the researchers to see if they wanted to take part in 
the study and they were provided with participant information sheets. If they gave informed 
consent, they were assessed, using the same battery of neuropsychological tests, as a 
baseline measure. After 11 months, healthy volunteers were re-contacted, by either letter or 
telephone, to arrange their 12 month appointment. The healthy volunteers were assessed 
either at home or at a place that was most convenient for them (for example, seven were 
assessed at work and three at the University of Liverpool).
The author was responsible for recruiting and assessing the healthy volunteer group and was 
assisted by an undergraduate psychology student, as part of a third year undergraduate 
project. The author completed 112 (72%) assessments personally, which represents 
approximately 170 hours of direct assessment and 112 hours of scoring. The author was also 
responsible for training the undergraduate on administering the neuropsychological test 
battery and for checking their assessments to ensure that scoring was accurate and 
standardised.
5.3.6 Neuropsychological test battery
The neuropsychological test battery for the SANAD Neuropsychology study was chosen 
based on the recommendations of an International Cognitive Function Expert Panel which met 
in the USA in April 1996 (see original protocol in Appendix A). The battery comprised 
measures from the FePsy computerised test program (Alpherts, 1987) as well as traditional 
paper and pencil measures. As shown in Table 5.3, the test battery aimed to assess a wide 
variety of cognitive domains measuring both objective and subjective cognitive functioning. 
Each of the tests was selected on the basis of their proven reliability, validity and use in 
people with epilepsy (Cochrane etal., 1998, Baker & Marson, 2001).
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Table 5.3: Neuropsychological test battery
Domain Test Reference Outcome variable
Finger tapping (Alpherts, 1987) • The average number of taps for 
the dominant and non-dominant 
hand across five trials
Psychomotor
speed
Visual reaction time (Alpherts, 1987) • The average reaction time for 
the dominant and non-dominant 
hand (in milliseconds)
AMIPB
psychomotor speed
(Goughian &
Hallows, 1985)
• The mean number of digits 
crossed through over two trials
Recognition of 
words/figures
(Alpherts, 1987) • The number of words or figures 
correctly answered on the 
serial/simultaneous version of 
the task
Memory
Rey Auditory Verbal 
Learning Task
(Rey, 1964) • The sum of words recalled over 
the five trials and the number of 
words recalled after a 30-min 
delay
Story recall (Wilson etal.,
1989)
• The number of story units 
recalled immediately and after a 
10-min delay
AMIPB information Goughian & • The mean number of correct
processing Hallows (1985) responses over the two tasks
Information
processing
Binary choice 
reaction time
(Alpherts, 1987) • The average response speed (in 
milliseconds)
Computerised
Visual Search Task
(Alpherts, 1987) * The average speed of response 
(in seconds)
Mental
flexibility
Stroop (Trenerry et a/.,
1989)
• The number of correct 
responses on the colour-word 
task
Benton verbal 
fluency
(Benton &
Hamsher, 1976)
• The total number of acceptable 
words produced
Mood
Profile of Mood
State
(McNair ef a/.,
1992)
• T ransformed scores (/100) for 
each mood factor
Subjective 
report of 
cognitive 
complaints
Aldenkamp-Baker
Neuropsychological
Assessment
Schedule
(Aldenkamp et 
aL, 1995)
• Transformed scores (/100) for 
each sub-scale
AMIPB=Adult Memory and Information Processing Battery
FePsy computerised test program
The FePsy computerised test program was originally developed in the Netherlands in 1978 for 
the psychological assessment of people with epilepsy. In 1984, a computerised 
neuropsychological test battery was developed for use in both adults and children (aged over
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8 years) with epilepsy (Moerland et at., 1986, 1988). It compromises a number of different 
tasks that measures aspects of attention and concentration, memory, information processing, 
motor speed and reaction time. The FePsy was chosen for use in this study for several 
reasons, as shown in Table 5.4. Five tests were selected from the program because they are 
the most commonly used [Computerised Visual Search task (CVST), Finger Tapping, Visual 
Reaction time (VRT), Binary Choice Reaction Time (BCRT) and Recognition of words and 
figures].
Table 5.4: Reasons for the use of the FePsy computerised test program
• it was developed specifically for use with PWE (Moerland et a/., 1986,1988, Alpherts, 1987)
• It assesses domains of cognitive functioning known to be affected in epilepsy, for example, 
memory, psychomotor speed, attention and concentration (Alpherts, 1987, Moerland etai,
1988)___________________ '______________________________________________________
• it is thought to be sensitive to detect subtle effects of AEDs (Aldenkamp et al, 1987, Alpherts,
1987, Moerland etai., 1988, Alpherts & Aldenkamp, 1990)_______________________________
• It has been employed in several studies assessing the cognitive side effects of AEDs (Alpherts
etai., 1987, Aldenkamp etai, 1987,1993,1997,2000, 2002b, Sveinbjornsdottir ef a/., 1994, 
Neyens etai, 1995, Kalviainen etai., 1996, Ogunrin etai, 2005, Aldenkamp & Alpherts, 2006, 
Donati etai, 2006, Pressleretai, 2006, Aikia etai, 2006b)______________________________
• Computerised assessments are highly standardised and limit the interaction between the
examiner and participant, which is a potential source of bias. As several research assistants 
were involved in the administration of data, this was particularly relevant for this study (Moerland 
etai, 1986, Strauss etai, 2006)_______
• The recording of computerised data is automatic and very accurate (can be measured in 
milliseconds) so scoring and administration errors are reduced (Alpherts & Aldenkamp, 1990)
• Test items are selected randomly from a pool of items to reduce practice effects (Moerland et al,
1986,1988)_____________________________________________________________________
• It has been shown to have reliability and validity even when used to assess PWE several times 
in one day (Aldenkamp etai, 1987)
Computerised Visual Search Task
This task, adapted from Goldstein’s visual searching task (Goldstein et al, 1973), aims to 
assess information processing and perceptual-visual skills. The participant is presented with 
24 patterns on the screen with an arrow pointing to a target pattern in the centre of the screen, 
as shown in Figure 5.3. The participant is asked to find the pattern that is identical to the 
target pattern. The participant is asked to respond as quickly as possible. If the participant 
correctly identifies the matching pattern (e.g. ‘13’), a new one is presented. If they are 
incorrect, they have to re-try until they get the answer correct. The participant has three
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practice trials before they have a total of 24 different patterns to match. The outcome variable 
is the average speed of response, measured as the average time taken (in seconds), to 
correctly find the identical pattern.
Figure 5.3: An example from the Computerised Visual Search Task
Finger tapping
This task, adapted from the Halstead-Reitan battery, aims to assess psychomotor speed and 
motor fluency. The participant is asked to tap with their index finger on the space bar of the 
keyboard as quickly as possible for 10 seconds. Tapping speed is measured for each hand. 
The participant is told to tap with their dominant index finger first (for 10 seconds); then their 
non-dominant index finger (for 10 seconds) and then alternate until they have tapped 10 times 
in total (five times each hand). Feedback is provided on the screen. There is a counter in the 
centre and the number of taps obtained on previous trials is recorded across the bottom of the 
screen. The outcome variables are the average number of taps for the dominant and non- 
dominant hand across the five trials.
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Visual Reaction Time
This task aims to assess alertness, speed of activation of the information processing system 
and psychomotor speed. The participant is asked to respond as quickly as possible, by 
pressing the space bar, when a white square appears in the middle of the screen. The interval 
between presentations of the white square is randomly varied between 2.5 and 4 seconds. 
The participant is asked to respond with their dominant hand first and then half-way through 
the task is asked to use their non-dominant hand. Reaction time is recorded for both hands 
separately. The outcome variables are the average reaction time for the dominant and non­
dominant hand in milliseconds.
Binary Choice Reaction Time
This task aims to assess information processing and attention. As this task comprises a 
decision-making component, it is more complex than the previously described simple visual 
reaction time task. The participant is asked to respond as quickly as possible when a block 
appears on the screen. When a red block appears on the right hand side of the screen, they 
have to press a key with their right hand and if a green block appears on the left side of the 
screen, they have to press a key with their left hand. The blocks appear on the left or right 
side in a random sequence. The task is self-paced and continuous. A new block appears 
instantly after the participant has responded to the previous one. The participant has an initial 
practice phase before they are presented with 60 stimuli. The outcome variable is the average 
response speed in milliseconds.
Recognition of words and figures
This task assesses recognition memory of both verbal and visual stimuli. The task is divided 
into four versions depending on the study material to be remembered (words vs. figures) and 
the presentation of study material (simultaneous vs. serial). However, due to technical 
problems with the simultaneous recognition of figures task (e.g. program crashing/freezing), 
the results of this particular task were considered to be both inaccurate and incomplete. 
Therefore, only the three other tasks will be described and reported on. The words to be 
remembered are four-letter words, which are randomly selected from a pool of 100 words.
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The figures are randomly built from basic shapes (e.g. triangles and shapes) and are difficult 
to verbalise, as shown in Figure 5.4.
Figure 5.4: Examples of the visual stimuli used in the serial recognition of figures task
Serial recognition of words
Figure 5.5 illustrates the serial recognition of words task. In the study phase, the participant is 
presented with six words that appear one after the other in the centre of the screen at a rate of 
one per second (see Figure A). The participant is asked to remember the order in which the 
words appeared. After two seconds, one of the six words appears again and the participant 
has to type in the order of presentation of that word in the study phase (see Figure B). For 
example, ‘shot’ was the second word that appeared, so they would type ‘2’. No feedback is 
provided. There is an initial practice phase of three trials. The outcome variable is the number 
of words correctly answered out of 24 trials.
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Figure 5.5: An example of the serial recognition of words task. Figure A represents the study phase. 
Figure B represents the test phase
Figure A Figure B
Serial recognition of figures
This task is the non-verbal equivalent of the serial recognition of words task described above. 
In the study phase, the participant is presented with four figures that appear one after the 
other in the centre of the screen at a rate of one per second. The participant is asked to 
remember the order in which the figures appeared. After two seconds, one of the four figures 
appears again and the participant has to type in the order of presentation of that figure in the 
study phase. No feedback is provided. There is an initial practice phase of three trials. The 
outcome variable is the number of figures correctly answered out of 24 trials.
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Simultaneous recognition of words
As shown in Figure 5.6, in the study phase, the participant is presented with six words that 
appear on the screen at the same time for six seconds (see Figure A). The participant is 
asked to remember all of them. After two seconds, a second set of six words are presented 
containing one of the words from the previous set (see Figure B). The participant has to 
correctly identify which of these words was in the study phase (e.g. rose, number ‘2’). There is 
an initial practice phase of three trials. The outcome variable is the number of words correctly 
identified out of 24 trials.
Figure 5.6: An example of the simultaneous recognition of words task. Figure A represents the study 
phase. Figure B represents the test phase
Figure A Figure B
plan word
1
bank rose
shot skin cake
4
shoe
rose year
5
cave
Which word appear*
6
vase
id m the previous set’ (1.6]
Paper and pencil neuropsychological tests
Traditional paper and pencil measures were also used along with the FePsy computerised 
test battery to obtain a comprehensive assessment of cognitive functioning (see Appendix B). 
These remaining tests were chosen because they have good reliability and validity and have 
previously been used in studies with people with epilepsy. For the purposes of this thesis, in 
evaluating the reliability of a test, those with reliability coefficients >.80 were considered to
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have high levels of reliability and those with >.70 were considered to have adequate and 
acceptable levels for research (Strauss etai, 2006).
Rey Auditory Verbal Learning Test (RAVLT)
This task aims to assess verbal memory and learning (Strauss et ai, 2006). It has been 
developed for use in individuals aged between 6-89 years (Rey, 1964). The participant is 
presented with a list of 15 unrelated words which are read aloud by the examiner at a rate of 
one per second. The participant is then asked to free recall as many of the words as they can 
remember. The list is read a second time and again the participant has to free recall as many 
words as they can remember, including the words they have said previously. This is repeated 
until the list has been read aloud five times. The participant is then asked to remember the list, 
as they will be asked to recall it later. After a 30 minute delay, the participant is asked to free 
recall as many words as they can from the original list without being presented with it again. 
The outcome variables are: the sum of the words recalled over the five trials, as a measure of 
immediate memory and total acquisition; and the number of words recalled after a 30 minute 
delay, as a measure of delayed recall.
Alternate parallel forms, developed by Crawford, Stewart and Moore (1989), are available for 
this task and different versions of the list were used at each assessment. This has been 
shown to reduce practice effects (Crawford et ai., 1989, Lemay et at., 2004).
This test has adequate test-retest reliability. After a one month test-retest interval using the 
alternate forms, correlations for the different outcome measures ranged between 0.61 -0.86 
(Delaney et ai., 1992). After one year, correlations coefficients were not as high, but ranged 
from .60-.70 (Mitrushina & Satz, 1991). The test also has good validity, correlating with other 
measures of learning and memory such as the Wechsler Memory Scale-Revised (WMS-R) 
Logical Memory subscale (Johnstone et at., 2000) and the California Verbal Learning Test 
(Crosson & Wiens, 1994). This task has been used in other studies assessing the cognitive 
side effects of antiepileptic drugs (e.g. Dodrill et at, 1993,1995,1997,1999, 2000, Prevey et 
at, 1996, Blum etai., 2006, Donati etai, 2006).
127
Story recall
Recall of stories or short paragraphs have been used in several studies assessing cognitive 
functioning in people with epilepsy (e.g. Curran & Java, 1993, Craig & Tailis, 1994, Grunewald 
et al., 1994, Kalviainen et al., 1995, 1996, Meador et al., 1995, 1999, 2001, 2005, 2007, 
Martin et al., 2001, Salinksy et al., 2002, 2004, 2005, Aikia et al., 2006b; Bum et al., 2006). 
These tasks are designed to resemble everyday verbal memory functioning (Lezak et al., 
2004, Strauss et al., 2006). The stories used in this study were taken from the story recall 
sub-test of the Rivermead Behavioural Memory Test, which has been developed for use in 
individuals aged between 11-94 years. This test was designed to have high ecological validity 
and the stories resemble news items containing British characters (Wilson etal., 1989).
In this task, the participant is presented with a short story. After presentation of the story, the 
subject is asked to free recall as much of the story as they can remember. According to the 
scoring criteria, points are awarded for each piece of information correctly recalled and half 
points are awarded for partially correct information. The participant is then asked to remember 
the story as they will have to recall it later. After a ten minute delay, the participant has to free 
recall the story without hearing it again. Recall is scored using the same scoring system. A 
cue can be provided if the participant cannot remember any information from the story. The 
outcome variables are the immediate and delayed recall score.
Alternate parallel forms are available for this test and different versions of the story were used 
at each assessment. The test-retest reliability of the Rivermead Behavioural Memory Test 
battery is high (.89) when assessed in stroke patients over a two week period (Man & Li, 
2001). But test-retest reliabilities for each individual sub-test are not available. The Rivermead 
Behavioural Test correlates with other tests of memory functioning, such as the Warrington 
Recognition Memory Test, Wechsler Memory Scale and Rey Auditory Verbal Learning Test 
(Strauss et al., 2006).
Verbal fluency task
This task aims to assess the spontaneous production of words under restricted search 
conditions (Strauss et al, 2006). The test has been developed for use in individuals aged
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between 7-95 years (Benton & Hamsher, 1976). The participant is asked to generate as many 
words as possible beginning with three specified letters of the alphabet in 60 seconds. 
However, they have to follow three rules: they are not allowed to use proper nouns; numbers; 
or altered/extended versions of words. The outcome variable is the total number of acceptable 
words produced over the three letters.
Three alternate, parallel forms (FAS, CFL and PRW) have been developed by Benton & 
Hamsher (1976) and so these different versions were used for the baseline, three month and 
12 month assessments. The first version (FAS) had to be re-administered in the follow-up 
study, however, as this was between three and seven years later, practice effects were 
considered to be small. After an interval of more than five years, test-retest reliability was .74 
in elderly individuals (Tombaugh et a/., 1999). When alternate parallel versions are used, the 
test-retest reliability coefficient for 120 participants over an interval of six months was similar 
(.77) (Ruff et a/., 1996). In terms of validity, the verbal fluency task has been found to correlate 
with verbal IQ (Lacy et a/., 1996). Verbal fluency has been used in several studies to assess 
the cognitive side effects of AEDs (e.g. Curran & Java, 1993, Helmstaedter et al., 1993, 
Dodrill et a/., 1993,1995,1997, Prevey etai, 1996; Martin etai, 1999, 2001, Aldenkamp et 
al., 2000, Ojemann eta!., 2001, Salinsky etai., 2005).
Stroop Neuropsychological Screening Test
This task aims to assess attention and concentration as well as the ability to inhibit responses 
and ignore distracting stimuli. The version used was that developed by Trenerry et al. (1989). 
In the first part of the task, the colour task, the participant is presented with a list of 112 colour 
words (red, blue, green, tan) which they have to read aloud as fast as they can. The 
participant has two minutes to respond. The second part of the task is the colour-word task. 
The participant is presented with the same 112 colour words printed in conflicting ink colours. 
The participant is asked to name the colour of the ink that the word is printed in rather than 
read the words. The participant has two minutes to complete the task. This task was not 
administered to those who reported being colour-blind [7 (3.1%) patients with epilepsy and 3 
(3.4%) healthy volunteers]. The outcome variable is the number of ink colours correctly 
named on the colour-word task within the two minutes.
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The normative data for the Stroop Neuropsychological Screening Test is based on 156 adults 
aged between 18-79 years. There are age differences in performance on the colour-word task 
and so normative data is divided into those aged above/below 50 years (Trenerry et al., 
1989). The normative sample was used to derive percentiles, with lower percentiles indicating 
greater difficulty on this task. Separate percentiles were derived for those aged 18-49yrs and 
those aged over 50yrs. The high test-reliability correlation coefficient (.90) was assessed by 
retesting 30 participants in the normative sample over an average of 59 days interval. There 
are no alternate forms of this task and practice effects were observed over the 59 day interval, 
with an approximate 5% increase from baseline (Trenerry et al., 1989).
The Stroop Neuropsychological Screening Test was validated in patients with left- and right- 
hemisphere cerebrovascular accidents; closed head injuries and other central nervous system 
disorders. The test was able to correctly classify 79% of those aged under 50 years as either 
'brain-damaged' or from the ‘normative’ sample and correctly classify 91.8% of those aged 
over 50 years. The Stroop Neuropsychological Test correlated, as was expected, with other 
tests, for example Category Test errors (-.57); Wechsler Adult Intelligence Scale-Revised 
(WAIS-R) Full scale IQ (.46); Verbal IQ (.44); Performance IQ (.49); WAIS-R Block Design 
(.77) and Vocabulary scores (.31) (Trenerry et al, 1989). The Stroop task is the most 
commonly used task in randomised clinical trials in epilepsy (Cochrane et al, 1998, Baker & 
Marson, 2001), however, the particular version used is not always stated.
Adult Memory and Information Processing Battery (AMIPB)
The Adult Memory and Information Processing Battery (AMIPB) comprises a series of 
memory and information processing tasks (Goughian & Hallows, 1985). Two sub-tests from 
the AMIPB were selected for their ability to measure psychomotor speed and information 
processing.
Psychomotor speed
In this task, the participant is presented with three columns containing 11s and is asked to 
cross through the 11s as fast as they can. They have 20 seconds to work as quickly as
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possible. This task is completed twice and the outcome variable is the mean number of 11s 
crossed through over the two trials.
Information processing
This task is thought to measure performance on timed, repetitive, mentally engaging activities 
(Goughian & Hallows, 1985). Performance on this task is thought to be independent of 
memory skills or general intelligence but is sensitive to cerebral dysfunction (Goughian & 
Hallows, 1985). This task comprises two similar cancellation tasks (A and B). In task A, the 
participant is presented with a page containing 105 rows of numbers. Each row is made up of 
five two-digit numbers (e.g. 28, 16, 49, 21, 72). The participant is asked to cross out the 
second highest number in each row e.g. 49. There are five demonstration items and five 
practice items to ensure that the participant has understood the task. The participant has four 
minutes to work through as many rows as possible. They are told to work as quickly and as 
accurately as possible.
In task B, the participant is presented with a similar page containing 105 rows of numbers. 
Each row comprises nine numbers separated by a hyphen, with four on the left side and five 
on the right side (e.g. 2 8 7 1 -482 1 7). The participant is asked to cross out the number on 
the right side that does not appear on the left side (e.g. 4). There are five demonstration times 
and five practice items to ensure that the participant has understood the task. The participant 
has four minutes to work through as many rows as possible. They are told to work as quickly 
and as accurately as possible. Two alternate versions of this task (Form 1 and Form 2) are 
available and these were used alternately at each assessment. The outcome variable is the 
mean number of correct responses within four minutes over the two tasks.
Each form of the Adult Memory and Information Processing Battery was standardised on 180 
healthy volunteers from the UK. Test-retest reliability was assessed in 30 subjects tested 
between 1-6 days, who were given a different form at their second assessment. Test-rest 
reliability for the information processing tasks was high (.79 for Task A and .89 for Task B). 
Test-retest reliabilities for psychomotor speed were also high (.83 for Task A and .81 for Task 
B) (Goughian & Hallows, 1985).
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The test was validated by comparing the data from the normative sample with 54 patients with 
generalised cerebral dysfunction (e,g. severe head injury defined as post-traumatic amnesia > 
7 days; encephalitis; cerebral atrophy; raised intracranial pressure and acute vitamin 
deficiency). The patients scored significantly lower on both the information processing 
{p<.001) and psychomotor speed tasks (p<.001).This task has been also been used in studies 
comparing the cognitive side effects of AEDs (e.g. Sveinbjornsdottir et al., 1994, Grunewald et 
al., 1994).
Profile of Mood States (POMS)
This self-report questionnaire, revised by McNair et al., (1992), aims to assess participant’s 
current mood state. The questionnaire comprises 65 adjectives that describe feelings. For 
each item, the participant is asked to rate how often they have felt like that over 'the past 
week including today’ using a five point scale (0=not at all to 4=extremely). The POMS 
assesses six mood factors: Tension-Anxiety; Depression-Dejection; Anger-Hostility; Vigour- 
Activity; Fatigue-Inertia; Confusion-Bewilderment (see Table 5.5).
Table 5.5: Example of items on the Profile of Mood States questionnaire
Mood factor Description Example items No of 
items
Range of 
scores
Tension-
Anxiety
Heightened musculoskeletal 
tension
Tense, shaky, on edge 9 0-36
Depression-
Dejection
Depression accompanied by a 
sense of personal inadequacy
Unworthy, hopeless, 
guilty
15 0-60
Anger-
Hostility
Anger and antipathy towards 
others
Grouchy, resentful, 
spiteful
12 0-48
Vigour-
Activity
Vigorousness, ebullience and 
high energy
Lively, active, energetic 8 0-32
Fatigue-
Inertia
Weariness, inertia and low 
energy level
Listless, exhausted, 
sluggish
7 0-28
Confusion-
Bewilderment
Bewilderment and muddle 
headedness
Confused, unable to 
concentrate, muddled
7 0-28
Scores for each mood factor are calculated by summing the participant's responses to the 
appropriate items. Based on normative data, raw scores can be converted into standardised T 
scores (mean=50, SD=10) by plotting scores onto the POMS profile sheet, which is available
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for psychiatric outpatient males and females and a healthy college sample. However, it is 
recommended that raw scores are used for research purposes, as the standardised scores 
remove any potential sex differences, therefore the raw scores were used in this study 
(McNair et al.t 1992). As each mood factor is made up of a different numbers of items, for the 
purposes of this thesis, the raw scores were transformed to scores out of 100. This is to allow 
comparison across the sub-scales. This was calculated by: (mood factor score/max possible 
score)*100. The outcome variables are the transformed scores (out of 100) for each mood 
factor. A high score on each of the mood factors reflects higher mood disturbance except for 
the vigour factor, which is negatively weighted, so a higher score reflects greater energy and 
vigour.
The POMS mood factors have high internal reliability (.85-.95). However, its test-reliability 
after a median 20 days (3-110 days) in a sample of 100 patients from the psychiatric 
normative sample is marginal-adequate (.65-.74). After six weeks, test-retest reliability was 
low (.43-.53) (McNair et al., 1992). Several validation studies have been undertaken on the 
POMS, which have provided evidence of the factorial validity of the six mood factors as well 
as its predictive, construct and concurrent validity (McNair et al., 1992). The POMS has been 
used frequently in studies investigating the cognitive and behavioural effects of AEDs (e.g. 
Meador etal., 1990, 1995, Dodrtll etal., 1993, 1997, 1999, 2000, Pulliainen & Jokelainen et 
al., 1995; Martin etal., 1999, 2001, Aldenkamp etal., 2000, Salinsky etal., 2002, 2004,2005, 
Blum etal., 2006).
Aldenkamp-Baker Neuropsychological Assessment Schedule (ABNAS)
This self-report questionnaire was designed to assess the subjective report of cognitive 
effects of antiepileptic drugs (Aldenkamp et al., 1995, Aldenkamp & Baker, 1997, Brooks et 
al., 2001). The questionnaire comprises 24 statements associated with difficulties in six 
cognitive domains: fatigue, slowing, memory, concentration, motor co-ordination and 
language. The participant is asked to rate on a four point scale (0=no problem to S^serious 
problem) to what extent they agree with each statement (see Table 5.6).
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Table 5.6: Example of items on the ABN AS
Sub-scale Example item No of items Range of 
scores
Fatigue I tire easily and have little energy 5 0-15
Slowing My mind does not work as fast as it should 5 0-15
Memory I have difficulties remembering names of 
people
4 0-12
Concentration I have difficulties following a book or film 4 0-12
Motor I feel clumsy 3 0-9
Language I have problems finding the correct word 3 0-9
Total 24 0-72
Scores for each sub-scale are calculated by summing the participant’s responses to the 
appropriate items. A total ABNAS score is calculated by summing the scores across all the 
sub-scales. As each sub-scale is made up of different numbers of items, for the purposes of 
this thesis, the raw scores were transformed to scores out of 100. This is to allow comparison 
across the sub-scales. This was calculated by: (sub-scale/max possible score)*100. The 
outcome variables are the transformed total ABNAS score and the transformed score (out of 
100) for each sub-scale.
As this questionnaire was developed to assess the adverse effects of antiepileptic drugs on 
cognition and primarily for use in clinical trials (Aldenkamp et al, 1995), it was only 
administered to the patients with epilepsy.
Test-retest reliability of the ABNAS has not been assessed formally; however, it is a reliable 
measure, with a high internal reliability [Cronbach’s alpha .95 (Aldenkamp & Baker, 1997), .96 
(Brooks et al., 2001)]. The ABNAS has been validated in healthy volunteers as part of a 
double-blind placebo-controlled parallel group design, where participants were randomised to 
a benzodiazepine (temazepam 10mg or 20mg) or placebo (Aldenkamp et al., 1995). It has 
also been validated for use in people with epilepsy (Aldenkamp & Baker, 1997, Brooks et al., 
2001). The ABNAS has been shown to be significantly correlated with the Adverse Events 
Profile; Hospital Anxiety and Depression Scale and Everyday Memory Questionnaire (Brooks 
et al., 2001) and neuropsychological tests from the FePsy computerised test battery 
(Aldenkamp et al., 2002b). It has also been used in several studies assessing the subjective
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report of cognitive side effects of AEDs (Aldenkamp et al., 1998, 2000, 2002a, Meador et ai, 
2001,2005, 2007, Blum etal., 2006)
Administration
The neuropsychological test battery took approximately 1 Vz hours to complete. The tests 
were administered in a fixed order to ensure adequate time passed to test delayed recall on 
the memory tasks. However, regular breaks were offered and taken to reduce fatigue effects. 
Neuropsychological assessment was postponed and rearranged for a later date in those 
patients who reported having a seizure within 24 hours of the assessment. As described, 
parallel alternate forms were used, where available, in the follow-up sessions to reduce 
practice effects associated with repeat neuropsychological testing (Beglinger et al., 2005).
5.4 Neuropsychology follow-up study
Patients with epilepsy, who took part in the SANAD Neuropsychology study, were invited to 
take part in a neuropsychology follow-up study. This study was designed to investigate the 
third objective of this thesis:
• To document the longer term effects of epilepsy and its treatment on cognitive 
functioning in people with newly diagnosed epilepsy.
The design, recruitment of participants and procedure for this study will be described below.
5.4.1 Design
This follow-up study was an observational longitudinal study investigating the cognitive profile 
of patients with epilepsy three to eight years after their diagnosis.
5.4.2 Recruitment
Patients with epilepsy who had completed the 12 month assessment as part of the SANAD 
Neuropsychology study were invited to take part in the follow-up assessment. As patients had
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various reasons for not completing the 12 month assessment (see section 7.2.1), only those 
who had completed the study were invited to take part. The number of patients who 
completed the 12 month assessments at each of the hospital centres is shown in Table 5.7.
Table 5.7: Number of patients at each recruiting centre who had completed the 12 month SANAD 
assessment
Hospital centre Number completed (n, %)
Walton Centre for Neurology and Neurosurgery, Liverpool 39 (67.2)
Royal Bolton Hospital, Bolton 32 (71.1)
University Hospital of Wales, Cardiff 30 (66.7)
Royal Hallamshire Hospital, Sheffield 12(70.6)
Wrexham Maelor Hospital, Wrexham 11 (55.0)
Gian Ciwyd Hospital, Bodelwyddan 8(61.5)
Hope Hospital, Salford 8(61.5)
Doncaster Royal Infirmary, Doncaster 4(57.1)
Leigh Infirmary, Leigh 2 (66.7)
Whiston Hospital, Prescot 1 (100.0)
Total 147 (66.2)
Two hospital centres were not included in the follow-up study (Leigh Infirmary and Whiston 
Hospital), as they only had very few eligible patients at each site. Due to the lengthy time 
procedures involved in obtaining Research & Development approval at each NHS trust, 
particularly the process of obtaining honorary contracts, it was not considered an effective use 
of time and resources to apply for R&D approval within these trusts. Therefore, patients were 
recruited from the remaining eight hospital centres. Patients were recruited between 
November 2007 and November 2008.
Inclusion/exclusion criteria
Patients were approached to take part in the follow-up study if they had completed the 12 
month assessment as part of the SANAD neuropsychology study; they still had a diagnosis of 
epilepsy and they gave informed consent. Patients were excluded from taking part in the 
study if they had undergone epilepsy surgery or they expressed a wish not to take part in any 
further research, which was recorded either at the end of the SANAD Neuropsychology study 
or through the SANAD Quality of Life study.
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Those who had undergone epilepsy surgery were excluded from this study, as epilepsy 
surgery is associated with neuropsychological consequences (see section on Epilepsy 
surgery in section 3,3.2) and this thesis is concerned with the natural history of cognitive 
functioning in people with newly diagnosed epilepsy, without surgical intervention. Eligibility 
was checked by asking patients about their medical history informally in a semi-structured 
interview prior to the assessment.
5.4.3 Power calculation
The power calculation for this follow-up study was conducted by Dr Ruwanthi Kolamunnage- 
Dona and Dr Catrin Tudur Smith at the CMSHE at the University of Liverpool. The power 
calculation revealed that follow-up assessments for 95 patients with epilepsy were needed to 
detect a meaningful clinically significant change of 2.12 taps on the Finger Tapping task from 
baseline to follow-up, setting the power at 0.80, correlation of .491, and adjusting for a finite 
sample.
5.4.4 Ethical approval
The follow-up study was considered to be a separate study, rather than an amendment to the 
SANAD Neuropsychology study, and so ethical approval was granted separately (along with 
approval to assess the healthy volunteers). Ethical approval to follow up the patients with 
epilepsy was obtained and approved by the North West Research Ethics Committee in 
October 2006 (Ref: 06/MRE08/51). Research governance approval was obtained from the 
local R&D committees. All participants gave written informed consent.
5.4.5 Procedure
Up to date contact details were checked with the on-going SANAD quality of life study 
database and by contacting each of the hospital centres. This also ensured that letters were 
not sent to patients who may have died since their 12 month assessment. Invitation letters 
and patient information sheets were sent out to those patients who had completed the 12 
month assessment and had up to date contact details.
137
Patients were asked to either contact the researcher by telephone or by returning a reply slip 
in the prepaid envelope, if they did or did not want to take part in the follow-up study. A follow­
up letter and telephone calls were made to those patients who had not responded after one 
week. Half way through the recruitment period, a newsletter produced by the author, was also 
sent out with the follow-up letters. This was to try and maximise recruitment and the amount of 
data available for analysis.
If patients wanted to take part in the study, a mutually convenient time and place to complete 
the assessment was arranged. Patients were assessed either at home or at an outpatient 
department of their local hospital. Once they had given informed consent, a semi-structured 
interview was conducted to obtain up-to-date demographic and clinical information. This 
information included: current medication; current seizure frequency or how long they had been 
seizure free; whether they had any other medical or psychological problems since their 12 
month assessment and socio-demographic characteristics such as, employment status and 
educational history.
Patients were then assessed using the same battery of neuropsychological tests. After their 
assessment, letters were sent to their GPs informing them of their participation in the 
research.
The author was responsible for recruiting and assessing the patients with epilepsy in the 
follow-up study and was assisted by a Trainee Clinical Psychologist, as part of a Clinical 
Psychology doctoral thesis. The author completed 43 (86%) assessments personally, which 
represents approximately 64.5 hours of direct assessment and 43 hours of scoring. The 
author was also responsible for training the Trainee Clinical Psychologist on administering the 
neuropsychological test battery; co-ordinating assessments including sending letters to 
patients and their GPs, and for checking the assessments to ensure that scoring was accurate 
and standardised.
After the follow-up assessment, some patients requested feedback on their 
neuropsychological test performance. Under the supervision of Professor Gus A Baker, 
feedback letters were written by the author outlining any changes in cognitive functioning from
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baseline to the end of the follow-up study period. This included providing strategies to help 
with memory functioning, where appropriate. If necessary, letters were sent to the patient's 
GP informing them of any significant changes or concerns.
5.5 Data entry and statistical analysis
The assessments for both the patients with epilepsy and healthy volunteers at all time points 
(baseline, 12 months and follow-up) were scored according to the scoring criteria set out in 
the test manuals. They were checked by two trained research assistants and entered onto a 
Statistical Package for Social Sciences (SPSS) database (version 16.0). Confidentiality was 
ensured by providing participants with a unique code, which was used on databases and 
record sheets. No other identifying information was stored alongside the data collected by the 
researchers. At the end of the data collection in November 2008, the whole database was 
checked and audited by the author to ensure accuracy of data entry.
The author conducted all the statistical analysis but advice was sought from Dr Ruwanthi 
Kolammunage-Dona at the CMSHE at the University of Liverpool. All data was analysed using 
SPSS version 16.0 and Stats Direct 2.6.8. The author was responsible for the interpretation of 
this data.
The results are divided into three separate results chapters answering each of the three 
objectives of this thesis. Therefore, the statistical analysis that was conducted on the data will 
be described in three separate sections below (sections 5.5.2, 5.5.3 and 5.5.4). As there are 
various methods which can be used to assess change in cognitive functioning over time, a 
brief description of these methods and justification for their use is provided in the section on 
‘Measuring change1 in section 5.5.3.
5.5.1 Checking outliers
Before analysing the neuropsychological test data, raw scores on all test variables at all time 
points, were checked for the presence of outliers. These were defined as scores that fell more 
than three standard deviations above or below the mean. Three standard deviations is a
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criterion that has been used in several similar studies (e.g. Oyegbile et al., 2004, Hermann et 
a/., 2007a). Each outlier was checked to see if it was a genuine result or a recording error. If it 
was a recording error, then the score was corrected on the database. However, the majority of 
outliers were considered to be due to measurement error, particularly on the FePsy computer 
tasks (e.g. the tapping task had not recorded the numbers of taps correctly on a trial). These 
scores were deleted. In total, 113 outliers were removed from the dataset (113/13 350), which 
represents 0.8% of the data.
5.5.2 Statistical analysis for chapter 6
Demographic and clinical characteristics
Descriptive statistics were used to describe the demographic and clinical characteristics of the 
patients with epilepsy and healthy volunteers who were assessed at baseline, independent t 
tests and chi square tests were carried out to investigate any differences in characteristics 
between the two groups.
Neuropsychological and psychological test data
Assessing the spread of the data
The raw scores on each of the measures were assessed to see whether they met the 
assumption of normality. The spread of the data was assessed by visually inspecting 
histograms, Q-Q plots, the values of skewness and kurtosis for each test variable and the 
results of the Kolmogorov-Smirnov test.
For the neuropsychological test variables, 11 of the 17 neuropsychological test variables did 
not differ from the normal distribution and so parametric analyses (independent t tests) were 
conducted on these. However, VRT (both dominant and nondominant hand), BCRT and 
CVST were positively skewed. Reaction time data is often skewed because there is a limit to 
how quickly an individual can respond to a stimulus but no limit to how slowly an individual 
can respond (Alpherts & Aldenkamp, 1990, Strauss etal., 2006). Simultaneous recognition of 
words and the Stroop test were negatively skewed. A low ceiling was observed on the Stroop
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colour-word task, with the majority of patients and healthy volunteers achieving maximum 
scores.
Due to the low ceiling effect observed on the Stroop Neuropsychological Screening Test, this 
variable was converted to a categorical one based on normative data (Trenerry et al., 1985). 
Using the age-adjusted percentile, an individual was classified as falling within the borderline 
range if their score fell below the 10th percentile; in the low average range if their score fell 
between the 10^ and 25th percentile; and in the average range if they performed above the 
25th percentile. Chi square analysis was then applied to test differences between the two 
groups.
Log transformations were carried out on the five skewed variables, so that they met the 
assumption of normality for parametric analysis. However, scores on the BCRT and 
simultaneous recognition of words became more skewed after transformations so log 
transformations were only performed for the two VRT measures and CVST. Therefore, to test 
significant differences between the two groups, non-parametric (Mann Whitney) tests were 
carried out on the binary choice reaction time and simultaneous recognition of words.
For the mood variables, tension, depression, anger, fatigue and confusion were positively 
skewed. Only the vigour mood factor was normally distributed. As several participants had a 
score of zero, log transformations could not be carried out on these variables. Therefore, non- 
parametric (Mann Whitney) analyses were carried out on the mood factor scores to test 
differences between groups. To maintain consistency within the POMS, non-parametric 
analyses were also applied to the vigour factor, despite it meeting the assumptions of 
normality for parametric analysis. For the ABNAS scales, all sub-scales were positively 
skewed so box and whisker plots were used to present the data.
Age, sex and education adjusted z-scores
Raw scores on the 14 normally distributed neuropsychological test variables were converted 
to z-scores adjusted for age, sex and education relative to the control mean [Mean (M)=0, 
SD=1] using multiple regression techniques. This method has been employed in previous
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studies involving adults with epilepsy (Oyegbiie et al., 2004, Hermann et ai, 2007a), children 
with epilepsy (Hermann et al.t 2006a) and those with early, untreated Parkinson’s disease 
(Aarsland et al., 2009). This method was used because it corrects for the effects of age, sex 
and education, which are important potentially confounding variables on cognitive functioning. 
Additionally, by putting all scores on a common metric, comparisons across tests and across 
domains can be made directly (Oyegbiie et al., 2004, Hermann etal., 2006b, 2007a).
Using the healthy volunteers as a reference group, multiple regression techniques were used 
to create regression equations (see Table C.1). The regression equations regressed age, sex 
and education on baseline score. Age in years was entered as a continuous variable, sex as a 
dichotomous variable (0=female, 1=male) and education was divided into three categories 
(low ^11yrs, medium 12-15yrs, high >15yrs). Two dummy variables were created so 
education could be entered into the regression. These equations were then applied to the 
patients with epilepsy to obtain age, sex and education predicted scores. The adjusted z- 
scores were calculated by applying the formula: [(observed score-predicted score)/Standard 
Error estimate of the regression equation]. The adjusted z-scores were transformed by 
multiplying the timed tasks by minus one, so that higher scores on all tasks reflected better 
performance (Temkin etal., 1999).
Investigating relationships
Spearman’s correlational analyses were carried out to investigate the relationship between 
neuropsychological test performance and previous seizure activity. One-way between 
subjects analysis of variance (ANOVAs) were carried out on each of the cognitive measures 
to investigate potential differences in epilepsy type. Spearman’s correlations were performed 
to assess the relationship between cognitive test performance and mood.
Individual-level analysis
To investigate the clinical significance of results, the adjusted z-scores were used to identify 
individuals who demonstrated abnormal performance across the test battery. Abnormal 
performance was defined either as an adjusted z-score of <-1.5 or ^-2.0.
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A summary impairment index was created, which represents the proportion of test scores 
(from a total of 14) that are classified as abnormal. This reflects the degree of cognitive 
impairment exhibited by each individual (Oyegbile et ai, 2004, Hermann et al., 2006b, 2007a). 
Exploratory analyses (using independent f, Mann Whitney and chi square tests) were 
conducted to try and identify the characteristics of those who were classified as impaired 
based on the impairment index. Impairment was defined as more than one abnormal test 
performance across the neuropsychological test battery. For this analysis, the more 
conservative value of z^-2.0 was used. Several studies have classified performance of more 
than two standard deviations below the control mean as abnormal (Oyegbile et al., 2004, 
Hermann et al., 2006b, 2007a). Finally, odds ratios were calculated to see if baseline 
cognitive impairment was a predictor of recurrent seizures at 12 months and longer term 
follow-up.
5.5.3 Statistical analysis for chapter 7
Demographic and clinical characteristics
Descriptive statistics were used to describe the demographic and clinical characteristics of the 
patients with epilepsy and healthy volunteers who were assessed at baseline and 12 months. 
Independent t tests, Mann Whitney tests and chi square tests were carried out to investigate 
any differences in demographics between the patients with epilepsy and healthy volunteers. 
These were also carried out to see if there were differences in demographic, clinical and 
baseline neuropsychological characteristics between those who did or did not respond at 12 
months. However, for some of the variables, expected frequency counts for were less than 
five, so chi square analysis could not be carried out. Descriptives were provided instead.
Neuropsychological and psychological test data
Assessing the spread of the data
The raw scores and the difference scores between baseline and 12 months on each of the 
measures were assessed to see whether they met the assumption of normality. The spread of
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the data was assessed by visually inspecting histograms, Q-Q plots, the values of skewness 
and kurtosis for each test variable and the results of the Kolmogorov-Smirnov test.
Fifteen of the 17 neuropsychological change scores did not differ from the normal distribution 
so paired t tests were carried out on these variables to investigate changes from baseline to 
12 months in both groups. VRT with the non-dominant hand differed from the normal 
distribution in the patient group so Wilcoxon sign tests were carried out on this variable. 
Change scores on the Stroop colour-word task also differed from the normal distribution, 
however, because of the low ceiling observed on this task, this was converted to a categorical 
variable using the procedure described in section 5.5.2. Descriptive statistics were then used 
to describe the proportion of patients in each category at baseline and 12 months.
The 12 month neuropsychological variables were also assessed to see if they met the 
assumption of normality for use as criterion variables in the creation of standardised 
regression-based z-scores (see section on 'Measuring change’ below). Twelve of the 17 
variables did not differ from the normal distribution but five variables did not meet the 
assumption of normality. VRT with both the dominant and non-dominant hand and the CVST 
were positively skewed. The simultaneous recognition of words was negatively skewed and a 
low ceiling was observed on the Stroop colour-word task. Log transformations were carried 
out on the skewed variables, so that they met the assumption of normality for parametric 
analysis. However, simultaneous recognition of words became more skewed after 
transformation so this variable was not used in the standardised regression-based z-scores.
For the mood variables, all of the mood factor change scores met the assumption of normality 
for both groups except the depression factor for the healthy volunteers. Therefore, paired t 
tests will be used to evaluate change for each of the mood factors except this one where the 
Wilcoxon sign will be used instead. For the ABNAS, all the variables did not meet the 
assumption for normality so the Wilcoxon sign test will be used to assess changes in self- 
reported cognitive complaints by the patients with epilepsy.
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Measuring change
As there are various methods to assess change in cognitive functioning over time, a brief 
description of these methods ad justification for their use is provided below.
Factors that affect test-retest performance
Assessing cognitive change in neuropsychology is not a straightforward process. Test-retest 
situations are affected by a number of factors, as shown in Table 5.8, which make determining 
whether an observed change is a ‘true’ change or due to measurement error (e.g. practice 
effects, regression to the mean) or other factors difficult (Temkin et al., 1999). Being able to 
determine whether a change is a ‘true1 change in performance is particularly important when 
assessing the effects of interventions, for example, outcomes after surgery or in clinical drug 
trials (McSweeney et al., 1993, Chelune et a/., 1993, Hermann et al., 1996, Salinsky et al., 
2001). In these cases, it is important to know whether the change observed is greater than 
that would be expected for comparable individuals who are retested over similar intervals but 
are not exposed to the intervention (Chelune et al., 1993). Evaluating clinically meaningful 
change is also made more difficult because normative data on change over time for many 
neuropsychological measures do not exist (McSweeney et al., 1993).
Over the last two decades, several statistical techniques have been developed to evaluate 
clinically meaningful and statistically reliable cognitive change. These correct for some of 
these sources of error and bias, in particular, practice effects and regression to the mean. 
Temkin et al., (1999) and Frerichs & Tuokko (2005) have reviewed and compared these 
different methods of evaluating change. Two of these main methods will be described in the 
section below.
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Table 5.8: Potential sources of bias and error in test-retest situations (adapted from Strauss et a!., 
2006)
Source Example
Intervening variables
•
•
Events of interest (e.g. surgery, medical 
intervention, rehabilitation)
Extraneous events
Practice effects
•
•
•
Memory for content
Procedural learning
Other factors
Bias •
•
Familiarity with testing context and examiner 
Performance anxiety
•
•
Age (maturational effects and ageing) 
Education
Demographic considerations •
•
•
Gender
Ethnicity
Baseline ability
Error
Statistical errors
•
•
Measurement error
Regression to the mean
Random or uncontrolled • Random or uncontrolled events
events
Reliable change index (RCI)
The reliable change index was first developed by Jacobson & Truax (1991) as a way of 
evaluating outcomes from psychotherapy research. Using a comparable control group, 
calculating the RCI for a test measure involves dividing change scores by the standard error 
of the difference between the two scores. The standard error of the difference is derived from 
the standard error of the measurement and describes the spread of the distribution of change 
scores that would be expected if no actual change had occurred (Chelune et a/., 1993). This 
distribution is used to establish confidence intervals for the test measure (usually 90% Cl). 
The 90% confidence intervals are created by multiplying the standard error of the difference 
by ± 1.64. This then determines two cut-off points which clinically significant change can be 
evaluated against. The 90% CIs are the most commonly used cut-off points, as they are the 
values that statistically would be expected to occur without real change only 10% of the time 
by chance, 5% in a positive direction and 5% in a negative direction (Chelune et al., 1993). If 
a change score is greater than the RCI in either direction, this means that a change score of 
that magnitude would only have occurred in the comparable population less than 5% of the
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time and is considered to be a statistically reliable change (Chelune et al., 1993; Hermann ef 
ai, 1996). Initially, the RCI did not correct for practice effects. However, Chelune and 
colleagues (1993) introduced the subtraction of a constant into the equations to correct for the 
effects of practice.
RCIs have been used in epilepsy research, particularly in assessing neuropsychological 
outcome after epilepsy surgery (Chelune et ai, 1993, Hermann et ai, 1996). The main 
advantages and disadvantages of using RCIs are summarised in Table 5.9.
Table 5.9: Advantages and disadvantages of using RCIs
Advantages Disadvantages
• They allow clinicians to determine whether 
an individual has shown statistically 
meaningful decline by providing information 
on how large a change needs to be to be 
considered statistically meaningful (Chelune 
etal., 1993)
• They do not provide information about the 
relative magnitude of change, only that a 
change has exceeded the cut-off point to be 
considered meaningful (Hermann etal.,
1996)
• They take into account the effects of 
practice and measurement error
• They do not allow comparisons across 
other measures and cognitive domains 
(Hermann etal., 1996)
• They do not correct for regression to the 
mean effects (Salinsky etal., 2001, Strauss 
etal., 2006)
• They performed less well in predicting 
follow-up scores when evaluated in a large 
sample of neurologically normal adults 
(Temkin efa/., 1999)7
Standardised regression-based change scores (SRBs)
Standardised regression-based change scores are an alternative and complementary method 
to the reliable change index. They were first developed by McSweeney et al., (1993) to 
assess outcomes following epilepsy surgery. Using a comparable control group, linear
7 However, Frerichs & Tuokko (2005) found that RCIs were the most accurate method for defining normal 
change in a sample of older adults, aged over 65 years, followed-up as part of the population-based Canadian 
Study of Health and Ageing.
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regression techniques are employed to create regression equations that predict retest 
performance using baseline test scores as the predictor variable (simple regression) 
(McSweeney et al., 1993). Other factors that might also affect follow-up test performance can 
be included in the regression model (multiple regression). These can include; age; gender; 
education; race; duration of illness; age of onset; test-retest interval; a measure of general 
intellectual function or overall neuropsychological competence at baseline (Hermann et al., 
1996, 2006b, Temkin et al., 1999, Salinsky et al., 2001, Martin et al., 2002, Duff et al., 2005, 
Frerichs & Tuokko et al., 2005, Martin et al., 2006). However, baseline score is the most 
important predictor of follow-up score (McSweeney etal., 1993, Hermann etal., 1996, Temkin 
etal., 1999; Martin etal., 2002, 2006, Dutietal., 2005).
The regression equations derived from the comparable control group are then applied to the 
individual or group of interest. These generate predicted scores that are compared with the 
observed scores. The difference between the observed and predicted scores can then be 
converted to standardised T scores (M=50, SD=10) (McSweeney et al., 1993) or z-scores 
(M=0, SD=1) (Hermann et al., 1996) by dividing the difference by the standard error of the 
estimate of the regression equation. Similar to the RCis, cut-off values can be calculated to 
determine statistically reliable change (e.g. p<.05). For example, an SRB >±1.64 means that 
a change score of that magnitude would only have occurred in the comparable population less 
than 5% of the time (Martin et al., 2002).
SRB change scores have been used in studies involving people with epilepsy to assess 
cognitive outcomes following epilepsy surgery (McSweeney et al., 1993, Hermann et al., 
1996, Martin et al., 2002); the cognitive side effects of antiepileptic drug treatment (Salinsky et 
al., 2002, 2004, 2005); cognitive change in patients with chronic temporal lobe epilepsy 
(Hermann et al., 2006b) and to evaluate change scores on a health-related quality of life 
instrument (Martin et al., 2006). They have also been used to develop regression equations 
for a battery of tests for use in community-dwelling older adults (Duff et al., 2005). The 
advantages and disadvantages of using SRB change scores are summarised in Table 5.10.
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Table 5.10: Advantages and disadvantages of using SRB change scores
Advantages^ Disadvantages
• They put all changes on a common metric 
so the relative change across measures 
and cognitive domains can be compared
• Less accurate for those individuals whose 
baseline neuropsychological test scores are 
at the extremes (Duff et al., 2005)
• They can be plotted on graphs to provide 
visual profiles of cognitive change relative 
to a comparison control group
• They take into account practice effects and 
regression to the mean, as well as other 
factors that affect test-retest performance 
(e.g. baseline performance, age, sex and 
education)
• They provide information about expected 
change, which can be compared to 
observed change
• Multiple regression techniques were 
considered to be the most accurate at
predicting follow-up scores in a large 
sample of neurologically normal adults 
(Temkin etal., 1999)
P These are summarised from McSweeney etal., 1993, Hermann etal., 1996, 2006b, Temkin etai, 1999, 
Salinsky etal., 2001, Martin etal., 2002
For this 12 month analysis, SRB change scores were chosen to evaluate cognitive change for 
several reasons, described in Table 5.11. The test-retest scores for the healthy volunteers 
were used to create the regression equations, using the method by McSweeney et al., (1993) 
described above. The regression equations involved regressing baseline scores, age, sex and 
education on 12 month scores (see Table C.2). Age in years was entered as a continuous 
variable, sex as a dichotomous variable (0=female, 1=male) and education was divided into 
three categories (low ^11yrs, medium 12-15yrs or high >15 yrs). Two dummy variables were 
created so that education could be entered into the regression. These regression equations 
were then applied to the patients with epilepsy to predict their test performance at 12 months. 
The difference between predicted and observed scores was calculated and divided by the 
standard error of the estimate of the regression equation to obtain standardised z-scores. The 
standardised z-scores were transformed by multiplying the timed tasks by minus one, so that 
higher scores on all tasks reflected better performance (Temkin et al., 1999). Dependent f 
tests were undertaken to see if there were significant differences between the observed and 
predicted 12 month scores.
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Table 5.11: Reasons for using SRB change score techniques in this research
Reason Importance in this research
Takes into account • in order to ascertain the impact of epilepsy and its treatment, need to
other factors adjust for other potentially confounding effects
Expected vs • PWE vs. healthy controls have retest performances that are
observed change characterised by a lack of a practice effect (Hermann et ai, 2006b). 
Comparisons of baseline and retest scores only looking at measures 
of central tendency (e.g. paired f tests) can lead to misinterpretation of 
data because practice effects are not taken into account (Chelune et 
a/., 1993)
• No change in performance may be interpreted as stable performance 
when a lack of a practice effect might actually reflect a decline in 
performance (Martin et ai., 2002)
Common metric • Useful to see if particular cognitive domains were vulnerable to the 
effects of epilepsy and its treatment over the first 12 months
Individual analysis • Identify those patients who exhibit clinically significant changes and 
explore their characteristics (Hermann etai, 2006)
Continuous measure • Able to evaluate potential demographic and clinical factors associated 
with cognitive decline
Replication • Several similar studies have used these statistical techniques to 
investigate change in people with epilepsy (Salinsky etai, 2001,
2002,2005, Hermann et ai., 2006b)
Investigating relationships
Spearman’s correlations were carried out to investigate relationships between regression- 
based z-scores and the number of seizures and the number of tonic-clonic seizures since 
baseline. Differences in the standardised regression based z-scores between those who were 
or were not seizure free for the 12 month period were assessed by independent t tests. One 
way ANOVAs were undertaken to investigate differences between those with partial, 
generalised and unclassified epilepsy. Pearson correlations were undertaken to assess 
relationship between change scores and mood.
Individual level analysis
As described in section 5.5.2 (‘Individual-level analysis'), an impairment index was created, 
which represents the proportion of test scores that were classified as abnormal (Oyegbile et 
ai, 2004, Hermann et a/., 2006b, 2007a). Abnormal test performance was defined as a SRB 
z-score <-2.0. This criterion for abnormal test performance has been used in other similar
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studies (Hermann et al.t 2006b). Exploratory analyses (using independent t, Mann Whitney 
and chi square tests) were conducted to identify the characteristics of those who were 
classified as having abnormal test performance.
5.5.4 Statistical analysis for chapter 8
Demographic and clinical characteristics
Descriptive statistics were used to describe the demographic and clinical characteristics of the 
patients who took part in this follow-up study. As consent to access medical records had not 
been given by refusers or non-responders, differences in current demographic and clinical 
characteristics between patients who took part and those that did not could not be evaluated. 
However, differences in baseline demographic and clinical characteristics and 
neuropsychological test scores at baseline and 12 months could be compared.
Independent t tests and chi square analysis were undertaken to investigate possible 
differences between those who agreed to participate and those who did not in terms of their 
demographic, clinical and neuropsychological characteristics. However, for some of the 
clinical variables (e.g. previous/current neurological disorders) several cells in the contingency 
tables had expected counts of less than five, so chi square tests were not undertaken for 
these variables. Instead, descriptive statistics were provided.
Neuropsychological and psychological test data
Assessing the spread of the data
The differences between baseline and follow-up neuropsychological test scores were 
assessed to see whether they met the assumption of normality. The spread of the differences 
were assessed by visually inspecting histograms, Q-Q plots, the values of skewness and 
kurtosis and the results of the Kolmogorov-Smirnov test.
For the neuropsychological test variables, thirteen of the difference scores did not differ from 
the normal distribution and so parametric analyses (dependent t tests) were carried out on 
these. However, differences for BCRT, simultaneous recognition of words and the delayed
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subtest of the RAVLT differed significantly from the normal distribution and so non-parametric 
analyses (Wilcoxon signed-rank test) were used for these measures. The scores for the 
Stroop colour-word task were negatively skewed due to low ceiling effects, and the difference 
scores were also skewed, so this variable was again converted to a categorical one based on 
normative data (see section 5.5.2).
For the mood variables, the difference scores for each mood factor did not differ from the 
normal distribution and so parametric analyses (dependent t tests) were used to assess 
change in these measures. For the ABNAS, half the sub-domains (fatigue, motor and 
language) differed from the normal distribution and half did not (memory, concentration, 
slowing). To maintain consistency within the ABNAS, non-parametric (Wilcoxon signed-rank 
tests) were used to assess differences between self-reported cognitive complaints at baseline 
and follow-up for ail sub-domains.
Percentage change scores
A discussed in section 5.5.3 above ('Measuring change’), several statistical methods have 
been developed to evaluate reliable cognitive change. However, for this part of the thesis, 
reliable change indices or standardised regression-based change scores could not be applied 
because the control group had not been evaluated over the same test-retest interval (range 
3.5-7 years). As baseline score is the most important predictor of follow-up score 
(McSweeney et al., 1993, Hermann etal., 1996; Temkin et a!., 1999, Martin et a/., 2002,2006, 
Duff et al., 2005), percentage change scores were calculated instead that take into account 
the individual’s baseline score. These were calculated by: [(follow-up score-baseline 
scorej/baseline score]*100. These percentage change scores were transformed for timed 
tasks so that for all tests positive values indicated improvement from baseline and negative 
values indicated decline from baseline (Temkin etal., 1999).
The spread of the percentage change scores were also investigated by inspecting histograms, 
Q-Q plots, values of skewness and kurtosis and the results of the Kolmogorov -Smirnov test. 
The percentage change scores differed from the normal distribution and so non-parametric 
analyses were carried out on these variables.
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Factors associated with cognitive change
Several demographic, clinical and psychological factors were identified that might influence 
cognitive change, based on the literature described in Chapter 3 and Chapter 4. Their 
relationship with percentage change scores were assessed through separate univariable 
analyses. These independent variables were either analysed as continuous variables or 
transformed into dichotomous ones. The independent variables were: seizure freedom for at 
least the previous 12 months (yes/no); age; years of education; duration of epilepsy; presence 
of co-morbidities at follow-up (yes/no); tension factor of the POMS; prior neurological deficit or 
abnormal imaging at baseline (yes/no).
Seizure type was not analysed due to the small numbers of patients who were classified as 
having generalised or unclassified seizures. Relationships between percentage change 
scores and these demographic, clinical and psychological factors were explored through 
Spearman correlations, Mann Whitney and Kruskal-Wallis tests.
Individual cognitive change
To assess cognitive change at an individual-level and evaluate the clinical significance of 
results, the proportion of patients who had experienced cognitive decline was calculated. This 
was calculated relative to the cross-sectional standard deviation of the relevant baseline 
scores (follow-up score-baseline score/ SD of the baseline score) (Aldenkamp et al, 2000, 
Frerichs & Tuokko, 2005, Gomer et al., 2007). Cognitive decline was defined in two ways: as 
a decline of more than or equal to 1.5SD or 2SD in performance on any of the 
neuropsychological tests.
Some studies have used less conservative values of £1SD to define decline (e.g. Gomer et 
al., 2007). However, several previous studies have also defined cognitive decline using the 
more conservative values above (e.g. Andersson-Roswall et al., 2004). The more 
conservative values were chosen so as not over-estimate the number of patients who were 
classified as experiencing cognitive decline, especially as evaluating change using this 
standard deviation method has been found to over-classify deterioration in test performance
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compared with other methods (e.g, RCIs and regression-based models) (Frerichs & Tuokko, 
2005).
An exploratory analysis was conducted to identify the demographic and clinical characteristics 
of those who were identified as having cognitive decline (defined using the more conservative 
criterion of ^2SD). Independent t, Mann Whitney and chi square tests were undertaken to 
assess differences between those characterised as having or not having cognitive decline. 
However, where more than two cells in the contingency tables had expected counts of less 
than five, only descriptive statistics were provided.
5.5.5 Reporting of statistics
Throughout all the results chapters, for each inferential test, differences in means and 
medians are reported along with 95% confidence intervals and corresponding p-values. The 
95% confidence intervals for differences in medians are not provided in SPSS so were 
calculated using Stats Direct. For independent t tests, Levene's test was carried out to test for 
equality of variance. The p-values reported are the corrected values, when equality of 
variance was not assumed.
5.5.6 Significance level
The significance level for the inferential statistics was set at p<.01. This was to reduce the 
likelihood of making a Type I error due to the number of multiple comparisons being made. A 
Bonferroni correction could have been applied but due to the number of inferential tests 
conducted this would have been too conservative a value and would have increased the 
likelihood of making a Type II error.
5.6 Summary
The SAN AD Neuropsychology study, as part of the SAN AD trial, provided a unique 
opportunity to investigate the natural history of cognitive impairment in a sample of previously 
untreated patients with newly diagnosed epilepsy. Patients were assessed using a 
comprehensive, sensitive neuropsychological test battery before the start of antiepileptic drug
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treatment and were re-assessed after three and 12 months. The recruitment of a healthy 
volunteer reference control group meant the performance of people with epilepsy at the time 
of diagnosis could be compared with people from the general population and evaluated 
against ‘normal’ test-retest performance after 12 months of AED treatment. The follow-up 
study provided an opportunity to study the cognitive effects of epilepsy and its treatment, 
without the effects of surgical intervention, three to eight years after diagnosis.
The results will be divided into three chapters and the next chapter will present the results of 
the comparison between patients with newly diagnosed epilepsy and healthy volunteers at the 
baseline assessment.
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Chapter 6 Results: The immediate impact
6.1 Overview of chapter
This chapter documents and compares the cognitive profile of healthy volunteers with newly 
diagnosed patients with epilepsy and no known cerebral pathology, before the administration 
of antiepileptic drug medication. These results have formed the basis of a peer-reviewed 
publication by Taylor and colleagues (2009) (see Appendix D).
This chapter will describe the number of patients and healthy volunteers that were recruited 
and eligible for the SANAD Neuropsychology study and this analysis. Their demographic and 
clinical characteristics will be reported. The neuropsychological test scores of the patients with 
epilepsy and healthy volunteers will be compared and the impact of epilepsy, seizure and 
mood-related variables on cognitive functioning will be assessed. The characteristics of those 
who already demonstrate cognitive impairment at baseline will be explored. Finally, the 
relationship between subjective report of cognitive problems and objective test performance 
will be investigated.
6.2 Participants
6.2.1 Patients with epilepsy
A total of 257 patients with newly diagnosed epilepsy were initially recruited and assessed at 
baseline. The median time interval between baseline assessment and randomisation was 0 
days (range 0-19 days). Three patients were excluded because later investigations found that 
they did not have a diagnosis of epilepsy and one was excluded because they had a learning 
disability. A further 31 patients were removed prior to analysis because they were found to 
have been previously treated with antiepileptic drugs. Therefore, 222 patients were eligible for 
the SANAD Neuropsychology study at baseline. Table 6.1 illustrates the number of patients 
recruited, assessed and were eligible from each centre.
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Table 6.1: Numbers recruited, eligible and assessed at each centre
Centre Recruited 
(n, %)
Eligible 
(n, %)
Walton Centre for Neurology & Neurosurgery, Liverpool 63 (24.5) 58 (26.1)
Royal Bolton Hospital, Bolton 53 (20.6) 45 (20.3)
University Hospital of Wales, Cardiff 49 (19.1) 45 (20.3)
Wrexham Maelor Hospital, Wrexham 27 (10.5) 20 (9.0)
Royal Hallamshire Hospital, Sheffield 21 (8.2) 17(7.6)
Gian Ciwyd Hospital, Bodelwyddan 16(6.2) 13(5.9)
Hope Hospital, Salford 15(5.8) 13(5.9)
Doncaster Royal Infirmary, Doncaster 8(3.1) 7 (3.2)
Leigh Infirmary, Leigh 3(1.2) 3(1.2)
Whiston Hospital, Prescot 1 (0.4) 1 (0.5)
Royal Victoria Infirmary, Newcastle upon Tyne 1 (0.4) 0 (0.0)
Total 257 222
Thirty-eight patients had a previous or current neurological disorder, as can be seen in Table 
6.2, Some patients had more than one prior neurological disorder.
Table 6.2: Previous or current neurological disorders
History N
Neurological deficit 9
Stroke/Cerebrovascular 10
Intracranial surgery 3
Head injury 6
Meningitis/encephalitis 3
Other 17
EEGs and clinical CT/MRIs were carried out for 204 (91.9%) patients. Of those who had 
EEGs, EEGs were normal for 102 (50.0%) and abnormalities were found for 89 (43.6%) 
patients. There were no EEG reports for 13 (6.4%) patients. As shown in Table 6.3, of those 
with abnormal EEGs, 34 (38.2%) had a non-specific abnormality; 21 (23.6%) had a 
generalised abnormality and 34 (38.2%) had a focal abnormality. Scans were normal for 136 
(66.7%) and abnormalities were found for 49 (24.0%) patients. There were no scan reports for 
19 (9.3%) patients. The specific abnormalities were only recorded for two patients and these 
were white matter abnormalities and a cavernoma.
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Table 6.3: EEC and imaging results
EEG/imaging abnormalities N (%)
Non-specific abnormality 34 (38.2%)
Generalised abnormality
Slow wave activity with spiking 13 (14.6%)
Slow wave activity without spiking 8 (9.0%)
Focal abnormality
Paroxysmal slow activity with spiking 22 (24.7%)
Paroxysmal slow activity without spiking 12(13.5%)
CT/MRI
Abnormal scan 49 (24.0%)
A total of 67 patients had either a previous or current neurological history and/or abnormal 
neuroimaging on clinical CT or MRI. As this part of the thesis is interested in the impact of 
seizures and epilepsy and not the impact of a specific structural lesion or prior neurological 
condition, these patients were excluded from this analysis but not from the 12 month or follow­
up analysis. Therefore, this analysis focuses on 155 untreated patients with newly diagnosed 
epilepsy who are otherwise ‘neurologically’ normal on the basis of the available evidence.
6.2.2 Healthy volunteers
A total of 90 healthy volunteers from the general population were recruited into the 
Neuropsychology study to act as a non-epilepsy control group. Three healthy volunteers were 
excluded from the study. One because they disclosed a severe head injury as a child; one 
withdrew consent part way through the assessment; and the FePsy computer program 
crashed during one assessment and the participant was not able to arrange a convenient time 
to complete the assessment Therefore, 87 healthy volunteers were eligible at baseline.
6.3 Demographic and clinical characteristics
Table 6.4 summarises the demographic characteristics of the two groups at baseline. There 
were no differences in sex (x2(1)=0.01, p=.910) or age (f(160.09)=-0.05, p=.962) between the 
two groups. The mean age of the patients with epilepsy was 35.04 years (±14.41), ranging 
from 15-78 years and the healthy volunteers had a mean age of 35.14years (±16.37), ranging 
from 15-80 years. The healthy volunteers had significantly more years of education than the
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patients with epilepsy (x2(2}=33.44) p<.001). A higher proportion of the healthy volunteers 
(40.2%) had more than 15 years of education, compared with 14.2% of the patients with 
epilepsy. A higher proportion of patients with epilepsy (57.4%) had 11 years or less of 
education compared with 21.8% of healthy volunteers.
Table 6.4: Demographic characteristics of patients with epilepsy and healthy volunteers
Characteristics PWE (n=155) Controls (n=87) Diff (95%CI) p-value
Sex (n, %)
Male
Female
79 (51.0)
76 (49.0)
45 (51.7)
42 (48.3)
-0.7 (-13.7,12.3)
0.7 (-12.3,13.7)
.910
Mean age, yrs 
(SD, range)
35.04
(14.41, 15-78)
35.14
(16.37,15-80)
-0.10 (-4.3,4.1) .962
Education, yrs (n, %)
<11
12-15
>15
89 (57.4)
44 (28.4)
22 (14.2)
19(21.8)
33 (37.9)
35 (40.2)
35.6 (23.2,46.5) 
-9.5 (-22.1, 2..6) 
-26.0 (-37.7, -14.6)
<001***
*p<.05, **p<.01, ***p<.001
As shown in Table 6.5, on average patients with epilepsy experienced nine seizures before 
randomisation to SANAD. There were six patients (3.9%) whose number of seizures before 
randomisation could be considered outliers but despite their number of seizures being in the 
thousands, they had never been treated with antiepileptic drugs previously. Unfortunately, as 
part of the recruitment process, the reasons why they had never previously sought treatment 
were not recorded. Possible reasons were that they had ignored or misinterpreted their 
symptoms or were unaware of them (Sander, 2003). This is plausible as the majority of their 
prior seizures included myoclonic seizures, typical absences and simple or complex partial 
seizures, which may have gone undetected. Seizure unawareness, particuiariy of partial 
seizures is common, as patients are often dependent on signs such as muscle pain, tongue 
biting and reactions of others to become aware that a seizure has occurred (Hoppe et al., 
2007). Only one patient had experienced 300 tonic-clonic seizures, which had not previously 
been treated. Alternatively, they may not have wanted to take AEDs because of concerns 
about the harmful effects of treatment and its role as a ‘stigma cue’ (Scambler, 1989, Jacoby 
et a/., 2007).
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The majority of people with epilepsy (70.3%) had experienced partial seizures, 15.5% had 
experienced generalised seizures and 14.2% had experienced tonic-clonic seizures that could 
not be classified as either primary or secondarily generalised. The mean age of first seizure 
was 29.90 years (±15.68), ranging from 2-76 years. The median length of time between first 
seizure and randomisation was 597 days (25th-75th centiles 188-1953). A small proportion 
(3.9%) had previously had febrile convulsions and 10.3% had a familial history of epilepsy.
Table 6.5: Clinical characteristics of the patients with epilepsy
Clinical characteristics
History of seizures, n (%)
Febrile convulsions 6 (3.9)
Any other acute symptomatic seizures 1 (0.6)
Epilepsy in 1st degree relatives, n (%) 16(10.3)
Median no of seizures (25th-75th %iles) 9 (3-100)
Mean age at first seizure, yrs (SD, range) 29.90 (15.68, 2-76)
Median interval between 1st seizure and rand, days (25-75th %iles) 597 (188-1953)
Classification of seizures (n, %)
Partial
Simple partial 6 (3.9)
Complex partial 25 (16.1)
Simple or complex with secondarily generalised tonic-clonic 33 (21.3)
Combination of partial-onset seizures 45 (29.0)
Generalised
Typical absence 1 (0.6)
Tonic-clonic 11 (7.1)
Combination of generalised-onset seizures 12(7.7)
Unclassified
Tonic-clonic (uncertain whether or not secondarily generalised) 22 (14.2)
As shown in Table 6.6, the majority of patients (69.7%) were classified as having 
symptomatic/cryptogenic partial epilepsy; 14.8% were classified as having idiopathic 
generalised epilepsy and 14.2% were classified as having unclassified epilepsy. One patient 
was classified as having idiopathic partial epilepsy (0.6%) and one (0.6%) was classified as 
having photosensitive epilepsy.
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Table 6.6: Epilepsy syndrome
N (%)
Idiopathic partial
Childhood epilepsy with occipital paroxysms 1 (0.6)
Symptomatic/cryptogenic partial
Temporal lobe 38 (24.5)
Frontal lobe 1 (0.6)
Parietal lobe 2(1.3)
Occipital lobe 2(1.3)
Partial epilepsy localisation not specified 65(41.9)
Idiopathic generalised
Juvenile absence 2(1.3)
Juvenile myoclonic 10(6.5)
Epilepsy with tonic-clonic seizures on awakening 2(1.3)
Other idiopathic generalised epilepsy not specified 9 (5.8)
Other syndrome 1 (0.6)
Unclassified 22 (14.2)
6.4 Differences at baseline
6.4.1 Neuropsychological test raw scores
Table 6.7 compares the performance of patients with epilepsy and healthy volunteers across 
the neuropsychological test battery at baseline. Looking at the raw scores, patients performed 
worse than healthy volunteers on 13/16 cognitive measures and this reached statistical 
significance for 10/16 measures. Patients demonstrated significantly worse performance on 
the finger tapping task using both dominant (f(210.54)=-3.75, p<.001) and non-dominant hand 
(f(223)=-2.99, p= 003). They performed more poorly on the information processing (f(240)=- 
3.78, p<0.001) and motor speed (f(218.90)=-4.45, p<.001) tasks of the Adult Memory and 
Information Processing Battery. They recalled fewer story units both immediately (f(240)=- 
5.47, p<.001) and after a delay (f(240)=-5.31, p<.001) on a story recall task. They recalled 
fewer words immediately (f(240)=-4.27, p<.001) and after a delay (f{240)=-3.54, p<.001) on 
the Rey Auditory Verbal Learning Task. They performed more poorly on the serial recognition 
of figures task (f{234)=-4.36, p<.001) and generated fewer words on the verbal fluency test 
(f(240)=-5.03, p<.001). There was a trend for patients with epilepsy to respond more quickly 
than healthy volunteers on the visual reaction time task with the non-dominant hand (f(229)=-
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2.31, p= 022) but respond more slowly on the computerised visual search task (/(235)=1.75;
p= 082).
Table 6.7: Baseline performance of patients with epilepsy and healthy volunteers
Variable PWE Controls Diff (95% Cl) p-value
Finger Tapping
Dominant 57.11 (9.25,144) 61.10(6.61,81) -3.99 (-6.09,-1.89) <001***
Non-dominant 52.03 (7.87,144) 55.02 (5.86,81) -2.99(4.97, -1.02) .003**
Log Visual RT 
(ms)t
Dominant 5.71 (0.22,143) 5.72 (0.14,87) -0.01 (-0.06, 0.03) .563
Non-dominant 5.69 (0.18,144) 5.74 (0.15, 87) -0.05 (-0.10, -0.01) .022*
Binary Choice
RT (ms) t
354
(306426,147)
359
(318.75410,86)
0.00(49.00,20.00) .986
Log CVST (s) t 2.34 (0.29,151) 2.27 (0.29,86) 0.07 (-0.01,0.15) .082
Word recog
Serial 15.39(4.11,152) 16.10(3.76, 87) -0.71 (-1.76, 0.35) .187
Simultaneous 20.00
(18.00-22.00,152)
21.00
(18.00-22.00, 84)
-1.00 (-1.00,0.00) .157
Figure recog
Serial 14.42(3,85,149) 16.73(4.08, 87) -2.31 (-3.36, -1.27) <001***
Story recall
Immediate 7.69 (2.92,155) 9.92 (3.26, 87) -2.23 (-3.04,-1.43) <001***
Delayed 6.78 (3.06,155) 9.02(3.31,87) -2.24 (-3.07, -1.41) <.001***
ReyAVLT
Immediate 45.17(9.66,155) 50.70 (9.66,87) -5.53 (-8.08, -2.98) <.001***
Delayed 8.80 (3.33,155) 10.37 (3.28,87) -1.57 (-2.44,-0.69) <001***
Verbal fluency 34.15(11.58,155) 41.75(10.70,87) -7.59 (-10.57, 4.62) <.001***
AMIPB
Info Processing 60.15(15.89,155) 68.17(15.69,87) -8.02 (-12.19, -3.84) <_ooi***
Motor speed 46.44 (9.85,152) 51.86 (7.47,87) -5.42 (-7.65, -3.19) <ooi***
Values reported are means and SD or medians and 25th-75,h centiles, f higher score means worse performance, 
*p<0.05, ‘‘pc.Ol.^pc.OOl
Figure 6.1 compares the performance of patients with epilepsy and healthy volunteers on the 
Stroop Neuropsychological Screening Test, after adjusting for age. Significantly more patients 
with epilepsy (31.5%) than healthy volunteers (4.8%) fell in the borderline ranges and 
significantly fewer patients with epilepsy (55.0%) compared with healthy volunteers (84.5%) 
fell in the average ranges (x2(2)=25.03, p<.001)
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Figure 6.1: Performance of patients with epilepsy and healthy volunteers on the Stroop colour-word 
task
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6.4.2 Age, sex and education adjusted z-scores
Table 6.8 compares the age, sex and education adjusted z-scores of patients with epilepsy 
and healthy volunteers across the neuropsychological test battery. After adjusting for sex, age 
and education, there were statistically significant differences on 6/14 measures. Patients 
demonstrated significantly worse performance on the finger tapping task with the dominant 
hand (f(209.77)=-4.10, p<001). They performed more poorly on the motor speed task of the 
Adult Memory and Information Processing Battery (f(232.88)=-3.49, p<001). They recognised 
fewer figures on the serial recognition task (f(234)=-5.78, p<001). They recalled fewer words 
immediately (f(240)=-5.65, p<.001) and after a delay (f(240)=-4.29, p<001) on the Rey 
Auditory Verbal Learning Task. They also recalled significantly fewer units of a story recall 
task immediately (f(240)=-2.59, p=.010) and there was a trends for patients with epilepsy to 
recall fewer story units after a delay (f(240)=-2.28, p=.024).
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Table 6.8: Performance of patients with epilepsy compared with healthy volunteers (age, sex and
education adjusted z-scores)
Variable PWE
(mean, SD, n)
Controls 
(mean, SD, n)
Diff
(95% Cl) p-value
Finger Tapping
Dominant -0.66(1.39,144) 0.00(1.00, 81) -0.66 (-0.97, -0.34) <0.001***
Non-dominant
Log Visual RT (ms)
-0.31 (1.33,144) 0.00(1.00, 81) -0.31 (-0.64, 0.03) 0.070
Dominant 0.24(1.65,143) 0.00(1.00, 87) 0.24 (-0.11, 0.58) 0.177
Non-dominant 0.20(1.21,144) 0.00(1.00,87) 0.20 (-0.09, 0.49) 0.171
Log CVST (s)
Word recognition
0.10(1.05,151) 0.00(1.00,86) 0.10 (-0.17, 0.38) 0.457
Serial
Figure recognition
-0.10(1.12,152) 0.00(1.00, 87) -0.10 (-0.38, 0.19) 0.495
Serial
Story recall
-0.75 (0.94,149) 0.00(1.00, 87) -0.75 (-1.01,-0.50) <0.001***
Immediate -0.32 (0.90,155) 0.00 (1.00,87) -0.32 (-0.57, -0.08) 0.010**
Delayed
ReyAVLT
-0.30 (0.97,155) 0.00(1.00,87) -0.30 (-0.56, -0.04) 0.024*
Immediate -0.76(1.01,155) 0.00(1.00,87) -0.76 (-1.03, -0.50) <0.001***
Delayed -0.61 (1.09,155) 0.00 (1.00, 87) -0.61 (-0.89, -0.33) <0.001***
Verbal fluency
AMIPB
-0.25(1.06,155) 0.00 (1.00, 87) -0.25 (-0.52,0.03) 0.079
Info Processing -0.14(1.08,155) 0.00 (1.00, 87) -0.14 (-0.42, 0.14) 0.322
Psychomotor
speed -0.57(1.53,152) 0.00(1.00, 87) -0.57 (-0.90, -0.25) <0.001***
p<.05, ** p<.01, ***p<.001
Figure 6.2 illustrates the neuropsychological test performance of patients with epilepsy 
compared with healthy volunteers, with the x-axis representing the control mean. After 
correcting for age, sex and education, patients with epilepsy performed worse than healthy 
volunteers across the majority of measures. However, patients with epilepsy performed better 
than the healthy volunteers on a visual reaction time task with both the dominant (f(228)=1.35, 
p=0.177) and non-dominant hand (f(207.27)=1.37, p=0.171) and they responded more quickly 
on the Computerised Visual Search Task (f(235)=0.75, p=0.457) but these differences did not 
reach statistical significance. Memory and psychomotor speed domains were most affected, 
with patients demonstrating subtle dysfunction, performing between 0.5 and 1 SD below the 
control mean.
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6.5 Impact of epilepsy, seizure and mood related variables
6.5.1 Impact of previous seizure activity
Despite a large proportion of patients experiencing several seizures before enrolment, Table 
6.9 illustrates that there were no relationships between the total numbers of seizures or the 
total number of generalised tonic-clonic seizures (primary and secondarily generalised) and 
any of the cognitive measures. Although, there was a trend for performance on the immediate 
subtest of the Rey Auditory Verbal Learning Test to be associated with the total number of 
seizures before baseline. Serial recognition of figures was significantly associated with the 
time interval since first seizure. Shorter duration of epilepsy was associated with poorer 
performance on this task, although there were no relationships on any other measure.
Table 6.9: Relationship between no of seizures, time since first seizure and test performance
Variable Total number of 
seizures
Total number of 
GTCS
No of days since first 
seizure
Finger Tapping
Dominant .043 {p=612) .104 (p=217) .057 (p=.499)
Non-dominant .016 {p=M0) .117 (p=.161) .099 (p=.239)
Log Visual RT (ms)
Dominant .102 (p=.224) -.013 (p=.878) .116 (p=.169)
Non-dominant .031 {p=716) -.042 {p=618) .046 (p=.584)
Log CVST (s) .076 (p=351) .018 (p= 826) .125 (p=. 126)
Word recognition
Serial .066 (p=.420) .026 (p= 749) .151 (p=.063)
Figure recognition
Serial .031 (p=. 711) .084 (p=309) .212 (p=.010)**
Story recall
Immediate .112 (p=.167) -.013(p= 874) .015 (p=.855)
Delayed .129 (p=.111) .086 {p=289) .054 (p=.506)
ReyAVLT
Immediate .180 (p=,025)* -.058 (p=472) .099 (p=.218)
Delayed .031 (p= 701) .031 {p= 706) .049 (p=543)
Verbal fluency .031 (p= 700) -.023 (p=. 778) .105 (p=.195)
AM1PB
Info Processing 0.106 {p=189) -0.109 (p=. 176) .123 (p=.128)
Psychomotor 0.002 (p=976) -0.050 (p~543) .006 (p=.944)
Values reported are Spearman’s rho correlation coefficient and p-values, *p<.05, **p<.01, ***p<.001
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6.5.2 Impact of epilepsy type
The numbers were too small to look at the cognitive profiles of each epilepsy syndrome. 
Instead, patients were classified into those with partial (n=109), generalised (n=24) and 
unclassified (n=22) epilepsy. Figure 6.3 plots the performance of the different epilepsy types, 
with the x-axis representing the control mean. The pattern of performance is similar across the 
three epilepsy groups.
When one-way ANOVAs were conducted (see Table 6.10), the only task that had significant 
differences between the epilepsy groups was the motor speed task of the Adult Memory and 
Information Processing Battery. Those with generalised epilepsy performed significantly 
worse than those with partial and unclassified epilepsy. Significant differences were found on 
four other tasks but Tukey post hoc tests revealed the differences were between patients and 
healthy volunteers and not between the three epilepsy groups. On the dominant hand finger 
tapping task those with partial epilepsy performed significantly worse than healthy volunteers. 
On the serial recognition of figures task, and the delayed Key Auditory Verbal Learning Test, 
those with partial and generalised epilepsy performed significantly lower than the healthy 
volunteers. On the immediate part of this task, all three epilepsy groups performed 
significantly lower than the healthy volunteers but did not perform differently from each other. 
However, these results should be interpreted with caution due to the unequal numbers.
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Table 6.10: One wayANOVAs investigating differences in epilepsy type and healthy volunteers
Cognitive domain F p-value
Finger Tapping
Dominant 5.01 .002**
Non-dominant 1.14 .334
Log Visual RT (ms)
Dominant 1.12 .341
Non-dominant 0.85 .469
Log CVST (s) 1.04 .376
Word recognition
Serial 2.48 .062
Figure recognition
Serial 11.54 <001***
Story recall
Immediate 2.38 .071
Delayed 1.79 .149
ReyAVLT
Immediate 11.05 <001***
Delayed 6.40 <001***
Verbal fluency 2.02 .111
AMIPB
Info Processing 1.82 .145
Psychomotor speed 7.44 <001***
*p<.05, **p<.01 ***p<.01
6.5.3 Impact of mood
Differences between patients with epilepsy and healthy volunteers
On the Profile of Mood States, as shown in Table 6.11, patients with epilepsy reported 
experiencing significantly more symptoms of tension (z=-3.57, p<.001), confusion (z=-3.64, 
p<.001) and significantly less vigour (z—3.48, p=.001) than healthy volunteers.
As shown in Table 6.12, there were no significant relationships between the adjusted z-scores 
and the mood factors when each group was analysed separately. There was a trend for 
higher levels of tension to be associated with poorer serial recognition of figures (rs=-1.63, 
p<.047). But generally, this suggests that the differences found on the neuropsychological 
tests are not mediated by mood disturbances.
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Table 6.11: Differences in self-reported mood between patients with epilepsy and healthy volunteers
Variable
PWE
(median,
25ttl-75th %iles, n)
Controls
(median,
25th-75th %iles, n)
Diff
(95% Cl)
p-value
Vigour 43.75 (28.13-56.25,155) 53.13(43.75-59.38,87) -9.38 (-12.5,-3.13) .001***
Tension 36.11 (22.22-58.33,155) 25.00(11.11-47.22,87) 11.11 (5.56,16.66) <.001***
Confusion 35.71 (21.43-53.57,154) 21.43(14.29-35.71,87) 10.71(3.57,14.29) <.001***
Fatigue 35.71 (21.43-53.57,154) 32.14(21.43-53.57,87) 3.57{-3.57,7.14) .558
Depression 15.00 (6.67-31.67,155) 10.00 (3.33-23.33, 87) 3.33 (0, 6.67) .042*
Anger 14.58 (8.33-28.13,153) 14.58(4.17-29.17, 87) 2.08 (-2.08,4.17) .485
*p<.05, **p<.01, ***p<0.001
Table 6.12: Relationships between neuropsychological test performance and mood
Variable
Vigour
PWE Control
Tension
PWE Control
Confusion
PWE Control
Finger Tapping
Dominant .038 -.045 -.108 -.077 -.159 -.106
(p=655) (p=.689) (p=.198) (p=.494) (p=.057) (p=.347)
Figure
recognition
Serial -.126 .010 -.163 -.035 -.061 -.175
(p=.125) (p=.926) (p=.047)* (p=.745) (p=.458) (p=105)
Story recall
Immediate -.123 .093 -.062 .137 .039 .004
(p=.126) (p=.393) (p=.441) (p=.206) (p=.632) (p=.970)
ReyAVLT
Immediate -.141 -.077 -.051 -.036 -.059 -.098
(p=.080) (p=.478) (p=.532) (p-742) (p=.469) (p=0.369)
Delayed -.131 -.090 -.087 -.037 -.103 .001
(p= 104) (p=.408) (p=.283) (p=.734) (p=.206) (p=.993)
AMIPB
Psychomotor .124 -.040 -.073 -.165 -.142 -.177
speed (p=.129) (p=.716) (p=370) (p=.128) (p=.082) (p=. 101)
Values reported are Spearman’s rho correlation coefficient and p values, *p<.05, **p<.01, ***p<0.001
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6.6 Individual-level analysis
Figure 6.4 illustrates the percentage of patients with epilepsy and healthy volunteers who had 
abnormal scores for each test. A higher proportion of patients with epilepsy had abnormal test 
scores compared with healthy volunteers. This is particularly evident for those measures that 
assess memory and psychomotor speed.
Figure 6.4: Percentage of patients and healthy volunteers with abnormal scores (>2SD below the 
control mean) for each neuropsychological test variable
20
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Neuropsychological tests
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dom=dominant, nondom=non-dominant, ser=serial, imm=immediate, del=delayed, exec=executivelmpairment 
index
Using the impairment index, Table 6.13 compares the number of individuals who have some 
degree of cognitive impairment across the test battery when different criterions of abnormality 
were applied. When an adjusted z-score of ^-1.5 was used as a marker of abnormality, 74.8% 
of the patients with epilepsy had at least one abnormal test score compared with 48.3% of the 
healthy volunteers. Even when the more conservative value of ^-2.0 was used, 53.5% of the 
patients with epilepsy had at least one abnormal score compared with 20.7% of healthy 
volunteers. A higher proportion of patients with epilepsy (9.7%) had impairments on at least a 
quarter of the test variables compared with 2.3% of healthy volunteers. One patient had 
abnormal scores on more than half of the measures compared with none of the healthy 
volunteers.
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Table 6.13: Number of patients and healthy volunteers demonstrating impairments across the test
battery
Criterion of abnormal test performance
Proportion of 
tests impaired £-2.0 <-1.5
PWE (n, %) Controls (n, %) PWE (n, %) Controls (n, %)
0 72 (46.5) 69 (79.3) 39 (25.2) 45 (51.7)
>1% 83 (53.5) 18(20.7) 116(74.8) 42 (48.3)
>25% 15(9.7) 2 (2.3) 38 (24,5) 9(10.3)
£50% 1 (0.6) 0 (0.0) 11 (7.1) 1 (1.1)
Using the more conservative criterion of <-2.0, 83 patients with epilepsy had at least one 
abnormal test score. These individuals were classified as being impaired. Patients were 
significantly more likely to be in the impaired group compared with healthy volunteers 
(X2(1}=24.74, p<.001, Odds Ratio (OR) 4.42, 95%CI 2.41, 8.11). An exploratory analysis was 
conducted to try and identify the demographic and clinical characteristics of those patients in 
the impaired group. Table 6.14 presents the results of this analysis.
There were no differences between those who were classified as impaired and those who 
were not in terms of sex (x2(1)=0.05, p=.822), age at assessment (f{153)=-.03, p=.980) or 
education (x2(2)=3.30, p~A92). There were no differences between the two groups on any 
epilepsy-related variables. There were no differences in epilepsy type (x2(2)=3.73, p=.155); 
number of seizures at baseline (z=-1.64, p=.101) or age at first seizure (f(153)=-0.61, p=.542), 
although there was a trend for those with a shorter interval since their first seizure to be in the 
impaired group (z=-2.39, p= 017). There were no differences between the two groups on any 
of the mood variables.
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Table 6.14: Exploratory data analysis looking at the characteristics of those classified as impaired
Variable Impaired
(n=83)
Not impaired 
(n=72)
Diff
(95%CI)
p-
value
Sex, n (%)
Male 43 (51.8) 36 (50.0) 1.8 (-13.9,17.4) .822
Female 40 (48.2) 36(50.0) -1.8(-17.4,13.9)
Mean age, yrs (SD) 35.01 (15.05) 35.07 (13.73) -0.06 (-4.66,4.54) .980
Mean age at first 30.61 (16.21) 29.07 (15.12) 1.54 (-3.45, 6.54) .542
seizure, yrs (SD)
Education, yrs (n,%) 
<11 53 (63.9) 36 (50.0) 13.9 (-1.8,28.9) .192
12-15 19(22.9) 25 (34.7) -11.8 (-26,0,2.4)
>15 11 (13.3) 11 (15.3) -2.0 (-13.8, 9.2)
Seizure type, n {%)
Partial 53 (63.9) 56 (77.8) -13.9 (-27.7,0.6) .155
Generalised 15(18.1) 9(12.5) 5.6 (-6.2,17.1)
Unclassified 15(18.1) 7 (9.7) 8.4 (-2.9,19.5)
Median no of 7(3-98) 11 (4-100) -2.00 (-5.00,0.00) .101
seizures 
(25th-75th %iles) 
Median interval from 381.00 1030.50 -234.50 (-691,-34) .017*
1st seizure to rand, 
days (25th-75th %iles)
Mood(median, 25th- 
75th%iles)
Tension
(129-1739)
38.89
(276-2671.75)
34.72 2.78 (-2.78,11.11) .393
Depression
(22.22-61.11)
15.00
(19.44-52.78)
15.00 0.00 (-5.00, 5.00) .901
Anger
(6.67-30.00)
14.58
(5.42-31.67)
14.58 0.00 (-4.17,4.17) .927
Vigour
(8.33-27.08)
43.75
(6.77-30.73)
40.63 6.25 (-3.13,12.5) .163
Fatigue
(31.25-59.38)
35.71
(22.66-53.13)
35.71 0.00 (-10.71,7.14) .747
Confusion
(17.86-50.00)
39.29
(21.43-59.82)
32.14 0.00 (-7.14, 7.14) .896
(21.43-53.57) (21.43-56.25)
*p<.05, ***p<.001
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Relationship of baseline cognitive impairment with future seizure status
Table 6.15 illustrates the proportion of patients who continued to have seizures at 12 month 
(68.7%) and longer term follow-up (42%). Being classified as impaired at baseline was not a 
risk factor for active seizures at 12 months (OR=1.08J 95%CI 0.53, 2.19) or after a mean five 
years follow-up (OR=1.08, 95%CI 0.35, 3.36).
Table 6.15: Relationship between baseline cognitive impairment and future seizure status
Seizure status
12 months (n, %) 5 year FU (n, %)
Seizures Seizure free Seizures Seizure free
Baseline Impaired
Not impaired
59 (58.4) 26 (56.5)
42(41.6) 20(43.5)
12(57.1)
9 (42.9)
16(55.2)
13 (44.8)
6.7 Subjective report of cognitive problems
6.7.1 Most commonly reported perceived cognitive problems
As shown in Figure 6.5, patients with epilepsy were already reporting problems in the areas of 
memory, slowing, fatigue, concentration and language before the administration of 
antiepileptic drug medication. The least subjective complaints were given for motor abilities.
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Figure 6.5: Self-reported cognitive problems on the ABN AS
Based on their total ABNAS score, patients with epilepsy were divided into two groups: ‘high 
scores’ (^15) or ‘low scores’ (<14). A cut-off of 15 was used based on the normative data for 
the measure (Aldenkamp et al., 2002). Table 6.16 illustrates that 56.5% of the patients with 
epilepsy rated themselves as experiencing a high number of cognitive complaints. However, 
those who were classified as impaired were no more likely than those who were not impaired 
to report a high number of cognitive complaints (OR 0.91, 95%CI 0.48,1.73).
Table 6.16: Relationship between ABNAS scores and impairment index
Impairment index
Impaired Not impaired
I otai
ABNAS Low 37 (44.6) 30 (42.3) 67 (43.5)
scores High 46 (55.4) 41 (57.7) 87 (56.5)
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6.8 Summary
The aim of this chapter was to document and compare the cognitive profile of newly 
diagnosed untreated patients with epilepsy with healthy volunteers before the administration 
of antiepileptic medication. A total of 155 newly diagnosed previously untreated patients with 
epilepsy, who were otherwise ‘neurologically normal1, were assessed at baseline. The majority 
had adult onset partial epilepsy, with a mean age of first seizure of 29.9 years. They had 
experienced on average nine seizures before the baseline assessment. The average duration 
of untreated epilepsy was one and a half years. These patients with epilepsy were compared 
with 87 healthy volunteers who were recruited from the general population. They were 
equated for age and sex; however, the healthy volunteers had significantly more years of 
education than the patients with epilepsy.
As a group, patients with epilepsy performed statistically significantly worse than healthy 
volunteers on 11/17 measures. They demonstrated significantly worse performance on the 
finger tapping task using both dominant and non-dominant hand. They performed more poorly 
on the information processing and motor speed tasks of the Adult Memory and Information 
Processing Battery. They recalled fewer story units both immediately and after a delay on a 
story recall task. They recalled fewer words immediately and after a 30 minute delay on the 
Rey Auditory Verbal Learning Task. They performed more poorly on the serial recognition of 
figures task and generated fewer words on the verbal fluency test. After adjusting for age, 
they made more errors on the Stroop task.
After adjusting for age, sex and education, patients performed significantly worse than healthy 
volunteers on 6/14 measures. They performed significantly worse on the finger tapping task 
with the dominant hand. They performed more poorly on the motor speed task of the Adult 
Memory and Information Processing Battery, They recognised fewer figures on the serial 
recognition task. They recalled fewer words immediately and after a delay on the Rey Auditory 
Verbal Learning Task. They also recalled significantly fewer units of a story recall task 
immediately. The domains that appeared to be most affected were memory and psychomotor 
speed.
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The observed differences were not mediated by the type or frequency of seizure activity. 
There were no differences between those with partial, generalised and unclassified epilepsy, 
except for the motor speed task of the Adult Memory and Information Processing Battery. 
However, these results must be interpreted with caution due to the unequal numbers in the 
groups. There were no relationships between the total number of seizures or the total number 
of generalised tonic-clonic seizures before the baseline assessment and any of the 
neuropsychological test variables. The number of days since the first seizure was also not 
associated with neuropsychological test performance, except for the serial recognition of 
figures task.
There were differences between the current mood state of patients with epilepsy and healthy 
volunteers. Patients with epilepsy reported experiencing more mood disturbance, in particular, 
more symptoms of tension and confusion and less vigour than healthy volunteers. However, 
these mood disturbances were not related to cognitive performance except for the serial 
recognition of figures task.
At an individual level, patients with epilepsy had a higher proportion of abnormal scores 
(adjusted z-score ^-2.0) across the test battery and were four times more likely than healthy 
volunteers to demonstrate cognitive impairment (defined as at least one abnormal test score). 
Fifty four percent were classified as having cognitive impairment. Epilepsy, demographic or 
mood variables did not explain the differences between those patients who were or were not 
classified as impaired, although there was a trend for those with more recent onset seizures to 
be in the impaired group. Being classified as impaired at baseline was not a predictor of 
continuing seizures at 12 months or longer term follow-up.
The most commonly reported cognitive problems on the ABN AS self-report measure were in 
the areas of memory and slowing, consistent with the objective findings. However, patient’s 
subjective report of cognitive impairments did not always correspond with their objective 
neuropsychological test performance. Fifty eight percent of patients reported a high number of 
cognitive complaints, despite not experiencing abnormal cognitive performance across the 
test battery. The patients and healthy volunteers have been followed-up after 12 months of 
treatment. Chapter 7 presents the results of this analysis.
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Chapter 7 Results: The shorter term impact
7.1 Overview of chapter
This chapter will compare the cognitive trajectory of healthy volunteers with patients with 
newly diagnosed epilepsy after the first 12 months of epilepsy treatment. The numbers of 
patients and healthy volunteers who were re-assessed after 12 months will be reported. The 
demographic and clinical characteristics of the patients and healthy volunteers will be 
described and changes in cognition from baseline to 12 months will be compared. The factors 
related to cognitive change will be investigated and exploratory analyses will be carried out to 
identify the characteristics of those who exhibit the most cognitive impairment.
7.2 Participants
7.2.1 Recruitment
Patients with epilepsy
A total of 147 (66.2%) patients with epilepsy were re-assessed a median 12 months after their 
baseline assessment (range 9-18 months). As shown in Table 7.1, patients with epilepsy 
dropped out of the study for several reasons including death (n=4); being lost to follow-up 
(n=22) and withdrawal of consent (n=14). Three withdrew due to family pressures and one 
withdrew due to depression. Reasons for withdrawal of consent were not given in the 
remaining 10 cases. Four patients were mistakenly withdrawn by the study team because 
they had stopped taking their antiepileptic drug medication8. One patient was excluded from 
the analysis because they had surgery to remove a brain tumour between their 3 month and 
12 month assessment. Unfortunately, reasons for lack of follow-up were not recorded in every 
case (n=30). The numbers of patients who withdrew before their three month assessment is
8 These were mistakenly withdrawn due to early confusion over whether those who stopped taking AEDs should 
remain in the SANAD Neuropsychology. However, a later decision was made to include these patients (as a 
potential no treatment control group) and any future cases were considered eligible for 12 month assessment.
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also presented in Table 7.1 but as discussed in section 5.3.5, this neuropsychological data will 
not be presented in this thesis.
Table 1,1: Reasons for withdrawal in those who did not complete the 3 or 12 month assessment
People with epilepsy Healthy volunteers 
3 months 12 months
Study withdrawals, n (%)T 43 (19) 75 (34) 18(21)
Reasons for withdrawal, n (%)
Not eligible 0(0) io) 2(11)
Withdrawn in error 2(5) 4(5) 0(0)
Death 3(7) 4(5) 0(0)
Withdrew consent 11 (26) 14(19) 6(33)
Lost to follow-up 12(28) 22 (29) 10(56)
Reason not recorded 15(35) 30 (40) 0(0)
Completed assessment, n (%) 179(81) 147 (66) 69 (79)
Tpercentages for the study withdrawals and completed assessment are expressed as % of those who took part at 
baseline (i.e. PWE=222 or healthy controls=87). Percentages for the reasons for study withdrawal are expressed 
as % of withdrawals.
Healthy volunteers
A total of 69 (79.3%) healthy volunteers were reassessed after a median 12 months (range 
11-16 months). This was a significantly longer test-retest interval than the patients with 
epilepsy (z=4179.00, p=.023). However, all the healthy volunteers were assessed within the 
same period as the patients with epilepsy (i.e. between 9-18 months) so this is not thought to 
be a meaningful difference. Two healthy volunteers did not complete the 12 month 
neuropsychological assessment because they had suffered a CNS injury between the 
baseline and 12 month assessment. One was involved in a serious road traffic accident and 
one experienced a sporting injury, where they were rendered unconscious for several minutes 
and they reported still experiencing headaches and poor concentration six months after this 
incident. Ten healthy volunteers were lost to follow-up (including four who cancelled or did not 
attend several appointments made for them) and six withdrew their consent to undertake the 
12 month assessment. Five cited lack of time as their main reason for not wanting to 
participate (e.g. due to work commitments, caring for a sick relative) and the other person did 
not give a reason.
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7.3 Demographics and clinical characteristics
Table 7.2 illustrates the demographic characteristics of the 147 patients with epilepsy and the 
69 healthy volunteers who completed the 12 month assessment compared with those who did 
not complete the assessment in each group. There were no differences in sex between the 
patients with epilepsy and healthy volunteers (x2(1)=0.42, p= 516). However, the patients with 
epilepsy were older (z=4231.00, p=.05). They had a median age of 40 years (range 16-79yrs) 
at the time of the 12 month assessment compared with a median age of 29 yrs (range 16- 
81yrs) for the healthy volunteers. As at baseline, there were significant differences in 
education between the two groups (x2(2)=27.13, p=<.001). The majority of the patients with 
epilepsy (56.5%) had 11 years or less of education compared with 21.7% of the healthy 
volunteers. A lower proportion of patients with epilepsy (15.6%) had more than 15 years of 
education compared with 42.0% of the healthy volunteers.
There were no differences in sex (x2(1)=0.50, p= 480) or education (x2(2)=2.27, p=.322) 
between patients with epilepsy who did or did not complete the 12 month assessment. 
Similarly, there were no differences in education 0f2(2)=0.59, p=.792) between healthy 
volunteers who did or did not complete the 12 month assessment. However, a higher 
proportion of healthy males dropped out of the study 0f2(1)=6.17, p=.013).
There were no differences in baseline neuropsychological test performance between the 
healthy volunteers who did or did not complete the 12 month assessment. However, those 
patients who completed the 12 month assessment had poorer baseline finger tapping scores 
with the non-dominant hand compared to those who did not participate at 12 months 
(f(206)=2.73, p=.007). There were also similar trends for poorer baseline performance in the 
completers on the finger tapping task with the dominant hand (fpOTJ^^I, p~.028) and the 
visual reaction time task with the non-dominant hand (f(204)=-2.44, p= 016). There were no 
differences on the remaining measures.
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Table 7.2: Demographic characteristics of those patients and healthy volunteers who completed the 12 
month assessment
Characteristics
PWE
assessed
(n=147)
Controls
assessed
(n=69)
PWE not 
assessed 
(n=75)
Controls not
assessed
(n=16)
Sex (n, %)
Male
Female
73 (49.7)
74 (50.3)
31 (44.9)
38 (55.1)
41 (54.7)
34 (45.3)
14(77.8)*
4 (22.2)
Median age at 12 
mths, yrs (25th-75th 
centiles)
40 (28-54) 29 (24-50)* - -
Education at baseline, 
yrs (n, %)
<11
12-15
>15
83 (56.5)
41 (27.9)
23 (15.6)
15(21.7)
25 (36.2)
29 (42.0)***
50 (66.7) 
15(20.0) 
10(13.3)
4 (22.2)
8 (44.4)
6 (33.3)
Test-retest interval, 
mths
(25th-75th centiles)
12(12-12) 12(12-13)* - -
*p<.05, **p<.01, ***p<.0Q1
Table 7,3 illustrates the clinical characteristics of those patients with epilepsy who did and did 
not complete the 12 month assessment. Of those who completed the assessment, eight 
(5.4%) had a neurological deficit and 27 (18.4%) had a previous or current neurological 
disorder at the time of the baseline assessment. Twenty-eight (19.0%) had either a prior 
neurological deficit or disorder. There were no significant differences in the number of patients 
with either a prior neurological deficit or disorder between those who did or did not complete 
the 12 month assessment (x2{1)=1-14, p= 285).
Patients with prior neurological disorders or known cerebral pathology were excluded from the 
analysis in the previous chapter, as the aim was to understand the cognitive impact of 
epilepsy at the time of diagnosis without the impact of other pre-existing neurological 
conditions or structural lesions. However, this analysis is investigating cognitive change in 
patients with newly diagnosed epilepsy over time. As these are conditions that are not thought
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to present with progressive neurological disease and those with progressive neurological 
disease were excluded from SANAD, these patients will not be excluded from this analysis.
Of those who completed the 12 month assessment, 137 (93.2%) had an EEC undertaken at 
baseline and 135 (91.8%) had a CT or MRI scan. Of these, 63 (46.0%) had an abnormal 
EEG, 67 (48.9%) had a normal EEG and EEG reports were unavailable for seven (5.1%) 
patients. Scans were abnormal for 35 (25.9%) patients; normal for 90 (66.7%) and reports 
were unavailable for 10 (7.4%) patients. For those who did not complete the 12 month 
assessment, 67 (89.3%) had an EEG undertaken at baseline and 69 (92%) had a CT or MRI 
scan. Of these, 26 (38.8%) had an abnormal EEG, 35 (52.2%) had no abnormality and 6 
(9.0%) did not have an EEG report. Scans were abnormal for 14 (20.3%) patients, were 
normal for 46 (66.7%) and reports were unavailable for nine (13.0%) patients.
Table 7.3: Clinical characteristics at baseline of those who did or did not complete the 12 month 
assessment
Characteristics PWE assessed 
(n=147)
PWE not 
assessed (n=75)
History at baseline (n, %)
Neurological deficit 8 (5.4) 1 (1.3)
Neurological disorder (n, %)
Stroke/cerebrovascular 8 (5.4) 2 (2.7)
Intracranial surgery 2(1.4) 1 (1.3)
Head injury 2(1.4) 4 (5.3)
Meningitis/encephalitis 3 (2.0) 0 (0.0)
Other 13 (8.9) 4 (5.3)
EEG (n, %)
Abnormal EEG 63 (46.0) 26 (38.8)
Non-specific abnormality 22 (34.9) 12(46.2)
Generalised abnormality
o Slow wave activity with spiking 9(14.3) 4(15.4)
o Slow wave activity without spiking 5 (7.9) 3(11.5)
Focal abnormality
o Paroxysmal slow activity with spiking 17(27.0) 5(19.2)
o Paroxysmal slow activity without spiking 10(15.9) 2 (7.7)
CT/MRI (n, %)
Abnormal scan 35 (25.9) 14(20.3)
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As shown in Table 7.4, there were no differences in seizure type between those who did or 
not complete the 12 month assessment (x2(2)=0.07, p= 966). Of those who completed the 
assessment, the majority experienced partial seizures (72.1%). The majority (71.4%) were 
classified as having symptomatic or cryptogenic partial epilepsy; 12.2% had idiopathic 
generalised epilepsy; 15% had unclassified epilepsy; one (0.7%) had idiopathic partial 
epilepsy and one (0.7%) was classified as having an other epilepsy syndrome. They 
experienced a median number of three seizures since their baseline assessment (IQR 0-18, 
range 0-1760) and the majority (66.0%) experienced no tonic-clonic seizures since baseline 
(IQR 0-1, range 0-76). The person who reported experiencing 1760 seizures during the first 
12 months had a combination of myoclonic and typical absence seizures. A total of 46 
(31.3%) patients were seizure free during the first 12 months and none of the patients 
reported experiencing episodes of status epilepticus.
Table 7,4: Epilepsy-related characteristics of those who did or did not complete the 12 month 
assessment
Characteristics PWE assessed 
(n=147)
PWE not 
assessed (n=75)
Seizure type at baseline (n, %)
Partial 106 (72.1) 54 (72.0)
Generalised 19(12.9) 9 (12.0)
Unclassified 22 (15.0) 12(16.0)
Epilepsy syndrome at baseline (n, %)
Idiopathic partial
Childhood epilepsy with occipital paroxysms 1 (0.7) 0 (0.0)
Symptomatic or cryptogenic partial
Temporal lobe 41 (27.9) 16(21.3)
Frontal lobe 5 (3.4) 3 (4.0)
Parietal lobe 3 (2.0) 2 (2.7)
Occipital lobe 1 (0.7) 3 (4.0)
Partial epilepsy localisation not specified 55 (37.4) 30 (40.0)
Idiopathic generalised (IGE)
Juvenile absence 1 (0.7) 1 (1.3)
Juvenile myoclonic 9(6.1) 1 (1.3)
Tonic-clonic seizures on awakening 1 (0.7) 1 (1.3)
Other IGE not specified 7 (4.8) 4 (5.3)
Other syndrome 1 (0.7) 1 (1.3)
Unclassified 22 (15.0) 13(17.3)
183
Information was collected from the healthy volunteers at the 12 month assessment on their 
experience of life events or medical problems since baseline. Five reported experiencing 
events but these were not considered have a significant impact on cognition to warrant 
exclusion from the study. One had experienced episodes of vertigo; one had been taking 
medication for low thyroid; one had sought medical treatment for gastric problems; one had a 
baby and one had recently become a father.
Antiepileptic drug treatment
After their baseline assessment, patients with epilepsy started to take their randomised 
antiepileptic drug. Figure 7.1 illustrates the numbers of patients randomised to each 
antiepileptic drug group. This figure combines those who were randomised to both Arm A and 
Arm B, which is why higher numbers of patients have been randomised to iamotrigine and 
topiramate compared with the other drug groups. These drugs were involved in both arms of 
the study. The lower numbers of patients randomised to valproate, may reflect the reluctance 
of clinicians to randomise women of child-bearing age into Arm B, due to the teratogenic 
effects associated with valproate (e.g. Adab eta!., 2004).
After 12 months, 104 (70.7%) patients had remained on their randomised drug for the duration 
of the 12 month period; six (4.1%) were on their randomised drug but in a polytherapy 
combination; two (1.4%) were on their randomised drug but had tried others in between and 
35 (23.6%) had changed drugs. Of those who had not remained on their randomised AED, 25 
(58.1%) had altered their medication due to unacceptable side effects; 15 (34.9%) due to 
inadequate seizure control; one (2.3%) due to inadequate seizure control and unacceptable 
adverse events; one (2.3%) patient admitted to being non-compliant with their medication 
(carbamazepine) and one (2.3%) stopped taking their medication (topiramate) because of life 
events. During the first 12 months, 19 patients (12.9%) reported experiencing adverse events 
that were classified as cognitive (e.g. memory problems, confusion and difficulty thinking).
As discussed in section 5.3.3, a power calculation showed that 50 patients were needed in 
each drug group to detect medium-sized differences between the different AEDs. However, as 
Figure 7.1 shows, the numbers randomised to each drug group fell short of this. Only
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lamotrigine and topiramate exceeded the 50 required. Furthermore, the numbers of patients 
who remained on their randomised medication for the duration of the 12 month period were 
small. This varied between nine patients for valproate to 27 for topiramate. Therefore, this 
study is underpowered to detect anything other than the largest differences between drugs. 
However, this thesis aims to compare the differences between the cognitive performance of 
people with epilepsy and healthy volunteers over the first 12 months rather the differential 
cognitive side effects of AEDs.
To further illustrate the difficulties in evaluating the cognitive side effects of AEDs in this 
particular study, Table 7.5 shows the number of patients taking each antiepileptic drug at the 
time of the 12 month assessment. The majority of patients (95.2%) were treated with 
monotherapy. The most commonly prescribed drug at the 12 month assessment was 
topiramate (23.8%) closely followed by lamotrigine (23.1%). Levetiracetam is a relatively new 
AED and this was prescribed to three patients (2.0%) as monotherapy at the time of the 12 
month assessment. Six patients (4.1%) were treated in polytherapy with six different 
antiepileptic drug combinations.
Table 7.5: AED medication taken at the time of the 12 month assessment
Monotherapy N (%) Polytherapy N {%)
TPM 35 (23.8) CBZ + CLB 1 (0.7)
LTG 34 (23.1) CBZ+LEV 1 (0.7)
CBZ 24(16.3) GBP + CBZ 1 (0.7)
OXC 16(10.9) GBP + OXC 1 (0.7)
VPA 15(10.2) LTG + LEV 1 (0.7)
GBP 13 (8.8) OXC + LTG 1 (0.7)
LEV 3 (2.0)
Total 140 (95.1) Total 6(4.1)
Non-compliant 1 (0.7)
CLB=clobazam
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Figure 7.1: Flow diagram of the patients involved in the SAN AD Neuropsychology study
Number randomised
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7.4 The shorter term changes
7.4.1 Changes in neuropsychological functioning
Table 7.6 illustrates the performance of the patients with epilepsy and healthy volunteer 
groups at baseline and 12 months. During the first 12 months, patients with epilepsy 
experienced significant declines in performance on five measures. This contrasts with the 
performance of the healthy volunteer group who only experienced a significant decline on one 
measure and experienced significant improvements in performance on four measures.
Patients with epilepsy had poorer performance after 12 months on the visual reaction time 
task with the non-dominant hand (z=-4.04, p<.001). They crossed through fewer digits on the 
psychomotor speed task of the AMIPB (f(139)=2.77, p=.006); they remembered fewer words 
both immediately (f(146)=3.19, p=.002) and after a delay (f(146)=3.50, p=.001) on the Rey 
Auditory Verbal Learning Task and generated fewer words on the verbal fluency task 
(f(145)=4.08, p=<.001). There was also a trend for them to recognise fewer words on the 
simultaneous recognition of words task {f(135)=2.40, p=.018) after 12 months.
The healthy volunteers remembered fewer words on the delayed sub-test of the Rey Auditory 
Verbal Learning Task (f(68)=2.49, p=.015) but were able to remember more story units after a 
delay on the story recall task (f(68)=-2.88, p= 005). They also had a trend towards recognising 
more figures on the serial recognition of figures task (f(66)=-2.09, p= 04). They also 
responded more quickly on the Binary Choice reaction time task (f(66)=2.80, p=.007) and 
improved on the both the information processing (f(68)=-2.95, p=.004) and psychomotor 
speed (f(68)=-3.53, p= 001) tasks of the AMIPB.
At 12 months, a significantly higher proportion of healthy volunteers were classified as falling 
in the average range on the Stroop colour word task compared with the patients with epilepsy 
(85.3% vs. 65.0%). A higher proportion of patients with epilepsy fell in the borderline ranges 
(19.7% vs. 2.9%) (x2(2)=12.06, p= 002). The numbers of people who fell in the average 
ranges at 12 months increased compared with baseline in both groups, suggesting that both 
patients with epilepsy and healthy volunteers improved on this task (see Figure 7.2).
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Table 7.6: Neuropsychological test performance of patients with epilepsy and healthy volunteers at 
baseline and 12 months
PWE Controls
Variable Baseline 12 months Baseline 12 months
Finger Tapping
Dominant 55.87 (9.55,131) 55.17(9.25,131) 61.41 (6.51,61) 62.24 (7.05, 61)
Non-dominant
Visual RT (ms) f
50.61 (8.60,131) 49.55(8.56,131) 55.40 (5.83, 61) 56.10(6.34,61)
Dominant 316.86 332.04 311.93 314.43
(76.33,128) (100.73,128) (45.05, 68) (44.45, 68)
Non-dominant 293.00 311.50
314.84 
(49.47,68)
316.69 
(36.95, 68)
(266.75-347.25,
130)
(279.00-392.25,
130)***
BCRT (ms) t 383.70 376.20 368.40 351.07**
(107.31,132) (110.65,132) (58.23, 67) (63.47, 67)
CVST (s) |
Word recognition
10.88 (3.17,131) 11.12(3.61,131) 10.00 (3.17,67) 10.04 (3.31,67)
Serial 15.23 (4.06,137) 15.20(4.55,137) 16.22 (4.02,68) 17,01 (4.33, 68)
Simultaneous
Fig recognition
19.18(3.44,136) 18.43 (3.76,136)* 20.24 (2.77,63) 20.19 (3.29, 63)
Serial
Story recall
13.99 (3.72,132) 14.61(4.14,132) 16.64 (4.25,67) 17,69(4.02, 67)*
Immediate 7.84 (2.80,147) 7.62 (3.38,147) 10.11 (3.32,69) 10.57 (3.70, 69)
Delayed
6.84 (3.00,147) 6.93 (3.32,147) 9.31 (3.27, 69) 10.25
(3.88, 69)**
ReyAVLT
Immediate 44.85 42.57 51.25 49.62
(9.11,147) (9.62,147)** (9.34, 69) (9.45, 69)
Delayed 8.52 7.73 10.62 9.96
(3.25,147) (3.08,147)*** (3.20, 69) (2.87,69)**
Verbal fluency 35.45 32.32 42.16 41.75
(11.54,146) (11.06,146)*** (10.66,69) (9.91,69)
AMIPB
Info Processing 59.40 59.15 68.54 70.58
(16.48,147) (17.85,147) (16.25, 69) (16.48, 69)**
Motor speed 46.28 44.25 51.99 54.02
(10.26,140) (9.70,140)** (7.76, 69) (8.69, 69)***
Values reported are means and SD or medians and 25th-75th percentiles and corresponding n, t higher score 
means worse performance, *p<.05, ** p<.01, *** p<,001
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Figure 7.2: Performance of people with epilepsy and healthy volunteers at baseline and 12 months on 
the Stroop colour-word task
7.4.2 Changes in the ABNAS
Despite experiencing significant declines on objective measures of cognitive functioning, there 
were no changes in the frequency of self-reported cognitive complaints between the baseline 
and 12 month assessments. However, as illustrated in Table 7.7, memory and cognitive 
slowing problems were the most commonly reported problems by people with epilepsy at 12 
months, which were the domains that experienced significant declines.
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Table 1.7: Changes in self-reported cognitive complaints between baseline and 12 months
Variable
PWE
(median, 25th-75th centiles, n)
Baseline 12 months
Memory 33.33 (16.67-58.33,143) 33.33 (16.67-58.33)
Slowing 33.33 (13.33-60.00,143) 33.33(13.33-53.33,143)
Fatigue 33.33 (13.3346.67,143) 26.67 (6.67-53.33,143)
Concentration 25.00 (8.33-50.00,143) 25.00 (8.3341.67,143)
Language 22.22 (11.1144.44,143) 22.22(11.1144.44,143)
Motor 11.11(0.00-33.33,143) 11.11 (0.00-22.22)
Values reported are medians and 25th-75th percentiles and corresponding n, t higher score means a more 
negative mood state, *p<.05, ** p<.01, *** p<.001
7.4.3 Standardised regression-based z-scores
Table 7.8 reports the predicted 12 month score for the patients with epilepsy based on the 
regression equations derived from the healthy volunteer group. These take into account 
practice effects, regression to the mean as well as other factors that affect re-test 
performance (i.e. baseline performance, age, sex and education). Table 7.8 also shows the 
difference between the observed and predicted 12 month score; the corresponding 
standardised regression-based z-score and the p-value for the difference between the 
observed and predicted 12 month scores.
After 12 months of treatment, patients with epilepsy were performing significantly lower than 
expected on 12 of the 15 neuropsychological test variables, with a trend towards significance 
on the immediate story recall task (f(146)=-2.31, p=.023). They performed as expected on the 
binary choice reaction time task (f(131)=0,00, p=.998). Interestingly, patients performed 
significantly better than expected on the Computerised Visual Search task (f(130)=-3.22, 
p=.002).
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Table 7.8: Standardised regression-based z-scores for the patients with epilepsy
Variable Predicted 12 
month
Observed vs. 
Predicted SRB z-score p-value
Finger Tapping
Dominant 57.66 -2.50 -0.54 002**
Non-dominant 53.88 -4.34 -1.27 <001***
Log Visual RT
Dominant 5.88 -0.20 -1.75 <001***
Non-dominant 5.63 -0.19 -2.05 <001***
BCRT 376.18 -0.02 0.00 .998
Log CVST 2.43 0.07 0.33 .002**
Word recognition
Serial 16.14 -0.94 -0.28 001***
Figure recognition
Serial 17.99 -3.39 -1.03 <001***
Story recall
Immediate 8.19 -0.57 -0.23 .023*
Delayed 8.66 -1.72 -0.68 <001***
ReyAVLT
Immediate 48.18 -5.61 -0.88 <001***
Delayed 9.20 -1.48 -0.79 <.001***
Verbal fluency 38.15 -5.84 -0.98 <001***
AMIPB
Info Processing 62.92 -3.77 -0.66 <001***
Psychomotor speed 48.87 -4.62 -0.97 <001***
*p<.05, **p<.01, ***p<,001
Figure 7.3 plots the performance of patients with epilepsy across the neuropsychological test 
battery with the x-axis representing their expected 12 month performance. Performance on 
the visual reaction time task, particularly with the non-dominant hand, was the most affected 
with patients performing more than 2SD below their predicted re-test score. For the majority of 
the remaining measures, patients were performing between 0.5SD and 1SD below expected.
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7.5 Impact of epilepsy, seizures and mood related variables 
7.5.1 Impact of number of seizures
There were no relationships between the number of seizures since baseline and any of the 
neuropsychological test measures (see Table 7.9). Although, there was a trend for serial 
recognition of words to be negatively associated with number of tonic-clonic seizures (rs= 
-.197, p-021).
Table 7.9: Impact of number of seizures on 12 month performance
Variable No of seizures No of tonic-clonic seizures
Finger Tapping
Dominant .020(0.817,131) -.099 (.260,131)
Non-dominant .027 (0.758,131) -.142 (.107,131)
Log Visual RT
Dominant .072 (0.420,128) -.057 (.524,128)
Non-dominant -.022 (.806,130) -.109 (.215,130)
BCRT .071 (.420,132) .017 (.843,132)
Log CVST -.041 (.641,131) -.065 (.459,131)
Word recognition
Serial -.072 (.403,137) -.197 (.021,137)*
Figure recognition
Serial -.031 (.726,132) -.027 (.762,132)
Story recall
Immediate -.045 (.588,147) -.091 (.271,147)
Delayed -.119 (.151,147) -.141 (.089,147)
ReyAVLT
Immediate -.082 (.326,147) -.101 (.223,147)
Delayed -.100 (.228,147) -.076 (.363,147)
Verbal fluency .095 (.256,146) .054 (.518,146)
AMIPB
Info Processing -.038 (.647,147) -.025 (.760,147)
Psychomotor speed .024 (.774,140) .003 (.967,140)
Values presented are Spearman's correlation coefficients (p-values and n); *p<.05, **p<.01, ***p<.001.
There were no differences in regression-based z-scores between those who had been seizure 
free for the 12 month period and those who had experienced seizures. However, there was a 
trend towards who had remained seizure free to perform worse on verbal fluency task 
(f(144)=2.03, p= 044).
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7.5.2 impact of seizure type
Figure 7.4 plots the performance of patients with partial, generalised and unclassified epilepsy 
across the neuropsychological test battery, with the x axis representing expected 
performance. The pattern of change across the neuropsychological test battery is similar 
across the three groups, however, those with generalised seizures perform better than the 
other two groups on the psychomotor speed sub-test of the Adult Memory and Information 
Processing Battery (F2,144=5.723, p= 004) but perform worse on the immediate subtest of the 
Rey Auditory Verbal Learning Test (F2,i44=4.50, p= 013). Further, those with partial epilepsy 
perform better than those with generalised epilepsy on the serial recognition of words 
(F2,134=5.44, p=.005). However, these results should be interpreted with caution due to the 
unequal numbers in each group.
7.5.3 Impact of mood
Changes in mood
As shown in Table 7.10, patients with epilepsy reported experiencing significantly fewer 
symptoms of tension over the first 12 months of treatment (f(145)=3.74, p<.001). There were 
no changes in the other mood factors. The healthy volunteers reported significantly fewer 
symptoms of tension (f(68)=2.78, p=.007) and depression (z=-2.73, p= 006) at their 12 month 
assessment There was also a trend for them to report fewer symptoms of anger (f(68)=2.52, 
p=.014) and confusion (f(68)=2.49, p=.015).
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At 12 months, people with epilepsy had significantly more symptoms of tension (f(213)=-3.62, 
p<.001), depression (f(213)=-4.25, p<.001), anger (/(213)=-2.32, p=.022), confusion (f(213)=- 
4.57, p<.001) and less vigour (f(213)=3.82, p<.001) than the healthy volunteers.
Table 7.10: Changes in mood in patients with epilepsy and healthy volunteers between baseline and 
12 months
PWE Controls
Variable Baseline 12 months Baseline 12 months
Tensionf 41.88
(21.97,146)
35.12
(24.59,146)***
29.91
(21.28, 69)
23.59
(14.20, 69)**
Depressionf 22.50(19.76,146) 21.16(21.14,146)
8.33
(3.33-23.33,169)
8.33
(1.37-15.83,169)**
Angerf 21.21
(18.21,145)
21.39
(20.25,145)
19.75
(18.01,69)
14.79
(16.27,69)*
Vigour 39.49
(19.95,146)
41.03
(20.69,146)
50.68 
(16.67, 69)
51.86 
(16.24,69)
Fatiguef 40.52
(25.14,145)
40.17
(27.73,145)
38.98 
(22.39, 69)
34.94 
(19.35, 69)
Confusiont 40.39
(21.73,145)
37.86
(22,30,145)
29.50 
(19.39, 69)
24.43
(13.57, 69)*
Values reported are means and SD or medians and 25th-75th percentiles and corresponding n, t higher score 
means a more negative mood state, *p<.05, ** p<.01, *** p<.001
Relationships with mood
For the patients with epilepsy, current mood state was significantly associated with the 
regression-based z-scores for several of the neuropsychological test variables (see Table 
7.11). Higher levels of depression were significantly associated with lower regression-based 
z-scores for the visual reaction time with the dominant hand. Poorer z-scores on the visual 
reaction time task with the non-dominant hand were significantly associated with higher 
symptoms of depression and anger. Higher levels of tension, depression and anger were 
associated with lower regression-based z-scores for psychomotor speed on the AMIPB. 
Higher levels of vigour were associated with higher regression-based z-scores on the visual 
reaction time task with the dominant hand.
196
Ta
bl
e 7
.1
1:
 Im
pa
ct
 o
f m
oo
d 
on
 p
er
fo
rm
an
ce
 a
t 1
2 
m
on
th
s
Va
ria
bl
e_
__
__
__
__
__
_
Te
ns
io
n_
__
__
__
__
__
D
ep
re
ss
io
n_
__
__
__
An
ge
r_
__
__
__
__
_
Vi
go
ur
__
__
__
__
__
Fa
tig
ue
__
__
__
__
_
C
on
fu
si
on CO oo CD
rv- oo
CT> T- 
CN CM 
CD CD
CD
CO
CO
CDOD
CM
CO h- 
h- CO 
CM U3
CO t- 05 IXD 
CD CD
CD CM CD CD CD- 
co cd i''- co
CM-^^-COt'- 
CO CD CM O CMt- T- T- O T-
1^— CD -t— CD CO t— 
CM CM OO CO CO CO
CD CD -t— -M" O CO
CM OO CD CO x— CM CO
co co oocMcoh^r^-.
f^-CO LO UD CD -T— 'Cf
COt- h- o cx> co cm
OO CM-'r-'t— OOO
CO'Cf CO'Cf co co
CO feo 22 in 3^
CD OO 
to LO 
O CD
f"— CD t— CD CD — CO CD
CM CM CO CO CO CO -'si-'M-
CD-M-r-~-CDx-00 CO CD
O O LO CO CO OO OO-M-
O O 'M" "sj* CO t— f— t—
O CO CO -C— CD CD OO o
CO LO CO CO CO -5— CM CM
CMCMOOOx- O T-
co in’ci- S2 ^
-d- -in 
°o XT in ^ ^ oo
7 S S
co co in’M" "M"
CO CM CO i— in co 
CM CM h-.
^ in m
CD CD CM 
■C— CD CD
CD
CM CM 't— CDco co
CO -t-
co co
CD CO —r CO CM 
CO V- OO 0° GO 
CD CD CD
CM
CD
CM
I . _ ^ CM
s ^ ^
CD
Cm
CL CZ
[2 c
im, pi a> q
2* Q
c
.E DC 
E 
o CQ
c
CQc
"E 'e
CD o
.E TD
M- oo
CO CD 
CO CM^ o
* *
o
CO
h-
CM
CD CD c^r-
CM CO IIJCO CO co f § CO■M- g in' coM"
r—"
CD
co
CM
CD
co" -rP cm" /r
CM 22 CD
2_ co 2, ^
cd"
in p: 2.
CM~
CO
13$
CD
in
CD
o
h-.
CD ^ o oo
3 CD ^ CD
in
CD
o £5s 0
co
CO
CD
in 3"
Csl
0 co 
cd
in
0
CD
in
CD CD
r-~- cd 
cn v: 
cd in
CD CM 
CD CO
oCD
V
.o.
CO co' CO CO in co~ crT
Mt- M- M* co
■* ■"C— ■* ■*""
h-T 10 co" CD CD in
00 00 s ro1— CM CM to co O
•-—Z' '—I- >—2*
0 CD CD CM "mJ* OO 00
c<-> 00 OO Is-. co 00
CD CD O 0 CM
o^
 D)o
Olo
O CD
S? ° o*
-n £ — & c
I— t *" JO .E "D J— .E TD 2co 2 oiJ^td aj_jTD gjj2
E dz . ^ E ^ E — 15 00
O o ^ « « « ^|a5<|aD5a-
Q^OoQ>a3^-QS*-QS5S
OQ —1 CO CO tO Ol > <
"O
CD
CD
g-
CD o c_> E 
2 On -i= l-L- o o >>
■*= CD_E Ol
(D
D_03
CO
(0>
197
7.6 Individual-level analysis
Figure 7.5 illustrates the proportion of patients with epilepsy who had abnormal scores for 
each test when different criterions of abnormality were applied (regression-based z-score 
1.5 or ^-2.0). Even when the more conservative criterion was used, a high proportion of 
patients (41.5%) had abnormal scores on the visual reaction time task with the non-dominant 
hand and 38.3% had abnormal scores with the dominant hand. Other psychomotor speed 
measures were also vulnerable to lower than expected re-test performance. On the finger 
tapping task with the non-dominant hand, 28.2% of patients had abnormal scores and 25.7% 
had poorer than expected scores on the psychomotor speed task of the Adult Memory and 
Information Processing Battery. A high proportion of patients (21.9%) also performed lower 
than expected on the verbal fluency task.
Figure 7.5: The proportion of people with epilepsy with abnormal test scores at 12 months
60
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7.6.1 Impairment index
The regression-based z-scores were used to identify individual patients who had experienced 
at least one abnormal score across the neuropsychological test battery (see Table 7.12). 
When the more conservative criterion of a regression-based z-score of ^-2.0 was applied, 
85.0% of patients with epilepsy had some degree of cognitive impairment (> 1 abnormal test 
score) and 31.3% had abnormal scores on at least a quarter of the test measures. When a 
regression-based z-score of ^-1.5 was used as a marker of abnormality, this increased to 
94.6% having at least one abnormal test score and 59.9% having abnormal scores on at least 
a quarter of the tests.
Table 7.12: Number of patients demonstrating abnormal performance across the test battery
Proportion of tests with 
abnormal scores
Criterion for abnormal performance
z-score £1.5 (n, %) z-score ^2.0 (n, %)
None 8 (5.4) 22 (15.0)
*1% 139 (94.6) 125 (85.0)
£25% 88 (59.9) 46 (31.3)
£50% 17(11.6) 5 (3.4)
An exploratory data analysis was conducted to investigate the clinical and demographic 
characteristics of those who were classified as having an abnormal test performance. Table 
7.13 illustrates the results of this analysis. There were no significant differences between 
those who demonstrated an abnormal test performance and those who performed as 
expected on any demographic, seizure-related and mood-related variables. However, there 
was a trend for those with lower levels of education (/2{2)=8.95, p<.011); a higher number of 
tonic-clonic seizures (z=-2.04, p<.041) and experiencing higher levels of confusion (z=-1.96, 
p<.050) to be in the abnormally performing group.
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Table 7.13: Characteristics of those who demonstrated abnormal test performance
Characteristics Abnormal
performance
(n=125)
Expected
performance
(n=22)
Diff (95%CI) P-
value
Sex
Male 63 (50.4) 10 (45.5) 4.9 (-17.0, 25.8) .669
Female 62 (49.6) 12(54.5) 4.9 (-25.8,17.0)
Age at 12 mths, yrs 40 (27.50-53.50) 44 (30.50-58.25) 4 (-11,4) .276
Age at first seizure 34 (2046.50) 26 (1748.25) 3 (-5,12) .403
Education at baseline, yrs
<11 75 (60.0) 8 (36.4) 23.6 (1.1,42.7) .011*
12-15 35 (28.0) 6 (27.3) 0.7 (-21.6,17.6)
>15
Seizure type at baseline
15(12.0) 8(36.4) -24.4 (45.8, -6.4)
Partial 92(73.6) 14(63.6) 10.0 (-8.9,32.1) -
Generalised 15(12.0) 4(18.2) -6.2 (-27.2, 6.9)
Unclassified 18(14.4) 4(18.2) -3.8 (-24.9,9.6)
Number of seizures 4 (0-19) 2(0-7) 1(0,5) .201
Number of GTCS 0(0-1.5) 0 (0-0) 0(0,0) .041*
Immediate 12mth remission 36 (28.8) 10(45.5) -16.7 (-38.2,3.9) .120
Baseline aetiology/pathology 44 (35.2) 4(18.2) 17.0 (4.8,31.6) .116
Remained randomised drug 88(70.4) 16(72.7) -2.3 (-19.2, 20.0) .825
TPM at 12 months 32 (25.6) 3(13.6) 12.0 (-8.9,24.8) .224
Reported cognitive AEs 5 (4.0) 1 (4.5) -0.5 (-18.1,5.9) .905
Mood
Tension 33.33
(11.11-54.86)
23.61
(13.19-50.69)
5.6 (-5.6,16.7) .341
Depression 15.83
(3.75-33.33)
9.17
(3.33-27.08)
5(4.67,11.67) .214
Anger 14.58
(4.17-33.33)
13 *14
(7.29-24.48)
2.1 (4.2,10.4) .673
Vigour 40.63
(25.00-53.13)
46.88
(37.50-65.63)
-9.4 (-18.8,0) .060
Fatigue 35.71
(17.86-64.29)
23.21
(13.39-50.00)
7.2 (-3.6, 21.4) .171
Confusion 35.71
(18.75-60.71
23.21
(14.2940.18)
10.7 (0, 21.4) .050*
Classified as impaired at 
baseline
74(59.2) 11 (50.0) 9.2(42.2,30.5) .420
Values reported are either n and % or median with 25th-75th centiies, AEs-adverse events, *p<.05, **p<01,
***p<.001;
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7.7 Summary
The aim of this chapter was to compare the cognitive trajectories of people with epilepsy with 
healthy volunteers during the first 12 months of epilepsy and its treatment. A total of 147 
newly diagnosed previously untreated patients with epilepsy were assessed at baseline and 
after 12 months. The majority (72.1%) had partial seizures and had experienced a median of 
three seizures between the baseline and 12 month assessment None had experienced 
episodes of status epilepticus. The majority (70.7%) had remained on their randomised drug 
throughout the 12 month period and 31.3% had achieved an immediate 12 month seizure 
remission.
There were no differences in demographic or clinical characteristics between those patients 
who did or did not complete the 12 month assessment. For the majority of measures, there 
were no differences in baseline neuropsychological performance between those who did or 
did not complete the 12 month assessment. However, those who completed had poorer 
baseline finger tapping scores and trends towards poorer scores on the visual reaction time 
task with the non-dominant hand.
The cognitive profile of patients was compared with 69 healthy volunteers who were recruited 
from the general population and were also assessed at baseline and after 12 months. They 
were equated for age and sex at baseline, however after 12 months the healthy volunteers 
were younger and had significantly more years of education than people with epilepsy. There 
were no differences in the demographic or baseline neuropsychological characteristics of the 
healthy volunteers who did or did not complete, although more healthy males dropped out of 
the study.
After 12 months of treatment, patients with epilepsy experienced significant declines on five 
measures, in contrast to the healthy volunteers who had a decline on one measure but 
experienced significant improvements on four measures. The tasks most affected were those 
that assessed memory, psychomotor speed and higher executive functioning, as assessed by 
the verbal fluency task.
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After taking into account baseline performance, age, sex and education, patients performed 
significantly worse than expected on 12 out of the 15 neuropsychological test measures. The 
domains that were most at risk of poor performance were memory, higher executive 
functioning and psychomotor speed, particularly the visual reaction time task. Interestingly, 
patients performed significantly better on the Computerised Visual Search Task.
There were no significant relationships between the number of seizures or the number of 
tonic-clonic seizures since baseline and any of the regression-based z-scores. Similarly, there 
were no differences between those who achieved an immediate 12 month remission and 
those that did not. There were few differences between patients with partial, generalised and 
unclassified epilepsy. Patients with generalised epilepsy performed better than the other two 
groups on the psychomotor speed test of the AMIPB but worse on the immediate subtest of 
the Rey AVLT and the serial recognition of words compared with those with partial epilepsy. 
However, these results should be interpreted with caution due to the unequal numbers in each 
group.
The healthy volunteers reported significantly fewer symptoms of tension and depression at 
their 12 month assessment. The patients with epilepsy reported fewer symptoms of tension. 
However, at the time of assessment, people with epilepsy had significantly higher levels of 
tension, depression, anger and confusion and significantly less vigour than the healthy 
volunteers. Their current mood state was significantly related to several of the regression- 
based z-scores, suggesting that mood may be related to change in cognitive functioning on 
measures, particularly those that assess psychomotor speed.
A high proportion of patients were classified as having abnormal scores, particularly on the 
psychomotor speed measures. A total of 85% of patients had at least one abnormal test score 
across the neuropsychological test battery. There were no significant differences between 
those who were classified as having or not having an abnormal test performance on 
demographic, epilepsy and mood-related variables. However, there were trends for those with 
had fewer years of education, had experienced higher numbers of tonic-clonic seizures and 
more symptoms of confusion to be in the abnormally performing group.
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A proportion of these patients were followed-up after an average of five years, the results of 
this analysis will be presented in the next chapter.
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Chapters Results: The longer term impact
8.1 Overview of the chapter
This chapter outlines the results of the Neuropsychology follow-up study, which aims to 
assess cognitive change over a longer term period in a sub-set of patients with epilepsy, who 
had taken part in the SANAD Neuropsychology study. The numbers of patients who were 
recruited and assessed as part of this follow-up study will be described. The demographic and 
clinical characteristics of these patients with epilepsy will be reported. Changes in 
neuropsychological performance from baseline to follow-up will be analysed and the factors 
that influence cognitive change will be investigated. The amount of cognitive change 
experienced at an individual-level will be explored. These results have formed the basis of a 
peer-reviewed publication by Taylor & Baker (in press) (see Appendix D).
8.2 Participants 
8.2.1 Recruitment
A total of 144 patients had completed all three assessments from the participating hospital 
centres. As shown in Table 8.1, seven patients had died since their 12 month assessment and 
one patient had undergone epilepsy surgery. A further two patients had requested, as part of 
the SANAD trial and associated quality of life study, that no further requests to take part in 
research be made. Therefore, 134 patients were eligible for the study. Despite using the NHS 
tracking system and contacting local hospital centres, up to date contact details could not be 
found for two patients (one from Royal Hallamshire Hospital and one from Gian Clwyd 
Hospital). Invitation letters and participant information sheets were sent to 132 patients.
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Table 8.1: Number of patients from each centre recruited and assessed in the follow-up study
WCNN RBH UHW RHH WMH GCH HH DRI Total
12 month ass 39 32 30 12 11 8 8 4 144
Not eligible
Deceased 4 1 0 0 0 0 0 2 7
Surgery 1 0 0 0 0 0 0 0 1
Other 2 0 0 0 0 0 0 0 2
Eligible 32 31 30 12 11 8 8 2 134
Approached 32 31 30 11 11 7 8 2 132
Responded
Yes 12 8 17 8 4 3 2 0 54
No 12 11 5 1 2 2 4 0 37
No response 8 12 8 2 5 2 2 2 41
Completed 11 7 15 8 4 3 2 0 50
WCNN=Walton Centre for Neurology and Neurosurgery, RBH=Royal Bolton Hospital, UHW=University Hospital 
of Wales, RHH= Royal Hallamshire Hospital, WMH^ Wrexham Maelor Hospital, GCH=Glan Clwyd Hospital, HH^ 
Hope Hospital, DRI=Doncaster Royal Infirmary
8.2.2 Assessment
Ninety-one patients (69%) either returned the reply slip or responded to telephone calls, There 
was no response from 41 (31%) patients, despite telephone calls and follow-up letters being 
made. Of those approached, 54 (41%) patients wanted to take part but 37 (28%) refused. 
Reasons for not wanting to take part included: ill health (n=3); did not feel they had the time 
(n=2); family or work circumstances [work commitments (n=2), pregnancy (n=1), family 
bereavement (n=1)]; tired of taking part in research (n=1); no longer had epilepsy so did not 
want to contribute (n=1) or a reason was not given (n=26).
Of the 54 patients who wanted to take part, 50 completed the follow-up assessment. 
Assessments were not completed for four patients for various reasons: the frequency and 
severity of seizures made it too difficult to carry out an assessment for one patient; one 
cancelled their appointment and did not want to rearrange, and after responding to the 
invitation letter, contact could not be made with two patients to arrange an assessment time.
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8.3 Demographic and clinical characteristics
Table 8.2 illustrates the clinical and demographic characteristics of the 50 patients who 
completed the neuropsychology follow-up assessment. The majority (62%) were females with 
an average age of 46 yrs, ranging from 21-84 years. It was a mean 64 months since their 
baseline assessment, ranging from 43 months to 85 months. This test-retest interval will be 
used as surrogate for duration of epilepsy, as these patients were newly diagnosed at the time 
of the baseline assessment There were no differences in terms of age at baseline (f(130)=- 
1.11, p=.267) or gender (x2(1)=2.184, p= 139) between those who did and did not take part in 
this follow-up study.
At baseline, the majority of patients with epilepsy (84%) had no previous neurological 
disorders. However, two had experienced head injuries prior to the first assessment; one had 
a stroke; one had meningitis; one had intracranial surgery; one had intracranial surgery and 
an intracerebral abscess; one had idiopathic intracranial hypertension and the other had 
eclamptic seizures. A higher proportion of those who did not take part in this follow-up study 
had a neurological deficit at baseline (8.5% vs. 0%). A higher proportion also had previously 
had a stroke (6.1% vs. 2.0%) or an other neurological disorder (11% vs. 6%). But a higher 
proportion of patients in this follow-up study had intracranial surgery (4% vs. 0%) or a head 
injury (4% vs. 0%). However, the differences between the two groups were too small to make 
statistical comparisons.
At baseline, 44 (88%) of those who took part in follow-up study had a CT/MRi scan. Of these 
10 had an abnormal scan, 33 had a normal scan and the report was unavailable for one. The 
abnormalities were not detailed for eight but were white matter abnormalities and a 
cavernoma for two patients.
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Table 8.2: Clinical and demographic characteristics of those who did or did not take partin follow-up
study
Characteristics Took part in follow-up 
(n=50)
Eligible but did not take 
part in follow-up (n=82)
Sex (n, %)
Male 19 (38.0) 42 (51.2)
Female 31 (62.0) 40 (48.8)
Mean age at baseline, yrs (SD, range) 41.34 (15.01,15-78) 38.32 (15.20,15-69)
Mean age at FU, yrs (SD, range) 46.76 (15.22, 21-84) -
Mean duration, mths (SD, range) 64.24 (10.75,43-85) -
History at baseline (n, %)
Neurological deficit 0(0) 7 (8.5)
Neurological disorder (n, %)
Stroke/cerebro vascu lar 1 (2.0) 5(6.1)
Intracranial surgery 2 (4.0) 0(0)
Head injury 2(4.0) 0(0)
Meningitis/encephalitis 1 (2.0) 2 (2.4)
Other 3 (6.0) 9(11.0)
Abnormal imaging at baseline (n, %) 10(20) 20 (24.4)
Seizure type at baseline (n, %)
Partial 42 (84.0) 55 (67.1)
Generalised 4 (8.0) 13(15.9)
Unclassified 4 (8.0) 14(17.1)
Seizure frequency at FU (n, %)
None 29 (58.0) -
Daily 3 (6.0) -
Weekly 3 (6.0) .
Monthly 12(24.0) -
Yearly 3 (6.0) -
Seizure free previous 12 months (n, %) 29 (58.0) -
Other co-morbidities (n, %) 20 (40.0) -
As in SANAD, the majority (84%) had partial epilepsy. There were no differences in baseline 
seizure type between those who did and did not take part (x2(2)=4.574J p= 102). The majority 
(58%) of patients in this study had also been seizure free for at least the 12 months prior to 
the assessment Of those who continued to have seizures, three experienced them daily;
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three weekly and three experienced only one seizure in the previous year. The remaining 
twelve reported having them monthly.
Forty per cent of those who took part in the follow-up assessment reported experiencing other 
medical conditions unrelated to their epilepsy since their 12 month assessment. These 
included cancer (e.g. carcinoma tumour, cancerous carcinoma on the hand, breast cancer); 
lymphodema and cellulitis as a result of breast cancer; diabetes; sleep apnoea; surgical 
procedures (e.g. hysterectomy, gall bladder operation); gynaecological problems; a neck 
injury affecting the left arm and two reported head injuries. Three patients reported being 
currently under investigation (one for fainting spells, one for a low cortisol response) and five 
reported previous psychological problems. Two reported experiencing episodes of 
depression; one had been hospitalised for a suicide attempt and one had been referred to 
psychological services for anger management. One patient reported feeling under stress due 
her husband being ill and other stressful life events; however, she had not sought treatment. 
Of those who had reported experiencing psychological problems since the 12 month 
assessment, none reported still experiencing them at the time of the follow-up assessment.
At baseline, 15 (30%) patients were classified as having temporal lobe epilepsy; 1 (2%) as 
having frontal lobe epilepsy and 26 (52%) as having partial epilepsy but the localisation was 
not specified. Two (4%) patients were classified as having juvenile myoclonic epilepsy; 1 (2%) 
as having an other unspecified idiopathic generalised epilepsy and 1 (2%) as having an other 
epilepsy syndrome. The remaining 8% had unclassified epilepsy.
Two patients reported not taking AEDs at the time of the follow-up assessment. Of those who 
were taking AEDs, 83.4% were treated with monotherapy and 16.6% with polytherapy. As 
shown in Table 8.3, lamotrigine, carbamazepine and topiramate were the most commonly 
prescribed drugs. However, one patient admitted that they were non-compliant with 
topiramate and self-medicated when they felt they needed to. The eight patients treated with 
polytherapy were on six different combinations. Three were taking carbamazepine and 
levetiracetam; one carbamazepine and topiramate; one lamotrigine and valproate; one 
lamotrigine and clobazam (CLB); one levetiracetam and clobazam and one was on a 
combination of topiramate and pregabalin. As patients had changed their drugs throughout
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the five year period, differences in cognitive functioning between drugs will not be analysed in 
this thesis.
Table 8.3: AEDs prescribed at the time of the follow-up assessment
Monotherapy N (%) Polytherapy N (%)
LTG 10(20.0) CBZ+LEV 3(6)
CBZ 9(18.0) CBZ+TPM 1(2)
TPM 9 (18.0) P LTG+VPA 1(2)
GBP 4 (8.0) LTG+CLB 1(2)
LEV 4 (8.0) LEV+CLB 1(2)
OXC 2 (4.0) TPM+PGB 1(2)
PGB 1 (2.0)
VPA 1 (2.0)
Total 40 (80) Total 8(16.0)
None 2 (4.0)
• Pone patient admitted to being non-compliant with TPM.
At the time of follow-up, half of the patients were in paid employment; one was still in full-time 
education; 18% had retired and 30% were unemployed. As shown in Table 8.4, they had a 
median of 12 years of education and 82% had achieved formal educational qualifications. 
Forty four percent had achieved school-level qualifications (GSCEs/CSEs or equivalent) and 
30% had achieved the equivalent of A-levels or higher. They had significantly more years of 
formal education at baseline than those who were eligible but did not take part in the follow-up 
study (x2(2) =11.30, p=.004). However, there were no differences between the two groups on 
any of the baseline neuropsychological measures, although there was a trend for those who 
did not take part to have lower scores on both aspects of the Adult Memory and Information 
Processing Battery (AMIPB information processing f(130)=-2.36,0=020; AMIPB psychomotor 
speed f(125)=-2.13, p =.035). Similarly, there were no differences between the two groups on 
any of the 12 month neuropsychological measures.
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Table 8.4: Socio-demographic characteristics of those who did or did not take part in the follow-up
study
Characteristics
Took part in follow­
up (n=50)
Eligible but did not 
take part in follow-up 
(n=82)
Employment status at FU (n, %)
In paid full/part-time work 25 (50.0) -
In full-time education 1 (2.0) -
Retired 9(18.0) -
Unemployed 15 (30.0) -
Median education at FU, yrs (25th-75th 
centiles) 12(11-16) -
Education at baseline, yrs (n, %)
<11 20 (40.0) 53 (64.6)**
12-15 17 (34.0) 23 (28.1)
>15 13(26.0) 6 (7.3)
Highest qualification obtained at FU (n, %)
None 9(18.0) -
Other 2 (4.0) -
GCSE/CSE or equivalent 22 (44.0) -
A-levels or equivalent 4 (8.0) -
Diploma 4 (8.0) -
Degree or higher 9 (18.0) -
*p<.05, **p<.0V**p<.001
8.4 The longer term changes
8.4.1 Changes in neuropsychological functioning
Table 8.5 illustrates the differences between baseline and follow-up on the 
neuropsychological test variables. Patients with epilepsy had statistically significantly slower 
reaction times at follow-up on the visual reaction time task with both the dominant (f(45)=- 
3.85, p<.001) and non-dominant (f(47)=-5.62, p<.001) hand. They also had significantly lower 
scores at follow-up compared with baseline on the immediate (f(49)=3.92, p<.001) and 
delayed (z=-3.901 p=.001) tasks of the of the Key Auditory Verbal Learning Test.
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There were also trends for worse performance at follow-up on serial recognition of words 
(f(46)=2.35 p= 023); the information processing task of the AMIPB (f(49)=2.60, p= 012) and 
on the CVST (f(45)=-2.29, p=027). However, there was a trend towards improved 
performance on the serial recognition of figures task (f(44)=:-2.09I p= 043).
Table 8.5: Changes in neuropsychological test variables from baseline to follow-up
Variable Baseline Follow-up Diff (95% Cl) p-value
Finger Tapping
Dominant 56.02(9.75,48) 56.34(9.23,48) -0.32 (-3.42, 2.78) .836
Non-dominant
Visual RT (ms)t
51.34 (8.57,47) 50.43 (6.70,47) 0.90 (-1.46,3.26) .446
Dominant 309.37 (62.97, 46) 348.13(54.00, 46) -38.76(-59.04, -18.48) <.001***
Non-dominant
311.98 (68.84,48) 366.33 (68.07,48) -54.35
(-73.82, -34.89) <.001***
Binary Choice RT 341.00 361.00
-7 (-27, -16) .519(ms)t (308.00424.00,45) (313.00419.00,45)
CVST (s)| 10.80(4.10,46) 11.87 (3.60,46) -1.06(-2.00, -0,13) .027*
Word recognition
Serial 15.94(4.11,47) 14.23(4.75,47) 1.70(0.24,3.16) .023*
Simultaneous 20.00
(17.00-22.00,43)
19.00
(17.00-21.00,43)
0.5 (-0.5,15) .249
Fig recognition
Serial
14.29(4.00,45) 15.56(4.65,45)
-1.27
(-2.49, -0.04)
.043*
Story recall
Immediate 8.34 (2.64,50) 7.89 (2.73,50) 0.45 (-0.24,1.14) .197
Delayed
ReyAVLT
7.20(2.62,50) 7.39 (2.88,50) -0.19 (-0.90, 0.52) .593
Immediate 45.88 (9.16,50) 40.34 (10.79,50) 5.54 (2.70, 8.38) <.001***
Delayed 10.00
(7.00-11.00,50)
8.00
(6.00-10.00,50) -1.5(-2, -1) .001***
Verbal fluency 
AMIPB
35.90 (12.48,50) 35.78(12.68,50) 0.12 (-2.69, 2.93) .932
Info Processing 63.39 (16.33,50) 59.80(18.49,50) 3.59 (0.81,6.37) .012*
Psychomotor
speed
48.65 (10.91,49) 46.71 (9.07,49) 1.94 (-0.82,4.70) .164
Values reported are means and SD or medians and 25th-75th percentiles and corresponding n, t higher score 
means worse performance, *p<,05, ** p<.01, *** p<.001
Figure 8.1 illustrates the percentage of patients whose performance fell in the different 
categories at baseline and follow-up on the Stroop colour-word task. A higher proportion of
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patients were performing in the average range at follow-up compared with baseline (71.7% vs. 
66.7%). Fewer patients were performing in the borderline ranges at follow-up compared with 
baseline (15.2% vs. 16.7%). This suggests that, as a group, patients improved over time on 
this task.
Figure 8.1: Changes in classification on the Stroop colour-word task from baseline to follow-up
8.4.2 Changes in mood variables
On the Profile of Mood States questionnaire, as shown in Table 8.6, patients reported feeling 
significantly fewer symptoms of tension at the follow-up assessment (f(49)=3.00, p=.004). 
They also reported fewer symptoms of depression, anger, fatigue and more vigour but 
reported feeling more confusion. However, none of these changes were statistically 
significant.
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Table 8.6: Changes in mood factors from baseline to follow-up
Variable
Baseline 
(mean, SD, n)
Follow-up 
(mean, SD, n)
Diff
(95% Cl)
p-value
Tensionf 37.89 (20.19, 50) 29.17 (20.28,50) 8.72 (2.88,14.56) .004**
Depressionf 18.80 (16.63, 50) 17.60 (20.02,50) 1.20 (-3,35, 5.75) .598
Angerf 19.42 (18.11,50) 17.50(20.30, 50) 1.92 (-2.63, 6.47) .401
Vigour 41.38(20.33, 50) 44.06 (20.32, 50) -2.69 (-7.90,2.53) .305
Fatiguef 41.14(25.06, 50) 38.64 (31.13, 50) 2.50 (-5.23,10.23) .519
Confusiont 34.07 (20.81,50) 34.86 (23.32, 50) -0.79 (-6.08,4.51) .767
*p<.05, **p<.01,***p<.001
8.4.3 Changes in the ABNAS self-report measure
As shown in Table 8.7, patients reported experiencing less fatigue but more memory,
language and concentration problems and cognitive slowing at the follow-up assessment. 
However, these were not statistically significant changes. Although, not statistically significant, 
reports of increased cognitive problems in these areas are consistent with the findings of more 
attention and memory problems at follow-up on the objective measures.
Table 8.7: Changes in the ABNAS self-report measure from baseline to follow-up
Variable
Baseline
(median, 25th-75th 
centiles, n)
Follow-up 
(median, 25th-75th 
centiles, n)
Diff
(95% Cl)
P-
value
Fatiguef 30.00(13.33-51.67,48) 26.67 (6.67-53.33,48) 3.33 (-3.33,6.67) .658
Slowingf 33.33 (13.33-60.00,48) 40.00 (13.33-65.00,48) -3.33 (-10.00,3.33) .509
Memoryf 33.33 (16.67-58.33,48) 41.67 (25.00-66.67,48) -4.17 (-12.5,4.17) .268
Concentrationf 25.00 (8.33-50.00,48) 33.33 (8.33-50.00,48) -4.17 (-12.5,4.17) .343
Motorf 11.11 (0.00-22.22,48) 11.11 (0.00-22.22) 0 (5.56, 0) .797
Languagef 22.22(11.11-44.44,48) 27.78 (22.22-55.56) -5.56 (-11.11,0) .063
t higher score means more cognitive complaints, * p<.05, ** p<.01, *** p<.001
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8.5 Percentage change
Figure 8.2 plots the median percentage change scores across the neuropsychological test 
battery. The tests with the most decline from baseline are the delayed sub-test of the Rey 
Auditory Verbal Learning Task; visual reaction time with the dominant and non-dominant hand 
and the CVST. This is consistent with the results of the dependent t tests. However, the 
declines are subtle and most measures have on average less than 5% decline from baseline. 
The Rey Auditory Verbal Learning Task and visual reaction time tasks seem to be the most 
vulnerable to decline at follow-up, with an average decline of 17% from baseline for the Rey 
AVLT. Interestingly, improvements were found on the story recall tasks and serial recognition
of figures.
Figure 8.2: Median percentage change score across the neuropsychological test battery
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8.6 Factors associated with cognitive change
Table 8.8 contains the results of the univariabie analyses. There were no differences between 
those with or without a previous/current neurological disorder or abnormal imaging at 
baseline; or those who had seizures in the previous year and those who had not for any of the 
percentage change scores. Similarly, there were no differences between those who had other 
co-morbid diagnoses, between the 12 month assessment and follow-up and those who did not 
on any of the scores.
There was a trend for years of education to be significantly associated with change on the 
delayed story recall task (i*=.316, P=.025) and duration of epilepsy with simultaneous 
recognition of words («=-.326, p=.033). Age at the time of the follow-up assessment was 
significantly associated with psychomotor speed sub-tests of the Adult Memory and 
Information Processing Battery (rs=-.442, p=.001) and had trends with the information 
processing sub-test (rs=-.321, p=.023) and serial recognition of words (ri=-.297, p=.042). 
Scores on the Tension factor of the Profile of Mood States were significantly associated with 
tapping with the dominant (^-.527, p<.001) and non-dominant hand (ft=-.383, p=.008); the 
psychomotor speed sub-test of the Adult Memory and Information Processing Battery («=- 
.385, p=.006) and a trend with delayed recall (rs=-.282, p=.047) on the Rey Auditory Verbal 
Learning Test.
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Table 8.8: Univariable analyses effectors affecting cognitive change (values reported are p-values)
Variable
Finger 
Tapping 
Dominant 
Non­
dominant 
Visual RT (ms) 
Dominant 
Non­
dominant 
BCRT (ms) 
CVST (s)
Word recog 
Serial
Simultaneous
Figure recog
Serial
Story recall 
Immediate 
Delayed 
Rey AVLT 
Immediate 
Delayed 
Verbal fluency 
AMIPB 
info
Processing 
Motor speed
*p<.05, **p<.01, ***p<.001
Seizures Age Education Duration Co­
morbidities
Tension Neurological
deficit
.530 .770 .999 .280 .509
<001*** .764
.983 .813 .834 .778 .965 .008** .698
.126 .171 .228 .342 .060 .574 .830
.442 .077 .882 .580 .359 .055 .456
.963 .323 .421 .417 .694 .161 .634
.540 .290 .904 .690 .311 .831 .166
.308 .042* .489 .708 .435 .381 .832
.213 .278 .274 .033* .195 .505 .703
.331 .950 .308 .092 .879 .339 .475
.302 .836 .120 .341 .559 .119 .617
.672 .293 .025* .521 .112 .887 .573
.875 .317 .254 .903 .205 .153 .518
.783 .788 .567 .677 .905 .047* .546
.331 .525 .295 .145 .607 .932 .924
.387 .023* .580 .693 .759 .425 .130
.808 .001*** .928 .834 .200 .006** .386
* .
8.7 Individual change
Figure 8.3 illustrates the percentage of patients who experience cognitive decline across each 
of the measures when the different criterions (i.e. >1.5 SD or >2SD) of decline were applied. 
Using a more liberal criterion of 1.5SD, 20.0% of patients experienced cognitive decline on the 
immediate subtest of the Rey Auditory Verbal Learning Test; 19.6% on the visual reaction 
time with the dominant hand; 16.7% with the non-dominant hand and 17.0% on the 
recognition of words serially. However, when a more conservative criterion of 2SD was 
employed, the number of patients experiencing cognitive decline decreased. Only 10.0% were
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still classified as experiencing decline on the delayed recall of the Rey Auditory verbal 
Learning Test; 10.4% on the non-dominant hand visual reaction time task and 8.7% with the 
dominant hand. The proportions classified as declined on the serial recognition of words also 
decreased to 6.4%. Again, it appears that the Rey Auditory Verbal Learning test and visual 
reaction time tasks are more vulnerable to decline in a sub-set of patients with epilepsy.
Figure 8.3: The proportion of patients who declined by more than 1.5 and 2SD between baseline and 
follow-up
Tipping Tipping AMIPB VRT dotr 
doir nondon- speed
Psyf hon'd tor speed
VRT BCRT CV5T AMIPB Words Words Royirorr Rey dsl
Story
nondorr scoro s«r sim
wrm
Info processing
Neuropsythologitil tests
Higher e«ec
1.5 SD ■>2$D
Those patients who had experienced cognitive decline on at least one neuropsychological test
measure were identified. Table 8.9 illustrates that 64% of patients had experienced a decline
of more than 1.5 SD from baseline on at least one test measure. This figure reduced to 38%
when the more conservative value of 2SD was applied. Only one patient had cognitive
declines on more than a quarter of the test measures* * * * * 9.
9 After this patient’s assessment, under the supervision of Prof GA Baker, a letter was sent to the GP informing 
them of the significant declines that had been observed and the difficulties that this patient had in completing
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Table 8.9: Number of patients demonstrating cognitive decline across the test battery
Proportion of tests declined Criterion for cognitive decline
1.5 SD (n, %1 2SD (n, %)
None 18 (36.0) 31 (62.0)
*1% 32 (64.0) 19 (38.0)
>25% 4(8) 1 (2.0)
£50% 0(0) 0(0)
8.7.1 Characteristics of those experiencing cognitive decline
An exploratory data analysis was conducted to investigate the clinical and demographic 
characteristics of those who were classified as having cognitive decline. Table 8.10 illustrates 
the results of this analysis. There were no significant differences between the two groups on 
any of the demographic, psychological or epilepsy-related variables entered into this
exploratory data analysis.
several of the neuropsychological tasks. A letter was also sent to the patient providing feedback on the 
assessment.
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Table 8,10: Characteristics of those classified as having or not having cognitive decline at follow-up
Characteristics
Declined
(n=19)
Not declined
(n=31)
Diff (95%CI) P-
value
$ex(n, %)
Male 7 (36.8) 12(38.7} -1.9 (-27.9,25.9) .895
Female 12(63.2) 19(61.3) 1.9 (-25.9, 27.9)
Mean age at FU, yrs (SD, range)
51.11 44.10 7.01 .115
(14.17, 22-84) (15.45, 21-71) (-1.77,15.79)
.097Mean age at baseline, yrs 45.84 38.58 7.26
(SD, range) (13.89,17-78) (15.21,17-65) (-1.37,15.89)
.301Mean duration, months 
(SD, range)
62.21
(11.23,43-85)
65.48
(10.43,46-84)
-3.27(-9.56,3.02)
Seizure type at baseline (n, %)
Partial 15(78.9) 27 (87.1) -8.1 (-32.7,12./)
Generalised 1 (5.3) 3(9.7) -4.4 (-21,16.4)
Unclassified 3(15.8) 1 (3.2) 12.6 (-3.5,35.1)
.242Seizure free previous 12 mths 13(68.4) 16(51.6) 16.8 (-11.7,41.7)
(n,%)
0 0(0) 2(6.5) -6.5(20.9,11.1) -
1 15(78.9) 25(80.6) -1.7 (-27.1,20.3)
2 4(21.1) 4(12.9) 8.1 (-12.7,32.7)
.382TPM at FU (n, %) 5(26.3) 5(16.1) 10.2(42.4,35.5}
Baseline abnormal 
imaging/neurological disorder
7 (36.8) 8(25.8) 11.0(44.6,37.5) .409
(n,%)
Co-morbidities at FU (n, %) 8(42.1) 12(38.7) 3.4 (-23.5, 30.9) .812
Classified as impaired at 
baseline (n, %)
9(47.4) 19(61.3) 43.9
(-40.4,14.2)
.336
Median education at FU, yrs 
(25th-75th centiles)
12(11-18) 12(11-15) 0(4,2)
-8.33
.812
.136Mean tension at FU 30.56 22.22
(25th-75th centiles) (16.6744.44) (13.89-36.11) (-2.78,19.44)
Employment status at FU (n, %)
18(58.1) 46.0(41.9,
12.5)
.273Employed/FT education 8(42.1)
Unemployed/retired 11 (57.9) 13(41.9) 16.0 (42.5,41.9)
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8.8 Summary
Fifty people with epilepsy were assessed as part of this follow-up study. They were assessed, 
on average, five years after their baseline assessment (minimum 3 % years, maximum 7 
years). The majority were females with an average age of 46 years. The majority had partial 
epilepsy and were well-controlled on monotherapy. The majority had not had any seizures for 
at least the 12 months prior to the assessment. These patients were comparable to the group 
of patients who were eligible to take part but did not in terms of their demographic (age and 
gender) and clinical characteristics (epilepsy type) at baseline. However, they did have more 
years of formal education. Despite having more years of formal education at baseline, they 
were comparable in terms of their neuropsychological test performance at baseline and 12 
months. This suggests that there was not a bias for those experiencing more cognitive 
problems during SANAD to return to the study. Equally, there is no evidence to suggest that 
those who experienced more cognitive problems during the course of SANAD did not want to 
take part.
After an average of five years, their performance was poorer compared with baseline, on 
measures of memory (immediate and delayed Rey Auditory Verbal Learning Test) and visual 
reaction time (dominant and non-dominant hand). There were also trends for poorer 
performance on other memory measures (serial recognition of words) and information 
processing (Adult Memory and Information Processing Battery and CVST). Interestingly, there 
were improvements on the serial recognition of figures task. Visual inspection of the 
proportions of people who fell into the different classifications of the Stroop, also suggested 
improvements on this task from baseline. The remaining measures had stable performance 
from baseline. Taking into account baseline scores, most declines were again seen for the 
Rey Auditory Verbal Learning Test, visual reaction time measures and information processing 
on the CVST. But these declines were subtle and for most measures, declines were on 
average less than 5% from baseline.
There were no differences in the amount of cognitive change experienced between those who 
continued to have seizures and those who had been seizure free for at least the previous 12 
months. Similarly, there were no differences between those who had other medical diagnoses
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during the 12 month and follow-up interval or those who had a previousor current neurological 
disorder or known cerebral pathology at baseline. There was only a trend for years of 
education to be associated with change on delayed story recall and duration of epilepsy with 
simultaneous recognition of words. Age was significantly associated with cognitive change on 
the psychomotor speed subtests of the Adult Memory and Information Processing Battery and 
symptoms of tension were associated with cognitive change the three psychomotor speed 
variables (tapping with both hands and psychomotor speed of AMIPB). Having a poorer 
baseline performance was associated with most cognitive decline on five of the measures.
In terms of mood, people with epilepsy reported experiencing fewer symptoms of anxiety at 
the time of the follow-up assessment but there were no other statistically significant changes 
in mood. On the ABNAS self-report measure, patients reported experiencing more cognitive 
problems but these were not statistically significant changes.
At an individual-level, 38% of patients were classified as having cognitive decline, when 
cognitive decline was defined as having a follow-up score more than 2 SD below baseline. 
However, there were no differences in demographic, epilepsy or psychological related 
variables between those who were classified as having or not having cognitive decline. These 
results and the ones from the previous chapters will be discussed in Chapter 9.
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Chapter 9 Discussion
9.1 Overview of the chapter
This chapter will discuss the results of this research programme, which aimed to explore the 
natural history of cognitive functioning in people with newly diagnosed epilepsy. There will be 
a discussion of the three results chapters, which aimed to fulfil the three objectives of this 
thesis. Each series of results will be considered within the context of the previous literature. 
Finally, the strengths, limitations, importance and clinical implications of the research will be 
reviewed and recommendations for future investigation will be proposed.
9.2 The immediate impact of epilepsy
9.2.1 Findings from this research
Cognitive impairments are frequently reported by people with epilepsy, but when these arise 
in the course of the disorder is an important issue. Many patients attribute their impairments to 
the side effects of AED medication (International Bureau for Epilepsy, 2004, Carpay et ai, 
2005, Baker et ai, 2008). However, the results of this research suggest that patients with 
newly diagnosed epilepsy, who are otherwise neurologically normal (on the basis of available 
evidence), were performing significantly worse than healthy volunteers on 11 of 17 cognitive 
measures before the start of AED treatment. After adjusting for age, sex and education, these 
differences persisted for the domains of memory and psychomotor speed. At an individual- 
level, patients with epilepsy had a higher proportion of abnormal test scores (i.e. an adjusted 
z-score ^-2.0) across the battery (e.g. on the AMIPB psychomotor speed task 18.4% of 
people with epilepsy had an abnormal score vs. 2.3% of the healthy volunteers). They were 
also four times more likely than healthy volunteers to demonstrate cognitive impairment 
(defined as at least one abnormal test score). Fifty-four per cent were classified as having 
impairment at baseline compared with 21% of healthy volunteers.
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Previous studies have suggested that adults with newly diagnosed epilepsy already 
demonstrate evidence of cognitive dysfunction, in particular, memory impairments, at the time 
of diagnosis (Brodie et al., 1987, Smith et al, 1987, Kalviainen et al., 1992, 2003, 
Helmstaedter et a/., 1993, 2005, Aikia et al., 1995, 2001, Prevey et al., 1998, Ogunrin et al., 
2000, Pulliainen et al., 2000a). The current research, in concordance with these, has shown 
that cognitive impairments occur in patients without structural brain abnormalities on clinical 
CT/MRI, before AED treatment and following relatively few seizures. Consistent with the 
previous literature, this research found that it was a proportion of patients (54%) that were 
most affected. In a series of studies by Kalviainen and colleagues, approximately 30-56% of 
patients were found to have mild memory and attention problems (Kalviainen et al., 1992, 
Aikia etal., 1995,2001).
9.2.2 Potential causes of cognitive impairment
Effects of seizures
Some of these studies have suggested a potential role for seizures as a cause of cognitive 
impairment. Prevey et al., (1998) and Aikia et a/., (2001) found greater cognitive impairment to 
be associated with secondarily generalised seizures. However, in this research programme 
there were no differences between those with partial, generalised and unclassified seizures 
across the cognitive measures, except for the psychomotor speed task of the AMIPB; 
although this finding must be interpreted with caution due to the unequal numbers in the 
groups. Similarly, there were no differences in seizure type between those with or without 
cognitive impairments. This supports the findings of Pulliainen et al., (2000a) who also found 
no differences between those with partial or generalised seizures in 52 adults with newly 
diagnosed epilepsy.
The observed differences were also not mediated by the frequency of seizure activity. 
Patients had experienced a median number of nine seizures before the baseline assessment 
but there were no significant relationships between the total number of seizures or the number 
of GTCS experienced and any of the neuropsychological test variables. There were no 
differences in the median number of seizures experienced by those who were or were not
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classified as impaired. This was surprising, as previous research has suggested that a larger 
number of seizures are associated with greater cognitive impairment (e.g. Dodrill, 1986, 
Vlooswijk et al, 2008); although these studies were not conducted in those who were newly 
diagnosed. However, those whose first seizure was more recent had poorer scores on a 
visual recognition memory task and there was a trend for those with a shorter interval since 
their first seizure to be classified as having impairments at baseline. Helmstaedter et al., 
(2005) also found shorter duration of untreated epilepsy to be associated with poorer 
performance but the mechanism underlying this finding was unclear. Whether this reflects 
greater CNS dysfunction due to a more recent seizure; the effects of an acute psychological 
reaction to their first seizure or another reason entirely requires further investigation and 
explanation.
Role of the underlying aetiology
The specific mechanisms leading to cognitive dysfunction at epilepsy onset remain uncertain. 
As reviewed in Chapter 4, three potential factors are the underlying aetiology, the effects of 
epileptogenesis or the result of psychological adjustment to epilepsy. The fact that these 
differences were found after excluding 67 patients with a previous or current neurological 
disorder and/or abnormal neuroimaging implies that their poorer performance was not a result 
of their underlying aetiology. This is consistent with studies by Kalviainen et al., (1992) and 
Aikia et al., (1995) who also found poorer cognitive performance, particularly in attention and 
memory, in adults with new-onset epilepsy, after excluding those with a known cerebral 
pathology. Similarly, studies from the paediatric literature have found that children with new- 
onset idiopathic and cryptogenic epilepsy have generalised cognitive dysfunction at the time 
of diagnosis (Oostrom et al., 2003, Berg et al., 2005, Hermann et al., 2006a, Bhise et al., 
2009). However, some patients in this research programme may have had underlying 
abnormalities or pathologies that were not detected by these methods. Structural brain 
abnormalities, such as gliosis, atrophy and reduced grey matter volumes, have been 
associated with poorer neuropsychological functioning in children with newly diagnosed 
epilepsy (Hermann et al., 2006a, Byars et al., 2007). Differential relationships between white 
matter volumes and cognition have also been found between children with idiopathic new- 
onset epilepsy and healthy first-degree cousin controls (Hermann et al., 2006a). Therefore,
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future work should include structural and functional imaging to uncover whether specific 
neuroabnormalities underlie these cognitive deficits (see section 9.7.1 below).
Role of psychological factors
Oostrom et a/., (2003) found that the differences in cognitive functioning between children with 
newly diagnosed epilepsy and healthy gender-matched classmate controls were not related to 
their epilepsy characteristics but to the reaction of the child and their parent(s) to the 
diagnosis of epilepsy. In the current research, patients were also assessed at the time of 
diagnosis, which is a period of complex psychological adjustment (Chaplin et a/., 1992, Kemp 
et al., 1999). It may be that those who demonstrated most dysfunction had a more pervasive 
loss of control and a more extensive adjustment process (Velissaris et al., 2007).
Whilst psychological adjustment was not measured formally at baseline [e.g. using measures 
such as the COPE (Carver et al., 1989) or semi-structured interview (Oostrom et al., 2003)], 
the POMS was used to assess current mood state and has been employed previously as a 
measure of psychological adjustment in patients with breast cancer (Taylor et al., 1984, Taylor 
et al., 1985). There were significant differences between the current mood state of people with 
epilepsy and healthy volunteers. Patients with epilepsy reported experiencing more mood 
disturbance, in particular, more symptoms of tension and confusion and less vigour than 
healthy volunteers. This is not surprising, as there is a significant body of literature that has 
found epilepsy to be associated with an increased number of psychosocial difficulties (e.g. 
Jacoby et al., 1996, Baker et al., 1997, Hermann et al., 2000, Gaitatzis et al., 2004, Kanner, 
2007). These mood factors were also rated more highly by people with newly diagnosed 
epilepsy compared with healthy volunteers in a study by Pulliainen et al., (2000b). These 
difficulties, particularly anxiety and depression, may be a reaction to the onset of epilepsy or 
reflect a shared pathophysiology (Kanner, 2006). However, consistent with the findings of 
Pulliainen et al., (2000b), there was no relationship between neuropsychological test variables 
and current mood state. Self-reported mood states did not differentiate between those who 
were or were not classified as impaired, suggesting that the observed differences were not 
mediated by mood disturbance. In addition, the impact of anxiety on test performance was 
limited during the testing session, as researchers administering the neuropsychological tests
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were trained to postpone the assessment in any patient who demonstrated experiencing 
significant levels of distress based on clinical judgement.
Role of epileptogenesis
In this research programme it appears unlikely that negative psychological adjustment to a 
diagnosis of epilepsy caused the cognitive impairments observed at epilepsy onset. In support 
of this, several studies have suggested that cognitive, academic and behavioural problems 
antedate the first recognised seizure in some children with epilepsy (e.g. Austin et al.f 2001, 
Berg et a/„ 2005, Hermann et ai, 2006a); although this was not found in a study by McNelis 
et al., (2007). However, the different findings may be due to the measurement of academic 
problems. McNelis et al., (2007) compared teacher ratings of classroom performance before 
the first seizure rather than comparing objective measures, such as use of special education 
services or measure of academic skills (e.g. reading, writing and maths). The existence of 
these problems before the first seizure implies a possible role for the underlying 
epileptogenesis (Hermann et al., 2006a, 2008a, 2008b). Epileptogenesis is the process by 
which a normal neural network becomes a hyperexcitable one that predisposes to recurrent 
seizures (Badawy et al., 2009a, 2009b). This process may cause cerebral alterations, such as 
network reorganisation, that impact on cognition. Whilst the results of the current research 
cannot provide direct evidence in support of this hypothesis, this is an explanation that is 
worthy of further exploration,
9.2.3 Predictors of cognitive impairment and future outcome
It was surprising that demographic, epilepsy or mood-related variables did not differentiate 
between those who were or were not classified as impaired. On the basis of the literature 
reviewed in Chapter 3, differences were expected for seizure type, number of seizures, 
education and age. The lack of findings may have arisen for several reasons:
• the definition of impairment employed in this research programme (i.e. an 
abnormal test score on any cognitive measure) may have resulted in a 
heterogeneous group that reduced the likelihood of finding significant differences.
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A more conservative criterion, for example, impairment on at least two cognitive 
measures, may have led to the identification of potential predictive factors;
• they are ‘genuine’ results and these factors are not associated with cognitive 
impairment at the time of diagnosis in adults with newly diagnosed epilepsy;
• the groups differed on some other indicator (e,g. socioeconomic status, coping 
style, quantitative MRl volumetries, white matter tract integrity, genetic 
susceptibility) that was not measured in this research. This emphasises the need 
for further studies to specify the mechanisms underlying these impairments and 
to identify prognostic factors that are able to predict those who are most at risk 
of baseline cognitive impairment.
Finally, in the current research, baseline cognitive performance was not related to seizure 
outcome at 12 months or longer-term follow-up (mean five years). This was unexpected, as it 
does not support the findings of Aikia et al., (1999b) and others who have suggested early 
cognitive impairment to be a predictor for intractable epilepsy (Kalviainen et al., 1992, Aikia et 
al., 1995). Also, it does not support results from the Multicentre study of Early Epilepsy and 
Single Seizures (MESS), which found that individuals who had recurrent seizures throughout 
a four-year follow-up period, had poorer baseline quality of life outcomes (on domains of 
physical, cognitive, psychological and social functioning) compared with those who only ever 
had a single seizure (Jacoby et al., in preparation). Whilst the outcomes of the MESS study 
were subjective, baseline differences, particularly in ratings of anxiety and depression, 
suggest that these may be precursors to epilepsy or reflect common underlying
susceptibilities.
However, this may reflect how cognitive impairment was classified in this research 
programme and the definition of seizure outcome employed (i.e. at 12 months; immediate 12 
month remission vs. any seizure in the previous 12 months; at five years: any seizure in the 
last 12 months vs. seizure free for the previous 12 months). In the study by Aikia et al., 
(1999b), it was presence of verbal memory impairment (i.e. on immediate recall and delayed 
recognition of a word list) that was a predictor of poor two year seizure outcome (defined as 
more than one generalised seizure or more than four partial seizures during one year), along
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with presence of a spike focus in EEG; complex partial or mixed seizure type, remote 
symptomatic aetiology and age at time of diagnosis. Therefore, it is possible that a different 
definition of cognitive impairment or a consideration of specific cognitive domains or cognitive 
measures (e.g. measures of memory functioning) may have identified prognostic factors. 
Additionally, those who only had one seizure in the previous 12 months were classified as 
being in the active epilepsy group, which means this group could comprise those who had 
frequent, daily seizures and those who may have had only one seizure in the previous year. 
This heterogeneity of epilepsy frequency may have led to the failure to find significant 
relationships. Interestingly, baseline cognitive impairment was also not related to the 
experience of abnormal test performance at 12 months or experience of cognitive decline at 
five years. Again, this finding may reflect the definition of impairment employed in this 
particular research programme or may provide support for Huang ef a/., (2005) who found that 
those with abnormal scores at baseline testing had significant improvement in overall 
cognition scores, short-term memory and semantic fluency after three years. Those who were 
in the normally functioning group at baseline had no significant change.
9.2.4 Summary
Overall, the results of this part of the thesis suggest that, as a group, people with epilepsy are 
already cognitively compromised at the time of diagnosis. Although the mechanisms 
underlying these impairments cannot be ascertained; it is speculated that this is most likely 
due to the result of the epileptic process and/or an unidentified neurobiological abnormality10. 
The next section will discuss how cognitive functioning changed over the next 12 months in 
comparison with the healthy volunteer group.
10 However, the limitations of the research may also account for the poorer cognitive performance of people with 
epilepsy, in’particular, the composition of the two groups and effects of subclinical epileptiform discharges. This 
will be discussed in section 9.5.
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9.3 The shorter term impact of epilepsy and its treatment 
9.3.1 Findings from this research
How these baseline cognitive impairments develop and progress after the start of AED 
treatment is also an important issue. In this research, the cognitive functioning of people with 
epilepsy after the first 12 months of treatment was compared with a healthy volunteer control 
group, statistically controlling for confounding factors such as practice effects, regression to 
the mean, baseline performance, age, sex and education. People with epilepsy performed 
significantly worse than expected on 12 of the 15 neuropsychological test measures. The 
cognitive domains most affected were psychomotor speed, higher executive functioning and 
memory. At an individual-level, 42% of patients had abnormal scores on the VRT task with the 
non-dominant hand and 38% had abnormal scores on the equivalent task with the dominant 
hand. More than 20% of patients also had abnormal test scores on other psychomotor speed 
measures (finger tapping with the non-dominant hand and psychomotor speed task of the 
AMIPB) and a measure of higher executive functioning (verbal fluency). Eighty-five per cent of 
patients had at least one abnormal test score (i.e. an adjusted z-score <-2.0) and 31.3% had 
an abnormal score on at least a quarter of the cognitive measures.
Performing worse than expected may reflect absolute cognitive decline or reflect a lack of 
‘normal’ improvement in cognitive performance (i.e. practice effects). The results of this 
research programme support the recent work of Hermann et al, (2006b) who, using the same 
standardised regression-based change techniques, showed that people with chronic TLE had 
a different cognitive trajectory to control subjects over a four-year period, which was mainly 
characterised by a lack of practice effects. Consistent with the results of the current research, 
bilateral motor speed and memory functioning were the domains most affected in their 
longitudinal study. Similarly, Andersson-Roswall et al., (2004) and Dodrill (2002) also found a 
lack of practice effects in people with epilepsy in their longitudinal studies. Andersson-Roswall 
et al., (2004) suggested that a lack of practice effect may reflect a deficit or impaired capacity 
for learning from prior exposure to the initial testing experience.
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The design of this research programme cannot ascertain the causes and mechanism 
underlying the different cognitive trajectory, as in this programme it is impossible to separate 
out the effects of treatment from the effects of epilepsy (e.g. the underlying aetiology, epileptic 
process and seizures). However, it is plausible that AED treatment is contributing to the 
poorer than expected performance. Several RCTs investigating the cognitive side effects of 
AEDs, involving both healthy volunteers and people with newly diagnosed epilepsy, have 
demonstrated a lack of practice effects after the administration of AED medication (Smith et 
ai, 1987, Pulliainen & Jokelainen, 1994, Prevey et a/., 1996, Dodrill et ai, 1999, Salinsky et 
al, 2004,2005). The authors of these studies suggested that a lack of practice effects may be 
the first indicator of an AED effect. In the randomised clinical trial undertaken by Pulliainen 
and Jokelainen (1994), an untreated healthy control group demonstrated practice effects for 
42% of variables but only 17% of variables improved for people with epilepsy after they 
started treatment with either carbamazepine or phenytoin. In a healthy volunteer study by 
Salinsky et al., (2004), healthy volunteers declined on 25% of variables relative to an 
untreated reference group after the start of AED treatment and consistent with the current 
research, these variables mainly assessed motor speed. Psychomotor speed, along with 
attention, vigilance and mental speed have been shown to be vulnerable to the effects of 
AEDs (e.g. Loring & Meador, 2001, Aldenkamp et al., 2003). This is because they work by 
decreasing neuronal irritability and suppressing epileptiform discharges but this reduction in 
neuronal excitability can lead to their cognitive side effects (e.g. Motamedi & Meador, 2003,
2004, Loring et al., 2007).
In this research programme, the differential side effects of AEDs could not be assessed due to 
a lack of adequate power. However, there was a brief consideration of the effects of 
topiramate. Topiramate was the most commonly prescribed AED at the time of the 12 month 
assessment, taken by 23.8% of patients. Topiramate is also associated with a more negative 
cognitive profile compared with other newer AEDs, particularly for the measures most affected 
in this research (i.e. verbal memory, psychomotor speed and verbal fluency) (Martin et ai, 
1999, Aldenkamp et al., 2000, Meador et al., 2003, 2005, Fritz et al., 2005, Salinsky et al.,
2005, Blum et ai, 2006). Therefore, it was expected that a higher proportion of those in the 
abnormally performing group (i.e. at least one abnormal test score) compared with the
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performing as expected group would be taking topiramate. This hypothesis was not 
supported. However, this may reflect the fact that those who had either remained on, or 
changed to, topiramate at the time of 12 month assessment were possibly well-controlled and 
had not experienced serious adverse advents on the drug or they would have withdrawn 
during the course of SANAD.
It was surprising that after taking into account practice effects, regression to the mean, 
baseline performance, age, sex and education, people with epilepsy performed significantly 
better than expected on the Computerised Visual Search Task, especially, as they 
experienced declines for another information processing task (AMIPB). Whether this finding 
reflects a genuine improvement in performance on this particular task; is a statistical artefact 
related to the construction of the standardised regression-based z-scores; or is due to another 
reason is something that would require further investigation by replication in another study.
9.3.2 Factors associated with poorer than expected performance
As discussed above, the causes of the differing cognitive trajectory could not be determined, 
however, the factors associated with obtaining poorer than expected performance were 
investigated in the analyses.
Effects of seizures
Patients had experienced a median number of three seizures since the baseline assessment 
and the majority had not experienced any GTCS. The number of seizures was not related to 
any of the neuropsychological test variables and there were no differences in cognitive test 
scores between those who achieved an immediate 12 month remission and those that 
continued to have seizures. These findings are at odds with the significant body of literature 
suggesting greater cognitive impairment with recurrent seizures (Rodin, 1968, Seidenberg et 
a/., 1981, Dodrill, 1986, Upton & Thompson, 1997, Meador, 2002), However, this finding is in 
concordance with the findings of Dodrill (2002) who found no relationships between the 
number of partial seizures and cognitive change.
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Whilst not statistically significant, there was a trend for verbal recognition memory to be 
negatively associated with number of GTCS and there was a trend for those who had 
experienced a higher number of tonic-clonic seizures to be in the abnormally performing 
group. Similarly, those with generalised epilepsy also performed worse than those with partial 
and unclassified epilepsy on immediate verbal recall of a list learning task and worse than 
those with partial epilepsy on a serial recognition of words task but performed better on the 
psychomotor speed test of the AMIPB; although these results should be interpreted with 
caution due to the unequal numbers in the three groups. This supports studies that have 
found generalised seizures to be associated with greater cognitive impairment (Thompson & 
Duncan, 2005, Piazzini et a/., 2006). However, there were no differences on the remainder of 
measures and there were no differences in seizure type between those who were or were not 
classified as having abnormal test performance. This supports others who have found that 
there are no differences between those who experience partial and generalised seizures 
(O’Leary etal., 1983, Puiliainen etal., 2000a).
An unexpected finding was the trend towards those who had achieved a 12 month seizure 
remission to perform worse on a verbal fluency task. It is unclear what mechanisms might 
underlie this, albeit non-significant, finding but it may possibly be mediated by other factors, 
such as the characteristics of those who had achieved an immediate 12 month remission (e.g. 
their medication or other demographic factors).
Effects of mood
Current mood state was significantly associated with poorer than expected levels of 
performance for several measures, particularly, those measuring psychomotor speed. At 12 
months people with epilepsy reported significantly fewer symptoms of tension compared with 
baseline, which may suggest a positive psychological adjustment to their diagnosis of epilepsy 
(e.g. Velissaris et al.t 2007). Despite this improvement, people with epilepsy still reported 
significantly more symptoms of tension, depression, anger, vigour and confusion than the 
healthy volunteers. Their current mood state was significantly associated with several of the 
neuropsychological test variables. Psychomotor speed tasks, especially the psychomotor 
speed task of the AMIPB and the visual reaction time tasks, were associated with symptoms
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of tension, depression, anger and a lack of vigour. This is consistent with the general 
neuropsychological literature that has found mood disturbance to interfere with performance 
on neuropsychological tasks, particularly timed tasks (Reitan & Wolfson, 1997, Paradiso et al., 
2001, Douglas & Porter, 2009). However, current mood state, apart from symptoms of 
confusion (discussed in section 9.3.3 below), were not different between those who were or 
were not classified as having more abnormal test performance.
9.3.3 Characteristics of those with poorer than expected outcomes
Similar to the findings at baseline, it was interesting that demographic, epilepsy or mood- 
related variables did not differentiate between those who were or were not classified as 
having abnormal performance; although there were trends for number of tonic-clonic seizures 
(as discussed in section 9.3.2 above), education and self-reported symptoms of confusion. 
The lack of findings at 12 months may have arisen for the same reasons as discussed in 
section 9.2.3. Firstly, the definition of abnormal test performance employed in this research 
programme may be too lenient, which may explain why 85% of patients in this thesis had 
abnormal test performance compared with 20-25% in the study by Hermann et al., (2006b). 
Secondly, patients may not differ on these factors but on some other indicator that was not 
measured.
In the study by Hermann et al., (2006b) abnormalities in baseline quantitative MRI 
volumetries; lower baseline IQ; longer duration of epilepsy and older age predicted risk of poor 
cognitive prognosis. In this current research, neither age at assessment nor age at first 
seizure differentiated the two groups. Previous research has suggested that those with an 
early age of onset may have poorer cognitive outcomes (e.g. Dikmen et al., 1975, O’Leary et 
al., 1983, Schoenfeld et al., 1999, Aikia et al., 2001, Meador, 2002, van Mil et al., 2008). 
However, the lack of an age-effect in this research probably reflects the fact that patients had 
adult-onset epilepsy with a mean age of 29 years at first seizure. As this seizure would have 
occurred within the context of a developed brain, this would have avoided the consequences 
of disruption to normal developmental processes, such as synaptogenesis and myelination, 
that are associated with an early age of onset (Anderson, 2001, Brown, 2006). However, more 
severe disruption can sometimes occur in adulthood due to the lack of plasticity and potential
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for compensation or cerebral and functional reorganisation (e.g. Muller et al., 1998). As 
discussed in section 9.2.3, baseline cognitive impairment was not associated with 12 month 
cognitive outcome and possible explanations for this have been proposed. The finding of 
more abnormal baseline quantitative MRl volumetries to be associated with poorer cognitive 
outcome cannot be directly compared with this results from this research. However, those with 
an underlying aetiology or abnormal neuroimaging on CT/MRI were not more likely to be in 
the abnormally performing group.
There was a trend for those with lower years of education at baseline to be in the abnormally 
performing group and those with higher levels of education to be in the ‘as expected' group. 
This is in concordance with the findings from a longitudinal study by Piazzini et al., (2006) who 
also found lower levels of education to be associated with cognitive decline after five years in 
adults with TIE. It also lends support to the findings from cross-sectional studies that have 
found that higher levels of education slow the rate of decline in those with longer duration of 
epilepsy (Jokeit & Ebner, 1999, Oyegbile etal., 2004). Higher levels of education may act as a 
proxy marker for cognitive reserve, which is the ability to process tasks in a more efficient 
manner (possibly through the differential recruitment of brain networks), so that greater brain 
damage can be sustained before a functional deficit is demonstrated (Stern, 2002).
The trend towards those with higher symptoms of self-reported confusion at 12 months to be 
in the abnormally performing group most probably reflects the nature of this POMS sub-scale. 
This sub-scale measures feelings of bewilderment and muddleheadedness and comprises 
items such as ‘being unable to concentrate’, ‘forgetful1 and ‘confused’ (McNair et al., 1992). 
Therefore, it is unsurprising that these characteristics are found in those who have a lower 
than expected cognitive performance.
9.3.4 Summary
Overall, the results of this analysis suggest that, as a group, people with newly diagnosed 
epilepsy have a different pattern of cognitive performance than a non-epilepsy healthy 
volunteer control group after 12 months of treatment. The majority of patients had poorer than 
expected scores on at least one of the cognitive measures, after correcting for practice
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effects, regression to the mean, age, sex and education. Whilst this research programme 
cannot specify the mechanisms underlying this differing cognitive trajectory, AED treatment is 
the most likely explanation11. Current mood state was associated with poorer than expected 
performance, particularly for psychomotor speed measures. There were no differences in 
demographic, epilepsy or mood-related variables between those who were or were not 
classified as having abnormal performance; although there were trends for increased number 
of tonic-clonic seizures; lower levels of education and more feelings of confusion to be 
associated with poorer performance. The next section will discuss how cognitive functioning 
changed from baseline in a proportion of patients who were followed-up after an average of 
five years.
9.4 The longer term impact of epilepsy and its treatment
9.4.1 Findings from this research
Despite the importance of understanding how cognition changes over time in people with 
epilepsy, relatively few longitudinal studies have been undertaken to investigate this issue 
(Arieff & Yacorzynski, 1942, Rodin, 1968, Seidenberg et al., 1981, Dodrill & Wilensky, 1990, 
1992, Kalska, 1991, Selwa, ef a/., 1994, Holmes eta/., 1998, Helmstaedter ef a/., 2000, 2003, 
Aikia et al., 2001, Bjernaes et al., 2001, Dodrill, 2002). Of these, only one has included those 
with newly diagnosed epilepsy (Aikia et al., 2001).
This research programme has shown that after a mean of 64 months since baseline 
assessment, the majority of cognitive measures remained stable but there were significant 
declines for four of the 16 measures. Measures affected were those assessing psychomotor 
speed and immediate and delayed verbal recall. However, the magnitude of this change was 
subtle, representing a 10-15% change from baseline. At an individual-level, approximately 
10% of patients had scores that were more than 2SD below their baseline performance for 
immediate recall on a list learning task and on a VRT task with the dominant hand. A total of
11 However, as at baseline, the limitations of the research (see section 9.5), particularly the composition of the two 
groups may also account for their poorer than expected cognitive performance.
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38% of patients were classified as experiencing cognitive decline (i.e. at least one cognitive 
test score >2SD below baseline).
The relatively stable findings must be interpreted with caution due to the lack of a control 
group (the implications of which are discussed in more detail in section 9.5). However, the 
findings of decline for some measures, particularly verbal memory, in the current research are 
inconsistent with the previous study by Aikia et al., (2001) and a previous published abstract 
by Aikia et at., (1999a). Aikia et al., (1999a) reported no significant declines on measures of 
verbal ability, verbal learning and memory, attention and flexibility of mental processing in 58 
untreated patients with newly diagnosed epilepsy after five years. They also found statistically 
significant (although small) improvements in several neuropsychological measures due to 
normal practice effects; although, they did not report which measures improved. Aikia et al., 
(2001) found no deteriorations and some improvements (delayed recall of a list learning task) 
in verbal memory in 20 adults with newly diagnosed TIE after five years.
Possible explanations for the differences between the current research and these prior studies 
include the characteristics of the patients with epilepsy12. Firstly, in the study by Aikia et al., 
(2001) all patients were seizure free. In the abstract by Aikia et al., (1999a) all patients were 
either seizure free or had only occasional seizures. In this research programme, only 58% of 
patients were seizure free for at least the previous 12 months at five year follow-up. Six 
percent of patients reported having seizures every day, six per cent at least once a week and 
a further 24% reported having seizures at least once a month. The higher frequency of 
seizures reported by patients in this research may have contributed to their observed declines 
on some measures or may reflect that they had a more severe form of epilepsy, which may be 
associated with more cognitive impairment. However, there were no differences on any of the 
neuropsychological test variables between those who had been seizure free for the previous 
12 months and those that continued to have recurrent seizures. Similarly, the proportions of 
people who were seizure free for the previous 12 months did not differentiate those that did or
12 Comparisons between this current research and the study by Aikia et al., (2001) should be made with caution, 
as all their patients had newly diagnosed TLE. In this research, while the majonty had partial ep'lepsy, the 
localisationwas mixed. For the majority (52%), localisation was not specified and only 30 /o had been diagnosed
with TLE.
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did not experience cognitive decline [as discussed previously, this may represent how seizure 
outcome was classified (see section 9.2.3)].
Secondly, whilst the specific AEDs taken were not reported in either prior study, Aikia and 
colleagues described patients as ‘adequately treated’ in the abstract (1999a) and patients 
were treated with monotherapy in the published study (2001). In the current research, 16% of 
patients were being treated with poiytherapy (maximum two drugs) and 20% were taking 
topiramate. Both are known risk factors for cognitive impairment (e.g. Kwan & Brodie, 2001, 
Aldenkamp et a/., 2003, Mula & Trimble, 2009). However, as at 12 months, there was no 
relationship between taking topiramate and cognitive decline. Again, this possibly reflects the 
fact that those continuing to take topiramate at five year follow-up are more likely to be able to 
tolerate this drug. A comparison of the number of drugs taken at follow-up in these two groups 
was too small for statistical analysis; however, the difference in proportions and their 
respective 95% confidence intervals, suggested that there were no differences.
Thirdly, the differences in findings could be related to symptoms of mood disturbance. In this 
research, current mood state, particularly levels of tension, was associated with measures of 
psychomotor speed (finger tapping task with the dominant and non-dominant hand and 
psychomotor speed task of the AMIPB). As discussed in relation to the 12 month results (see 
section 9.3.2), mood disturbance may interfere with neuropsychological test performance 
(Reitan & Wolfson, 1997, Paradiso et al.} 2001, Douglas & Porter, 2009). However, the 
current mood state of patients with newly diagnosed epilepsy in the previous studies was not
reported.
Fourthly, the patients in this research programme had a mean age of 46 years at five year 
follow-up compared with 38 years in the study by Aikia et al., (2001). Whilst, this difference 
may only represent an average of 8 years, older age was associated with poorer performance 
on the psychomotor speed task of the AMIPB in this research; although there were no 
differences in age between those who did or did not have cognitive decline. Older age has 
been associated with poorer performance on this particular task (Goughian & Hallows, 1985) 
and declines in processing speed, memory and executive functions are known to decline from 
early adulthood from the normal ageing literature (Deary et al., 2009). Therefore, it is possible
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that the older age of this cohort may have contributed to the memory and psychomotor speed 
declines observed.
Finally, the inconsistencies may also reflect differing levels of education in the studies. The 
patients included in this research programme had higher levels of education than those 
involved in the study by Aikia et al., (2001) (12 years vs. 9 years). They also represented a 
high functioning group with 18% having a degree or higher qualification. This figure is slightly 
higher than the proportion of the UK population of working age who hold a degree (16.3%) 
(Office for National Statistics, 2003). The 50 patients who took part in the neuropsychology 
follow-up study also had higher levels of education than those who were eligible but did not 
take part. Whilst years of education was not significantly associated with any of the 
neuropsychological test variables in this research, Pai & Tsai (2005) found that those with 
high education deteriorated in mental manipulation and those with low education improved in 
verbal memory but deteriorated in attention over a 12 month period. However, this seems 
paradoxical and is at odds with with the cerebral/cognitive reserve hypothesis theory 
discussed in section 9.3.3.
9.4.2 Predictors of cognitive outcome
A failure to find factors that differentiated those who were classified as experiencing cognitive 
decline from those that were not is consistent with the findings from the previous time-points. 
The possible explanations for this have been reported in those sections and, for brevity, will 
not be repeated here. However, the proportion of patients experiencing cognitive decline 
(38%) is in concordance with other longitudinal studies investigating cognitive change in 
people with epilepsy. Arieff & Yacorzynski (1942) identified 37% of patients with symptomatic 
epilepsy who significantly declined in intellectual functioning. Helmstaedter ef al., (2000) also 
identified 37% of patients with TLE who declined in memory functioning after a mean of 56 
months. Similarly, Kalska (1991) found that 64-89% of people with epilepsy remained 
unchanged on the various tasks after an average of 10 years.
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9.4.3 Summary
After a mean of five years, people with newly diagnosed epilepsy demonstrated relatively 
stable measures of cognitive performance across a comprehensive neuropsychological test 
battery. However, there were statistically significant (although subtle) declines on measures of 
verbal memory and psychomotor speed. Cognitive changes were most associated with higher 
levels of tension and older age was significantly associated with poorer performance on a 
measure of psychomotor speed. A proportion of patients seemed to demonstrate most 
declines; however, the characteristics of this group could not be identified. The next section 
will discuss the limitations of this research.
9.5 Limitations of this research
All of the above findings must be interpreted within the context of the study limitations. Many 
of these are associated with the healthy volunteer control group.
9.5.1 Healthy volunteer group
Firstly, the healthy volunteers were not assessed at the same time as the people with epilepsy 
due to resource limitations. They were recruited between three to eight years later. In the 
SANAD Neuropsychology study the people with epilepsy served as their own controls. 
However, it was felt that a healthy control group was necessary to inform on the impact of 
epilepsy at the time of diagnosis and to provide an estimate of the test-retest effects of the 
neuropsychological test battery. The later data collection, whilst not ideal, was felt to be a 
necessary compromise to having no control group for the first 12 months, for the purposes of 
this thesis.
Secondly, as the healthy volunteers were collected at a later time point, there was no control 
group involved in the neuropsychology follow-up study. As discussed in Chapter 4, a lack of a 
comparison control group was identified as a methodological shortfall of previous longitudinal 
studies of this type. This is because the neuropsychological test performance of people with 
epilepsy has been characterised by ‘abnormal’ functioning rather than abject deterioration
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(Dodrill, 2002, Andersson-Roswall ef al., 2004, Hermann et al, 2006b, Piazzini et al., 2006, 
Griffith et al., 2007). Therefore, the stable performance on the majority of measures identified 
in Chapter 8 needs to be interpreted with caution, especially In light of the results in Chapter 
7, which supports the idea of a differing cognitive trajectory. Additionally, again due to 
resource limitations (financial and time), the healthy volunteers were not assessed at three 
months. However, the findings of a lack of practice effect at 12 months are even more 
significant, as this implies that people with epilepsy did not benefit from their additional 
exposure to the neuropsychological test material highlighting poorer learning and memory 
ability.
Thirdly, the control group assessed as part of this research programme may not have been 
the best possible control group. Whilst, healthy volunteers were matched for age and sex at 
baseline, they had significantly higher levels of education. Education is correlated with IQ 
(Smith et al., 1987), which implies that the healthy volunteer group were more intelligent 
possibly accounting for their superior performance at baseline and 12 month follow-up. 
However, education was adjusted for in the statistical analysis at both time-points. 
Additionally, socio-economic status of the patients involved in the SANAD Neuropsychology 
study was not recorded, so it was not possible to match the healthy volunteers for this. A 
preferred control group would have been friends or family of the people with epilepsy (possibly 
siblings or first-degree cousins), which would have controlled for sociodemographic 
characteristics. Two interesting additional control groups could also have been:
• a small control group comprising people who had been diagnosed with epilepsy 
but for whatever reason had made a decision not to be treated with AEDs (e.g. 
women of childbearing age). This would allow for a comparison of the absolute 
effects of AED treatment separate to the effects of epilepsy. People with single 
seizures have been used as a reference group in other previous AED studies 
(Kalviainen et al., 1995; 2003, Aikia et al., 2006a). If those who were untreated 
had similar cognitive trajectories to those who were treated this would imply that 
the abnormal cognitive trajectory observed at 12 months was related to the 
underlying epileptic process. However, practically, as part of this research, these
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individuals may have been difficult to identify and of course it would be unethical 
to randomise people to this group.
• a control group comprising people with a recent diagnosis of another chronic 
condition, for example asthma or diabetes mellitus. This would enable a direct 
assessment of the contribution of psychological adjustment to baseline cognitive 
impairment. These controls have been recruited in studies of children with 
epilepsy (e.g. Williams et ai, 1998, McNelis et al., 2007) but to the best of my 
knowledge, there is no similar study in adults. This would be a useful and 
interesting endeavour, especially, as psychological adjustment to a diagnosis of 
epilepsy was not formally assessed in this research. However, epilepsy may be 
associated with a more negative reaction than these other conditions due to the 
felt stigma associated with the condition (Scambler, 1989, Jacoby, 2002, Jacoby 
& Austin, 2007).
9.5.2 People with epilepsy
There are also limitations associated with the epilepsy group. Firstly, the people with epilepsy 
involved in this research programme represent a heterogeneous group. They had differing 
aetiologies, seizure types and syndromes. This means that caution should be made when 
drawing conclusions from this group to particular individuals. Previous research has 
suggested that different syndromes are associated with different cognitive profiles, for 
example, memory deficits found in people with temporal lobe epilepsy (e.g. Baxendale et al., 
1998, Hermann et al., 1997) and executive function deficits in people with juvenile myoclonic 
epilepsy (e.g. Hommet et al., 2006, Piazzini et al., 2008, Iqbal et al., 2009). This may be the 
reason why generalised cognitive deficits were found at baseline and may offer a potential 
explanation as to why none of the epilepsy-related characteristics were associated with 
cognitive impairment. One potential avenue for future research would be to recruit specific 
epilepsy syndromes at the time of diagnosis and follow these more homogenous groups over 
the course of the disorder. This would also make a significant contribution to the literature, as 
the majority of research has been undertaken in people with TIE, mainly because it is the 
most common type of epilepsy; it is often refractory to medication and is associated with
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cognitive morbidity. There is a lack of knowledge on the natural history of other epilepsy 
syndromes.
Secondly, the participants in this research programme may also reflect a selection bias. 
Whilst, the SANAD trial was a randomised clinical trial, the SANAD Neuropsychology trial was 
not. It was a prospective, longitudinal study that was undertaken as part of the larger trial and 
people with newly diagnosed epilepsy from the 11 hospital centres were invited to take part in 
the study. The numbers and characteristics of SANAD patients who were approached to take 
part but did not consent, were unfortunately not recorded, therefore, a comparison of their 
characteristics cannot be made. It is possible that those who felt they already had cognitive 
problems at baseline were more willing to take part.
Similarly, selection bias may have occurred at the 12 month or longer-term follow-up 
assessments. There was a large loss to follow-up (66% completed 12 month assessment and 
23% of the original sample at five-year follow-up). Those that remained in the study may have 
been those who were concerned about cognitive problems and so wanted neuropsychological 
assessment (particularly as a large proportion of them were on topiramate), or those who felt 
that their epilepsy did not have a significant impact on their cognitive functioning may not have 
felt that the study was relevant to them and dropped-out. This is plausible as one of the most 
common reasons people gave for not wanting to take part in the follow-up study was a lack of 
time, mainly due to work commitments. This implies that these patients may have had better 
cognitive outcomes as their epilepsy was not impacting on their occupational functioning. 
Equally, those who found the neuropsychological tasks most challenging, or were most 
impaired, may not have wanted to take part, ill health was cited as a reason for not wanting to 
take part by three people and an assessment could not be carried out for one person because 
of their severe seizures.
However, this is unlikely to have affected the findings because at 12 months, there were no 
differences in demographic characteristics of those who did or did not take part. There were 
no differences on the neuropsychological measures except for those who remained in the 
study had significantly poorer baseline finger tapping scores with the non-dominant hand and 
there were trends for poorer performance on the finger tapping task with the dominant-hand
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and the visual reaction time tasks with the non-dominant hand. At longer-term follow-up, those 
who took part had significantly more years of formal education than those who were eligible 
but did not take part. There were no differences on any of the baseline or 12 month measures, 
except a trend towards those who did not take part to have lower scores on the information 
processing and psychomotor speed sub-tests of the AMIPB. Therefore, at these follow-up 
times, patients seemed to be representative of the original sample.
9.5.3 Study design
There are also limitations with the design of the research that affect the conclusions that can 
be made. Not only was the SANAD Neuropsychology study underpowered to detect 
differential drug effects, the neuropsychology follow-up study fell short of recruiting the 95 
patients that were required in the power calculation and so the lack of cognitive change from 
baseline may reflect insufficient power. However, this follow-up study assessed 50 patients, 
which is more than half of the previous longitudinal studies in this area. Recruitment of 
patients into the follow-up study was challenging. Sixty-nine percent of approached patients 
responded to the invitation letter but only 41% wanted to take part. There was no response 
from 31% and 28% refused. The majority of those who responded but refused did not give a 
reason, but of those who did, the most common was a lack of time due to family or work 
commitments or ill health. Half-way through the recruitment period, a newsletter was produced 
to try and increase the response rate. This tried to emphasise the importance of the research 
and the progress in data collection so far.
In addition, as the neuropsychology follow-up study was designed after the SANAD 
Neuropsychology study had finished, patients were not told prospectively to record their 
number of seizures during the interval since their 12 month assessment. Therefore, the 
number of lifetime seizures could not be included in the longer term analysis. Previous 
research has suggested that a higher lifetime number of seizures are associated with 
cognitive decline (Dodrill, 1986, Vlooswijk et aL, 2008) and several authors have 
recommended that the number of seizures is incorporated into analyses (Dodrill, 2002, Mula & 
Trimble, 2009). However, these were recorded during the first 12 months and patients were
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asked about their seizure frequency in a semi-structured interview prior to their follow-up 
assessment.
Not only is the thesis limited in drawing conclusions about the effect of number of seizures on 
cognitive change, it cannot rule out the negative effects of interictal epileptiform EEG 
discharges. It is possible that the cognitive dysfunction observed may have been the result of 
transitory cognitive impairment (Aarts et al., 1984, Binnie et al., 1987, Aidenkamp, 1997, 
Binnie, 2001, Aidenkamp & Arends, 2004). However, it would have been expensive and 
impractical to carry out EEG and video-monitoring at the time of neuropsychological 
assessment as part of this research programme.
Finally, the presence of structural pathology was based on the results of routine clinical brain 
imaging (CT/MRI) that were undertaken within three months of randomisation. In the analysis 
of the results at baseline, those with an abnormal scan were excluded from this analysis but 
some patients may have had abnormalities that were undetected, which may have contributed 
to their poorer cognitive functioning.
9.5.4 An ideal study
All research studies are constrained by resource limitations and the majority of the limitations 
of this thesis reflect a lack of time and money. In an ideal world, this research programme 
would have been designed to include an age, sex and education-matched control group from 
the beginning comprised of siblings or first-degree cousins of the people with epilepsy. There 
would also be two other control groups comprising people with a chronic illness and a small 
group of those who have been diagnosed with epilepsy but were untreated. They would be 
assessed at the same fixed time points using a comprehensive neuropsychological battery 
and would undergo structural (e.g. quantitative MRI) and functional imaging (e.g. fMRl, 
diffusion tensor imaging) at baseline and follow-up to identify whether specific 
neuroabnormalities underlie their differences. EEG and video-monitoring would be undertaken 
whilst patients perform the neuropsychological tests to ensure they are not experiencing 
subclinical epileptiform EEG discharges and transitory cognitive impairment. Participants 
would be followed-up for a longer period of time (>10 years) and with more frequent interim
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assessments to more accurately chart their cognitive trajectories. Clinical information, such as 
number of seizures, number of generalised tonic-clonic seizures and medication changes and 
dosages would be collected to be used as covariates in analyses. Ideally, the study would 
only include those with one type of epilepsy, for example, unilateral TIE (to reduce 
heterogeneity effects and to control for localisation of the epileptogenic focus) or those with 
idiopathic generalised epilepsy (to control for the effects of the underlying lesion or other 
identifiable pathology).
9.6 Importance of this research
Despite these methodological shortfalls, this is an important piece of research. Cognitive 
abilities allow us to process information, which enable us to interact with the world and other 
people. Cognitive difficulties can impact on day-to-day functioning, academic and 
occupational achievement, social relationships, psychological well-being and overall quality of 
life [for a review see Baker et a/., (2009), and Mitchell et a/., (2010)]. In fact, in this research, 
people with epilepsy reported experiencing a high number of cognitive problems in their daily 
lives, particularly in areas of memory (e.g. difficulty remembering names of people; forgetting 
appointments) and slowing (e.g. takes longer to do day to day things; react too slowly to 
things that are said) on the ABNAS self-report measure. Therefore, knowledge and 
understanding of how cognitive functioning is affected and progresses in people with newly 
diagnosed epilepsy is important in order to inform patients of the risks of cognitive impairment; 
guide appropriate interventions and ultimately ameliorate its impact on quality life. The 
importance of this thesis is further highlighted in the strengths and clinical implications 
discussed below.
9.6.1 Strengths of this research
Firstly, this research contributes to the growing literature that people with epilepsy are already 
cognitively compromised at the time of epilepsy onset, before the administration of AED 
medication. Unlike several of the previous studies (e.g. Brodie et al., 1987, Smith et al., 1987, 
Prevey et al., 1998; Pulliainen et al., 2000a, Ogunrin et al., 2000; Aikia et al., 2001), patients 
in this research programme were newly diagnosed and had never previously been treated
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with AEDs. They had a relatively short duration of untreated epilepsy (median time from first 
seizure 597 days) and had only experienced a small number of seizures prior to their baseline 
assessment (median 9 seizures). The research employed a comprehensive 
neuropsychological test battery with cognitive assessments chosen on the basis of their 
reliability, validity and previous use in people with epilepsy. By finding that patients 
demonstrate cognitive impairments, even after excluding those with a known cerebral 
pathology or previous/current neurological disorder, it adds to the debate about what factors 
might be causing these impairments. The failure to find a relationship with mood suggests that 
it is not the result of psychological adjustment factors, and imply that one of the main causes 
may be the underlying epileptogenesis or epileptic process. Gaining an understanding of 
these mechanisms is worthy of future research.
Secondly, using standardised regression-based change score techniques, the research has 
shown that people with newly diagnosed epilepsy have a different cognitive trajectory 
compared with a comparison healthy volunteer group after 12 months of AED treatment. As 
discussed in Chapter 5 this statistical technique has several advantages, in particular, it takes 
into account practice effects, regression to the mean, baseline performance, age, sex and 
education. Using this technique, people with epilepsy performed more poorly than would be 
expected based on their age, sex and education for the majority of measures. This supports 
previous work that suggests that people with epilepsy may have an ‘abnormal test 
performance that is characterised by differential patterns of learning. Importantly, this thesis 
represents a shift from studying these trajectories in those with severe, intractable and chronic 
temporal lobe epilepsy.
Thirdly, 50 patients were followed-up after a mean of five years to assess the longer term 
impact of epilepsy and treatment. Although, the number of patients recruited for the follow-up 
assessment was smaller than required from the power calculation, this follow-up study was 
larger than the majority of previous longitudinal studies in this area, in addition, there has only 
been one previous peer-reviewed study that has followed-up those with newly diagnosed 
epilepsy. This study only included 20 patients with left temporal lobe epilepsy and only 
assessed verbal memory and learning. Despite the absence of a comparison control group for
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this time point assessment, the results of these analyses suggested that memory and 
psychomotor speed measures declined from baseline.
Fourthly, this research programme has suggested that not all people with epilepsy are 
affected. A proportion of people with epilepsy appear to be most at risk both at baseline (54%) 
and five year follow-up (38%). While prognostic factors for cognitive impairment could not be 
identified, this thesis has highlighted the need for further work identifying those most at risk, 
with a particular focus on structural and functional abnormalities, and a need to screen people 
for cognitive dysfunction at the time of diagnosis.
9.6.2 Clinical implications
Currently, the National Institute for Health and Clinical Excellence (NICE) guidelines 
recommend referral for neuropsychological assessment when MRI has identified 
abnormalities in areas associated with cognitive function; the person with epilepsy is having 
educational or occupational difficulties and the person with epilepsy complains of memory or 
other cognitive deficits and/or cognitive decline (Stokes ef a/., 2004). As the results of this and 
previous research have suggested that cognitive problems are already present at epilepsy 
onset, patients should be screened for cognitive dysfunction at the time of diagnosis. This is 
so that those who are already experiencing cognitive problems can be referred for more 
comprehensive neuropsychological assessment and appropriate intervention [e.g. retraining 
or compensation method for attention deficits (Engelberts et a/., 2002); external or internal 
memory strategies such as, diaries, timers, pill boxes or visual imagery and method of loci 
(Thompson, 1997)]. The guidelines state that awareness of the neuropsychological deficits 
associated with epilepsy and its treatment may facilitate education, social integration and 
employment. Therefore, this should be extended to newly diagnosed patients.
Similarly, as this and prior studies have shown that people with epilepsy are at risk of 
developing further cognitive deficits, particularly in areas of memory functioning, patients 
should be monitored for cognitive changes. This could take place as part of their annual 
review by their GP or epilepsy specialist; however, this would require the development of a 
short screening tool (see section 9.7.3), which could be used to identify those experiencing
247
cognitive decline who would then be referred for further neuropsychological assessment and 
intervention. Equally, as mood was found to be associated with poorer than expected 
performance at 12 months and five year foilow-up for some cognitive measures, psychological 
intervention to improve mood may help to alleviate some difficulties.
The finding that people with epilepsy are cognitively compromised at baseline before the start 
of AED treatment means that many patients need to be re-educated about the potential 
causes of their cognitive impairment. Many patients with epilepsy attribute their cognitive 
problems to the side effects of their AED treatment (International Bureau for Epilepsy, 2004; 
Carpay et a/., 2005; Baker et al., 2008), which may impact on treatment compliance. 
However, knowledge that they may have a learning and memory deficit (or another cognitive 
problem), which is part of their condition and not due to other factors, particularly their 
treatment, may relieve their anxiety about taking medication. Knowledge that cognitive 
impairments may be part of the clinical condition may also serve to reduce expectations of 
family and/or carers. Thompson (1997) suggests that confirmation of a memory deficit, in a 
young person who is struggling academically to achieve a standard comparable to their peers, 
may result in a reappraisal by the individual and their family and redirection to an alternative 
course that relies less on written examinations. However, lowered expectations may have a 
negative effect on self-esteem, effort and attitude about one’s own abilities (Cornaggia et al., 
2006). Finally, education and specific epilepsy knowledge are important factors in the long­
term self-care of epilepsy (Ridsdale, 2009); therefore, patients should be provided with 
information about the cognitive course of epilepsy so that they can learn how to manage its 
impact on their life.
9.7 Recommendations for future research
This thesis has highlighted several areas that may be worthy of future research. These will be 
discussed in the section below.
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9.7.1 Investigation of the mechanisms underlying impairments
The finding of cognitive impairment at epilepsy onset in those without an underlying aetiology 
or known cerebral pathology implies a possible causal role for the underlying epileptogenesis 
or an unidentified neurobiological abnormality. The use of structural and functional imaging in 
conjunction with neuropsychological assessment may help to determine whether specific 
neuroabnormalities underlie these deficits.
Byars et a/., (2007) have explored the relationship between MRI structural abnormalities and 
neuropsychological functioning in children after a first recognised seizure. Similarly, Hermann 
et a/., (2006a) have correlated quantitative MRI volumetries with cognitive functioning in 
children with idiopathic new-onset epilepsy. In addition, this group has found neuroanatomic 
abnormalities (e.g. abnormal cerebral volumes, cortical thinning and atrophy in subcortical 
structures) to be associated with poorer cognitive functioning in adults with TIE (Hermann et 
a/., 2007a; Dabbs et a/., 2009; Hermann et at., 2009). Using diffusion tensor imaging, 
McDonald et at., (2008) have also related white matter fibre tract integrity with language and 
memory performance in patients with TLE. Whilst these studies have increased our 
understanding of the abnormalities that might contribute to these cognitive deficits, there is a 
lack of similar studies in adults with new-onset epilepsy. Future work identifying the 
mechanisms that might lead to these cognitive impairments would be useful in predicting 
which patients have poorer neuropsychological functioning at diagnosis. Equally, longitudinal 
studies incorporating structural and functional imaging would be useful in revealing whether 
there are cerebral changes associated with increasing duration of epilepsy and whether these 
contribute to cognitive decline.
9.7.2 Development of prognostic models
As well as identifying mechanisms underlying cognitive impairments at baseline, there is a 
need to develop prognostic models in order to predict which patients are already at risk of 
cognitive impairments, and which are at risk of experiencing further cognitive decline, so that 
they can be referred for appropriate intervention and management.
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9.7.3 Development of a core battery of neuropsychological measures
As discussed in Chapter 3 and Chapter 4, there is a lack of uniformity in the selection of 
neuropsychological tests in studies of people with epilepsy. This issue was highlighted by 
Cochrane et al. in 1998 but over a decade later, there is still no agreement on which cognitive 
measures should be used. A recent survey by Witt & Helmstaedter (2009) of 14 epilepsy 
centres in German-speaking countries identified over 200 tests, of which only a quarter were 
selected based on their evidence.
Despite repeated calls for uniformity and recommendations [e.g. the Neuropsychological 
Battery for Epilepsy (Dodrill, 1978), Baker & Marson (2001), EpiTrack (Lutz & Helmstaedter, 
2005), NeuroCog Fx (Fliessbach et a/., 2006, Hoppe et a/., 2009)], these have not been 
consistently employed. In the longitudinal studies reviewed in Chapter 4, only four used the 
Neuropsychological Battery for Epilepsy (Dodrill & Wilensky 1990,1992, Homes et al., 1998, 
Dodrill, 2002). Unsurprisingly, these studies were those undertaken by the author of the 
battery. An interesting avenue for further research would be to qualitatively investigate the 
barriers to adoption of a core neuropsychological test battery. Understanding these barriers 
might help in the next stage of developing a core outcome set.
Developing standardised and agreed 'core outcome sets’ for use in clinical trials and practice 
is gaining increasing support [e.g. Core Outcome Measures in Trials [(COMET) initiative]. 
Outcome sets have been identified for several other conditions, for example, rheumatoid 
arthritis, cystic fibrosis and bipolar affective disorder. They have the advantage of allowing 
easier comparison across trials and synthesis of results; reduce the risk of inappropriate 
outcomes being measured and reduce outcome reporting bias. In clinical practice it would be 
beneficial to have a universally agreed battery to act as a screening tool. This could be used 
to identify those who require more comprehensive neuropsychological evaluation or monitor 
changes in functioning as a result of AED treatment. Future work should concentrate on 
identifying a core battery of tests by utilising structured consensus techniques (e.g. semi- 
structured discussion at consensus meetings and Delphi techniques) to reach agreement 
among interested parties, such as clinicians, academic researchers and patient groups 
worldwide. This battery needs to assess the domains most affected in people with epilepsy;
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be sensitive to change, as well as practical and cost-effective. This standardised approach 
has been adopted in the study of other neurological conditions, for example, multiple sclerosis 
(Rao, 1991, Benedict ef a/., 2002) and has been advocated by other neuropsychologists 
working in the field of epilepsy (e.g. Baker et al., 2009, Witt & Helmstaedter, 2009).
9.8 Conclusions
This research was conducted in the context of the SANAD trial. The SANAD trial was a 
prospective, randomised, pragmatic, unblinded, clinical trial, which provided a unique 
opportunity to investigate the natural history of cognitive functioning in people with newly 
diagnosed epilepsy. As a group, people with newly diagnosed epilepsy were cognitively 
compromised at the time of diagnosis. Once they started treatment, the majority had a 
different cognitive trajectory compared with healthy people from the general population. After 
an average of five years, they did not experience progressive declines on the majority of 
cognitive domains, although their performance on measures of memory and psychomotor 
speed were poorer compared with baseline. Memory and psychomotor speed measures were 
also the cognitive domains most affected at diagnosis and after 12 months.
However, not all people with epilepsy were affected. At baseline, 54% experienced cognitive 
dysfunction and 38% experienced cognitive decline after a mean five years. Therefore, all 
people with epilepsy should be screened for cognitive impairments at diagnosis, and 
monitored over time, so that those most at risk can be referred for more comprehensive 
neuropsychological assessment and appropriate intervention.
This research has contributed to our understanding of the cognitive course of cognitive 
functioning in people with new-onset epilepsy. This knowledge may help alleviate patient's 
anxiety about their own cognitive performance and inform them about likely changes over 
time. This research has attempted to identify the characteristics of those who had the most 
impairment and in doing so has highlighted other potential and important areas for further 
investigation.
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Appendix A SANAD Neuropsychology study
A-1
Dr. Gus A. Baker FBPsS
NEUROPSYCHOLOGICAL BATTERY FOR SANAD STUDY
1. Background Justification
Recent studies, that controlled for serum concentrations employing neuropsychological 
tests have reconfirmed cognitive side-effects of several antiepileptic drugs (AEDs) such 
as the central (Tnentar) slowing in patients using benzodiazepines or phenobarbital 
(Smith et a., 1987; Meador et al., 1987; Trimble & Thompson, 1984) and carbamazepine 
(Amman et aL, 1990; Galassi et al., 1988). Accordingly, the prevention of adverse drug 
effects is given due attention both in the development of new AEDs and in clinical 
practice (Committee on Drugs, 1985; Gram, 1990; Aldenkamp 1990).
Most studies use neuropsychological testing procedures to assess these adverse effects. 
In clinical practice and in early (phase II, Ilia) drug trials (in which the largest patient 
groups are involved), the opportunities for such time-consuming assessments are 
usually very limited (Baker et al., 1991). Patient complaints, suggestive of problems in 
cognitive behaviour then often represent the only available evidence of possible 
cognitive dysfunction.
The SANAD study provides a unique opportunity to compare the neuropsychological 
profile of both established and novel AED's. A number of identified centres in the UK 
with previous experience of conducting clinical trials of AED's involving 
neuropsychological assessment will be invited to participate in this aspect of the 
SANAD trial.
2. Selection Of Battery
The following battery represents the recommendations of an International Cognitive 
Function Expert Panel which met in the USA in April 1996. The panel were 
commissioned to recommend a battery which would be most likely to detect a 
difference in neuropsychological functioning in a randomised clinical trial.
The panel first outlined the domains in which the battery should test and then went on 
to recommend the most appropriate test(s) in each of those domains. In making the 
recommendations the panel considered which tests had already been demonstrated to 
be sensitive to changes due to AEDs and might be the best to highlight benefits of new 
drugs over established drugs, based on what is currently known about the newer 
AED'S (see Table 1).
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Table 1 Selection of tests and domains for the SAN AD study
DOMAINS TEST RECOMMENDED - AND COMMENTS
(i) Psychomotor Speed Binary Choice Reaction Time - any would be 
acceptable but recommend the one form FePsy
(ii) Attention Continuous Performance Task (computer version)
- this should be put at the end of the battery for the 
best results
(iii) Memory Pattern Recognition Test (from FePsy) Paragraphs 
(from Rivermead battery)
Paired Associate Learning
(iv) Mental Flexibility Colour & Colour-Word Tasks - both from Stroop
(v) Tracking Tasks Any tracking task - recommend the one already 
performed with Lamicatal in volunteers (Cohen, et 
al.)
(vi) Mood Profile of Mood Scale (POMS) Cornell Systymic 
Scale
(vii) Neurotoxicity A-B Neurotoxicity Scale (patient-based)
The battery is easy to administer and is unlikely to take more than 40 minutes to 
complete. It should be administrated by a qualified Clinical Neuropsychologist but 
under exceptional circumstances other staff can be trained to conduct the tests as long 
as they are supervised by a clinical neuropsychologist. Centres agreeing to participate 
in the study will require minimal rsources as much of the battery can be administrated 
through the FEPSy a computerised software programme developed by Professor Bert 
Aldenkamp. There are a number of centres in the UK that already have experience in 
conducting this or similar batteries.
3. Timing
It is proposed that assessment of neuropsychological functioning should be conducted 
at the following three time points:
1. baseline
2. 3 months after enrolment
3. 12 months after enrolment
Dr. Gus A. Baker FBPsS
4. Costing
This will obviously depend on the number of subjects recruited to the study by each 
centre but it is envisaged that a 1/2 time assistant psychologist will be required for 
those centres able to recruit a substantial number of patients. The cost of providing a 
half-time assistant will be approximately £7500.
5. Power Calculations
A systematic review of randomised clinical trials of antiepileptic drug treatment 
employing a neuropsychological battery was recently conducted. A number of studies 
demonstrated significant cognitive effects when comparing different AED treatments. 
Little information is available from these studies in respect of sample size calculations. 
Obviously, neuropsychological tests were not always the primary outcome and 
therefore little consideration was given to such calculations. The following table 
provides some indication on the number of subjects used in previous trials and some of 
the differences observed.
Table 2. A selection of clinical trials using standard neuropsychological assessments
REFERENCE COMPARISON AND 
DESIGN
NUMBER OF 
SUBJECTS
RESULTS PRESENTED
Smith et al, 1993 Lamotrigine v placebo 
- double blind cross 
over - add on study
62 No significant 
differences for limited 
battery
Kalvianen et al, 
1995
VGBv CBZ- 
Newly diagnosed 
parallel study
100 Short term memory.
Dot cancellation
Task, colour naming 
task, category task etc.
In favour of VGB
Meador et al, 1990 CBZ v PHT v pb - 
Double blind cross
over
45 Digit symbol. In favour 
of CBZ and
PHT
Mattson et al, 1985 CBZ v PB v PHT v PD - 
newly dignosed 
monotherapy parallel 
study
622 Finger tapping, colour 
naming, dst, and reaction 
time.
In favour of CBZ
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From the previously published data, it is estimated that the differences between two 
AED's, one with presumed side-effects (PHT) and one without (CBZ) on a 
psychomotor: the Finger-Tapping Test, requires larger sample sizes, as these 
differences are of smaller magnitude: 1/2 sd. (Mean 45.1 taps, s.d. 7.1). This would 
result in a required sample size of 15 patients for a crossover design and approximately 
50 patients per arm in a parallel group design).
6. Centres To Be Involved
Centre Lead Psychologist Lead Clinicians
Manchester Dr Hamira Riaz Dr Paul Cooper
Liverpool Dr Gus A. Baker Prof David Chadwick /Dr Dave Smith
Birmingham Mr Alan Moss Dr Tim Betts / Dr Heaffield
Bristol Mr Nigel Walton Dr Jonathan Bird
Sheffield Dr Paul Brooks Dr Steve Howell
Glasgow Dr Ruth Gillham Dr Rod Duncan
London Dr Robin Morris Dr Robert Elwes / Dr Leena Nashef
Cambridge Ms Rachel Blake Dr Steve Rowe
Appendix B Neuropsychological tests
B-2
SANAD Number: ----------------- Subject Initials: ________ Centre No: ________ First Assessment
Rey Auditory Verbal Learning Test
Read the following passage to subjects before presenting word list:
7 am going to read a list of words. Please listen carefully - when I stop you are to say back as 
many words as you can remember. It doesn’t matter in what order you repeat them. Just try to 
remember as many as you can."
Next present the word list to the left of the following table at a rate of one word per second. Following 
presentation look to subject, inviting their response. Record each correctly word with a tick.
When the subject indicates they can recall no more words read the following:
“Now I’m going to read the same list again and once more when I stop I want you to tell me as 
many words as you can remember, including words you said the first time. Again, it doesn't 
matter in what order you say the words, just say as many as you can remember. ”
Repeat these instructions prior to each of 5 repetitions of the test, recording responses in the following table. 
Record the time at which the fifth trial is completed in the appropriate space below.
Following the fifth trial inform subjects that they will be asked to recall the words later during the session 
30 minutes following the fifth presentation read the following:
“Earlier l asked you to remember a list of words several times over. Could you tell me all the 
words from that list which you can remember. ”
Record those words recalled in the table below.
List A 1 2 3 4 5 Delay
I DRUMJ CURTAIN
BELL
I COFFEE
I SCHOOL
I PARENT
MOON
I GARDEN
HAT
I FARMER
NOSE
I TURKEY
I COLOUR
HOUSE
RIVER
Total
Sum= Sum=
Time of 5th presentation
USE BLACK BALL PEN - PRINT LEGIBLY
Subject Initials: ________Centre No:
Paragraphs from RBMT-E
Read the following passage to subjects before reading the story:
“/ am going to read you a passage of about five or six lines. Listen carefully and when I have 
finished tell me as much as you can remember. Ready?"
"Mr Brian / Kelly, / a Security Express employee I was shot dead / on Monday / during a 
bank raid / in Brighton. / The four raiders / all wore masks / and one carried / a sawn-off / 
shotgun. / Police detectives / were sifting through / eye-witness accounts last night. / A 
police spokesman said/"he was a very brave man./He went for/the armed raider / and
put up a heH of a fight."
"Now tell me as much of the story as you can."
Tick each story unit correctly recalled perfectly or using a close synonym. Each of these scores 1 point.
Circle each story unit partially recalled or recalled with an approximate synonym. Each of these scores : a point.
SANAD Number:
Time of completion of test Initial recall score
Delayed Recall task
Ten minutes later read:
"Do you remember that story I read to you earlier? I would like to know how much of it you can 
remember now. Tell me as much as you can." Mark recall on paragraph below.
[If the subject cannot remember anything about the story then provide the following cue: It started off - Mr 
Bhan Kelly, a security express employee..." Note whether the subjected needed a cue]
"Mr Brian / Kelly, / a Security Express employee / was shot dead / on Monday / during a bank 
raid / in Brighton. / The four raiders / all wore masks / and one carried / a sawn-off / shotgun. / 
Police detectives / were sifting through / eye-witness accounts last night. / A police spokesman 
said / "he was a very brave man. / He went for / the armed raider / and put up a hell of a fight.
Delayed recall score Cue given?
Story sheet reproduced from ohginal by the Thames Valley Test Company
in accordance with copyhght restrictions
USE BLACK BALL PEN - PRINT LEGIBLY
SANAD Number: -----------------  Subject Initials: ________ Centre No: _________ First Assessment
BENTON VERBAL FLUENCY TEST
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Form C Stimulus Sheet
BLUE RED TAN RED
GREEN GREEN RED TAN
TAN TAN TAN RED
RED BLUE BLUE TAN
GREEN GREEN TAN BLUE
BLUE BLUE RED GREEN
GREEN TAN GREEN RED
BLUE GREEN RED BLUE
RED TAN BLUE RED
BLUE BLUE TAN TAN
TAN GREEN RED GREEN
RED BLUE GREEN TAN
TAN GREEN RED BLUE
GREEN RED TAN RED
BLUE BLUE BLUE BLUE
TAN GREEN TAN RED
GREEN TAN GREEN GREEN
RED RED TAN RED
TAN TAN BLUE BLUE
RED GREEN TAN TAN
TAN TAN BLUE BLUE
RED RED GREEN GREEN
GREEN BLUE RED BLUE
RED RED GREEN RED
TAN GREEN TAN BLUE
BLUE RED RED TAN
GREEN TAN GREEN BLUE
TAN BLUE BLUE GREEN
R4R Psychological Assessment Resources, Inc./P.O. Box 998/Odessa, FL 33556/TOLL-FREE 1-800-331-TEST 
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Form C-W Stimulus Sheet
BLUE GREEN RED GREEN
GREEN BLUE GREEN TAN
RED RED BLUE RED
TAN BLUE TAN TAN
GREEN TAN RED BLUE
BLUE RED TAN TAN
RED GREEN BLUE GREEN
TAN TAN TAN RED
RED GREEN RED GREEN
BLUE BLUE BLUE RED
RED RED RED BLUE
TAN TAN TAN GREEN
BLUE GREEN BLUE TAN
TAN RED GREEN BLUE
RED BLUE TAN GREEN
BLUE GREEN BLUE RED
GREEN RED TAN GREEN
TAN GREEN BLUE TAN
GREEN BLUE RED GREEN
TAN TAN GREEN BLUE
RED GREEN BLUE TAN
BLUE RED GREEN BLUE
RED TAN BLUE GREEN
TAN BLUE GREEN RED
RED TAN RED BLUE
TAN RED GREEN GREEN
GREEN TAN TAN RED
TAN GREEN RED BLUE
B4R Psychological Assessment Resources, Inc./P.O. Box 998/Odessa, FL 33556/TOLL-FREE 1-800-331-TEST 
Copyright © 1989 by Psychological Assessment Resources, Inc. All rights reserved. Reorder #RO-1483 Printed in the U.S.A.
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RECORD FORM
Max R Trenerry, Ph.D.
Bruce Crosson, Ph.D.
James DeBoe, Ph.D.
William R Leber, Ph.D.
: TAN
Name. 
Sex__
Reason for Referral 
Diagnosis/Notes__
Age, Date.
SCORES
Color Task Color-Word Task
Number of Responses 
Incorrect Responses 
Score 
Percentile 
Pr (Brain Damage)
RED
•: TAN
i. 1
TAN
GREEN
PAR Psychological Assessment Resources, Inc./P.O. Box 998/Odessa, FL 33556/Toil-Free 1-800-331-TEST
Copyright© 1989 by Psychological Assessment Resources, Inc. All rights reserved. May not be reproduced in whole or in 
part in any form or by any means without written permission of Psychological Assessment Resources, Inc. This form is 
printed in blue ink on white paper. Any other version is unauthorized.
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Form C Responses-Color Task
10 BLUE.
11 TAN-
12 RED-
13 TAN-
14 GREEN.
15 BLUE__
16 TAN___
38 BLUE.
39 GREEN.
40 BLUE—
41 GREEN-
42 RED___
43 BLUE-
44 GREEN-
1 BLUE 29 RED 67 TAN 36 RED
2 GREEN____- 30 ' GREEN 58 RED 86 TAN
3 TAN 31 TAN 69 TAN 37 RED
4 RED 32 RTJTE ' 60 RTJTE 33 TAN
fi GREEN 33 GREEN 61 TAN 89 BLUE
6 BLUE 34 RTJTE'..j 62 RED 90 GREEN
7 GREEN 3fi TAN 63 GREEN PI FED
8 BLUE 36 GREEN 64 RED 92 BLUE
9 RED 37 TAN 65 BLUE 93 RED
66 TAN-
67 RED-
68 GREEN-
69 RED___
70 TAN___
71 BLUE-
72 TAN-
94 TAN-
95 GREEN.
96 TAN___
97 BLUE.
98 RED-
99 BLUE. 
100 RED—
17 GREEN 45 TAN. 73 GREEN
13 RED 46 RED 74 TAN
19 TAN 47 TAN 75 RTJTE
20 RED 43 GREEN 76 TAN
21 TAN 49 TAN 77 RTJTE
22 RED 50 RED ... 73 GREEN ......
23 GREEN 51 RTJTE 79 RED
24 RED 52 RED SO GREEN
26 TAN____ 53 GREEN 31 TAN
26 RTJTE 54 RED 32 RED
27 GREEN 55 TAN 33 GREEN
28 TAN 56 BLUE 84 BLUE
101 GREEN
102 RED___
103 BLUE-
104 TAN-
105 BLUE.
106 GREEN.
107 BLUE—
108 RED___
109 BLUE-
110 TAN-
111 BLUE.
112 GREEN-
Form C-W Responses-Color-Word Task
1 RED 29 BLUE 57 RTJTE 85 TAN -
2 BLUE 30 TAN 58 TAN 88 RED
3 GREEN 31 GREEN 59 RED 87 GREEN
4 BLUE 32 RED... on GREEN ■ 88 BTJTE
5 RED 33 BLUE 81 TAN 89 TAN
fi TAN. 34 GREEN 82 RED 90 GREEN
7 BLUE 35 BLUE 88 GREEN 91 RED
8 RED _ - ' 36 GREEN ’ 84 BTJTE 92 TAN
9 TAN 37 RED 65 GREEN 98 BTJTE
10 GREEN 38 TAN 88 TAN 94 GREEN
11 BLUE 39 BLUE 87 BTJTE 95 RED
12 RED 40 RED ...... 88 green 98 TAN
13 TAN 41 BLUE 89 RED 97 RED
14 BLUE 42 TAN 70 BTJTE. 98 GREEN
15 GREEN . 43 RED 71 RED 99 RED
If? RED 44 TAN .... 72 GREEN 100 BTJTE
17 TAN 45 RTJTE 78 BTJTE 101 RED
18 GREEN 40 RED...... 74 TAN 102 BTJTE
19 BLUE 47 GREEN. 75 GREEN
■ft 1 >|| 1 »
108 TAN
20 RED 48 BLUE 78 BTJTE 104 GREEN
21 TAN 49 TAN 77 RED 1 05 RED
22 GREEN 50 GREEN 78 TAN ...... 108 TAN
23 BLUE 51 RED 79 GREEN 107 BTJTE
24 GREEN 52 TAN 80 RED 108 TAN
25 TAN 53 GREEN 81 TAN 109 RED
26 BLUE 54 TAN 82 BTJTE 110 BTJTE
27 TAN 55 BLUE • 88 GREEN 111 GREEN
28 RED 56 RED - ' 84 BLUE 112 TAN
Percentile/Probability Table •
Ages 18-49
Raw
Score
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
:-so
81
%ile
Pr
Value
.98
.97
.97
.97
.96
.96
.96
.95
.95
.94
.93
.93
.92
.91
.90
.89
.88
.87
Ages 50-
Raw
Score %ile
Pr
Value
Raw
Score %ile
<37
37
38
39
40
41
42
43
44 ;
45 i
46 :
47 1
48 i 
. 49 |
50 ;
51 .!
52 •
53 j
.99
.98
.98
.98
.97
.97
.96
.96
.95
.94
.93
.92
.90
.89
.87
.85
.83
.80
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99 
100 
101 
102
30
32
36
40
42
44
50
52
56
60
Pr
Value
.02
.01
.01
.01
.01
.01
.01
<.01
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AMIPB INFORMATION PROCESSING A FORM 1
NAME DATE
AGE DOB REF. NO.
Demonstration Motor Speed
38, 25, 79 11 11 11
97, 22, 18, 65 11 11 11
85, 27, 20, 48, 52 11 11 11
72, 50, 23, 74, 16 11 11 11
11 11 11
92, 18, 54, 77, 21
46, 39, 38, 16, 72 11 11 11
17, 54, 83, 11, 80 11 11 11
26, 87, 66, 39, 48 11 11 11
54, 56, 51, 63, 22 11
i 1
11 11
1 1 11 11
Demonstration
11 11 11 11
11 11 11 11
11 11 11 11
11 11 11 11
11 11 11 11
11 11 11
Score %i1e range 11 11 11
Task A Total 11 11 11
Errors % 11 11 11
Speed 11 11 11
Adjusted
11 11 11
11 11 11
11 11 11
11 11 11
11 11 11
11 11 11
11 11 11
11 11 11
11 11 11
© A K Goughian, 1985 11 11 11
91, 26, 43, 82, 17 *
00CM 62, 19, 12, 54 26, 56, 28, 93, 40
61, 59, 62, 18, 80 42, 25, 41, 33, 38 54, 90, 26, 81, 15
27, 48, 92, 36, 28 17, 12, 18, 15, 29 32, 37, 91, 15, 22
53, 29, 61, 19, 32 86, 42, 93, 28, 71 11, 42, 86, 90, 19
32, 41, 18, 24, 11 76, 72, 40, 60, 29 19, 53, 18, 92, 64
24, 82, 58, 26, 41 63, 20, 82, 18, 99 28, 21, 81, 47, 68
80, 36, 72, 43, 65 28, 40, 23, 76, 77 57, 52, 10, 69, 92
74, 19, 41, 28, 50 12, 15, 38, 65, 71 41, 60, 56, 78, 69
55, 41, 60, 11, 13 17, 57, 41, 91, 28 94, 79, 38, 20, 29
60, 99, 20, 22, 48 32, 39, 14, 56, 42 26, 94, 37, 50, 29
51, 29, 81, 16, 99 52, 91, 17, 86, 68 90, 27, 83, 41, 86
18, 32, 67, 77, 33 21, 20, 50, 94, 54 87, 15, 10, 85, 90
42, 83, 17, 56, 40 70, 13, 38, 62, 69 22, 56, 74, 36, 57
36, 98, 39, 19, 14 43, 21, 16, 50, 56 73, 80, 12, 72, 84
80, 22, 82, 75, 57 45, 48, 89, 21, 12 95, 41, 81, 70, 18
65, 26, 11, 72, 22 82, 37, 21, 97, 79 41, 30, 94, 50, 58
37, 55, 18, 53, 90 66, 29, 59, 23, 32 24, 95, 75, 81, 72
92, 49, 27, 19, 83 71, 62, 50, 82, 44 59, 26, 57, 19, 36
94, 93, 64, 11, 65 64, 97, 91, 63, 95 52, 17, 23, 60, 28
14, 18, 83, 73, 10 56, 12, 82, 43, 20 52, 68, 62, 30, 74
90, 52, 81, 23, 39 93, 78, 50, 12, 15 27, 29, 16, 23, 38
12, 49, 59, 92, 87 32, 70, 92, 65, 80 83, 81, 75, 77, 89
55, 27, 36, 84, 66 18, 29, 54, 28, 30 91, 61, 54, 80, 59
55, 86, 29, 38, 22 25, 56, 41, 39, 20 79, 82, 47, 16, 52
33, 55, 41, 61, 65 94, 34, 29, 36, 14 80, 83, 29, 90, 10
37, 51, 19, 36, 84 72, 26, 34, 61, 79 61, 14, 15, 50, 47
27, 64, 48, 63, 20 68, 17, 72, 65, 81 44, 19, 65, 24, 13
18, 16, 71, 23, 62 61, 98, 60, 27, 41 42, 40, 55, 84, 73
28, 21, 92, 74, 61 12, 83, 70, 65, 32 37, 49, 45, 38, 27
26, 54, 51, 29, 60 45, 72, 24, 59, 10 55, 25, 86, 20, 46
43, 52, 41, 80, 10 14, 45, 89, 53, 21 61, 96, 82, 85, 74
85, 22, 16, 45, 53 35, 58, 41, 65, 28 27, 86, 50, 16, 11
57, 17, 68, 98, 80 63, 30, 93, 21, 45 43, 30, 99, 36, 22
17, 23, 15, 30, 36 94, 92, 16, 82, 24 48, 50, 60, 44, 82
*
oCM 53, 50, 72, 29 22, 59, 21, 75, 48 68, 27, 63, 37, 45
AMIPB INFORMATION PROCESSING B FORM 1
NAME __________________________________________________  DATE ___
AGE DOB REF. NO.
Demonstration Motor Speed
3 1-13 9 11 11 11
275-5872 11 11 11
5216-61425 11 11 11
3799-59739 11 11 11
11 11 11
2695-12569
1448-84041 11 11 11
5027-20735 11 11 11
6981-48169 11 11 11
7 2 1 6 - 2 6 1 7 8 11 11 11
11 11 11
Demonstration 11 11 • 11
11 11 11 11
11 11 11 11
11 11 11 11
11 11 11 11
11
11 11 11
Score %i1e range 11 11 11
Task B Total 11 11 11
Errors % 11 11 11
Speed 11 11 11
Adjusted
11 11 11
11 11 11
11 11 11
11 11 11
11 11 11
11 11 11
11 11 11
11 11 11
11 11 11
© A K Goughian, 1985 11 11 11
5 1 8 4 - 1 3 4 8 5 
2910-71092 
8024-24089
7 5 1 4 - 7 6 1 4 5 
5672-27356
2941-17429
2824-82124
1309-93081
9467-57496
5436-73546
1 7 6 8 - 6 7 8 4 1 
4923-63942 
4594-44597 
2156-51326 
3182-27831
4 6 9 1 - 9 6 4 1 5 
3832-38213 
2527-57282 
1496-16549 
9134-45193
6012-20861
9063-62390
6572-75261
8489-88049
3817-21783
3556-52563
8 7 1 9 - 9 7 1 4 8
2 4 7 8 - 7 4 2 8 6 
4539-95346 
7952-82795
3864-46893 
6379-93867 
4920-30429 
4 7 1 3 - 1 3 7 4 5 
9474-49417
5238-84325
6022-20962
4953-84953
6597-75689
4818-18845
4157-57140 
2 5 8 1 - 8 6 2 5 1 
8043-40893 
2218-21248 
2709-74290
6316-56631
5748-38475
1246-12964
4926-26941
3295-59362
4005-50240 
3967-72396 
1 0 8 1 - 9 8 0 1 1 
9261-21968 
4513-37514
2716-91672
8407-33047
9165-65192
4756-84765
9039-36909
4683-38624
3157-47135
7256-65270
1964-14695
4875-45978
6719-92716 
9421-12394 
1 0 8 2 - 8 0 1 6 2 
9354-54319 
1759-13795
5619-91625 
8723-30872 
6556-64565 
19 12-29113 
7024-70842
9 1 2 7 - 2 1 7 9 4 
8352-53298 
1034-30541 
5243-64253 
8979-68 9 7 9
6317-71643
5418-25481
9037-70329
4521-15642
6459-84695
3078-87430
2972-72219
6180-67081
1245-15342
4126-21647
5982-90852
4176-67413
1289-92815
6134-41763
3519-61935
1028-85021
4695-74659
7138-83417
5029-92560
5814-49851
7069-90762 
3518-5184 3 
4276-36724 
7129-20917 
4518-84152
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0 = Not at all
1 = A little
2 = Moderately
3 = Quite a bit
4 = Extremely
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'21. Hopeless .................®©©©® |45. Desperate........................ ®©(D®®
[22. Relaxed.................... ®©©@® Ue. Sluggish........................... ®©©0®
d S ►- V 23- Unworthy...................®©©®© 47. Rebellious . . ®©©0©
< UJ < “ |
5 5 I ^ H 24. Spiteful ..................... ®©©®® 48. Helpless............................©©©©©
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1. Friendly  ...........®©©©© 25. Sympathetic ..............®©@®® Lg. Weary..............................©O©©®
2‘ TenSQ ........................©©©0® 26. Uneasy......................... ®©©®® Lq. Bewildered.....................©O®®®
3- Angry ........................ ©©©©© 27. Restless..................... ©0©®® 51. A(ert
4. Worn out ...................©©©®® 28. Unable to concentrate ®©©®® 52. Deceived
.©©©® ® 
.©® ©® ®
5. Unhappy......................©©©©© 29. Fatigued
6. Clear-headed............©©©®® 30. Helpful
.®©®®® 53. Furious
®©©©© 54. Efficient
.© © © © ® 
© © © ® ®
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8- C°n'^ed ..................©0®®© j32. Discouraged .............00®®® 56; Full of pep ......................@00®®
9. Sorryforthlngsdone .®0@®® 33. Resentful ................ ©0®®® 57. Bad-tempered ...............@©©®®
1°~ shaky ......................... ©0©®® 34. Nervous.....................©O®0® 58. worthless........................©0®®®
11. Listless
12. Peeved
®©©®® 35. Lonely........................©©©©© 59. Forgetful .©©©©©
61. Terrified............... .©©©©©
62. Guilty ........ . .®©©®®
63. Vigorous..................... .®©@©®
64. Uncertain about things .© © © ® ®
65. Bushed .................. .© © © ® ®
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13. Considerate...............©©©®® 37. Muddled......................©©©©©
14, Sad.............................. ©©©©© 38. Cheerful......................©©©©©
15. Active ........................ ®©®©© 39. Bitter........................... ®©©©®
16. On edge..................... ®©©©© I40. Exhausted...................®©©©®
17. Grouchy
18. Blue . .
©0©®© |41. Anxious...............'..©O0®®
©0©©® I42. Ready to fight . . . .©0®®®
19. Energetic 
?0. Panicky .
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©©©©© j44. Gloomy .  ...............®©©©©
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1.1 am less enthusiastic about day to day activities 
2. My mind does not work as fast as it should 
3-1 have difficulties remembering people's names 
4.1 have difficulties in following books or films
5. I feel clunisy
6. f have problems finding the correct words
7. I am less capable of undertalcing initiatives
8. My thinking has slowed down
-9. I forget all kind of things, for erample an 
appointment or where l put an object
10.111 ^difficulties concentrating on the things I
11. I cannot use a pen or pencil accurately
12. I have problems understanding what I read
13. I tire easily and have little energy
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0 ■
0
0
0
0
0
0
0
0
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0
0
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l
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2
2
2
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3
3
3
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3
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3
3
3
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No Problem A mild 
problem
A moderate 
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A scriou 
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15. I fnrRct things that people have said to me
1(5. I can't concentrate for more than a short period 
of time
3
3 •
17. r constantly bump against tablesVdoorframes etc.
18. T feel worn out
19. It takes more time for me to start doing things ,
20. I get confused and forget what I was doing
21. I get distracted more easily
22. I sometimes stutter or am unable to find the 
correct words
0
0
0
0
0
0
2
2
2
2
2
2
3
3
3
3
3
3
23. [ feel I react too slowly to things that are said to
me
24. r cannot keep an activity going for long
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2
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2
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3
3
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Use black ball pen - print legibly
Appendix C Supplementary data
Table C.1: Regression equations used to create age, sex and education adjusted z-scores
Variable___________ ___
Finger Tapping Task
Dominant hand 
Non-dominant hand 
Log Visual RT 
Dominant hand 
Non-dominant hand 
Log CVST
Word recognition task
Serial
Figure recognition task
Serial
Story recall
Immediate
Delayed 
ReyAVLT 
Immediate recall 
Delayed recall
Benton verbal fluency 
AMIPB
Info Processing 
Psychomotor speed
Constant Predictors SE estimate
61.487 6.65594
53.851 5.89813
5.673 (0.003*age)- (0.066*sex) 0.12804
5.759 (-0.079*sex) 0.14561
2.118 (0.007*age) 0.26818
15.758 3.66713
17.491 4.07817
10.148 (1.840*educ_c/'/)+(1,77Q*educ_d2)- 
(0.064*age)
3.04695
9.276 (1.91 *educ_d1)-{ 0.060*age) 3.12982
57.476 (-0.147*age) 9.40136
13.431 (-1.484*sex)-(0.042*age)- 
(1.898*educ_d1)
3.06952
33.975 (6.253*ecfi/c_cff)+(7.054*edac_d2) 10.53
67.284 (10.620*ecfuc_cH)+ 
(10.403*educ_d2)-( 0.273*age)
14.72407
56.339 (5.502‘educ d2l-(0.199*age) 6.45750
C-3
Table C.2: Regression equations used to create standardised regression-based change scores 
Variable R2 Constant Baseline Predictors SE estimate
Finger Tapping
Dominant hand .607 13.135 0.797 4.6217
Non-dominant .734 7.325 0.920 3.41862
hand
Log Visual RT
Dominant hand .321 5.262 0.001 0.11292
Non-dominant .373 5.317 0.001 0.09237
hand
BCRT .606 169.345 0.348 +(1.887*age at baseline) 41.46380
Log CVST .524 1.722 0.050 +(0.005*age at baseline) 
-(0M5*educ_d2)
0.21383
Word recog
Serial .425 .6509 0.632 3.41451
Figure recog
Serial .378 10.859 0.444 +(1.787*sex) 3.29808
Story recall
Immediate .580 1.838 0.810 2.49282
Delayed .606 2.749 0.863 2.53305
ReyAVLT
Immediate recall .577 25.916 0.611 (-0.129*age at baseline) 6.38064
Delayed recall .611 5.822 0.593 (-0.042*agre at baseline) 1.85842
Verbal fluency .667 10.643 0.776 5.93785
AMIPB
Info Processing .880 6.369 0.952 5.70015
Psychomotor .719 6.900 0.907 4.78113
speed
C-4
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FULL-LENGTH ORIGINAL RESEARCH
Patients with epilepsy: Cognitively compromised before 
the start of antiepileptic drug treatment?
♦Joanne Taylor, fRuwanthi Kolamunnage-Dona, *Anthony G. Marson,
JPhilip E. M. Smith, §Albert P. Aldenkamp, and *Gus A. Baker, 
on behalf of the SAN AD study group
'"Division of Neurological Science, f Centre for Medical Statistics and Health Evaluation, University of 
Liverpool, Liverpool, United Kingdom; |The Welsh Epilepsy Unit, University Hospital of Wales, Cardiff, 
United Kingdom; and §Epilepsy Centre Kempenhaeghe and Department of Neurology, Maastricht University
Hospital, Maastricht, The Netherlands
Summary
Purpose: To compare the cognitive profile of 
newly diagnosed untreated epilepsy patients with 
healthy volunteers using a comprehensive neuro­
psychological test battery.
Methods: A total of 155 untreated patients with 
newly diagnosed epilepsy, and no known brain 
pathology, were assessed before the start of treat­
ment with antiepileptic medication. Their scores 
across the neuropsychological measures were 
compared with 87 healthy volunteers from the 
general population equated for age and sex. 
Results: After adjusting for age, sex, and educa­
tion, patients with epilepsy performed significantly 
worse than healthy volunteers on 6 of 14 cognitive 
measures, particularly in the domains of memory 
and psychomotor speed. Cognitive performance
was not related to the number of seizures, type of 
epilepsy, or mood. When an impairment index 
was calculated, 53.5% patients had a least one 
abnormal score [>2 standard deviations (SD) 
below the control mean] on the test battery com­
pared with 20.7% of healthy volunteers.
Discussion: Newly diagnosed untreated patients 
with epilepsy are cognitively compromised before 
the start of antiepileptic drug medication. The 
domains most affected are memory and psycho­
motor speed. More than one-half of the patients 
had at least one abnormal test score across the 
test battery. There were no differences in epi­
lepsy-related or mood variables between those 
who demonstrated dysfunction and those that did 
not.
KEY WORDS: Epilepsy, Newly diagnosed epilepsy, 
Neuropsychology, Cognitive functioning, Cognition.
Many people with epilepsy report impairments in their 
cognitive functioning. The main factors that appear to 
contribute to cognitive dysfunction in people with epi­
lepsy are the side effects of antiepileptic medication, the 
underlying etiology of their epilepsy, psychosocial issues, 
and the effects of recurrent seizures (Kwan & Brodie, 
2001; Meador, 2002; Aldenkamp & Bodde, 2005). There 
is some evidence to suggest that these reported impair­
ments deteriorate over time (Dodrill, 2004; Seidenberg
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et al., 2007), although there is contrary evidence to suggest 
that these impairments remain stable and do not represent 
a progressive dementia-like disorder (Holmes et al., 1998; 
Helmstaedter & Eiger, 1999).
A number of studies have suggested that these impair­
ments are already present in people with epilepsy, before 
the start of their antiepileptic treatment and following few 
seizures; hence at epilepsy onset (Smith et al., 1987; 
Kalviainen et al., 1992; Aikia et al., 1995; Prevey et al., 
1998; Aikia et al., 2001; Pulliainen et al., 2000a). This 
implies that at least part of the cognitive impairment is not 
caused by the accumulating effects of seizures and medi­
cation but may be the result of epileptogenesis. These 
impairments occur across several cognitive domains, with 
previously untreated patients with newly diagnosed 
epilepsy performing worse than healthy volunteers on
48
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measures of attention, concentration, motor function, 
mental flexibility, memory, and learning. However, one 
study reported that although patients performed worse 
than healthy volunteers on measures of attention, learning, 
delayed recall, and recognition, it was a proportion (30%) 
of patients with epilepsy that demonstrated subtle memory 
and attention dysfunction (Kalviainen et al., 1992).
We have investigated further the cognitive profile of 
newly diagnosed untreated patients with epilepsy com­
pared with healthy volunteers from the general population, 
using a comprehensive neuropsychological test battery. 
This study forms part of a longitudinal study investigating 
the natural history of cognitive impairment in patients 
with newly diagnosed epilepsy.
Methods
Design
This study was conducted as part of the larger Standard 
and New Antiepileptic Drugs (SANAD) trial (Marson 
et al., 2007a,b); a prospective multicenter unblinded 
randomized clinical trial assessing the clinical and cost- 
effectiveness of standard and new antiepileptic drugs 
(AEDs). The focus of this article is on comparison of the 
baseline assessment between patients with epilepsy and 
healthy volunteers, in order to increase our understanding 
of the cognitive deficits experienced by patients with 
newly diagnosed epilepsy prior to starting AED treatment.
Participants
Patients with epilepsy
The SANAD study recruited patients with epilepsy 
from hospital outpatient clinics at 90 hospital centers in 
the United Kingdom. Patients were recruited into SANAD 
between October 2000 and August 2004. Patients were 
recruited if they satisfied the inclusion criteria consisting 
of a history of two or more clinically definite unprovoked 
epileptic seizures in the previous year and if treatment 
with a single AED represented the best therapeutic option. 
This allowed inclusion of patients with newly diagnosed 
epilepsy; patients who had failed treatment with previous 
monotherapy (provided that the drug failure did not 
include one of the drugs present in the randomization) and 
patients in remission of epilepsy, who had relapsed fol­
lowing the withdrawal of treatment. Patients were 
excluded if the clinician or patient felt that treatment was 
contraindicated, if all their seizures had been acute symp­
tomatic seizures, or if there was a history of progressive 
neurologic disease.
At the time of randomization into SANAD, those 
patients who were newly diagnosed, previously untreated, 
and older than 15 years of age, from 10 of the hospital 
centers, were invited to participate in the neuropsychology 
part of the study. They were assessed before the adminis­
tration of antiepileptic medication (min 0-max 13 days 
after randomization) and were reassessed after 3 and 
12 months of treatment with randomized study drug.
A total of 257 patients with newly diagnosed epilepsy 
were initially recruited and assessed. Three patients were 
excluded because they were subsequently found not to 
have epilepsy, and a further 31 were excluded because 
they had been treated previously with AEDs. Thirty-nine 
patients had either learning disability or previous or cur­
rent neurologic disorder, for example, stroke, intracranial 
surgery, head injury, and meningitis, which can impair 
cognitive functioning, and so these patients were also 
excluded from the analysis. An additional 29 were found 
to have abnormal neuroimaging on clinical magnetic reso­
nance imaging (MRI). Because we wanted to investigate 
the impact of seizures and epilepsy and not the impact of a 
specific structural lesion, these patients were also 
excluded from this analysis. Therefore, this analysis 
focuses on 155 untreated patients with newly diagnosed 
epilepsy who were otherwise neurologically normal.
Healthy volunteers
Eighty-seven healthy volunteers were recruited from 
the general population to act as a control group. Healthy 
volunteers from the general population have been used as 
a comparison group in several similar studies (Smith et al., 
1987; Kalviainen et al., 1992; Aikia et al., 1995; Prevey 
et al., 1998; Pulliainen et al., 2000a; Aikia et al., 2001). 
The use of a healthy volunteer group allows us to evaluate 
whether patients with epilepsy already differ from their 
peers in terms of cognitive functioning at the time of diag­
nosis. The healthy volunteers were recruited between 
March 2007 and October 2007. Efforts were made to 
equate the healthy volunteer group to the epilepsy group 
in age and sex. Healthy volunteers were not considered 
eligible for the study if they had a history of neurologic or 
psychiatric disorders, had a previous head injury, had pre­
viously been treated with AEDs, or had a history of sub­
stance abuse. Neurologic and psychiatric history was 
assessed informally by self-report in a semistructured 
interview prior to assessment.
The number of healthy volunteers recruited into the 
study was based on the finger tapping task. The tapping 
task was used in the sample size calculation, as it is 
thought to be sensitive to the effects of AED treatment and 
is one of the most frequently used tests employed in 
randomized clinical trials (Cochrane et al., 1998). To have 
a power of at least 80% to detect a difference between the 
two groups (patient and control), of approximately 
one-third standard deviations (SDs), 87 healthy volunteers 
were needed.
Neuropsychological test battery
The neuropsychological test battery was selected to be 
most able to detect a difference between drugs in a
Epilepsia, 51(1 ):48-56,2010 
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Table 1. Neuropsychological test battery
Domain Test (references) Outcome variable
Psychomotor speed Finger tapping (Alpherts, 1987) The average number of taps for the 
dominant and nondominant
hands across five trials
Visual reaction time (Alpherts, 1987) The average reaction time for the 
dominant and nondominant hands (ms)
AMIPB psychomotor speed (Coughlan & Hallows, 1985) The mean number of digits 
crossed through over two trials
Memory Recognition of words/figures (Alpherts, 1987) The number of words or figures 
correctly answered on the 
serial/simultaneous version of the task
Key Auditory Verbal Learning Task (Rey, 1964) The sum of the words recalled over
the five trials and the number of 
words recalled after a 30-min delay
Story recall (Wilson et al., 1989) The immediate and delayed recall score
Information AMIPB information processing (Coughlan & Hallows, 1985) The mean number of correct
processing responses over the two tasks
Binary choice reaction time (Alpherts, 1987) The average response speed (ms)
Computerized Visual Search Task (Alpherts, 1987) The average speed of response (s)
Mental flexibility Stroop (Trenerry et al., 1989) The number of correct responses 
on the color-word task
Benton verbal fluency (Benton & Hamsher, 1976) The total number of acceptable 
words produced
Mood Profile of Mood State (McNair et al., 1992) Transformed scores (/100) for 
each mood factor
AMIPB, Adult Memory and Information Processing Battery.
randomized clinical trial (Baker & Marson, 2001). The 
battery, illustrated in Table 1, comprised measures from 
the FePsy Computerized Test Battery (Alpherts, 1987) and 
traditional paper-and-pencil measures. The FePsy was 
administered, as it is thought to be sensitive to detect subtle 
cognitive effects of AEDs and has been developed specifi­
cally for use with people with epilepsy (Baker et al., 1998).
The neuropsychological test battery took approximately 
one and a half hours to complete. Tests were administered 
in a set order to ensure adequate time passed to test 
delayed recall on the memory subtests. However, regular 
breaks were offered and taken to reduce fatigue effects. 
Neuropsychological assessment was postponed and rear­
ranged for a later date in those patients who reported hav­
ing a seizure within 24 h of the assessment. The study was 
approved by the North West Research Ethics Committee. 
All participants in the study provided written informed 
consent.
Statistical analysis
Data were analyzed using SPSS version 16.0 (SPSS Inc, 
Chicago, IL, U.S.A.). Independent Mests and chi-square 
tests were carried out to investigate any differences in 
demographics between patients with epilepsy and healthy 
volunteers.
Independent Mests, Mann-Whitney U test, and chi- 
square test were performed on the neuropsychological test 
variables to detect statistically significant differences 
between the two groups. Ceiling effects were observed on
the Stroop Neuropsychological Screening Test, so this 
variable was converted to a categorical one based on nor­
mative data (Trenerry et al., 1989). Five variables were 
skewed so three of these were log-transformed so they met 
the assumption of normality for parametric analysis. 
Scores on the binary choice reaction time and simulta­
neous recognition of words became more skewed after 
transformations so nonparametric analyses were carried 
out on these.
Raw scores on the 14 normally distributed neuro­
psychological test variables were converted to z-scores 
adjusted for age, sex, and education relative to the control 
mean (mean = 0, SD = 1) using multiple regression tech­
niques. This method has been employed in previous stud­
ies involving adults and children with epilepsy (Oyegbile 
et al., 2004; Hermann et al., 2006, 2007). This method was 
used because it corrects for the effects of age, sex, and 
education, which are important potentially confounding 
variables on cognitive functioning. In addition, by putting 
all scores on a common metric, comparisons across tests 
and across domains can be made directly (Oyegbile et al., 
2004; Hermann et al., 2006, 2007).The adjusted z-scores 
were transformed by multiplying the timed tasks by -1, so 
that higher scores on all tasks reflect better performance.
Spearman’s rho correlations were carried out to investi­
gate the relationship between neuropsychological test per­
formance, mood, and previous seizure activity. One-way 
between-subjects analyses of variance (ANOVAs) were 
conducted to investigate differences in epilepsy type.
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To investigate the clinical significance of results, a 
summary impairment index was created, which represents 
the proportion of test scores that are classified as abnor­
mal. This reflects the degree of cognitive impairment 
exhibited by each individual (Oyegbile et al., 2004; 
Hermann et al., 2006, 2007). Exploratory analyses were 
conducted to investigate the demographic and clinical 
characteristics of those with cognitive impairment.
The significance level was set at p < 0.01. This was to 
reduce the likelihood of making a type I error due to the 
number of multiple comparisons being made. A Bonfer- 
roni correction could have been applied; however, given 
the number of inferential tests and exploratory analyses 
conducted this would have been too conservative a value 
and would have increased the likelihood of making a type 
II error.
Results
Baseline clinical and demographic characteristics
Supplementary Table SI illustrates the demographic 
and clinical characteristics of patients with epilepsy and
healthy volunteers at baseline. There were no differences 
in age (p = 0.962) and sex (p = 0.910) between the 
groups. The healthy volunteers had significantly more 
years of education than the patients with epilepsy
(p < 0.001).
Differences between patients with epilepsy and 
healthy volunteers
Table 2 compares the performance of patients with 
epilepsy and healthy volunteers across the neuropsycho­
logical test battery at baseline. Looking at the raw scores, 
patients performed worse than healthy volunteers on 13 
of 16 cognitive measures, and this reached statistical sig­
nificance for 10 of 16 measures. On the Stroop Neuro­
psychological Screening Test, after adjusting for age, 
significantly more patients with epilepsy (31.5%) than 
healthy volunteers (4.8%) fell in the borderline ranges. 
Significantly fewer patients with epilepsy (55.0%) com­
pared with healthy volunteers (84.5%) fell in the average 
ranges (/2 = 25.03, d.f. = 2, p < 0.001).
Fig. 1 plots the patients’ performance across the neuro­
psychological test battery with the x-axis representing the
Table 2. Baseline performance of patients with epilepsy compared with healthy volunteers
Variable Patients with epilepsy (mean, SD, n) Controls (mean, SD, n) Diff(95%CI) p-value
Finger tapping
Dominant 57.11 (9.25, 144) 61.10(6.61,81) -3.99 (-6.09,-1.89) <0.001*
Nondominant 52.03 (7.87, 144) 55.02 (5.86,81) -2.99 (-4.97,-1.02) 0.003*
Log visual RT (ms)°
Dominant 5.71 (0.22, 143) 5.72(0.14,87) -0.01 (-0.06,0.3) 0.563
Nondominant 5.69(0.18, 144) 5.74 (0.15,87) -0.05 (-0.10, -0.01) 0.022
Log CVST (s)° 2.34(0.29, 151) 2.27 (0.29,86) 0.07 (-0.01,0.15) 0.082
Word recognition
Serial 15.39(4.11. 152) 16.10(3.76,87) -0.71 (-1.76,0.35) 0.187
Figure recognition
Serial 14.42(3.85, 149) 16.73 (4.08,87) -2.31 (-3.36,-1.27) <0.001*
Story recall
Immediate 7.69(2.92, 155) 9.92 (3.26,87) -2.23 (-3.04,-1.43) <0.001*
Delayed 6.78 (3.06, 155) 9.02 (3.31,87) -2.24 (-3.07,-1.41) <0.001*
Rey AVLT
Immediate 45.17(9.66, 155) 50.70 (9.66,87) -5.53 (-8.08, -2.98) <0.001*
Delayed 8.80 (3.33, 155) 10.37(3.28,87) -1.57 (-2.44, -0.69) <0.001*
Verbal fluency 34.15(11.58, 155) 41.75(10.70,87) -7.59 (-10.57, -4.62) <0.001*
AMIPB
Info processing 60.15(15.89, 155) 68.17(15.69, 87) -8.02 (-12.19,-3.84) <0.001*
Psychomotor speed 46.44(9.85, 152) 51.86 (7.47,87) -5.42 (-7.65, -3.19) <0.001*
Binary choice RT (ms)a b 354.00(306.00-426.00, 147) 359 (318.75-410.00,86) 0.00 (-19.00,20.00) 0.986
Word recognition®
Simultaneous 20.00(18.00-22.00, 152) 21.00(18.00-22.00,84) -1.00 (-1.00, 0.00) 0.157
Data was missing for various reasons, for example, participants refused to complete the task, computer error meant FePsy data 
was not recorded.
RT, reaction time; CVST, Computerized Visual Search Task; Rey AVLT, Rey Auditory Verbal Learning Test; AMIPB, Adult 
Memory and Information Processing Battery.
°Lower scores reflect better performance. 
bValues reported are median, 25th-75th percentiles.
*Significantatp < 0.01.
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Performance of patients with 
epilepsy across the 
neuropsychological test battery 
relative to healthy volunteers 
(straight line). The x-axis 
represents the mean 
performance of the healthy 
volunteers. Dom, dominant; 
nondom, nondominant; AMIPB, 
Adult Memory and Information 
Processing Battery; VRT, visual 
reaction time; CVST, 
Computerized Visual Search 
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control mean. After adjusting for sex, age, and education, 
there were statistically significant differences on 6 of 14 
measures. Patients demonstrated significantly worse per­
formance on the finger tapping task with the dominant 
hand (p < 0.001). They performed more poorly on the 
motor speed task of the Adult Memory and Information 
Processing Battery (p < 0.001). They recognized fewer 
figures on the serial recognition task (p < 0.001). They 
recalled fewer words immediately (p < 0.001) and after a 
delay (p < 0.001) on the Rey Auditory Verbal Learning 
Task. They also recalled significantly fewer units of a 
story recall task immediately (p = 0.01), and there was a 
trend for patients with epilepsy to recall fewer story units 
after a delay (p = 0.024).
Differences between patients with partial, generalized, 
and unclassified epilepsy
Fig. 2 plots the performance of patients with partial, 
generalized, and unclassified epilepsy across the neuro­
psychological test battery with the x axis representing the 
control mean. The pattern of performance is similar across 
the three groups. When one-way ANOVAs were con­
ducted, the only task that demonstrated significant differ­
ences between the epilepsy groups was the motor speed 
task of the Adult Memory and Information Processing 
Battery (F(3j 235) = 7.441, p < 0.001). Those with general­
ized epilepsy performed significantly worse than those 
with partial and unclassified epilepsy. However, these 
results should be interpreted with caution due to the 
unequal numbers in the groups.
Impact of previous seizure activity
Because a large proportion of patients had experienced 
several seizures before enrollment, correlational analyses
Epilepsia, 51 (1 ):48-56, 2010
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were carried out to investigate the relationship between 
neuropsychological test performance and previous seizure 
activity. There were no relationships between the total 
numbers of seizures, the total number of generalized 
tonic-clonic seizures (including both primary and second­
ary generalized), and any of the cognitive measures.
Impact of mood
On the Profile of Mood States, patients with epilepsy 
reported experiencing significantly more symptoms of 
tension (p < 0.001), confusion (p < 0.001), and signifi­
cantly less vigor (p = 0.001) than healthy volunteers. 
There were no relationships between the adjusted z-scores 
and the mood factors, suggesting the differences found on 
the neuropsychological tests are not mediated by mood 
disturbances.
Impairment index
The adjusted z-scores were used to identify individuals 
who demonstrated abnormal performance across the test 
battery. An adjusted z-score of <-2.0 was used as a marker 
of abnormality. Fig. 3 illustrates the percentage of patients 
with epilepsy and healthy volunteers who had abnormal 
scores for each test. A higher proportion of patients 
with epilepsy had abnormal test scores compared with 
healthy volunteers for the majority of measures. This is 
particularly evident for those that assess memory and 
psychomotor speed.
Table 3 illustrates the proportion of tests that were 
impaired for the patients with epilepsy and healthy volun­
teers when different criterions of abnormality were 
applied. Even when the more conservative value of >2 SD 
below the control mean was used, 53.5% of the patients 
with epilepsy had at least one abnormal score compared
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with 20.7% of healthy volunteers. These individuals were 
classified as being impaired. Patients with epilepsy were 
significantly more likely to be in the impaired group com­
pared with healthy volunteers [(y2 = 24.74, d.f. = 1, 
p < 0.001, odds ratio (OR) 4.42, 95% confidence interval 
(Cl) 2.41,8.11].
Characteristics of patients with epilepsy in the 
impaired group
There were no differences between those who were 
classified as impaired and those who were not in terms of 
sex (p = 0.8.22), age at assessment (p = 0.980), or educa­
tion (p = 0.192). There were no differences between the
two groups on any epilepsy-related variables. There were 
no differences in epilepsy type (p = 0.155), number of 
seizures at baseline (p = 0.101), or age at first seizure 
(p = 0.542), although there was a trend for those with a 
shorter interval since their first seizure to be in the 
impaired group (p = 0.017). There were no differences 
between the two groups on any of the mood variables.
Discussion
Cognitive impairments are frequently reported by peo­
ple with epilepsy, but when these cognitive impairments 
arise in the course of the disease is an important issue.
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Table 3. The proportion of tests impaired for patients and healthy volunteers across test battery
Proportion of tests impaired (%)
>2 SD >1 .5 SD
PWE (n, %) Controls (n, %) PWE (n, %) Controls (n, %)
0 72 (46.5) 69 (79.3) 39 (25.2) 45 (51.7)
£1 83 (53.5) 18(20.7) 116 (74.8) 42 (48.3)
>25 15(9.7) 2(2.3) 38 (24.5) 9(10.3)
>50 1 (0.6) 0 (0.0) 11(7.1) 1(1.1)
PWE, patients with epilepsy.
Many patients attribute their impairments to the side- 
effects of AED treatment (Carpay et al., 2005). However, 
the results of this study suggest that patients with newly 
diagnosed epilepsy, who are otherwise neurologically nor­
mal, were performing significantly worse than healthy 
volunteers on 10 of 16 cognitive measures before the start 
of treatment with AEDs. After adjusting for age, sex, and 
education, these differences persisted for the domains of 
memory and psychomotor speed. At an individual level, 
patients with epilepsy had a higher proportion of abnormal 
test scores (adjusted z-score <-2.0) across the test battery 
and were four times more likely than healthy volunteers to 
demonstrate cognitive impairment (at least one abnormal 
test score).
Previous research has suggested that patients with newly 
diagnosed epilepsy already demonstrate evidence of cog­
nitive dysfunction, in particular memory dysfunction, at 
the time of diagnosis (Smith et al., 1987; Kalviainen et al., 
1992; Aikia et al., 1995; Prevey et al., 1998; Pulliainen 
et al., 2000a; Aikia et al., 2001). Our study, consistent with 
these, has shown that impairments, particularly in memory 
functioning, occur in patients without structural brain 
abnormalities on clinical MRI, following few seizures and 
before AED treatment.
The observed differences were not mediated by the type 
or frequency of seizure activity. There were no differences 
between those with partial, generalized, and unclassified 
epilepsy, except for the motor speed task of the Adult 
Memory and Information Processing Battery. This sup­
ports Pulliainen et al. (2000a) but not Prevey et al. (1998), 
who found greater impairments in those with secondarily 
generalized seizures. However, our results must be inter­
preted with caution due to the unequal numbers in the 
groups. There were no relationships between the total 
number of seizures or the total number of generalized 
tonic-clonic seizures before the baseline assessment and 
any of the neuropsychological test variables. Epilepsy- 
related variables also did not explain the differences 
between those patients who were classified as impaired 
based on the impairment index, although there was a trend 
for those with more recent onset of first seizure to be in the 
impaired group.
The mechanisms underlying the cognitive impairments 
observed at the time of diagnosis are unclear. Some stud­
ies have suggested that it may be the result of epileptogen- 
esis (Hermann et al., 2006). Studies in children with new- 
onset idiopathic and cryptogenic epilepsy have also shown 
generalized cognitive dysfunction at the time of diagnosis 
compared with healthy volunteers (Oostrom et al., 2003; 
Hermann et al., 2006). Some studies have found that 
behavior and academic problems in children antedate the 
first recognized seizure (Austin et al., 2001; Berg et al., 
2005). However, the factors that cause some patients to be 
more susceptible to impairments than others remain to be 
determined.
Alternatively, patients were assessed at the time of 
diagnosis, which is a period of complex psychological 
adjustment (Velissaris et al., 2007). It may be that those 
who demonstrate the most dysfunction have a more perva­
sive loss of control and have a more extensive adjustment 
process (Velissaris et al., 2007). Oostrom et al. (2003) 
found that differences in cognitive functioning between 
children with newly diagnosed epilepsy and control chil­
dren were not related to epilepsy characteristics but to the 
reaction of the child and their parent(s) to the diagnosis of 
epilepsy. By following up patients after 3 and 12 months, 
we will be able to see whether these deficits persist or 
improve with time and adjustment to the condition.
Equally, anxiety or depression may have affected 
patient’s performance, as they were assessed at or near the 
time of diagnosis. There were differences between the cur­
rent mood state of patients with epilepsy and healthy vol­
unteers. Consistent with previous literature (Kanner, 
2007), patients with epilepsy reported experiencing more 
mood disturbance, in particular, more symptoms of ten­
sion and confusion and less vigor than healthy volunteers. 
However, similar to the study by Pulliainen et al. (2000b), 
we found no relationship between the neuropsychological 
test variables and current mood state. Furthermore, in 
order to limit the impact of anxiety on test performance, 
psychometrists administering the neuropsychological tests 
were trained to postpone the assessment in any patient 
who demonstrated significant levels of distress based on 
clinical judgement.
There are limitations to this study. First, a better control 
group would have been family members of the patients 
with epilepsy to ensure similar sociodemographic back­
grounds. However, because of limited resources (time and
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financial) this was not possible. However, the healthy vol­
unteers were equated for age and sex, although, they did 
have higher levels of education. Education is significantly 
correlated with age and IQ (Smith et al., 1987), so we 
adjusted for the effects of education in our analysis. Sec­
ond, we did not formally assess the psychological reaction 
and adjustment to the diagnosis of epilepsy, which may be 
a possible explanation for the observed differences 
between patients and healthy volunteers. However, in our 
study, current mood, including symptoms of anxiety and 
confusion, were not related to cognitive test performance. 
Third, the effects of epilepsy syndrome could not be inves­
tigated due to the small numbers in each group. With lar­
ger numbers, it would be interesting to investigate the 
cognitive profiles of different epilepsy syndromes at the 
time of diagnosis. Finally, patients with abnormal neuroi­
maging on clinical computed tomography (CT)/MRI were 
excluded from the analysis to assess the impact of seizures 
and not the impact of underlying brain pathology on 
neuropsychological functioning. Future research needs to 
investigate whether potential structural or functional 
abnormalities underlie these deficits.
This cohort forms part of a longitudinal study investi­
gating the natural history of cognitive functioning in peo­
ple with newly diagnosed epilepsy. A proportion of these 
patients have now been followed up after 5 years, and this 
will form the basis of a further publication. A recent study 
has identified three different cognitive phenotypes in 
patients with temporal lobe epilepsy, and it has been sug­
gested that these three subgroups follow a different cogni­
tive course over a 4-year period (Hermann et al., 2007). It 
has also been suggested that those with cognitive dysfunc­
tion at the time of diagnosis are those who go on to 
develop intractable chronic epilepsy (Kalviainen et al., 
1992; Aikia et al., 1995). We hypothesize that our group 
of patients who demonstrated cognitive dysfunction at the 
time of diagnosis may also have cognitive trajectories dif­
ferent from those who did not demonstrate dysfunction, 
will experience greater cognitive decline, and may be at 
risk of developing more severe intractable epilepsy.
There is a need to identify those patients already at risk 
of cognitive impairments so they can be referred for 
appropriate intervention and management to try and pre­
vent further decline. Therefore, future research needs to 
focus on the characteristics of those patients who appear 
to be more susceptible to cognitive impairments, examine 
the mechanisms that may underlie their increased suscep­
tibility, and assess the impact of seizures and treatment on 
an already compromised brain.
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Many people with epilepsy experience cognitive problems as a consequence of their epilepsy and its 
treatment. However, relatively few longitudinal studies have been conducted to investigate how these 
problems progress during the course of the disorder, particularly in those who are newly diagnosed. Fifty 
patients with newly diagnosed epilepsy were assessed using a comprehensive neuropsychological test 
battery before they started antiepileptic treatment and after a mean of 5 years. At the 5-year follow-up, the 
majority of cognitive measures remained stable, although significant (but subtle) declines were noted for 
memory and psychomotor speed domains in 38% of people with epilepsy.
© 2010 Elsevier Inc. All rights reserved.
1. Introduction
People with epilepsy (PWE) are at risk of developing cognitive 
dysfunction. The causes of cognitive impairments in PWE are thought 
to be multifactorial. The main factors include the effects of the 
underlying etiology, the effects of recurrent seizures, the side effects 
of antiepileptic drug (AED) treatment, and psychosocial issues [1- 4]. 
The majority of research has focused on the nature and cause of these 
impairments, in particular the cognitive side effects of AED treatment; 
however, there is increasing interest in determining how these 
problems progress during the course of the disorder.
Although a number of cross-sectional studies have suggested that 
cognitive functioning declines with increasing duration of epilepsy 
[5-10], others have not found evidence of deterioration over time 
[11,12]. Even though cross-sectional studies are useful in studying the 
relationships between cognition and long duration of epilepsy in large 
samples of patients, they have several limitations (e.g., cause and 
effect and undetected cohort bias effects). Therefore, a more 
appropriate approach to answering this type of question is a 
longitudinal design.
Comparatively few longitudinal studies have been conducted in 
adults with epilepsy. Two recent reviews have identified all published 
longitudinal studies [13,14]. Similar to the findings from cross- 
sectional studies, the results are mixed. Some have suggested that 
as a group, PWE decline in areas of functioning, particularly in 
memory, attention, executive control, speed of response, and visual- 
spatial relations [15-22]. However, there is variability in cognitive
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outcome. Helmstaedter et al. [17] identified 37% of patients with 
temporal lobe epilepsy (TIE) who declined in memory functioning; 
Arieff and Yacorzynski [15] also identified 37% who significantly 
decreased in intellectual functioning, and Hermann et al. [21] 
identified 20-25% who had adverse cognitive outcomes. In contrast, 
several studies have suggested either improvements or general stable 
functioning over time [16,23-31]. These mixed findings probably 
reflect their differing methodologies. The studies have varied in their 
test-retest intervals, the cognitive domains studied, neuropsycholog­
ical tests used, and types of patients assessed.
In addition, the majority of these studies have included those with 
severe, chronic intractable epilepsy and often of long duration. Only 
two studies have included those with newly diagnosed epilepsy 
[27,28]. One was a published abstract from a study following 58 
patients with newly diagnosed partial epilepsy over 5 years. There 
were no significant declines across a comprehensive neuropsycho­
logical test battery [27]. The second study [28] presented only 
preliminary data on verbal intellectual and verbal memory function­
ing in 20 patients with newly diagnosed TIE. There were also no 
significant declines after 5 years. Therefore, in comparison to those 
with chronic, long-standing epilepsy, very little is known about the 
cognitive functioning of adults with new-onset epilepsy. This study 
aimed to document the longer-term effects of epilepsy and its 
treatment on cognitive functioning in adults with newly diagnosed 
epilepsy by following up patients who were involved in the Standard 
and New Antiepileptic Drugs (SANAD) Neuropsychology study 3 to 
8 years after their diagnosis [32].
2. Methods
This study included PWE who were involved in the SANAD trial. 
SANAD was a pragmatic, multicenter, randomized, unblinded, parallel
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group clinical trial comparing the clinical and cost effectiveness of 
standard (carbamazepine or valproate) and new (gabapentin, 
lamotrigine, oxcarbazepine, topiramate) AEDs. A full description of 
the study methods has been given elsewhere [33,34]. At the time of 
randomization into SANAD, newly diagnosed adults (aged >15 years) 
who were previously untreated from 10 of the hospital centers (most 
active recruiting centers) were invited to take part in the SANAD 
Neuropsychology study. The study methods have been described in 
[32]. Briefly, 222 PWE were assessed before the start of AED treatment 
using a comprehensive battery of neuropsychological tests. Baseline 
assessments were undertaken between October 2000 and August 
2004. They were then reassessed after 3 and 12 months of treatment. 
A total of 147 PWE were assessed at 12 months.
2.1. SANAD Neuropsychology follow-up study
Those who had completed all three assessments as part of the 
SANAD Neuropsychology study were invited to take part in a 
neuropsychology follow-up assessment. PWE were approached to 
take part in the follow-up study if they had completed the 12-month 
assessment as part of the SANAD Neuropsychology study; they still 
had a diagnosis of epilepsy, and they gave informed consent. PWE 
were excluded from taking part if they had undergone epilepsy 
surgery or they had expressed a wish not to take part in any further 
research as part of SANAD. Eligibility was checked with the clinical 
information obtained as part of SANAD and by asking patients about 
their medical history informally in a semistructured interview prior to 
the assessment.
Patients were recruited between November 2007 and November 
2008 and assessed using the same comprehensive battery of tests as in 
the SANAD Neuropsychology study. A semistructured interview was 
also conducted to obtain up-to-date demographic and clinical 
information. This included: current medication, seizure frequency or 
period of seizure freedom, occurrence of any other medical or 
psychological problems since the 12-month assessment, and socio­
demographic characteristics such as employment status and educa­
tional history.
Both the SANAD Neuropsychology study and the follow-up study 
received ethical approval from the North West Research Ethics 
Committee and local research governance approval. All participants 
gave written informed consent.
2.2. Neuropsychological test battery
The neuropsychological test battery comprised measures from the 
FePsy computerized test program [35] as well as traditional paper- 
and-pencil measures (see Table 1). The test battery was aimed at 
assessing a wide variety of cognitive domains. Each of the tests was 
selected on the basis of its proven reliability, validity, and use in 
people with epilepsy [36,37], The battery took approximately 
1 Vi hours to complete. The tests were administered in a fixed order 
to ensure adequate time passed to test delayed recall on the memory 
tasks. However, regular breaks were offered and taken to reduce 
fatigue effects. Neuropsychological assessment was postponed to a 
later date for those patients who reported having a seizure within 
24 hours of the assessment. Parallel, alternate forms were used, where 
available, in the follow-up sessions to reduce practice effects 
associated with repeat neuropsychological testing [38].
2.3. Statistical analysis
Data were analyzed using SPSS (Version 16.0). Independent t tests 
and x2 analysis were used to examine differences in demographic, 
clinical, and neuropsychological characteristics between those who 
did and those who did not participate in the follow-up assessment. 
Differences between baseline and follow-up neuropsychological test
Table 1
Neuropsychological test battery.
Domain Test Outcome variable
Psychomotor Finger tapping Average number of taps for
speed the dominant and 
nondominant hand across 
five trials
Visual reaction time Average reaction time (ms) 
for the dominant and 
nondominant hand
AMIPB"' psychomotor Mean number of digits crossed
speed through over two trials
Memory Recognition of Number of words or figures
words/figures correctly answered on the 
serial/simultaneous version 
of the task
Rey Auditory Verbal Sum of words recalled over
Learning Task the five trials and number of 
words recalled after a 30-min 
delay
Story recall Number of story units recalled 
immediately and after a
10-min delay
Information AMIPB information Mean number of correct
processing processing responses over the two tasks
Binary choice reaction 
time
Average response speed (ms)
Computerized Visual 
Search Task
Average speed of response (s)
Mental flexibility Stroop Number of correct responses 
on the color-word task
Benton verbal fluency Total number of acceptable 
words produced
Mood Profile of Mood States Transformed scores (per 100) 
for each mood factor
Subjective report Aldenkamp-Baker Transformed scores (per 100)
of cognitive Neuropsychological for each subscale
complaints Assessment Schedule
a AMIPB, Adult Memory and Information Processing Battery.
scores at a group level were examined using dependent tor Wilcoxon 
signed-rank tests, depending on whether scores were normally or 
nonnormally distributed. Because of the low ceiling observed on the 
Stroop color-word test, this was converted to a categorical variable 
based on normative data [39]. Descriptive statistics were used to 
describe the proportion of people in each category (borderline, low 
average, average). Percentage change scores were calculated and 
transformed so that for all tests, positive values indicated improve­
ment from baseline and negative values indicated decline from 
baseline. Separate exploratory analyses (e.g., Spearman correlations, 
Mann-Whitney, and Kruskal-Wallis tests) were conducted to assess 
variables that might influence cognitive change. These independent 
variables were either analyzed as continuous variables or transformed 
into dichotomous ones. The independent variables were: seizure 
freedom for at least the previous 12 months (yes/no), age, years of 
education, duration of epilepsy, presence of comorbidities at follow­
up (yes/no), and Tension-Anxiety factor from the Profile of Mood 
States (POMS).
To assess cognitive change at an individual level and evaluate the 
clinical significance of results, the proportion of patients who had 
experienced cognitive decline was calculated. This was calculated 
relative to the cross-sectional SD of the relevant baseline scores (40- 
42]. Cognitive decline was defined as a decline of more than 2SD on 
any of the neuropsychological tests. Some studies have used less 
conservative values of >1SD to define decline [e.g., 41], However, 
several previous studies have also defined cognitive decline using the 
more conservative values above [e.g., 19]. The more conservative 
values were chosen so as not to overestimate the number of patients 
who were classified as experiencing cognitive decline, especially as 
evaluating change using this SD method has been found to 
overclassify deterioration in test performance compared with other
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methods (e.g., reliable change indices and regression-based models) 
[42]. An exploratory analysis, using independent t, Mann-Whitney, 
and x2 tests, was conducted to identify the demographic and clinical 
characteristics of those who were identified as having cognitive 
decline. Because of the number of multiple comparisons being made, a 
Bonferroni correction was applied, setting the significance level for 
the inferential statistics as P<0.01.
Table 2
Clinical and demographic characteristics of PWE (n = 50).
Sex
19 (38.0%)'
31 (62.0%)
41.34(15.01) [15-78] 
46.76(15.22) [21-84] 
64.24(10.75) [43-85)
Male
Female
Mean age at baseline
Mean age at follow-up
Mean test-retest interval, months
3. Results
3.1. Response rate
A total of 147 PWE had completed all three assessments; of these, 
132 were eligible for the follow-up study (reasons for noneligibility: 7 
patients had died, 3 were from the two centers that did not participate 
in the follow-up study, 2 requested not to take part in future research, 
2 did not have up-to-date contact details, 1 had undergone epilepsy 
surgery). Of the 132 who were invited to undergo a follow-up 
assessment, 54 (41%) responded positively, 37 (28%) declined, and 41 
(31%) did not respond to the invitation letter. Reasons for not wanting 
to take part included: ill health (n = 3), did not feel that they had the 
time (n = 2), family or work commitments (n = 4), tired of taking part 
in research (n=l), no longer had epilepsy so did not want to 
contribute: (n=l) 26 did not provide a reason. Of the 54 who wanted 
to take part, 50 completed the follow-up assessment. Assessments 
were not completed for 4 patients for various reasons: frequency and 
severity of seizures made it too difficult to carry out an accurate 
assessment for one patient; one canceled and did not want to 
rearrange; and after responding to the initial invitation letter, two 
patients could not be contacted to arrange an assessment time.
3.2. Clinical and demographic characteristics
As outlined in Table 2, the majority of participants were females 
with an average age of 46 years (range: 21-84). It had been a mean of 
64 months since their baseline assessment (range: 43-85). This test- 
retest interval is used as a surrogate for duration of epilepsy, as these 
patients were newly diagnosed at the time of the baseline assessment. 
There were no differences in terms of age at baseline (t[ 130] = -1.11, 
P=0.267) or gender (j2[1] = 2.184, P=0.139) between those who 
did and those who did not take part in this follow-up study. The 
majority had partial epilepsy. There were no differences in baseline 
seizure type between those who did and those who did not take part 
(j2|2] = 4.574, P= 0.102). The majority had been seizure free for at 
least the 12 months prior to the assessment.
Eighty percent were on monotherapy at follow-up. Lamotrigine 
(20%), carbamazepine (18%), and topiramate (18%) were the most 
commonly prescribed drugs. Eight (16%) were treated with poly- 
therapy on six different combinations (three carbamazepine and 
levetiracetam, one carbamazepine and topiramate, one lamotrigine 
and valproate, one lamotrigine and clobazam, one levetiracetam and 
clobazam, and one topiramate and pregabalin).
Forty percent of those who took part in the follow-up assessment 
reported experiencing other medical conditions (e.g., cancer, diabetes, 
gynecological problems) unrelated to their epilepsy since their 12- 
month assessment. Previous psychological problems were reported 
by five participants, four of whom had sought treatment (three for 
depression, one for anger management). Of those who had reported 
experiencing psychological problems since the 12-month assessment, 
none reported still experiencing them at the time of the follow-up 
assessment.
At the time of follow-up, just over half were in paid employment or 
full-time education. They had a median of 12 years of education, and 
82% had achieved formal educational qualifications. Forty-four 
percent had achieved school-level qualifications (GSCEs/CSEs or 
equivalent) and 30% had achieved the equivalent of A-levels or
Seizure type at baseline
Partial 42 (84.0%)
Generalized 4 (8.0%)
Unclassified 4 (8.0%)
Seizure frequency at follow-up
None 29 (58.0%)
Daily 3 (6.0%)
Weekly 3 (6.0%)
Monthly 12 (24.0%)
Yearly 3 (6.0%)
Seizure free in preceding 12 months 29 (58.0%)
Other comorbidities 20 (40.0%)
Employment status at follow-up
In paid full/part-time work 25 (50.0%)
In full-time education 1 (2.0%)
Retired 9(18.0%)
Unemployed 15(30.0%)
Median years of education at follow-up, 12 [11-16|
(25th-75th centiles)
Highest qualification obtained at follow-up
None 9(18.0%)
Other 2 (4.0%)
CCSE/CSE or equiva!entb 22 (44.0%)
A-levels or equivalent13 4 (8.0%)
Diploma 4 (8.0%)
Degree or higher 9 (18.0%)
' Values are expressed as n (%) or mean (SD) (range).
b GCSE/CSE or equivalent are school-level qualifications (11-16 years): A-levels or 
equivalent are post-16 qualifications.
higher (postschool qualifications). They had significantly more years 
of formal education at baseline than those who were eligible but did 
not take part in the follow-up study (^[2] = 11.30, P=0.004). 
However, there were no differences between the two groups on any of 
the baseline neuropsychological measures, although there was a trend 
for those who did not take part to have lower scores on both aspects of 
the Adult Memory and Information Processing Battery (AMIPB 
information processing t[ 130] = -2.36, P=0.020; AMIPB psychomotor 
speed t[125] = -2.13, P= 0.035). Similarly, there were no differences 
between the two groups on any of the 12-month neuropsychological 
measures.
3.3. Changes in neuropsychological functioning
As outlined in Table 3, PWE had statistically significantly slower 
reaction times at follow-up on the visual reaction time task with both 
the dominant hand and nondominant hand compared with baseline. 
They also had significantly lower scores at follow-up compared with 
baseline on the immediate and delayed tasks of the Rey Auditory 
Verbal Learning Test (AVLT). There were also trends for worse 
performance at follow-up on serial recognition of words, the 
information processing task of the AMIPB, and the Computerized 
Visual Search Task (CVST). However, there was a trend toward 
improved performance on the serial recognition of figures task. A 
larger proportion of patients were performing in the average range at 
follow-up compared with baseline on the Stroop Color-Word task 
(71.7% vs 66.7%). Fewer patients were performing in the borderline 
range at follow-up compared with baseline (15.2% vs 16.7%). This 
suggests that, as a group, patients improved over time on this task.
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Table 3
Changes in neuropsychological test variables from baseline to follow-up.
Variable Baseline Follow-up Difference (95% Cl) P value
Finger tapping
Dominant 56.02 (9.75) [48)' 56.34 (9.23) [48]'1 -0.32(-3.42, 2.78) 0.836
Nondominant 51.34 (8.57) [47] 50.43 (6.70) [47] 0.90 (-1.46, 3.26) 0.446
Visual RT (ms)b
Dominant 309.37 (62.97) [46| 348.13 (54.00) [46] -38.76 (-59.04, -18.48) <0.001c
Nondominant 311.98 (68.84) [48[ 366.33 (68.07) [48] -54.35 (-73.82, -34.89) <0.001c
Binary choice RT (ms)b 341.00 (308.00-424.00) [45] 361.00 (313.00-419.00) [45] -7 (-27,-16) 0.519
CVST (s)b 10.80 (4.10) [46] 11.87 (3.60) [46] -1.06 (-2.00, -0.13) 0.027'1
Word recognition
Serial 15.94 (4.11) [47] 14.23 (4.75) [47] 1.70 (0.24, 3.16) 0.023'’
Simultaneous 20.00 (17.00-22.00) [43] 19.00 (17.00-21.00) [43] 0.5 (-0.5, 1.5) 0.249
Figure recognition
Serial 14.29 (4.00) [45] 15.56 (4.65) [45] -1.27 (-2.49, -0.04) 0.043“
Story recall
Immediate 8.34 (2.64) [50] 7.89 (2.73) [50] 0.45 (-0.24, 1.14) 0.197
Delayed 7.20 (2.62) [50] 739 (2.88) [50] -0.19(-0.90, 0.52) 0.593
Rey AVLT
Immediate 45.88 (9.16) [50] 40.34(10.79) [50] 5.54 (2.70, 8.38) <0.001'
Delayed 10.00 (7.00-11.00) [50] 8.00 (6.00-10.00) [50] -1.5 (-2,-1) 0.001c
Verbal fluency 35.90 (12.48) [50] 35.78 (12.68) [50] 0.12 (-2.69, 2.93) 0.932
AMIPB
Information processing 63.39 (1633) [50] 59.80(18.49) [50] 3.59 (0.81, 6.37) 0.012d
Psychomotor speed 48.65 (10.91) [49] 46.71 (9.07) [49] 1.94 (-0.82, 4.70) 0.164
a Values are expressed as the mean (SD) (n) or median (25th-75th percentiles) |n]. 
b Higher score means worse performance. 
c P< 0.001. 
d P<0.05.
In terms of mood, PWE reported feeling significantly fewer 
symptoms of tension at the follow-up assessment (r[49] = 3.00, 
P=0.004). There were no statistically significant changes in any of 
the other mood factors of the POMS. There were no statistically 
significant changes on the Aldenkamp-Baker Neuropsychological 
Assessment Schedule (ABNAS), although patients reported experi­
encing more memory, language, and concentration problems and 
cognitive slowing at the follow-up assessment.
3.4. Percentage change
Fig. 1 plots the median percentage change scores across the 
neuropsychological test battery. The tests with the most decline from 
baseline are the delayed subtest of the Rey AVLT, visual reaction time 
with the dominant hand and nondominant hand, and the CVST, 
consistent with the results of the dependent t tests. The declines are 
subtle, and scores on most measures on average declined less than 5% 
from baseline. The Rey AVLT and visual reaction time tasks seem to 
have been the most vulnerable at follow-up, with an average decline 
from 17% from baseline for the Rey AVLT. Interestingly, improvements 
were found on the story recall tasks and serial recognition of figures.
3.5. Factors associated with cognitive change
There were no differences in percentage change scores between 
those who had been and those who had not been seizure free in the 
preceding year, between those with daily/weekly/monthly seizures 
and those with yearly seizures, and between those with comorbid 
diagnoses and those without comorbid diagnoses for any cognitive 
measure. There was a trend for years of education to be significantly 
positively associated with percentage change on the delayed story 
recall task (rs = 0.316, P = 0.025) and duration of epilepsy to be 
significantly negatively associated with simultaneous recognition of 
words (rs =-0.326, P = 0.033). Age at the time of follow-up 
assessment was significantly negatively associated with psychomotor 
speed subtests of the AMIPB (r5 =-0.442, P= 0.001) and exhibited 
trends with the information processing subtest (rs =-0.321, 
P= 0.023) and serial recognition of words (rs =-0.297, P= 0.042).
Scores on the Tension-Anxiety factor of the POMS were significantly 
negatively associated with tapping with the dominant (rs =-0.527, 
P<0.001) and nondominant (rs =-0.383, P=0.008) hand and the 
psychomotor speed subtest of the AMIPB (rs = -0.385, P=0.006), and 
there was a trend with delayed recall (rs =-0.282, P=0.047) on the 
Rey AVLT.
3.6. Individual change
Thirty-eight percent of patients were classified as experiencing 
cognitive decline. An exploratory data analysis was conducted to 
investigate the clinical and demographic characteristics of those who 
were classified as having cognitive decline compared with those who 
were not so classified. There were no significant differences between 
the two groups on any of the demographic, psychological, or epilepsy- 
related variables (see Table 4).
4. Discussion
This study investigated the longer-term impact of epilepsy and its 
treatment on cognition in newly diagnosed people with epilepsy. The 
results indicate that after a mean of 5 years since diagnosis, the 
majority of cognitive measures remained stable but there were 
statistically significant declines in 4 of the 16 measures. Measures 
affected were those assessing psychomotor speed and verbal memory. 
However, the magnitude of this change was subtle, 10-15% from 
baseline. Cognitive changes, particularly for psychomotor speed 
measures, were most associated with higher levels of tension. Older 
age was also significantly associated with poorer performance on a 
measure of psychomotor speed. At an individual level, 38% of patients 
were classified as experiencing cognitive decline (i.e., at least one 
cognitive test score >2SD below baseline).
The relatively stable findings for the majority of measures support 
some of the previous work in this area [16.24-28,31], but must be 
interpreted with caution because of the lack of a control group. This 
has been identified as a methodological shortfall of previous studies of 
this type, as the neuropsychological test performance of PWE has 
been characterized by "abnormal” functioning rather than abject
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Fig. 1. Median percentage change score across the neuropsychological test battery, dom, dominant; nondom, nondominant; AMIPB, Adult Memory and Information Processing 
Battery; ser, serial; imm, immediate; del, delayed; exec, executive.
deterioration [14,43], To date, there have only been five controlled 
longitudinal studies, and these have arrived at conclusions different 
from those of studies that did not employ a control group. These 
studies have indicated that compared with healthy volunteers, PWE 
have different cognitive trajectories, which are characterized by a lack 
of practice effects [19,21,22,30,31]. Therefore, this study cannot make 
conclusions in comparison to ‘'normal” performance, but the lack of 
improvement despite prior exposure to the tests at baseline, 
3 months, and 12 months lends support to this hypothesis.
The finding of declines on some measures, particularly those 
assessing verbal memory, is congruent with several previous 
longitudinal studies [15,17,18,20-22], but is inconsistent with studies 
involving newly diagnosed PWE [27,28]. Aikia and colleagues 
reported no significant declines on measures of verbal ability, verbal 
learning and memory, attention, and flexibility of mental processing 
after 5 years. They also found statistically significant (although small) 
improvements in several neuropsychological measures as a result of 
normal practice effects, although they did not report which measures 
improved [27], In their later study, there was no deterioration and 
some improvement (delayed recall of a list learning task) in verbal 
memory in 20 adults with newly diagnosed TIE. The differences may 
possibly be explained by the demographic and clinical characteristics 
of the PWE in the studies (e.g., all participants were seizure free in 
[27]; there may be differences in AED treatment—20% were taking 
topiramate in our study, which is a known risk factor for cognitive 
impairment [44-49]; and there may have been differences in age, 
education, and type of epilepsy).
The finding that higher levels of tension were associated with 
declines in measures of psychomotor speed (finger tapping task and 
the psychomotor speed task of the AMIPB) is consistent with previous 
research that has suggested that mood disturbance may interfere with 
performance on neuropsychological tests, particularly timed tasks 
[50-52], Older age was also associated with poorer performance on 
the AMIPB psychomotor speed task; this association has previously
been reported [53], However, there were no differences in self- 
reported symptoms of anxiety or age between those who were and 
those who were not classified as having cognitive decline. The fact 
that this study failed to identify any factors that differentiated those 
who were and those who were not classified as experiencing 
cognitive decline is interesting. Possibly the definition of abnormal 
test performance employed in this study is too lenient; PWE may not 
differ on these factors but on some other indicator that was not 
measured (e.g., functional/structural neuroabnormalities identified 
from EEC and/or imaging data). Or it may reflect the heterogeneity of 
the sample. However, the proportion of PWE experiencing epilepsy is 
in concordance with other longitudinal studies investigating cognitive 
change in PWE [15,18,24].
4.1. Limitations of the study
There are limitations to this work. First, as discussed above, the 
lack of a control group at follow-up means that the results need to be 
interpreted with caution. Second, the PWE in this study represent a 
heterogeneous group with different etiologies, seizure types, and 
syndromes. Different syndromes have been associated with different 
types of deficits [54,55]. A potential avenue for future research would 
be to recruit participants with specific syndromes at the time of 
diagnosis and follow these more homogenous groups over the course 
of the disorder. Third, selection bias may have occurred at follow-up. 
There was a large loss to follow-up. Only 23% of the original sample 
from the SANAD Neuropsychology study was involved in the follow­
up assessment, and only 38% of those approached participated. Those 
who remained in the study may have been those who were concerned 
about cognitive problems and wanted a neuropsychological assess­
ment, or those who felt that their epilepsy did not have a significant 
impact on their cognitive functioning may not have felt that the study 
was relevant to them and dropped out. Equally, those who found the 
neuropsychological tasks most challenging, or were most impaired,
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Table 4
Characteristics of those classified as having or not having cognitive decline at follow-up.
Characteristic Declined (n= 19) Not declined (n = 31) Difference (95%CI) P value
Sex
Male 7 (36.8%)* 12 (38.7%) -1.9(-27.9, 25.9) 0.895
Female 12 (63.2%) 19(613%) 1.9 (-25.9, 27.9)
Age at follow-up, years 51.11 (14.17) [22-84] 44.10 (15.45) [21-71] 7.01 (-1.77, 15.79) 0.115
Age at baseline, years 45.84 (13.89) [17-78] 38.58 (15.21) [17-65] 7.26 (-1.37, 15.89) 0.097
Duration, months 62.21 (11.23) [43-85] 65.48 (10.43) [46-84] -3.27 (-9.56, 3.02) 0.301
Seizure type at baseline
Partial 15 (78.9%) 27 (87.1%) -8.1 (-32.7,12.7) NA’
Generalized 1 (5.3%) 3 (9.7%) -4.4 (-21. 16.4)
Unclassified 3 (15.8%) 1 (3.2%) 12.6 (-3.5, 35.1)
Seizure free in preceding 12 months 13 (68.4%) 16 (51.6%) 16.8 (-11.7, 41.7) 0.242
Number of AEDs at follow-up
0 0(0%) 2 (6.5%) -6.5 (20.9, 11.1) NAh
1 15(78.9%) 25 (80.6%) -1.7 (-27.1, 20.3)
2 4 (21.1%) 4 (12.9%) 8.1 (-12.7,32.7)
On topiramate at follow-up 5 (26.3%) 5 (16.1%) 10.2 (-12.4, 35.5) 0.382
Comorbidities at follow-up 8 (42.1%) 12 (38.7%) 3.4 (-23.5, 30.9) 0.812
Median education at follow-up, years (25th-75th centiles) 12 (11-18) 12 (11-15) 0 (-1, 2) 0.812
Median tension-anxiety at follow-up (25th-75th centiles) 30.56(16.67-44.44) 22.22 (13.89-36.11) -8.33 (-2.78, 19.44) 0.136
Employment status at follow-up
Employed/full-time education 8 (42.1%) 18 (58.1%) -16.0 (-41.9, 12.5) 0.273
Unemployed/retired 11 (57.9%) 13 (41.9%) 16.0 (-12.5, 41.9)
a Values are expressed as n (%) or mean (SD) [range], 
b Numbers in each cell are too small for tests of significance.
may not have wanted to take part. However, there were no differences 
on any of the baseline or 12-month cognitive measures, suggesting 
that they were representative of the original sample.
Despite these limitations, this study suggests that although 
cognitive function remains generally stable, some PWE may be at 
risk of experiencing cognitive decline, particularly in areas of verbal 
memory functioning. We feel this study provides important informa­
tion on the neuropsychological progression of epilepsy in new-onset 
patients. Future work needs to concentrate on identifying the 
prognostic factors that predict those most at risk and to follow-up 
PWE for longer periods. In addition, PWE should be monitored, as part 
of their routine clinical management, for cognitive changes over time 
so that they can be referred for more comprehensive neuropsycho­
logical assessment and appropriate intervention.
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